

ELI OWEN MELTZER, MD

Private Practice 1971 – present
Allergy & Asthma Medical Group and Research Center, A P.C.
5776 Ruffin Road
San Diego, California 92123
(858) 292-1144 ph
(858) 268-5145 fx

Clinical Professor, Department of Pediatrics, Division of Allergy and Immunology
University of California, San Diego, School of Medicine

California Medical License Number: G17138

EDUCATION:

College: University of Pennsylvania, BA degree, 1956-1960.
Medical School: Jefferson Medical College, MD degree, 1960-1964.
Internship: Michael Reese Hospital, Mixed Pediatrics, 1964-1965.
Residency: St. Christopher's Hospital for Children and Temple University, Pediatrics, 1965-1967.
Fellowship: National Jewish Medical and Research Center and University of Colorado, Pediatric Allergy and Clinical Immunology, 1967-1969.

BOARD CERTIFICATION:

American Board of Pediatrics in Pediatrics, July, 1969.
American Board of Pediatrics in Pediatric Allergy, October, 1969.
American Board of Allergy and Immunology, November, 1972.

ACADEMIC APPOINTMENTS:

Assistant Clinical Professor, 1970
Associate Clinical Professor, 1974
Clinical Professor, Department of Pediatrics, Division of Allergy and Immunology, University of California, San Diego, 1988 to present.
Adjunct Professor, College of Health and Human Services, San Diego State University, 1988 to 1993.
Consultant, Center for Behavioral Epidemiology and Community Health, Graduate School of Public Health, San Diego State University, 1990 to 2006
Consulting Faculty, California School of Professional Psychology, San Diego, 1978-1979.
Faculty, Allergy and Immunology Fellowship Training Program, Scripps Clinic Research Foundation, 1987 to present.
Pulmonary-Allergy Drugs Advisory Committee, U. S. Food and Drug Administration, 1993 to 1995.
Consultant, Center for Drug Evaluation and Research, U. S. Food and Drug Administration, 1995 to 1996.

PROFESSIONAL APPOINTMENTS: ELI O. MELTZER, MD

Fellow, American Academy of Pediatrics, Section on Allergy and Immunology.
Executive Committee, Section on Allergy and Immunology, 1987-1990.
Secretary/Treasurer, Section on Allergy and Immunology, 1989-1990.
Liaison to Committee on Drugs, 2000 to 2001
Visiting Professor Program, 2000 to 2003

Fellow, American College of Allergy, Asthma and Immunology.
Ear, Nose and Throat Committee, 1987-1990.
Rhinitis/Rhinosinusitis Committee, 2003 to 2009
Representative, Joint Council of Allergy and Immunology, 1987 to 1991.
Joint Task Force, Rhinitis Measures Subcommittee, 2007

Fellow, American Academy of Allergy, Asthma and Immunology.
Drugs/Pharmacotherapeutics Committee 1978 to 2003.
Chairman, 2001 to 2003.
Upper Airways Allergy Committee 1982 to 1992.
Undergraduate and Graduate Education Committee, 1984 to 1987.
Liaison Committee to Regional, State and Local Allergy Societies, 1987 to 1991.
Physicians and Public Service Council, Board of Governors, 1988 to 1991.
Professional Information Committee, Subcommittee for Public Relations, 1990 to 1993.
Rhinitis Committee, 1993 to 2002.
Chairman, 1996 to 1998.
Rhinosinusitis Committee, 1993 to 2009
Rhinitis, Rhinosinusitis, Ocular Allergy, 2009 to 2015
Workforce Committee, 1994 to 1997.
Chairman, 1994 to 1996.
Family Medicine Chief Residents Program, 1996 to 2001.
Ethics/Conflict of Interest Committee, 1997 to 2003.
Chairman, 1999 to 2001.
“Advances” Program Design Committee, 1998.
Rhinosinusitis Initiatives 2002 to 2006
Chairman, 2002 to 2006
Seminars Committee, ARRD Representative 2003 to 2005.
Chairman, 2004 to 2005
Asthma Pharmacotherapeutics Committee 2003 to 2005.

Joint Council of Allergy, Asthma and Immunology.
Board of Directors, 1987 to 1994.
President Elect 1988 to 1990.
President 1990 to 1992.

World Allergy Organization
Special Committee on Clinical Trials in Allergy and Immunology, 2008 to present
Allergic Rhinitis Working Group, 2011 to present

World Health Organization
Allergic Rhinitis and It’s Impact on Asthma Guidelines (ARIA), 1999 to present
Interaction Between Upper and Lower Airways (Inter Airways), 2007 to present

American Association of Certified Allergists.
Association for the Care of Asthma.
American Medical Association, 1970 to 2006
California Medical Association.
Allergy Scientific Advisory Panel, 1984 to 1987.
Scientific Assembly, Allergy Section, Program Planner, 1986.

California Society of Allergy, Asthma and Clinical Immunology.
Executive Committee, 1981 to 1988.
Secretary/Treasurer, 1984.
Vice President, 1985.
President, 1986.
California Chapter 3 of American Academy of Pediatrics.
San Diego County Medical Society.
San Diego Allergy Society.
President, 1976.
San Diego Pulmonary Society, 1970-1977.
Greater San Diego Health Plan.
Allergy Advisory Panel, 1981 to 1988, Chairman, 1985-1987.
Utilization Review/Quality Assurance Advisory Committee, 1985-1987.

EDITORIAL BOARDS:

Editorial Board, American Journal of Rhinology and Allergy, 1987 to present.
Editorial Board, New England and Regional Allergy Proceedings, 1987 to 1989.
Editorial Advisory Board, The American Journal of Asthma & Allergy for Pediatricians, 1987 to 1994.
Editorial Advisory Board, Clinical Advances in Allergic Disorders, 1989 to 1991.
Editorial Advisory Board, Allergy From the Nose to the Lung, Japan, Kido no Arerugi, 2003 to 2006 .
Editorial Advisory Board, Respiratory Digest, 2004 to 2007.

Reviewer:

Journal of Allergy and Clinical Immunology, 1984 to present.
Journal of Pediatrics, 1986 to present.
Annals of Allergy, 1988 to present.
Journal of Respiratory Diseases, 1989 to present.
New England Journal of Medicine, 1990 to present.
Journal of Asthma, 1993 to present.
American Journal of Medicine, 1996 to present.
PharmacoEconomics, 1997 to present
Pediatrics, 1997 to present.
Journal of the American Medical Association, 1998 to present.
Allergy – The European Journal of Allergy and Clinical Immunology, 2000 to present.
International Archives of Allergy and Immunology, 2006 to present.
Medical Letter 2011 to present.

MEDICAL STAFF:

Rady Children's Hospital and Health Center.
Chief, Division of Allergy and Immunology, 1991 to 1997.
Senior Staff, Department of Pediatrics and Division of Allergy.
Institutional Review Board, 1979 to 1992.
Credentials Committee, 1982 to 1989.
Chairman, 1984 to 1989.
Bioethics Committee, 1988 to 1990.
Physician Well Being Committee, 1989 to present.
Chairman, 1998 to 2013
Joint University of California, San Diego – Children’s Hospital Volunteer Faculty Committee, 2006 to 2010.
Grossmont Hospital.
Scripps Mercy Hospital.

Sharp Memorial Hospital.
United States Naval Hospital, San Diego
Lieutenant Commander, MC USNR, 1969-1971.

AWARDS:

American College of Allergy, Asthma and Immunology
Master in Allergy 1992
Distinguished Fellow 1993
Jaros Memorial Lecture 1994
American Academy of Allergy, Asthma and Immunology
William Pierson Lecutre 2000
Distinguished Clinician 2002
American Academy of Pediatrics, Section on Allergy and Immunology
Jerome Glaser Distinguished Service 2003
The Best Doctors in America, Allergy and Immunology
Published by Woodward/White, Aiken, SC
America's Top Doctors
Published by Castle Connolly Medical Ltd, New York, NY
Guide to Top Doctors, Allergy and Immunology
Published by Center for the Study of Services, Washington, D.C.
Guide to America's Top Pediatricians
Published by Consumers Research Council of America, Washington D.C.
San Diego Best Doctors, Allergy & Immunology
Published by San Diego Magazine
Sharp Community Medical Group
Excellence in Patient Satisfaction 2005
Mexican College of Clinical Immunology and Allergy
International Distinguished Professor 2009
Rady Children's Hospital
Recognition for "Outstanding dedication, counseling, and commitment to ensure the physical and mental well-being of all physicians on the medical staff of Rady Children's Hospital." 2009
Recognition for "Dedicated leadership and commitment to quality, and in appreciation of your time and effort to the hospital and the medical staff organization as Well Being Committee Chair 1998 to 2013." 2013

EXPERT DESIGNATION IN LEGAL MATTERS:

- Aventis Pharmaceuticals Inc. and Sanofi Aventis USLLC v. Barr Laboratories, Inc. Fexofenadine Litigation
 - No. 06-286 (GMS) (Dist. Delaware) – *Kaye Scholer, LLP*, 2005-2011
- MedPoint Healthcare Inc. v. Apotex Inc. and Apotex Corp., Azelastine Litigation
 - No. 06-164-SLR (Dist. Delaware) – *Kirkland & Ellis, LLP*, 2007
- Aventis Pharmaceuticals, Inc., et al. v. Barr Laboratories, Inc., Intranasal Triamcinalone Acetonide Litigation
 - No. 01-3627 (Dist. New Jersey) – *McDonnell Boehnen Hulbert & Berghoff, LLP*, 2007-2008
- Schering v. Zydus Pharmaceuticals, Desloratadine Litigation
 - No. 07-03930-MLC-TJB (Dist. New Jersey)– *Kirkland & Ellis, LLP*, 2008-2009
- Merck Sharp & Dohme Pharmaceuticals SRL v. Teva Pharmaceuticals, Montelukast Litigation
 - No. 07-1596 (Dist. New Jersey) - *Weil, Gotshal & Manges, LLP*, 2008-2009
- Sepracor, Inc. v. Barr Pharmaceuticals, Inc., Levocetirizine Litigation

- No. 5:08-CV-362H(3) (Eastern Dist. North Carolina) - *Patterson, Belknap, Webb & Tyler, LLP*, 2009
- Takeda Canada, Inc., et al. v. Apotex, Inc., et al. Ciclesonide Litigation
 - Federal Court File No. T-772-13 (Omnaris) – *Gowling, Lafleur, Henderson, LLP*, 2013

CONSULTANT/SPEAKER/RESEARCH SUPPORT DISCLOSURE (cumulative over career):

Abbott, Alcon, Alexza, Allergan, Allux, Amgen, Antigen Labs, Apotex, Armstrong, Arris, Astellas, AstraZeneca (Astra, AstraMerck, ICI, Zeneca), Baker Norton, Bausch + Lomb, Berlex, Boehringer Ingelheim, Boots, Boston MedTech, Bristol-Myers Squibb, Capnia, Cephalon, Chiesi, Church & Dwight, Circassia, Clay Park, Cooper, Critical Therapeutics, Dura, ElectroCore, Ferraris, Fisons, Flemmington, Forest, Frazier, Genentech, GlaxoSmithKline (Glaxo-Wellcome, Glaxo, Burroughs Wellcome, SmithKline Beecham), Greer, Hoffmann-LaRoche (Syntex), Immulogic, Immunetech, Immunex, Innervation, Inspire, ISTA, Janssen, Johnson & Johnson (Mead Johnson), Knoll, KOS, Kalypsys, Eli Lilly, Liposome Technology, MAP Pharmaceuticals, Mast, McNeil Consumer Products, Meda (MedPointe, Wallace), Medeva, Medicinova, MedImmune, Merck, Merck Sharp and Dohme, Miles, Millennium (Leukosite), Muro, Mylan (Dey), Nastech, Naryx, National Jewish Health, Nestle, Neurogen, Novartis (Sandoz, Ciba Geigy), Nycomed (Altana), ONO Pharma, OptiNose, Pennwalt, Pfizer (Parke-Davis, Warner Lambert), Pharmaxis, Proctor & Gamble, Revance, Rigel, Roberts, Sanofi-Aventis, (Aventis, Fisons, Hoechst Roussel, Marion, Merrell Dow, Rhone-Poulenc Rorer, Sanofi, Sterling, Winthrop), Sandoz, Schering-Plough (Schering, Key), Schering-Plough Integrated Therapeutics Group, Searle, Shinogi, SkyePharma, Sofinnova, SRxA, Stallergenes, State of California, Sunovion (Sepracor), Synergen, TAP, Teva (IVAX), 3M Pharmaceuticals, UCB, VentiRx, VOCEL, Watson, Whitehall-Robins, Winston, Wockhardt, Wyeth (Wyeth-Ayerst), and Zambon.

PUBLICATIONS: ELI O. MELTZER, MD

1. Meltzer EO, Ellis EF, Pearlman DS, Fulginiti VA, Hathaway WE. Five years survival in a child with thymic dysplasia. (abstr) *J Allergy* 1969;43:188.
2. Maselli R, Meltzer EO, Ellis EF. Pharmacologic effects of epinephrine in asthmatic children. (abstr) *J Allergy* 1970;49:117.
3. Miller JR, Meltzer EO. The use of egg-containing vaccines in egg-sensitive patients. (abstr) *J Allergy* 1972;49:109.
4. Meltzer EO. Asthma in childhood. In: Conn HF(ed): *Current therapy*. Philadelphia, 1974, WB Saunders, p 561.
5. Mendelson LM, Meltzer EO, Hamburger RN. Anaphylaxis-like reactions to corticosteroid therapy. *J Allergy* 1974;54:125.
6. Orgel HA, Kemp JP, Meltzer EO, Hamburger RN. Atopy and IgE in a pediatric allergy practice. *Ann Allergy* 1977;39:161.
7. Meltzer EO. Asthma and children. In: Dewey J. (ed): *Of life and breath*. San Diego, 1977, Beta Books, p 63.
8. Meltzer EO, Kemp JP, Orgel HA, Cooper WC. Flunisolide aerosol in the treatment of steroid independent bronchial asthma in children. (abstr) *J Allergy Clin Immunol* 1979;63:162.
9. Waldman JD, Meltzer EO, Miller KE, Park SM, Lamberti JJ. Vascular compression of the upper airway in children. *West J Med* 1980;132:209.
10. Meltzer EO, Kemp JP, Orgel HA, Izu AE. Flunisolide aerosol for treatment of severe chronic asthma in steroid independent children. *Pediatrics* 1982;69:340.
11. Meltzer EO, Jalowayski AA. Rhinitis. *West J Med* 1982;137:121.
12. Jalowayski AA, Meltzer EO, Orgel HA, Kemp JP. Nasal biopsy evaluation of the effect of topical corticosteroids on nasal mucosal cytology. (abstr) *J Allergy Clin Immunol* 1983;71:90.
13. Meltzer EO, Orgel HA, Kemp JP, Chubb JM, Ward JF. Effect of dosing schedule on efficacy and safety of beclomethasone dipropionate aerosol (BDP) in chronic asthma. (abstr) *J Allergy Clin Immunol* 1983;71:148.
14. Miller JR, Orgel HA, Meltzer EO. The safety of egg-containing vaccines for egg-allergic patients. *J Allergy Clin Immunol* 1983;71:568.
15. Arbesman C, Bernstein IL, Bierman CW, Bocles JS, Katz R, Lieberman PL, Mattucci K, Meltzer EO, Middleton E Jr., Noyes J, Pearlman DS, Pence HL, Slavin RG, Spector SL. Multicenter, double-blind, placebo-controlled trial of flucortin butyl in perennial rhinitis. *J Allergy Clin Immunol* 1983;71:597.
16. Orgel HA, Meltzer EO, Kemp JP. Flunisolide aerosol in the treatment of steroid dependent asthma in children. *Ann Allergy* 1983;51:21.
17. Kemp JP, Orgel HA, Meltzer EO, Welch MJ. Terbutaline sulfate and isoproterenol sulfate (metered-dose aerosols) in the treatment of asthma. *Ann Allergy* 1983;51:436.
18. Meltzer EO, Zeiger RS, Schatz M, Jalowayski AA. Chronic rhinitis in infants and children: etiologic, diagnostic and therapeutic considerations. *Pediatr Clin North Am* 1983;30:847.
19. Kemp JP, Chervinsky P, Orgel HA, Meltzer EO, Noyes JH, Mingo TS. Concomitant bitolterol mesylate aerosol and theophylline for asthma therapy, with 24 hour electrocardiographic monitoring. *J Allergy Clin Immunol* 1984;73:32.
20. Orgel HA, Kemp JP, Welch MJ, Meltzer EO. Rotahaler^R - a new mode of delivery of albuterol powder for inhalation treatment of asthma. (abstr) *J Allergy Clin Immunol* 1984;73:110.

PUBLICATIONS: ELI O. MELTZER, MD

21. Kemp JP, Pinnaas JL, Tinkelman DG, Meltzer EO, Campbell SC, Orgel HA, Welch MJ, Mingo TS. Comparison of the cardiopulmonary responses of bitolterol mesylate solution (BMS) in 2 different nebulizer system. (abstr) *J Allergy Clin Immunol* 1984;73:110.
22. Pinnaas JL, Chen TM, Kemp JP, Tinkelman DG, Meltzer EO, Campbell SC. Dose-response studies of bitolterol mesylate (BTM) and isoproterenol HC1 (I) solutions in patients with asthma. (abstr) *J Allergy Clin Immunol* 1984;73:132.
23. Romero LT, Kemp JP, Orgel HA, Meltzer EO, Welch MJ. Evaluation of procaterol liquid and tablets in the treatment of asthma in children. (abstr) *J Allergy Clin Immunol* 1984;73:132.
24. Welch MJ, Meltzer EO, Orgel HA, Kemp JP. Assessment of the correlation of rhinometry with the symptoms and signs of allergic rhinitis in children. (abstr) *J Allergy Clin Immunol* 1984;73:143.
25. Meltzer EO, Orgel HA, Kemp JP, Welch MJ. Rhinometric, clinical and cytologic evaluation of allergic rhinitis treated with beclomethasone dipropionate (BDP) as pressurized aerosol or aqueous nasal spray. (abstr) *J Allergy Clin Immunol* 1984;73:145.
26. Renard RL, Kemp JP, Meltzer EO, Welch MJ, Wessel M, Orgel HA. Duration of action of albuterol tablets in bronchial asthma - a ten hour study. (abstr) *Ann Allergy* 1984;52:228.
27. Meltzer EO: Rhinometry. *West J Med* 1984;141:510.
28. Orgel HA, Kemp JP, Welch MJ, Meltzer EO. Single-dose comparison of subcutaneous (SC), intramuscular (IM) and intravenous (IV) injectable albuterol in acute asthma. (abstr) *J Allergy Clin Immunol* 1985;75:162.
29. Welch MJ, Kemp JP, Meltzer EO, Orgel HA. Comparison of terbutaline (T) and isoetharine (I) when delivered by a closed intermittent flow nebulizer system. (abstr) *J Allergy Clin Immunol* 1985;75:162.
30. Kemp JP, Orgel HA, Meltzer EO, Welch MJ. Comparison of subcutaneous albuterol (Alb), terbutaline (Ter) and epinephrine (Epi) in acute asthma. (abstr) *J Allergy Clin Immunol* 1985;75:162.
31. Mingo TS, Kemp JP, Meltzer EO, Welch MJ, Orgel HA. Bitolterol mesylate (BMS) and isoproterenol (ISO) solutions by open, continuous flow nebulization in asthma. (abstr) *J Allergy Clin Immunol* 1985;75:163.
32. Hoernke JA, Kemp JP, Meltzer EO, Welch MJ, Orgel HA. Subcutaneous albuterol (ALB) and terbutaline (TER): A single-dose, crossover comparison in acute asthma. (abstr) *J Allergy Clin Immunol* 1985;75:179.
33. Meltzer EO, Kemp JP, Welch MJ, Orgel HA. An improved delivery system for nasal beclomethasone dipropionate (BDP). (abstr) *Ann Allergy* 1985;54:354.
34. Orgel HA, Meltzer EO, Welch MJ, Kemp JP. Inhaled albuterol powder for the treatment of asthma - A dose-response study. *J Allergy Clin Immunol* 1985;75:468.
35. Hartley TF, Lieberman PL, Meltzer EO, Noyes JN, Pearlman DS, Tinkelman DG. Efficacy and tolerance of fluocortin butyl administered twice daily in adult patients with perennial rhinitis. *J Allergy Clin Immunol* 1985;75:501.
36. Meltzer EO, Kemp JP, Welch MJ, Orgel HA. Effect of dosing schedule on efficacy of beclomethasone dipropionate aerosol in chronic asthma. *Am Rev Respir Dis* 1985;131:732.
37. Meltzer EO. The current outlook on chronic allergic rhinitis. *J Respir Dis* 1985;6:100.
38. Welch MJ, Meltzer EO, Orgel HA, Kemp JP. Assessment of the correlation of rhinometry with the symptoms and signs of allergic rhinitis in children. *Ann Allergy* 1985;55:577.

PUBLICATIONS: ELI O. MELTZER, MD

39. Kemp JP, Welch MJ, Meltzer EO, Orgel HA. Therapeutic efficacy and equivalence of tablet and syrup formulations of procaterol hydrochloride in childhood asthma. *Ann Allergy* 1985;55:588.
40. Welch MJ, Kemp JP, Orgel HA, Meltzer EO. Steady-state evaluation of twice-a-day dosing of a new sustained-release theophylline preparation for young children. *J Asthma* 1985;22:249.
41. Meltzer EO, Busse WW, Bush RK, Kemp JP, Orgel HA, Welch MJ. Beclomethasone dipropionate nasal aerosol spray in allergic rhinitis: a comparison of three delivery systems. *Ann Allergy* 1985;55:802.
42. Meltzer EO. Managing recalcitrant allergic rhinitis. The readers' forum. *J Respir Dis* 1986;7:11.
43. Rosen JP, Chervinsky P, Renard RL, Kemp JP, Mendelson LM, Selcow JE, Noyes JH, Meltzer EO, Welch MJ, Orgel HA, Trochelmann L, Wessell M. Duration of action of oral albuterol in an asthmatic population. *Ann Allergy* 1986;56:28.
44. Meltzer EO, Orgel HA, Welch MJ, Kemp JP. Rhinomanometric and clinical comparison of intranasal flucortin butyl powder (FCB) and beclomethasone dipropionate aerosol (BDP) for the treatment of perennial rhinitis. (abstr) *J Allergy Clin Immunol* 1986;77:140.
45. Furukawa CT, Kemp JP, Shapiro GG, Meltzer EO, Pierson WE, Welch MJ, Walker SB, Orgel HA, Bierman CW. Cardiopulmonary effects of albuterol aerosol versus albuterol rotacaps versus placebo in asthmatic children. (abstr) *J Allergy Clin Immunol* 1986;77:144.
46. Welch MJ, Orgel HA, Meltzer EO, Kemp JP, Tinkelman DG. Comparison of a new sustained-release theophylline preparation, Theobeads, with Theo-Dur tablets in children with asthma. (abstr) *J Allergy Clin Immunol* 1986;77:147.
47. Orgel HA, Bronsky EA, Meltzer EO, Kemp JP, Welch MJ. Evaluation of ketotifen in children with chronic extrinsic asthma. (abstr) *J Allergy Clin Immunol* 1986;77:148.
48. Dennis S, Haddad Z, Kniker W, Mansmann H, Meltzer EO, Mendelson L, Prenner B, Rosenthal R, Segall N, Tinkelman D, Wold R, Ziering R. HEPP (IgE pentapeptide) in allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1986;77:213.
49. Kemp JP, Meltzer EO, Orgel HA, Welch MJ, Lockey RF, Middleton E, Spector SL, Perhach JL, Newton JJ. A dose-response study of the bronchodilator action of azelastine (Azela) in asthma. (abstr) *J Allergy Clin Immunol* 1986;77:249.
50. Kemp JP, Pinnas JL, Tinkelman DG, Meltzer EO, Campbell SD, Orgel HA, Welch MJ, Mingo TS. Comparison of bronchodilator responses with bitolterol mesylate solution with the use of two different nebulizer systems in asthma. *J Allergy Clin Immunol* 1986;77:509.
51. Orgel HA, Meltzer EO, Kemp JP, Welch MJ. Clinical, rhinomanometric, and cytologic evaluation of seasonal allergic rhinitis treated with beclomethasone dipropionate as aqueous nasal spray or pressurized aerosol. *J Allergy Clin Immunol* 1986;77:858.
52. Haddad ZH, Mansman HC, Mendelson LM, Rosenthal RR, Tinkelman DG, Ziering RW, Wold RT, Segall N, Prenner BM, Meltzer EO, Ratner PH, Dennis SRK. Efficacy of IgE pentapeptide (HEPP) in allergic rhinitis. (abstr) *Ann Allergy* 1986;56:519.
53. Meltzer EO. Children and asthma. In: Dewey J (ed): *Of life and breath*. 2nd ed. New York, 1986, Warner Books, p. 76.
54. van As A, Chick TW, Bodman SF, Storms WW, Nathan RA, Selner JC, Koepke JW, Townley RG, Bewtra AK, Nair N, Kemp JP, Meltzer EO, Welch MJ, Prenner BM. A group comparative study of the safety and efficacy of nedocromil sodium (Tilade^R) in reversible airways disease: A preliminary report. *Eur J Respir Dis* 1986;69(suppl 147):143.

PUBLICATIONS: ELI O. MELTZER, MD

55. Shapiro G, Furukawa C, Pierson W, Kemp J, Meltzer E, Orgel A, Welch M. Two-center, double-blind, crossover trial of procaterol (P), albuterol (A) and placebo (Pl) in the prevention of exercise-induced asthma. Scientific Sessions of the Section on Allergy and Immunology of the American Academy of Pediatrics, p. 21, November, 1986.
56. Kemp JP, Meltzer EO. Nonsedating antihistamines in the treatment of allergic disease. *West J Med* 1986;146:81.
57. Jalowayski AA, Kemp JP, Meltzer EO, Orgel HA, Welch MJ, Ostrom NK. Flow-volume curves in young children aided by a hugger pressurized system (HPS). (abstr) *J Allergy Clin Immunol* 1987;79:147.
58. Shapiro G, Furukawa C, Pierson W, Bierman W, Kemp J, Meltzer E, Orgel A, Welch M. Two-center, double-blind, crossover trial of procaterol (P), albuterol (A) and placebo (Pl) in the prevention of exercise-induced asthma (EIA). (abstr) *J Allergy Clin Immunol* 1987;79:148.
59. Orgel HA, Kemp JP, Meltzer EO, Welch MJ, Bernstein IL, Podleski WK, Prenner BM, Schoenwetter WF, Stroh JE. A tolerance study of terfenadine- pseudoephedrine combination (TERF-PE) in comparison to pseudoephedrine (PE) in patients with allergic rhinitis (AR). (abstr) *J Allergy Clin Immunol* 1987;79:189.
60. Kemp JP, Meltzer EO, Orgel HA, Welch MJ, Bahna SL, Chervinsky P, Rachelefsky GS, Seltzer JM, Vande Stouwe RA, Valero RN. A comparison of loratadine, clemastine and placebo in patients with seasonal rhinitis. (abstr) *J Allergy Clin Immunol* 1987;79:190.
61. Meltzer EO, Storms WW, Pierson WE, Cummins LH, Perhach JL, Hemsworth GR. Efficacy of azelastine in perennial allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1987;79:205.
62. Novey HS, Imam AA, Orgel HA, Meltzer EO, Kemp JP, Welch MJ, Klein GL, Ziering RW, Miller, MF. Multi-allergen dipstick screening test for specific serum IgE (sIgE). (abstr) *J Allergy Clin Immunol* 1987;79:243.
63. Hubble MA, Jalowayski AA, Meltzer EO, Kemp JP. Saccharin/bismuth subgallate (S/BG) test for nasal mucociliary clearance (NMC) - an improved method. (abstr) *J Allergy Clin Immunol* 1987;79:254.
64. Meltzer EO, Orgel HA, Welch MJ, Kemp JP. Nonpharmacologic approaches to the management of asthma. In: Tinkelman DG, Falliers CJ, Naspitz CK (eds): *Childhood asthma: Pathophysiology and treatment*. New York, 1987, Marcel Dekker, Inc., pp. 281-326.
65. Meltzer EO. Allergic rhinitis: Current choices in therapy. *Proceedings of a symposium. J Resp Dis (Monograph Series)* 1987;7:12.
66. Meltzer EO, Orgel HA, Kemp JP, Welch MJ, Perhach JL, Hemsworth GR. Azelastine for perennial allergic rhinitis (PAR): Clinical and rhinomanometric evaluation. (abstr) *Ann Allergy* 1987;58:281.
67. Kemp JP, Meltzer EO, Geller BD, Mellon M, Siegel SC, Moore MAA, Long RA, Frosolono MF. Evaluation of acrivastine (A) for the treatment of seasonal allergic rhinitis. (abstr) *Ann Allergy* 1987;58:309.
68. Meltzer EO, Schatz M. Pharmacotherapy of rhinitis: 1987 and beyond. *Immunol Allergy Clin North Am* 1987;7:57.
69. Meltzer EO. Nasal and ocular uses for cromolyn sodium. *Proceedings of a symposium on asthma and cromolyn sodium. J Resp Dis May* 1987;(Suppl):S34.
70. Kemp JP, Meltzer EO, Orgel HA, Welch MJ, Bucholtz GA, Middleton E, Spector SL, Newton JJ, Perhach JL. A dose-response study of the bronchodilator action of azelastine in asthma. *J Allergy Clin Immunol* 1987;79:893.

PUBLICATIONS: ELI O. MELTZER, MD

71. Kemp JP, Meltzer EO. Gaining control of the allergic child's environment. *Am J Asthma Allergy Pediatricians* 1987;1:22.
72. Meltzer EO, Orgel HA, Berman BA, Pearlman DS, Slavin RG, Lauber-Huber C, Naadimuthu A. A comparison of the efficacy of flucortin butyl powder and beclomethasone dipropionate aerosol spray for the treatment of perennial rhinitis. *Am J Rhinology* 1987;1:141.
73. Meltzer EO, Ellis EF, Rosen JP, Shapiro GG, Siegel SC, Tinkelman DG, Valero RN, Roman IJ. A comparison of loratadine, chlorpheniramine and placebo suspensions in children with seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1988;81:177.
74. Simon RA, Meltzer EO, Settignano RA. Systemic anaphylaxis following ingestion of acetaminophen (Tylenol). (abstr) *J Allergy Clin Immunol* 1988;81:223.
75. Orgel HA, Meltzer EO, Kemp JP, Ostrom NK, Welch MJ. Comparison of intranasal cromolyn sodium and oral terfenadine for allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1988;81:256.
76. Shapiro GG, Furukawa CT, Bierman CW, Pierson WE, Altman LC, Kemp JP, Meltzer EO, Orgel HA, Welch MJ. Assessment of efficacy and duration of action of procaterol (P), albuterol (A) and placebo (PI) for prevention of EIA using repeated treadmill exercise. (abstr) *J Allergy Clin Immunol* 1988;81:278.
77. Welch MJ, Kemp JP, Rooklin A, Gawchik SM, Meltzer EO, Orgel HA, Tinkelman DG. Diurnal variation of serum theophylline levels in children on BID Theo-Dur (abstr) *J Allergy Clin Immunol* 1988;81:279.
78. Welch MJ, Meltzer EO, Orgel HA, Kemp JP. Treatment of seasonal allergic rhinitis (SAR) with triamcinolone acetonide (TA) nasal aerosol. (abstr) *Ann Allergy* 1988;60:166.
79. Meltzer EO, Schatz M, Zeiger RS. Allergic and nonallergic rhinitis. In: Middleton E Jr, Reed CE, Ellis EF, Adkinson NF, Yunginger JW (eds): *Allergy: Principles and practice*, 3rd ed. St. Louis, 1988, The CV Mosby Company, p. 1253.
80. Meltzer EO, Jalowayski AA. Nasal cytology in clinical practice. *Am J Rhinology* 1988;2:47.
81. Meltzer EO, Storms WW, Pierson WE, Cummins LH, Orgel HA, Perhach JL, Hemsworth GR. Efficacy of azelastine in perennial allergic rhinitis: Clinical and rhinomanometric evaluation. *J Allergy Clin Immunol* 1988;82:447.
82. American Academy of Allergy and Immunology, Committee on Drugs: The use of antihistamines in patients with asthma. (position statement) *J Allergy Clin Immunol* 1988;82:481.
83. Meltzer EO. The use of antihistamines for the treatment of airway disease. *Cutis* 1988;42:22.
84. Meltzer EO, Kemp JP, Orgel HA, Ostrom NK, Welch MJ. Intranasal fluticasone propionate for treatment of seasonal allergic rhinitis. (abstr) *N Engl Reg Allergy Proc* 1988;9:387.
85. Meltzer EO. Evaluating rhinitis: Clinical, rhinomanometric and cytologic assessments. *J Allergy Clin Immunol* 1988;82:900.
86. Meltzer EO. Terfenadine: A second generation antihistamine. *Immunol Allergy Pract* 1988;10:454.
87. Welch MJ, Orgel HA, Meltzer EO, Kemp JP, Gawchik S, Rooklin AR, Tinkelman DG. Comparison of a new sustained-release theophylline preparation, Theobeads with Theo-Dur tablets in children with asthma. *J of Asthma* 1988;25:269.
88. Meltzer EO. Allergic rhinitis due to inhalant allergens. In: Rakel RE (ed): *Conn's Current Therapy*. Philadelphia, 1989, WB Saunders, p. 678.

PUBLICATIONS: ELI O. MELTZER, MD

89. Orgel HA, Kemp JP, Meltzer EO, Ostrom NK, Welch MJ. Severe vocal cord dysfunction in a child with asthma. (abstr) *J Allergy Clin Immunol* 1989;83:176.
90. Welch MJ, Meltzer EO, Orgel HA, Ostrom NK, Kemp JP. Evaluation of self-administered blood theophylline testing in patients on regular theophylline therapy. (abstr) *J Allergy Clin Immunol* 1989;83:180.
91. Kemp JP, Meltzer EO, Orgel HA, Welch MJ, Ostrom NK, Gowarty HA, Cocchetto DM. A comparative study of salmeterol, albuterol and placebo via MDI in asthmatic adults. (abstr) *J Allergy Clin Immunol* 1989;83:186.
92. Ostrom NK, Kemp JP, Meltzer EO, Orgel HA, Welch MJ. Use of anterior rhinometry (AR) in assessing clinical response to a new inhaled nasal steroid in children. (abstr) *J Allergy Clin Immunol* 1989;83:278.
93. Meltzer EO, Bronsky EA, Furukawa CT, Grossman J, LaForce CF, Lemanske RF Jr, Paull BR, Pearlman DS, Ratner PH, Spector SL, Tinkelman DG, van As A. A dose ranging study of fluticasone propionate aqueous intranasal spray (FP) in patients with seasonal allergic rhinitis (SAR). (abstr) *J Allergy Clin Immunol* 1989;83:279.
94. van As A, Meltzer EO, Bronsky EA, Grossman J, Ratner PH, Reed CE, Rogenes PR, Shotwell, MJ. A dose-tolerance study of intranasal fluticasone propionate aqueous nasal spray in the treatment of seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1989;83:301.
95. Meltzer EO, Kemp JP, Orgel HA, Ostrom NK, Welch MJ. Evaluation of two formulations of flunisolide nasal spray in patients with perennial allergic rhinitis. (abstr) *Ann Allergy* 1989;62:239.
96. Welch MJ, Meltzer EO, Ostrom NK, Kemp JP, Orgel HA, Betlach CJ. Pharmacokinetic evaluation of Theo-Dur 450 mg (Theo 450) tablets given BID vs Theo-Dur 300 mg (Theo 300) TID. (abstr) *Ann Allergy* 1989;62:267.
97. Jacobs RL, Meltzer EO, Selner JC, Slavin RG. Rhinitis: Not just hay fever. *Patient Care* 1989;23:168-184.
98. American Academy of Allergy and Immunology, Committee on Drugs: The use of inhaled medications in school by students with asthma. (position statement) *J Allergy Clin Immunol* 1989;84:400.
99. Kemp JP, Meltzer EO. Use of beta₂-agonists as oral drugs and aerosols. *J Respir Dis* 1989;suppl (June):35-41.
100. Kemp JP, Meltzer EO: Gaining control of the allergic child's environment. *Pediatric Annals* 1989;18:801-809.
101. Druce HM, Kaiser HB, Weisber SC, Morris RJ, Spector SL, Fireman P, Meltzer EO, Boggs P, Wood CC. Randomized, double-blind comparison of intranasal atrovent versus placebo in nonallergic perennial rhinitis. (abstr) *Ann Allergy* 1990;64:74.
102. Dockhorn R, Meltzer EO, Paull B, van As A, Weakley S, Woehler T, Rogenes P. Fluticasone propionate aqueous nasal spray given once a day safely controls the symptoms of seasonal allergic rhinitis. (abstr) *Ann Allergy* 1990;64:77.
103. Georgitis JW, Meltzer EO, Druce H, Wood C. Efficacy of ipratropium bromide (Atrovent) nasal spray in perennial allergic rhinitis. (abstr) *Ann Allergy* 1990;64:78.
104. Meltzer EO, Banov C, Halverson P, Weiler J, Woehler T, Hemsworth G. Comparison of azelastine, clemastine fumarate and placebo for treatment of perennial allergic rhinitis. (abstr) *Ann Allergy* 1990;64:78.

PUBLICATIONS: ELI O. MELTZER, MD

105. Kemp JP, Meltzer EO, Orgel HA, Welch MJ, Ostrom NK. A comparison of the bronchodilator and adverse effects of a liposome-encapsulated metaproterenol and metaproterenol sulfate nebulizer solutions in patients with asthma. (abstr) *Ann Allergy* 1990;64:78.
106. Gonzales S, Jalowayski A, Meltzer EO. Correlation of histamine levels with nasal cytology using rhinoprobe mucosal scrapings. (abstr) *Ann Allergy* 1990;64:94.
107. Orgel HA, Meltzer EO, Doyle VR, Field E. Topical intranasal corticosteroid (fluticasone propionate) decreases cells of allergy and inflammation in nasal mucosa of patients with seasonal allergic rhinitis. (abstr) *J Allergy and Clin Immunol* 1990;85:162.
108. Welch MJ, Orgel HA, Meltzer EO, Bierman CW, Bronsky E, Connell JT, Lieberman PL, Nathan R, Pearlman DS, Pence HL, Slavin RG, Naadimuthu A. Intranasal fluocortin butyl in patients with perennial rhinitis: A 12-month study including nasal biopsy. (abstr) *J Allergy and Clin Immunol* 1990;85:163.
109. Druce HM, Spector SL, Fireman P, Meltzer EO, Kaiser H, Boggs P, Wood CC. Randomized, double-blind, parallel group comparison of intranasal atrovent nasal spray versus placebo in nonallergic perennial rhinitis. (abstr) *J Allergy Clin Immunol* 1990;85:165.
110. Meltzer EO, Ellis EF, Eigen H, Hemstreet MP. Comparison of 3 combinations of albuterol, theophylline, and beclomethasone in children with asthma. (abstr) *J Allergy Clin Immunol* 1990;85:199.
111. Grossman J, Halverson P, Meltzer E, Schoenwetter W, VanBavel J, Woehler T, Ball R, Schulan D, Osur S, Hemsworth G, Freitag J. Comparison of azelastine and clemastine to placebo in the management of perennial allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1990;85:243.
112. Kemp JP, Meltzer EO, Orgel HA, Ostrom NK, Welch MJ. Evaluation of tolerance during 8 weeks of astemizole or terfenadine therapy in patients with perennial allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1990;85:243.
113. Meltzer EO. To use or not to use antihistamines in patients with asthma. *Ann Allergy* 1990;64:183-186.
114. Imam AA, Novey HS, Orgel HA, Klein GL, Meltzer EO, Ziering RW. A simplified screening test for the diagnosis of allergy. *West J Med* 1990;152:313-316.
115. Meltzer EO. Air pollution and the upper respiratory tract. In: Naspitz CK, Tinkelman DG (eds.): *Childhood rhinitis and sinusitis*. New York, 1990, Marcel Dekker, Inc., pp. 63-86.
116. Meltzer EO. Antihistamine- and decongestant-induced performance decrements. *J Occup Med* 1990;32:327-334.
117. Meltzer EO (ed.). *Synopsis Book: 100 of the best articles relevant to pediatric allergy and immunology*. *Pediatrics* 1990;85:911-960.
118. Meltzer EO, Orgel HA, Bush RK, Haltom JR, Metzger WJ, Moss BA, Mitchell DQ, Ballas ZK, Seltzer JM, Shapiro GG, Van Bavel JH. Evaluation of symptom relief, nasal airflow, nasal cytology, and acceptability of two formulations of flunisolide nasal spray in patients with perennial allergic rhinitis. *Ann Allergy* 1990;64:536-540.
119. Meltzer EO. Antihistamines in asthma. Letters to the editor. *Ann Allergy* 1990;64:548.
120. Bronsky EA, Grossman H, Meltzer EO, Ratner PH, van As A, Rogenes PR. Dose-ranging studies of fluticasone propionate aqueous nasal spray in adults with seasonal allergic rhinitis. (abstr) *Clin Exper Allergy* 1990;20:98.
121. Meltzer E, Weiler J, Freitag J. Evaluation of the safety/efficacy of azelastine nasal spray in seasonal allergic rhinitis. (abstr) *Clin Exper Allergy* 1990;20:100.

PUBLICATIONS: ELI O. MELTZER, MD

122. Meltzer EO, Orgel HA, Bronsky EA, Furukawa CT, Grossman J, LaForce CF, Lemanske RF jr, Paull Be, Pearlman DS, Ratner PH, Spector SL, Tinkelman DG, van As A, Rogenes PR. A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology. *J Allergy Clin Immunol* 1990;86:221-230.
123. Cocchetto DM, Meltzer EO. Case report of a patient with acute appendicitis and hepatitis-A during a clinical trial: A setting for review of adverse event reporting requirements. *J Clin Res Pharmacoevidem* 1990;4:99-105.
124. Kemp JP, Meltzer EO, Orgel HA, Welch MJ. Effects of albuterol and procaterol on exercise-induced asthma. *Ann Allergy* 1990;65:273-276.
125. Kaliner MA, Meltzer EO, (eds.). Histamine and disease: A forum on current and future management. *J Allergy Clin Immunol* 1990;86:589-686.
126. Meltzer EO. Performance effects of antihistamines. *J Allergy Clin Immunol* 1990;86:613-619.
127. Meltzer EO. Antihistamine-decongestants: Future therapeutic options. *J Resp Dis* 1990;11:32-39.
128. Meltzer EO. Anticholinergic treatment of nasal disorders. *Immunol Allergy Clin North Am* 1991;11:31-44.
129. Welch MJ, Kemp JP, Meltzer EO, Orgel HA, Ostrom NK. Asthma in the schools. *Immunol Allergy Clin North Am* 1991;11:173-181.
130. Welch MJ, Meltzer EO, Kemp JP, Orgel HA, Ostrom NK, Jalowayski AA. Comparison of two different techniques for obtaining specimens for nasal cytology: Nose-blowing vs. nasal mucosa scraping. (abstr) *J Allergy Clin Immunol* 1991;87:144.
131. Jalowayski AA, Meltzer EO, Orgel HA, Welch MJ, Ostrom NK, Kemp JP. Nasal histamine levels in young children with allergic and non-allergic rhinitis and chronic otitis. (abstr) *J Allergy Clin Immunol* 1991;87:146.
132. Meltzer EO, Bronsky EA, Findlay SR, Georgitis JW, Grossman J, Ratner PH, Wood CC. Dose-response study of ipratropium bromide nasal spray in perennial allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1991;87:150.
133. Lumry M, Ahrens R, Dockhorn R, Galant S, Martin B, Meltzer E, Munk Z, Ransom J, Southern D, Stricker W, Field E, Kral K, Simonetto T, Rogenes P. Fluticasone propionate is safe and effective for children with seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1991;87:152.
134. LaForce C, Dockhorn R, Findlay S, Meltzer E, Nathan R, Stricker W, Weakley S, Beam J, Rogenes P. Fluticasone propionate treatment for seasonal allergic rhinitis is safe and effective in adults and adolescents. (abstr) *J Allergy Clin Immunol* 1991;87:153.
135. van As A, Bronsky E, Chervinsky P, Dockhorn R, Furukawa C, Grossman J, Lockey R, Lumry W, Meltzer E, Nathan R, Seltzer J, van Bavel J, Rogenes P. Fluticasone propionate once daily is as effective as beclomethasone dipropionate twice daily for perennial allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1991;87:154.
136. Weiler JM, Meltzer EO, Dockhorn R, Widlitz MD, D'Eletto TA, Freitag JJ. A safety and efficacy evaluation of azelastine (AZ) nasal spray (NS) in seasonal allergic rhinitis (SAR). (abstr) *J Allergy Clin Immunol* 1991;87:219.
137. Galindo G, Jalowayski A, Meltzer E, Canseco C. Correlation between nasal cytogram and blown technique for the diagnosis of allergic rhinitis. *Ann Allergy* 1991;66:86.
138. Aaronson DW, Meltzer EO, Naclerio RM. The evolving use of nasal corticosteroid therapy. *Faculty Perspectives, Allen and Hanburys Educational Service*. May 1991.

PUBLICATIONS: ELI O. MELTZER, MD

139. Meltzer EO (ed.). Synopsis Book: 100 of the best articles relevant to pediatric allergy and immunology. *Pediatrics* 1991;87:985-1040.
140. Meltzer EO, Jalowayski AA. Nasal cytology in clinical practice. In: Settupane GA (ed.): *Rhinitis*. Second Edition. Oceanside Publications, Inc., Providence, 1991, 291-298.
141. Meltzer EO. Antihistamine use in allergy patients with bronchial asthma. *Immunol Allergy Prac* 1991;13:63.
142. Meltzer EO. Comparative safety of H₁ antihistamines. *Ann Allergy* 1991;67:625-33.
143. Orgel HA, Meltzer EO, Kemp JP, Ostrom NK, Welch MJ. Comparison of intranasal cromolyn sodium, 4%, and oral terfenadine for allergic rhinitis: Symptoms, nasal ciliary clearance and rhinomanometry. *Ann Allergy* 1991;66:237-244.
144. Meltzer EO. Consider antihistamines in allergic asthma. *J Resp Dis* 1991;12(suppl 4):7-12.
145. Meltzer SB, Meltzer EO. Harmful health effects of passive smoking. *West J Med* 1991;154:457-458.
146. Meltzer EO, Orgel HA, Kemp JP, Welch MJ, Ostrom NK, Park SM, Kearns DB. Vocal Cord Dysfunction in a Child with Asthma. *J of Asthma* 1991;28(2):141-145.
147. Orgel HA, Meltzer EO, Bierman CW, Bronsky E, Connell JT, Lieberman PL, Nathan R, Pearlman DS, Pence HL, Slavin RG, Naadimuthu A. Intranasal flucortin butyl in patients with perennial rhinitis: A 12-month efficacy and safety study including nasal biopsy. *J Allergy Clin Immunol* 1991;88:257-264.
148. van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C. Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis. *Ann Allergy* 1991;67:156-162.
149. Meltzer EO. Comparative safety of H₁ antihistamines. *Ann Allergy* 1991;67:625-33.
150. Carey AB, Meltzer EO. Desensitization in tetanus toxoid hypersensitivity. (abstr) *Ann Allergy* 1992;68:83.
151. Bronsky EA, Berkowitz R, Dockhorn RJ, Furukawa C, Grossman J, Meltzer E, Munk Z, Pearlman DS, Segal AT, Weiss S. Pediatric dose-ranging trial of astemizole suspension in seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1992;89:157.
152. Boyer G, Aaronson D, Meltzer E, LaForce C, Grossman J, Yancey S. Enhancement of a general quality of life scale: validation of a sleep scale. (abstr) *J Allergy Clin Immunol* 1992;89:186.
153. Feiss G, Welch M, Meltzer E, Alderfer V, Smith J, Tobey R. The predictive value of nasal eosinophilia for therapeutic response to intranasal corticosteroid treatment in perennial allergic rhinitis (PAR). (abstr) *J Allergy Clin Immunol* 1992;89:209.
154. Meltzer EO, Busse WW, Druce HM, Metzger WJ, Mitchell DO, Selner JC, Shapiro GG, Van Bavel JH. Assessment of flunisolide nasal spray vs. placebo as an adjunct to antibiotic treatment of sinusitis. (abstr) *J Allergy Clin Immunol* 1992;89:301.
155. Orgel HA, Meltzer EO, Welch MJ, Banov C, Georgitis J, Morris R, Pedinoff A, Storms W: Comparison of intranasal therapy with beclomethasone dipropionate (BDP) vs. cromolyn sodium (CS) vs. placebo (P) in children with seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1992;89:303.
156. Meltzer EO. The runny/stuffy-nose kid: could it be allergy? *Masters in Allergy* 1992;4:4-11.
157. Meltzer EO. Today's approach to controlling allergic rhinitis. *J Resp Dis* 1992;13(Suppl):S30-39.
158. Druce HM, Spector SL, Fireman P, Kaiser H, Meltzer EO, Boggs P, Wood CC, Paluch EP. Double-blind study of intranasal ipratropium bromide in nonallergic rhinitis. *Ann Allergy* 1992;69:53-60.

PUBLICATIONS: ELI O. MELTZER, MD

159. Meltzer EO, Orgel HA, Ellis EF, Eigen HN, Hemstreet MPB. Long-term comparison of three combinations of albuterol, theophylline and beclomethasone in children with chronic asthma. *J Allergy Clin Immunol* 1992;90:2-11.
160. Meltzer EO, Orgel HA, Bronsky EA, Findlay SR, Georgitis JW, Grossman J, Ratner PH, Wood CC. Ipratropium bromide aqueous nasal spray for patients with perennial allergic rhinitis: A study of its effect on their symptoms, quality of life, and nasal cytology. *J Allergy Clin Immunol* 1992;90:242-249.
161. Meltzer EO. The value of the Joint Council of Allergy and Immunology. *Ann Allergy* 1992;69:281-4.
162. Carey AB, Meltzer EO. Diagnosis and "desensitization" in tetanus vaccine hypersensitivity. *Ann Allergy* 1992;69:336-8.
163. Meltzer EO. Treating allergic rhinitis: overview and update. *Am J Asthma Allergy Pediatr* 1992;6:13-17.
164. Wood WE, Meltzer EO. CSF rhinorrhea: a dangerous mimic of allergic rhinitis. *J Respir Dis* 1992;13:1354-5.
165. Meltzer EO. Intranasal anticholinergic therapy of rhinorrhea. *J Allergy Clin Immunol* 1992;90:1055-64.
166. Welch MJ, Ostrom NK, Meltzer EO, Orgel HA. Nonpharmacologic approaches to the management of asthma. In: Tinkelman DG, Naspitz CK (eds): *Childhood asthma: pathophysiology and treatment*. New York, 1993, Marcel Dekker, Inc., pp. 457-495.
167. Meltzer EO, Orgel HA, Jalowayski AA. Cytology. In: Mygind N, Naclerio RM (eds.): *Allergic and non-allergic rhinitis: clinical aspects*. Copenhagen, 1993, Munksgaard, pp. 66-81.
168. Eisen GF, Bronsky EA, Meltzer EO, Nathan RA, Nelson HS, Seltzer JM, Connolly MM. Double-blind western multicenter trial of levocabastine-D in allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1993;91:194.
169. Bronsky E, Boggs P, Findlay S, Gawchik S, Georgitis J, Mansmann H, Meltzer E, Morris R, Munk Z, Paull B, Pleskow W, Ratner P, Sholler L, Wolfe J, Greenstein S. Effects of SCH 434-QD vs. its components vs. placebo in patients with seasonal allergic rhinitis. (Abstr) *J Allergy Clin Immunol* 1993;91:196.
170. Grant JA, Glovsky MM, Meltzer EO, Settupane G, Nicodemus CF. Safety and efficacy of cetirizine in the prophylactic management of patients with seasonal allergic rhinitis (SAR) and asthma. (Abstr) *J Allergy Clin Immunol* 1993;91:197.
171. Meltzer EO, Jalowayski AA, Field EA, Rogenes PR, Kral KM. Intranasal fluticasone propionate reduces histamine and tryptase in the mucosa of allergic rhinitis patients. (Abstr) *J Allergy Clin Immunol* 1993;91:298.
172. Jalowayski AA, Meltzer EO. The correlation between radioimmunoassay and enzymeimmunoassay measured histamine levels from nasal epithelial scrapings. (Abstr) *J Allergy Clin Immunol* 1993;91:366.
173. Kemp JP, Meltzer EO, Welch MJ, Ostrom NK, Orgel HA, Robinson RE. Effectiveness of MDL 26,024GO in suppressing skin reactivity to antigen challenge. (Abstr) *J Allergy Clin Immunol* 1993;91:379.
174. Upper Airway Allergy Committee, American Academy of Allergy and Immunology, Georgitis JW, Druce HM, Goldstein S, Meltzer EO, Okada M, Selner JC, Schumacher MJ. Rhinopharyngolaryngoscopy. *J Allergy Clin Immunol* 1993;91:961-2.
175. Dockhorn RJ, Paull BR, Meltzer EO, van As A, Weakley S, Woehler TR, Kral KM, Rogenes PR. Once-versus twice-daily fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis. *Am J Rhinology* 1993;7:77-83.

PUBLICATIONS: ELI O. MELTZER, MD

176. Welch MJ, Kemp JP, Ostrom NK, Orgel HA, Meltzer EO, Romero LT, Klinger N, McCarville S, Harrison LI. A comparative study of a new once-a-day theophylline preparation with Theo-Dur given twice daily. *J of Asthma* 1993;30(3):211-18.
177. van As A, Bronsky EA, Dockhorn RJ, Grossman J, Lumry W, Meltzer EO, Seltzer JM, Rogenes PR. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone dipropionate. *J Allergy Clin Immunol* 1993;91:1146-54.
178. Meltzer SB, Hovell MF, Meltzer EO, Atkins CJ, dePeyster A. Reduction of secondary smoke exposure in asthmatic children: parent counseling. *J Asthma* 1993;30:391-400.
179. Meltzer EO, Meltzer SB. Passive smoking: an underrated problem in children? *J Respir Dis* 1993;14:950-4.
180. Welch MJ, Meltzer EO. Allergic rhinitis: a disease for all seasons. *Am Acad Phys Assist* 1993;6:553-60.
181. Meltzer E, Field B, Scott S. Is successful control of perennial rhinitis achievable? (abstr) *Allergy* 1993;48(suppl):219.
182. Baldwin JL, Meltzer EO. Should MDIs be used until they are completely empty? *J Resp Dis* 1993;14:1222-3.
183. Meltzer EO, Orgel HA, Backhaus JW, Busse WW, Druce HM, Metzger WJ, Mitchell DQ, Selner JC, Shapiro GG, Van Bavel JH, Basch C: Intranasal flunisolide spray as an adjunct to oral antibiotic therapy for sinusitis. *J Allergy Clin Immunol* 1993;92:812-23.
184. Bronsky E, Dockhorn R, Meltzer E, Shapiro G, Boltansky H, LaForce C, Ransom J, Weiler J, Blumenthal M, Weakley S, Field E, Wisniewski M, Milwee S. Intranasal fluticasone propionate is more effective than terfenadine for treatment of seasonal rhinitis. (abstr) *Ann Allergy* 1994;72:86.
185. Meltzer SB, Meltzer EO, Hovell MF, Wahlgren DR, Zakarian JM. The prevalence of cats and dogs in the homes of asthmatic children exposed to environmental tobacco smoke. (abstr) *Ann Allergy* 1994;72:93.
186. Jalowayski AA, Meltzer EO, Orgel HA, Kemp JP, Ostrom NK, Welch MJ, Basch C, Bynum L, Munchi A. Anterior rhinomanometry in allergic rhinitis patients treated with flunisolide, beclomethasone dipropionate or placebo nasal spray. (abstr) *J Allergy Clin Immunol* 1994;93:164.
187. Meltzer EO, Bronsky EA, Grossman J, Metzger J, Mitchell DQ, Selner J, Basch C, Bynum L, Munchi A. Flunisolide, beclomethasone dipropionate or placebo nasal sprays in patients with seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1994;93:164.
188. Selner J, Banov C, Boltansky H, Bronsky E, Chervinsky P, Druce H, Georgitis J, Kaiser H, LaForce C, Meltzer E, Munk Z, Webb D, Field E, Hamedani A, Milwee S. Fluticasone propionate aqueous nasal spray effectively treats perennial non-allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1994;93:165.
189. Galant S, Lawrence M, Meltzer E, Noonan M, Tomasko M, Baker K, Kellerman D, Kral K, Szymeczek J. A randomized, double-blind, parallel-group, placebo-controlled comparison of fluticasone propionate (FP) versus theophylline (T) in the treatment of patients with mild to moderate asthma. (abstr) *J Allergy Clin Immunol* 1994;93:260.
190. LaForce CF, Dockhorn RJ, Findlay SR, Meltzer EO, Nathan RA, Stricker W, Weakley S, Field EA, Rogenes PR. Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents. *J Fam Pract* 1994;38:145-152.
191. Meltzer EO, Weiler JM, Dockhorn RJ, Widlitz MD, Freitag JJ. Azelastine nasal spray in the management of seasonal allergic rhinitis. *Ann Allergy* 1994;72:354-9.
192. Meltzer EO. Is the successful control of perennial rhinitis achievable? *Eur Respir Rev* 1994;4:(20) 266-270.

PUBLICATIONS: ELI O. MELTZER, MD

193. Hovell MF, Meltzer SB, Zakarian JM, Wahlgren DR, Emerson JA, Hofstetter CR, Leaderer BP, Meltzer EO, Zeiger RS, O'Connor RD, Mulvihill MM, Atkins CJ. Reduction of environmental tobacco smoke exposure among asthmatic children: a controlled trial. *Chest* 1994;106:440-46.
194. Grossman J, Halverson PC, Meltzer EO, Shoenwetter WF, van Bavel JH, Woehler TR, Freitag JJ, Hemsworth GR. Double-blind assessment of azelastine in the treatment of perennial allergic rhinitis. *Ann Allergy* 1994;73:141-6.
195. Meltzer EO, Orgel HA, Rogenes PR, Field EA. Nasal cytology in patients with allergic rhinitis: effects of intranasal fluticasone propionate. *J Allergy Clin Immunol* 1994;94:708-15.
196. Meltzer EO. Prevalence, economic, and medical impact of tobacco smoking. *Ann Allergy* 1994;73:381-8.
197. Fluticasone Propionate Collaborative Pediatric Working Group: Galant SP, Ahrens RC, Dockhorn RJ, Lumry W, Martin B, Meltzer EO, Munk Z, Ransom J, Southern DL, Stricker WE, Field FA, Rogenes PR, Kral KM. Treatment of seasonal allergic rhinitis with once-daily intranasal fluticasone propionate in children. *J Pediatr* 1994;125:628-34.
198. Weiler JM, Meltzer EO, Benson PM, Weiler K, Widlitz MD, Freitag J. A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model. *J Allergy Clin Immunol* 1994;94:972-80.
199. Meltzer EO, Halverson PC, Banov CH, Weiler JM, Woehler TR, Hemsworth GR, Freitag JJ. The effectiveness of oral azelastine in the management of perennial allergic rhinitis. *Am J Rhinology* 1994;8:323-8.
200. Prenner B, Chervinsky P, Hampel FC, Howland WC, Lawrence M, Meltzer EO, Munk ZM, Ratner PH, Seltzer J, Settupane GA, Lorber RL, Harrison JE. Double strength beclomethasone dipropionate (84 mcg/spray) aqueous nasal spray in the treatment of seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1995;95:195.
201. Meltzer EO, Weiler JM, Widlitz MD. A 2-day outdoor double-blind parallel multicenter study of the safety and efficacy of cetirizine vs. loratadine and placebo in the treatment of seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1995;95:198.
202. Meltzer EO. Antihistamine Consensus Conference Statement. *Hospital Medicine* 1995;31(Suppl.):3-6.
203. Meltzer EO. CNS effects of antihistamines. Antihistamine Consensus Conference Statement. *Hospital Medicine* 1995;31(Suppl.):21-6.
204. Meltzer EO. Nasal cytological changes following pharmacological intervention. *Allergy* 1995;50(Suppl 23):15-20.
205. Meltzer EO, Orgel HA, Jalowayski AA. Histamine levels and nasal cytology in children with chronic otitis media and rhinitis. *Ann Allergy Asthma Immunol* 1995;74:406-10.
206. Grant JA, Nicodemus CF, Findlay SR, Glovsky MM, Grossman J, Kaiser H, Meltzer EO, Mitchell DQ, Pearlman D, Selner J, Settupane G, Silvers W. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective randomized, placebo-controlled trial. *J Allergy Clin Immunol* 1995;95:923-32.
207. Meltzer EO, Spector SL, (eds.). Anticholinergic therapy for allergic and nonallergic rhinitis and the common cold. *J Allergy Clin Immunol* 1995;95:1065-1152.
208. Meltzer EO. An overview of current pharmacotherapy in perennial rhinitis. *J Allergy Clin Immunol* 1995;95:1097-1110.
209. Meltzer EO, Tyrell RJ Jr., Rich D, Wood CC. A pharmacologic continuum in the treatment of rhinorrhea: The clinician as economist. *J Allergy Clin Immunol* 1995;95:1147-52.

PUBLICATIONS: ELI O. MELTZER, MD

210. Peretti-Sorenson D, Meltzer S, Mulvihill M, Hovell M, Meltzer E, Light M. Effect of cystic fibrosis and asthma in children on marital stress and divorce. (abstr) *Ped Pulmonol* 1994;Suppl 10, 290.
211. Meltzer EO. The use of anti-H₁ drugs in mild asthma. *Allergy* 1995;50:41-47.
212. Bronsky E, Boggs P, Findlay S, Gawchik S, Georgitis J, Mansmann H, Sholler L, Wolfe J, Meltzer E, Morris R, Munk Z, Paull B, Pleskow W, Ratner P, Danzig M, Harrison J, Lorber R. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. *J Allergy Clin Immunol* 1995;96:139-47.
213. Emerson JA, Hovell MF, Meltzer SB, Zakarian JM, Hofstetter CR, Wahlgren DR, Leaderer BP, Meltzer EO. The accuracy of environmental tobacco smoke exposure measures among asthmatic children. *J Clin Epidemiol* 1995;48:1251-9.
214. Spector SL, Nicklas RA, eds. and contributors (including Meltzer EO). Practice Parameters for the diagnosis and treatment of asthma. *J Allergy Clin Immunol* 1995;96:1A-8A, 707-870.
215. Naclerio RM, Meltzer EO, Mackay IS. Update on allergic and nonallergic rhinitis. Proceedings of a seminar presented at the American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting, New Orleans Louisiana, 1995.
216. Meltzer EO, Orgel HA, Biondi R, Georgitis J, Milgrom H, Munk Z, Van Bavel J, Drda K, Wood C. Ipratropium bromide nasal spray in children with perennial rhinitis. (abstr) *Ann Allergy Asthma Immunol* 1996;76:90.
217. Weiler JM, Meltzer EO. Patient perceptions of their single major symptom from seasonal allergies. (abstr) *Ann Allergy Asthma Immunol* 1996;76:116.
218. Reilly MC, Tanner LA, Meltzer EO. Allergy impairment questionnaires: validation studies. (abstr) *J Allergy Clin Immunol* 1996;97:430.
219. Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. *J Allergy Clin Immunol* 1996;97:617-26.
220. Welch MJ, Meltzer EO. Clinical review of the diagnosis and management of allergic rhinitis. Monograph, Clinical Communications Inc., Greenwich, Connecticut, March, 1996.
221. Meltzer EO, Welch MJ. Adverse effects of H₁-receptor antagonists in the central nervous system. In: *Histamine and H₁-Receptor Antagonists in Allergic Disease*, Simons FER (ed), New York, Marcel Dekker, 1996;357-81.
222. Bronsky EA, Dockhorn RJ, Meltzer EO, Shapiro G, Boltansky H, LaForce C, Ransom J, Weiler JM, Blumenthal M, Weakley S, Wisniewski M, Field E, Rogenes P. Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. *J Allergy Clin Immunol* 1996;97:915-21.
223. Meltzer EO. Antihistamines and adverse effects: what do doctors and patients know? *Patient Care* 1996;30:48-50.
224. Reilly MC, Tanner A, Meltzer EO. Work, classroom and activity impairment instruments: validation studies in allergic rhinitis. *Clin Drug Invest* 1996;11:278-88.
225. Baraniuk JN, Meltzer EO, Spector SL. Chronic airway diseases: reassessing the role of allergy. *J Resp Dis* 1996;17(Suppl):S1-S56.
226. Baraniuk JN, Meltzer EO, Spector SL. A contemporary approach to allergic rhinitis. *J Resp Dis* 1996;17(Suppl):S5.
227. Baraniuk JN, Meltzer EO, Spector SL. The pathophysiology of allergic rhinitis. *J Resp Dis* 1996;17(Suppl):S6-S10.

PUBLICATIONS: ELI O. MELTZER, MD

228. Baraniuk JN, Meltzer EO, Spector SL. Impact of allergic rhinitis and related airway disorders. *J Resp Dis* 1996;17(Suppl):S11-S23.
229. Baraniuk JN, Meltzer EO, Spector SL. Getting to the cause of chronic rhinitis. *J Resp Dis* 1996;17(Suppl):S24-S33.
230. Baraniuk JN, Meltzer EO, Spector SL. Putting together an effective plan for managing allergic rhinitis. *J Resp Dis* 1996;17(Suppl):S34-S44.
231. Baraniuk JN, Meltzer EO, Spector SL. Strategies for improving allergic rhinitis outcomes. *J Resp Dis* 1996;17(Suppl):S45-S50.
232. Baraniuk JN, Meltzer EO, Spector SL. Allergic rhinitis on the eve of the 21st century. *J Resp Dis* 1996;17(Suppl):S51-S52.
233. Galant SP, Lawrence M, Meltzer EO, Tomasko M, Baker KA, Kellerman DJ. Fluticasone propionate compared with theophylline for mild-to-moderate asthma. *Ann Allergy Asthma Immunol* 1996;77:112-8.
234. Prenner BM, Chervinsky P, Hampel FC Jr., Howland WC, Lawrence M, Meltzer EO, Munk ZM, Ratner PH, Seltzer JM, Settignano GA, Lorber RR, Harrison JE. Double-strength beclomethasone dipropionate (84 mcg/spray) aqueous nasal spray in the treatment of seasonal allergic rhinitis. *J Allergy Clin Immunol* 1996;98:302-8.
235. Meltzer EO. Productivity costs of antihistamines in the workplace. *Occupational Health Safety* 1996;65:46-50.
236. Corren J, Harris A, Fourre J, Chen R, Aaronson D, Beaucher W, Berkowitz R, Bronsky E, Chervinsky P, Cohen R, Grossman J, Meltzer E, Pedinoff A, Stricker W, Wanderer A. Efficacy and safety of Claritin-D® in patients with seasonal allergic rhinitis (SAR) and asthma. (abstr) *Ann Allergy Asthma Immunol* 1997;78:95.
237. Tanner LA, Reilly M, Meltzer EO, Bradford JE, Mason J. Evaluation of quality of life and health economic measures in patients treated with fexofednadin HCL for seasonal allergic rhinitis. (abstr) *Ann Allergy Asthma Immunol* 1997;78:125.
238. Milgrom H, Biondi R, Georgitis J, Meltzer E, Munk Z, Drda K, Wood C. Comparison of ipratropium bromide with beclomethasone dipropionate in the treatment of perennial rhinitis in children. (abstr) *Ann Allergy Asthma Immunol* 1997;78:125.
239. Meltzer E, Perhach JL, Rosenberg A, Azelastine Nasal Spray Clinical Study Group. Effects of azelastine nasal spray on individual rhinitis symptoms. (abstr) *Ann Allergy Asthma Immunol* 1997;78:143.
240. Meltzer E. Clinical and anti-inflammatory effects of intranasal budesonide (Rhinocort®) aqueous spray in adults and children with perennial allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1997;99:S439.
241. Bronsky EA, Meltzer EO, Perhach JL, Rosenberg A, Lyness WH. Cardiac safety of azelastine following 8 weeks of intranasal administration. (abstr) *J Allergy Clin Immunol* 1997;99:S445.
242. Blake KV, May JR, Landis WA, Meltzer EO. New Product Bulletin on Nasalcrom (cromolyn sodium nasal solution). American Pharmaceutical Association 1997.
243. Garbus SB, Moulton BW, Meltzer EO, Reich PR, Weinreb LF, Friedman JA, Orland BI. Considerations in pharmaceutical conversion: focus on antihistamines. *Am J Man Care* 1997;3:617-30.
244. Meltzer EO, Orgel HA, Biondi R, Georgitis J, Milgrom H, Munk Z., Van Bavel J, Wood CC, Drda K. Ipratropium nasal spray in children with perennial rhinitis. *Ann Allergy Asthma Immunol* 1997;78:485-91.
245. Meltzer, EO. The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids. *Allergy* 1997;52(Suppl 36):33-40.

PUBLICATIONS: ELI O. MELTZER, MD

246. Meltzer EO, Nolop K, Mesarina-Wicki B. A dose-ranging study of mometasone furoate nasal spray in children with seasonal allergic rhinitis. (abstr) *Allergy* 1997;52(Suppl 37):136.
247. Meltzer EO, ed. The prevalence and medical and economic impact of allergic rhinitis in the United States. *J Allergy Clin Immunol* 1997;99:S807-28.
248. Nathan RA, Meltzer, EO, Selner JC, Storms W. Prevalence of allergic rhinitis in the United States. *J Allergy Clin Immunol* 1997;99:S808-14.
249. Meltzer EO, Nathan RA, Selner JC, Storms W. Quality of life and rhinitic symptoms: results of a nationwide survey with the SF-36 and RQLQ questionnaires. *J Allergy Clin Immunol* 1997;99:S815-9.
250. Storms W, Meltzer EO, Nathan RA, Selner JC. The economic impact of allergic rhinitis. *J Allergy Clin Immunol* 1997;99:S820-4.
251. Storms W, Meltzer EO, Nathan RA, Selner JC. Allergic rhinitis: the patient's perspective. *J Allergy Clin Immunol* 1997;99:S825-8.
252. Wahlgren DR, Hovell MF, Matt GE, Meltzer SB, Zakarian JM, Meltzer EO. Toward a simplified measure of asthma severity for applied research. *J Asthma* 1997;34:291-303.
253. Grossman J, Meltzer E, Pearlman D, Rosenberg A. Onset of action and patient acceptance of azelastine in a nasal spray formulation. (abstr) *Allergy Clin Immunol International* 1997;Suppl 4:71.
254. Kemp JP, Hill MR, Vaughan LM, Meltzer EO, Welch MJ, Ostrom NK. Pilot study of bronchodilator response to inhaled albuterol delivered by metered-dose inhaler and a novel dry powder inhaler. *Ann Allergy Asthma Immunol* 1997;79:322-6.
255. Weiler JM, Meltzer EO. Azelastine nasal spray as adjunctive therapy to azelastine tablets in the management of seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 1997;79:327-32.
256. Corren J, Harris A, Aaronson D, Beaucher W, Berkowitz R, Bronsky E, Chen R, Chervinsky P, Cohen R, Foure J, Grossman J, Meltzer E, Pedinoff A, Stricker W, Wanderer A. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. *J Allergy Clin Immunol* 1997;100:781-8.
257. Meltzer EO. Treatment options for the child with allergic rhinitis. *Clin Pediatr* 1998; 37:1-10.
258. Malmstrom K, Meltzer E, Prenner B, Lu S, Weinstein S, Wolfe J, Wei LX, Reiss TF. Effects of montelukast (a leukotriene receptor antagonist), loratadine, montelukast + loratadine and placebo in seasonal allergic rhinitis and conjunctivitis. (abst) *J Allergy Clin Immunol* 1998;101: S97.
259. Meltzer EO, Jalowayski AA, Orgel HA, Capano D, Harris AG. Subjective and objective parameters demonstrate the therapeutic effectiveness of mometasone furoate for seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1998;101:S98.
260. Rachelefsky GS, Chervinsky P, Meltzer EO, Morris RM, Seltzer JM, Skoner DP, Storms WW, Wood RA. An evaluation of the effects of beclomethasone dipropionate aqueous nasal spray [Vancenase AQ (VNS)] on long-term growth in children. (abstr) *J Allergy Clin Immunol* 1998; 101: S236.
261. Juniper EF, Meltzer EO, Moreno J, Valacer D, Quinones H, Mear I, Tanner A. Translation/Validation of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) for Spanish speaking patients in N. America. (abstr) *J Allergy Clin Immunol* 1998; 101:S253.
262. Stein MT, Meltzer EO, Stein REK. Recurrent episodes of asthma in a 10 year old. *J Dev Behav Pediatr* 1998; 19:41-4.
263. Meltzer EO. Pharmacological treatment options for allergic rhinitis and asthma. *Clin Exp Allergy* 1998; 28 (suppl 2): 27-36.

PUBLICATIONS: ELI O. MELTZER, MD

264. Meltzer EO, Jalowayski AA, Orgel HA, Harris AG. Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray. *J Allergy Clin Immunol* 1998; 102:39-49.
265. Pearlman D, Grossman J, Meltzer E. Skin test reactivity to histamine after single and multiple doses of Astelin® nasal spray in rhinitis patients. (abstr) *Allergy and Asthma Proc* 1998;19:206.
266. Meltzer EO. Clinical and antiinflammatory effects of intranasal budesonide aqueous pump spray in the treatment of perennial allergic rhinitis. *Ann Allergy Asthma Immunol* 1998;81:128-34.
267. Meltzer EO, Orgel HA, Jalowayski AA. Nasal cytology. In: Naclerio RM, Durham SR, Mygind N, eds. *Rhinitis: mechanisms and management*. New York: Marcel Dekker, 1998; 175-202.
268. Meltzer EO, ed. Pediatric Allergy issue. *Pediatric Annals* 1998; 27:703-771.
269. Dykewicz MS, Fineman S, eds. and contributors (including Meltzer EO). Diagnosis and management of rhinitis: parameter documents of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. *Ann Allergy Asthma Immunol* 1998; 81:463-518.
270. Jones JA, Wahlgren DR, Meltzer SB, Hovell MF, Meltzer EO. Asthma management knowledge and home management procedures among latino primary caregivers with asthmatic children. (abstr) *Ann Allergy Asthma Immunol* 1999; 82:85.
271. Pearlman D, Grossman J, Meltzer E. Azelastine nasal spray and skin test reactivity to histamine in rhinitis patients. (abstr) *Ann Allergy Asthma Immunol* 1999;82:89.
272. Meltzer EO, Casale TB, Nathan RA, Thompson AK. Once-daily fexofenadine HCl improves quality of life and work and activity impairment in patients with seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1999; 103:S72.
273. Meltzer SB, Wahlgren DR, Jones JA, Hovell MF, Hofstetter CR, Meltzer EO. Health and social characteristics of low-income latino families with asthmatic children. (abstr) *J Allergy Clin Immunol* 1999; 103:S80.
274. Meltzer E, Busse W, Charous BL, Lorber R, Danzig M. Adjunctive treatment of acute sinusitis with mometasone furoate nasal spray. (abstr) *J Allergy Clin Immunol* 1999;103:S115.
275. Georgitis JW, Berkowitz R, Kaliner M, Meltzer E, Weiler J, Gardner E, Coyne T. Onset-of-action for antihistamine and decongestant combination during an outdoor challenge. (abstr) *J Allergy Clin Immunol* 1999; 103:S253.
276. Long J, Meltzer EO, Scott-Dawdy K, Qu R. Safety of fexofenadine HCl in children treated for seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1999; 103:S254.
277. Tanner LA, Reilly M, Meltzer EO, Bradford JE, Mason J. Effect of fexofenadine HCL on quality of life and work, classroom and daily activity impairment in patients with seasonal allergic rhinitis. *Am J Managed Care* 1999;5:S235-47.
278. Ledford DK, Ferguson BJ, Nathan RA, Meltzer EO. Recognition and management of nasal allergies. Cine-Med CME monograph, 1999.
279. Charous BL, Meltzer E, Busse W, Lorber R, Danzig M. Adjunctive treatment of acute sinusitis with mometasone furoate nasal spray. *Allergy* 1999;54(suppl 52):55.
280. Meltzer, E, Berger W, Berkowitz R, Bronsky E, Dvorin D, Finn A, Galant S, Grossman J, Hampel F, Ratner P, Ruff M, Schenkel E, Segal A, Segall N, Stewart II G, Tripathy I, Skoner D, Anolik R, Dockhorn R, van Bavel J, Mesarina-Wicki B, Nolop K. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. *J Allergy Clin Immunol* 1999;104:107-14.

PUBLICATIONS: ELI O. MELTZER, MD

281. Milgrom H, Biondi R, Georgitis JW, Meltzer EO, Munk ZM, Drda K, Wood CC. Comparison of ipratropium bromide 0.03% with beclomethasone dipropionate in the treatment of perennial rhinitis in children. *Ann Allergy Asthma Immunol* 1999;83:105-11.
282. Meltzer EO, Casale TB, Nathan RA, Thompson AK. Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 1999;83:311-17.
283. Nathan RA, Mason J, Bernstein DI, Howland WC III, Kaiser HB, Meltzer EO, Segall N. Long-term tolerability of fexofenadine in healthy volunteers. *Clin Drug Invest* 1999;18:317-28.
284. Meltzer EO, Ehrlich PM. A step approach to the clinical management of allergic rhinitis: prescription and over-the-counter therapeutic reference summary. *Managed Care Interface* 1999;12:70-7.
285. Meltzer EO, Grant JA. Impact of cetirizine on the burden of allergic rhinitis. *Ann Allergy Asthma Immunol* 1999;83:455-63.
286. Meltzer, EO, Zinreich SJ, Charous BL, Busse WW, Lorber RR, Danzig MR. Results of computerized tomography examinations during adjunctive treatment of acute sinusitis with mometasone furoate nasal spray (MFNS). (abstr) *Ann Allergy Asthma Immunol* 2000;84:129.
287. van Cauwenberge P, Juniper EF, Meltzer E, STAR Study Investigating Group. Efficacy, safety and quality of life – a comparison between fexofenadine, loratadine, and placebo in the treatment of seasonal allergic rhinitis. (abstr) *Ann Allergy Asthma Immunol* 2000;84:147.
288. Meltzer SB, Wahlgren DR, Meltzer EO, Jones JA, Hovell HA. Quality of life assessments in low income Latino asthmatic children. (abstr) *J Allergy Clin Immunol* 2000;104:S96
289. Meltzer EO, LaForce CF, Settupane GA, Charous BL, Goode-Sellers ST, Westlund RE, Rickard KA, Cook CK. Symptom relief from an acute episode of recurring sinusitis with fluticasone propionate aqueous nasal spray as adjunctive therapy to cefuroxime axetil. (abstr) *J Allergy Clin Immunol* 2000;104:S208
290. Charous BL, Meltzer EO, Busse WW, Lorber RR, Rikkens G, Danzig MR. Adjunctive treatment of acute sinusitis with mometasone furoate nasal spray – a comparison of two dose regimens. (abstr) *J Allergy Clin Immunol* 2000;104:S210
291. Wahlgren DR, Meltzer SB, Meltzer EO, Hovell MF. Residential mold exposure among Latino families with an asthmatic child. (abstr) *J Allergy Clin Immunol* 2000;104:S334
292. Heithoff K, Meltzer EO, Mellars L, Salmun LM. Desloratadine improves quality of life in patients with seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 2000;104:S383.
293. Michele TM, Lu S, Malice MP, Malmstrom K, LaForce C, Wolfe J, Meltzer EO, Reiss TF. Combination of montelukast and loratadine in seasonal allergic rhinitis: an analysis of three spring studies. (abstr) *J Allergy Clin Immunol* 2000;104:S387.
294. Wahlgren DR, Hovell MF, Meltzer EO, Meltzer SB. Involuntary smoking and asthma. *Curr Opin Pulm Med* 2000;6:31-6.
295. Meltzer EO. Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of “one linked airway disease”. *Ann Allergy Asthma Immunol* 2000;84:176-187.
296. Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM, Storms WW, Wood RA. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. *Pediatrics* 2000;105(2).
URL:<http://www.pediatric.org/cgi/content/full/105/2/e23>.
297. Meltzer EO, Bachert C, Mosges R, Slavin RG, Stierna P. Enhancing the treatment of sinusitis: The use of intranasal glucocorticoids. *Schering-Plough Proceedings*, 2000.

PUBLICATIONS: ELI O. MELTZER, MD

298. Georgitis JW, Meltzer EO, Kaliner M, Weiler J, Berkowitz R. Onset-of-action for antihistamine and decongestant combinations during an outdoor challenge. *Ann Allergy Asthma Immunol* 2000;84:451-459.
299. Meltzer EO, Malmstrom K, Lu S, Prenner BM, Wei LX, Weinstein SF, Wolfe JD, Reiss TF. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial. *J Allergy Clin Immunol* 2000;105:917-22.
300. Meltzer EO, ed. Quality of Life impairment from allergic rhinitis and health outcomes from antihistamine treatment: a review of recent articles. Adelphi, Inc. 2000.
301. Michele T, Lu S, Malice MP, Malmstrom K, LaForce C, Wolfe J, Meltzer EO, Reiss T. Combination of montelukast and loratadine improves quality of life in seasonal allergic rhinitis: an analysis of three spring studies. (abstr) *Allergy* 2000;55 (suppl 63):42.
302. Lorber RR, Charous BL, Meltzer EO, Busse WW, Rikken G, Danzig MR. Effective dose range of mometasone furoate nasal spray (MFNS) for adjunctive treatment of acute sinusitis. (abstr) *Allergy* 2000;55 (suppl 63):258.
303. Meltzer EO, Charous BL, Busse WW, Lorber RR, Rikken G, Danzig MR. Early relief of symptoms of recurrent acute sinusitis by adjunctive mometasone furoate nasal spray (MFNS). (abstr) *Allergy* 2000;55 (suppl 63): 258.
304. Charous BL, Meltzer EO, Busse WW, Lorber RR, Danzig MR. Early relief of symptoms of acute sinusitis with adjunctive 200 mcg twice daily (BID) and 400 mcg BID mometasone furoate nasal spray (MFNS). (abstr) *Allergy* 2000;55 (suppl 63): 259.
305. Danzig MR, Charous BL, Meltzer EO, Zinreich SJ, Busse WW, Lorber RR. Use of computed tomography (CT) to assess inflammatory reduction of acute sinusitis by adjunctive treatment with mometasone furoate nasal spray (MFNS). (abstr) *Allergy* 2000;55 (suppl 63):259.
306. Meltzer EO. Improving treatment compliance in chronic allergic rhinitis. *Respiratory Reviews* 2000; July:11-13.
307. Thompson AK, Juniper E, Meltzer EO. Quality of life in patients with allergic rhinitis. *Ann Allergy Asthma Immunol* 2000;85:338-348.
308. Meltzer EO, Charous BL, Busse WW, Zinreich SJ, Lorber RR, Danzig MR, and the Nasonex Sinusitis Group. Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray. *J Allergy Clin Immunol* 2000;106:630-7.
309. Meltzer EO, Prenner BM, Nayak A, and the Desloratadine Study Group. Efficacy and tolerability of once-daily 5mg desloratadine, an H₁-receptor antagonist, in patients with seasonal allergic rhinitis – assessment during the spring and fall allergy seasons. *Clin Drug Invest* 2001;21(1):25-32.
310. Jones JA, Wahlgren DR, Meltzer SB, Meltzer EO, Clark NM, Hovell MF. Increasing asthma knowledge and changing home environments for Latino families with asthmatic children. *Patient Education and Counseling* 2001;42:67-79.
311. Meltzer EO, Kalberg C, Srebro SH, Edwards L, Goode-Sellers ST, Rickard K. Low dose fluticasone is more effective than montelukast for the treatment of persistent asthma. (abstr) *Ann Allergy Asthma Immunol* 2001;86:82.
312. Prenner BM, Meltzer EO, Settiane GA, Rikken G, Lorber RR, Danzig MR. Mometasone (MF) is equally well tolerated when given as an intranasal spray (MFNS) or a metered-dose inhaler (MFNA) over 6-months of treatment. (abstr) *J Allergy Clin Immunol* 2001;107:S157.
313. Meltzer EO, The Desloratadine Study Group. Rapid onset of action of desloratadine in patients with seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 2001;107:S160.
314. Rikken G, Meltzer EO, Zinreich SJ, Charous BL, Busse WW, Lorber RR, Danzig MR. Prevention of recurrent acute episodes of sinusitis with prophylactic mometasone furoate nasal spray (MFNS). (abstr) *J Allergy Clin Immunol* 2001;107:S164.

PUBLICATIONS: ELI O. MELTZER, MD

315. Charous BL, Zinreich SJ, Meltzer EO, Busse WW, Lorber RR, Rikken G, Danzig MR. Prevention of recurrent acute episodes of sinusitis with prophylactic mometasone furoate nasal spray (MFNS). (abstr) *J Allergy Clin Immunol* 2001;107:S166.
316. Meltzer EO, Richard KA, Westlund RE, Cook CK. Onset of therapeutic effect of fluticasone propionate aqueous nasal spray. *Ann Allergy Asthma Immunol* 2001;86:286-91.
317. Geha RS, Meltzer EO. Desloratadine: a new, nonsedating oral antihistamine. *J Allergy Clin Immunol* 2001;107:751-62.
318. Meltzer EO, Charous BL, Danzig MR. Comparison of earliest observable relief of symptoms of acute or recurrent acute sinusitis using oral antibiotics and mometasone furoate nasal spray. (abstr) *Allergy* 2001;56 (suppl 68):75.
319. Graft DF, Bernstein DI, Goldsobel A, Meltzer EO, Portnoy J, Long J. Safety of fexofenadine in children treated for seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 2001;87:22-26.
320. Meltzer EO, ed. Quality of life in rhinitis management: a clinician's handbook on the use of quality of life instruments in daily practice. New York, 2001, Adelphi Inc.
321. Meltzer EO. Role of mometasone furoate nasal spray as an adjunct treatment of acute sinusitis. Correspondence to the Editor, *J Allergy Clin Immunol* 2001;108:148-9.
322. Meltzer EO. Quality of life in adults and children with allergic rhinitis. *J Allergy Clin Immunol* 2001;108:S45-53.
323. Thompson AK, Juniper E, Meltzer EO. Quality of life in patients with allergic rhinitis. In: Kaliner MA (ed): *Current Review of Rhinitis*, Philadelphia, 2002, Current Medicine, Inc., pp 13-21.
324. Bousquet J, van Cauwenberge P, Khaltaev N and coauthors (including Meltzer EO). Allergic rhinitis and its impact on asthma. *J Allergy Clin Immunol* 2001;108:S147-336.
325. Ratner PH, Meltzer EO, Byas L, Block EM. Randomized, Double-Blind, Placebo-Controlled, Evaluation of Cromolyn Sodium in the Treatment of Allergic Rhinitis in Young Children. *Journal of Applied Research* 2001;1:100-109.
326. Cook CK, Meltzer EO, Goode-Sellers ST, Prillaman BA et al. Fluticasone propionate aqueous nasal spray decreases frequency of recurrence and increases time to recurrence of acute sinusitis. (abstr) *J Allergy Clin Immunol* 2002;109:S86.
327. Meltzer EO, Corren J, Baumgartner RA. Tecastemizole effectively reduces total and nasal allergic symptoms. (abstr) *J Allergy Clin Immunol* 2002;109:S102.
328. Philip G, Meltzer EO, Malmstrom K, Marchal J, Reiss TF, Montelukast Seasonal Allergic Rhinitis Group. Montelukast in the treatment of nighttime symptoms associated with seasonal allergic rhinitis in double-blind, randomized, placebo-controlled studies. (abstr) *J Allergy Clin Immunol* 2002;109:S105.
329. Juniper EF, Rohrbaugh T, Meltzer EO. Development and validation of the nocturnal rhinitis quality of life questionnaire. (abstr) *J Allergy Clin Immunol* 2002;109:S121.
330. Martinez-Donate AP, Wahlgren DR, Meltzer SB, Meltzer EO, et al. Long-term effects of asthma management education for Latino families. (abstr) *J Allergy Clin Immunol* 2002;109:S211.
331. Meltzer SB, Meltzer EO, Hovell MF, Wahlgren DR, Hofstetter CR. Disparities in asthma morbidity between two pediatric populations: children with asthma specialty care versus minimal asthma care. (abstr) *J Allergy Clin Immunol* 2002;109:S211.
332. Meltzer EO. Intranasal corticosteroids in the treatment of rhinosinusitis. *Family Practice Recertification* 2002;24 (suppl no.1):26-32.
333. Meltzer EO. Allergic rhinitis: a systemic inflammatory process. *Patient Care* 2002;Spring Supplement:7-15.

PUBLICATIONS: ELI O. MELTZER, MD

334. Ratner PH, Ehrlich PM, Fineman SM, Meltzer EO, Skoner DP. Use of Intranasal Cromolyn Sodium for Allergic Rhinitis. *Mayo Clin Proc (Subspecialty Clinics: Allergic Diseases)* 2002;77:350-354.
335. Webb RD, Meltzer EO, Finn AF, Rickard KA, Pepsin PJ, Westlund R, Cook CK. Intranasal fluticasone propionate is effective for perennial nonallergic rhinitis with or without eosinophilia. *Ann Allergy Asthma Immunol* 2002;88:385-390.
336. Meltzer EO. Clinical evidence for antileukotriene therapy in the management of allergic rhinitis. *Ann Allergy Asthma Immunol* 2002;88 (Suppl):23-29.
337. Meltzer EO, Bronsky EA, Chervinsky P, Stewart GE, Baena-Cagnanni C, Lutsky B. Once daily mometasone furoate administered by dry powder inhaler improves pulmonary function in children with moderate persistent asthma. (abstr) *Am J Respir Crit Care Med* 2002; 165:8:A486.
338. Martinez-Donate AP, Wahlgren DR, Hofstetter CR, Meltzer EO, Meltzer SB, Matt GE, Hovell MF. Home bans among Latino families with asthmatic children: impact on environmental tobacco smoke exposure & health. (abstr) *Am J Respir Crit Care Med* 2002;165:8:A661.
339. Hovell MF, Wahlgren DR, Meltzer SB, Hofstetter CR, Matt GE, Meltzer EO, Jones JA, Bernert JT, Pirkle JL. Reducing environmental tobacco smoke exposure in Latino children with asthma: outcomes in a behavioral trial linked to asthma education. (abstr) *Am J Respir Crit Care Med* 2002;165:8:A662.
340. Meltzer EO, Lockey RF, Friedman BF, Kalberg C, Goode-Sellers S, Srebro S, Edwards L, Richard K. Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma. *Mayo Clin Proc* 2002;77:437-445.
341. Meltzer EO. Does rhinitis compromise night-time sleep and daytime productivity? *Clin Exper Allergy Rev* 2002;2:67-72.
342. Welch MJ, Meltzer EO, Simons FER. H₁-Antihistamines and the Central Nervous System. In: *Histamine and H₁-Antihistamines in Allergic Disease*, Simons FER (ed), New York, Marcel Dekker, 2002;337-88.
343. Baena-Cagnani CE, Bachert C, Rosado Pinto JE, Meltzer EO, Decosta P. Sensitization to pollen allergens in children with seasonal allergic rhinitis. (abstr) *Allergy* 2002;57 (suppl 73):271.
344. Meltzer EO, for the NasalCrom Study Group. Efficacy and patient satisfaction with cromolyn sodium nasal solution in the treatment of seasonal allergic rhinitis: a placebo-controlled study. *Clin Therapeutics* 2002;24:942-52.
345. Meltzer EO, faculty advisor. The allergic rhinitis response: clinical updates and insights. *Pragmation Office of Medical Education* 2002;vol 1, issue no 3.
346. Nayak AS, Settupane GA, Pedinoff A, Charous BL, Meltzer EO, Busse WW, Zinreich SJ, Lorber RR, Rikken G, Danzig MR, and the Nasonex Sinusitis Group. Effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. *Ann Allergy Asthma Immunol* 2002;89:271-278.
347. Hovell MF, Meltzer SB, Wahlgren DR, Matt GA, Hofstetter CR, Jones JA, Meltzer EO, Bernert JT, Pirkle JL. Asthma management and environmental tobacco smoke exposure reduction in Latino children: A controlled trial. *Pediatrics* 2002;110:946-956.
348. Allen, DB, Meltzer EO, Lemanske RF, Philpot EE, Faris MA, Kral KM, Prillaman BA, Rickard KA. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. *Allergy and Asthma Proc* 2002;23:407-413.

PUBLICATIONS: ELI O. MELTZER, MD

349. Ruff, ME, Szeffler SJ, Meltzer EO, Berger WE. Efficacy and safety of extrafine beclomethasone dipropionate aerosol therapy in children with asthma: a twelve-week placebo-controlled trial. *Pediatr Asthma, Allergy and Immunol* 2003;16:1-13.
350. Meltzer EO, Casale TB, Gold MS, O'Connor R, Reitberg D, del Rio E, Weiler JM, Weiler K. Efficacy and safety of clemastine-pseudoephedrine-acetaminophen versus pseudoephedrine-acetaminophen in the treatment of seasonal allergic rhinitis in a 1-day, placebo-controlled park study. *Ann Allergy Asthma Immunol* 2003;90:79-86.
351. Meltzer EO, Ice JC, LaVange LM, Kellerman DJ, Schaberg AE. INS37217, A P2Y₂ receptor agonist given intranasally, is well tolerated and decreases saccharin transport time in subjects with and without perennial allergic rhinitis. (abstr) *Ann Allergy Asthma Immunol* 2003;90:101.
352. Allen DB, Noonan MJ, Miller DL, Meltzer EO, Lamanske RF, Kral KM, Prillaman BA, Cook CK, Philpot EE, Rickard KA. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. (abstr) *Ann Allergy Asthma Immunol* 2003;90:110.
353. Hovell MF, Martinez-Donate AP, Meltzer SB, Wahlgren DR, Hofstetter CR, Matt GE, Meltzer EO. Reducing environmental tobacco smoke exposure in asthmatic children of Latino families: effect of a tobacco smoking ban in the home. (abstr) *Ann Allergy Asthma Immunol* 2003;90:142.
354. Gallet CL, Meltzer EO, Jalowayski AA, Diener PM, Liao Y, Georges GC. Triamcinolone acetonide and fluticasone propionate aqueous nasal sprays significantly improve nasal airflow in patients with seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 2003;111:S73.
355. Schaberg AE, Meltzer EO, LaForce CF, Pearlman DS, Ice JC, LaVange LM, Kellerman DJ. INS37217 intranasal, a P2Y₂ receptor agonist, is a novel treatment for allergic rhinitis. (abstr) *J Allergy Clin Immunol* 2003;111:S74.
356. Vogt K, Jalowayski AA, Meltzer EO, Harris AG. High resolution rhinomanometry, a new method to evaluate nasal patency in patients with allergic rhinitis. (abstr) *J Allergy Clin Immunol* 2003;111:S75.
357. Wahn U, Meltzer E, Simons F, Bernstein D, van Bavel J, Milgrom H, Ruuth E. Fexofenadine effectively relieves all symptoms of seasonal allergic rhinitis in children aged 6-11 years. (abstr) *J Allergy Clin Immunol* 2003;111:S80.
358. Jalowayski AA, Meltzer EO, Harris AG. Desloratadine treatment improves nasal patency as measured objectively by high-resolution rhinomanometry in patients with seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 2003;111:S81.
359. Meltzer EO, Harris AG. Desloratadine 5 mg once daily significantly improves individual and total symptoms compared with placebo in patients with seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 2003;111:S86.
360. Welch MJ, Gallet C, Ostrom NK, Meltzer EO. Evaluation of efficacy and patient preference of albuterol delivered via the PocketChamber (PC) versus the AeroChamber (AC Plus) in patients with asthma. (abstr) *J Allergy Clin Immunol* 2003;111:S145.
361. Israel E, Cohn J, Meltzer E, McCarty J, Zheng B, Carroll A. Omalizumab does not induce thrombocytopenia in the treatment of asthma. (abstr) *J Allergy Clin Immunol* 2003;111:S146-S147.
362. Juniper EF, Rohrbaugh T, Meltzer EO. A questionnaire to measure quality of life in adults with nocturnal allergic rhinoconjunctivitis. *J Allergy Clin Immunol* 2003;111:484-90.

PUBLICATIONS: ELI O. MELTZER, MD

363. Bousquet J, Van Cauwenberge P, Bachert C, Canonica GW, Demoly P, Durham SR, Fokkens W, Lockey R, Meltzer EO, Mullol J, Naclerio RM, Price D, Simons FER, Vignola AM, Warner JO. Requirements for medications commonly used in the treatment of allergic rhinitis. *Allergy* 2003;58:192-7.
364. Wahn U, Meltzer EO, Finn AF, Kowalski ML, Decosta P, Hedlin G, Scheinmann P, Bachert C, Rosado Pinto JE, Baena-Cagnani C, Potter P, Simons FER, Ruuth E. Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis. *J Allergy Clin Immunol* 2003;111:763-9.
365. Meltzer EO. Allergic rhinitis and its comorbidities. *Respiratory Digest* 2003;5:1-9.
366. Bousquet J, van Cauwenberge P, Khaltaev N and coauthors (including Meltzer EO). Management of allergic rhinitis symptoms in the pharmacy: ARIA in the pharmacy. 2003.
367. Gelfand EW, Plaut M and coauthors (including Meltzer EO). Current trends in allergic reactions: a multidisciplinary approach to patient management. *Clinician* 2003; 21:1-19
368. Rosenwasser LJ, Nash DB, Consensus Panel (including Meltzer EO). Incorporating omalizumab into asthma treatment guidelines: consensus panel recommendations. *Pharmacy & Therapeutics* 2003;28:400-10.
369. Meltzer E, Scheinmann P, Rosado Pinto J, Bachert C, Hedlin G, Wahn U, Finn A, Ruuth E. Evaluation of the safety and efficacy of oral fexofenadine in pediatric subjects with seasonal allergic rhinitis: pooled analysis of three studies. (abstr) *Allergy Clin Immunol Int: J World Allergy Org* 2003;(suppl)No.1:174.
370. Meltzer EO. The role of the immune system in the pathogenesis of asthma and an overview of the diagnosis, classification, and current approach to treating the disease. *J Managed Care Pharmacy* 2003;9(suppl)No.5:8-13.
371. Sullivan SD, Meltzer EO. Emerging therapeutic strategies for asthma management. *J Managed Care Pharmacy* 2003;9(suppl)No.5:14-21.
372. Pearlman, DS., Grossman, J., Meltzer, EO. Histamine skin test reactivity following single and multiple doses of azelastine nasal spray in patients with seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 2003;91:258-62.
373. J. van Adelsberg, G. Philip, A.J. Pedinoff, E.O. Meltzer, P.H. Ratner, J. Menten, T.F. Reiss. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. *Allergy* 2003;58:1268-1276.
374. Blaiss MS, Chipps BE, Gelfand EW, Meltzer EO. Pediatric Asthma: New horizons in assessment, treatment and management. *Medical Crossfire* 2003; 4: 3-15.
375. Segal AT, Meltzer EO, Lockey RF, Prenner BM, Mitchell DQ, Tinkelman DG, Hewlett D, Chapman D, Kramer B. Once-daily cetirizine is safe and effective for children with allergic rhinitis with and without intermittent asthma. *Pediatr Asthma Allergy Immunol* 2003;16:265-274.
376. Martinez-Donate AP, Hovell MF, Wahlgren DR, Meltzer SB, Meltzer EO, Hofstetter CR, Matt GE. Association between residential tobacco smoking band, smoke exposure, and pulmonary function: a survey of latino children with asthma. *Pediatr Asthma Allergy Immunol* 2003;16: 305-17.
377. Berg J, Wahlgren DR, Hofstetter CR, Meltzer SB, Meltzer EO, Matt GE, Matrinez-Donate A, Hovell MF. Latino children with asthma: rates and risks for medical care utilization. *J Asthma* 2003; 40: 1-11.
378. Meltzer EO, Hampel F, Ratner P, Bernstein D, Gawchik S, Larsen L, Berger W, Finn A, Wall GM, Brubaker M, Dimas C, Potts S, Silver L. Olopatadine HCl nasal spray is effective and safe for the treatment of seasonal allergic rhinitis. (abstr) *Ann Allergy Asthma Immunol* 2004; 92: 103.

PUBLICATIONS: ELI O. MELTZER, MD

379. Meltzer E, Spivey R. An open label-study of azelastine nasal spray in the treatment of nasal congestion in patients with seasonal allergic rhinitis. (abstr) *Ann Allergy Asthma Immunol* 2004; 92: 137-138.
380. Meltzer EO, Hadley J, Blaiss M, Benninger M, Kimel M, Kleinman L, Dupclay L, Garcia J, Georges G. Development of an instrument to evaluate patient preference for intranasal steroids in a clinical trial setting. (abstr) *Ann Allergy Asthma Immunol* 2004; 92: 142.
381. Meltzer EO, Berman GD, Doyle G, Cooper S, Butkerait P, Berlin R, Watson S. Low-dose ibuprofen augments the effects of pseudoephedrine and chlorpheniramine in the treatment of seasonal allergic rhinitis. (abstr) *Ann Allergy Asthma Immunol* 2004; 92: 149.
382. Meltzer EO. Allergic rhinitis: pathogenesis and implications for the management of this chronic inflammatory disease in children. *Today's Therapeutic Trends* 2004; 22: 1-16.
383. Meltzer EO, Gillman SA, Meeves S, Liao Y, Georges G. Fexofenadine HCl 180 mg provides greater and faster histamine-induced flare suppression than desloratadine 5mg. (abstr) *J Allergy Clin Immunol* 2004; 113: S26-27.
384. Bernstein D, Meltzer EO, van Bavel J, Menendez R, Milgrom H, Finn AF, Winder JA, Economides A, Hardy P, Ruuth E. Fexofenadine effectively relieves seasonal allergic rhinitis in children from the USA. (abstr) *J Allergy Clin Immunol* 2004; 113: S233.
385. Meltzer EO. Clinical evidence for antileukotriene therapy in the management of allergic rhinitis. *Allergy From the Nose to the Lung (Japan)* 2004; 2: 3-9.
386. Meltzer EO, Gallet CL, Jalowayski AA, Garcia J, Diener P, Liao Y, Georges G. Triamcinolone acetonide and fluticasone propionate aqueous nasal sprays significantly improve nasal airflow in patients with seasonal allergic rhinitis. *Allergy and Asthma Proceedings* 2004; 25: 53-8.
387. Bousquet J, van Cauwenberge P, Khaltayev N, Members of the workshops (including Meltzer EO). ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. *Allergy* 2004; 59: 373-387.
388. Meltzer EO, Szwarcberg J, Pill MW. Allergic rhinitis, asthma, and rhinosinusitis: diseases of the integrated airway. *J Manag Care Pharm* 2004; 10: 310-17.
389. Meltzer EO, Scheinmann P, Rosado Pinto JE, Bachert C, Hedlin G, Wahn U, Finn Jr AF, Ruuth E. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis- a pooled analysis of three studies. *Pediatr Allergy Immunol* 2004; 15: 253-260.
390. Philip G, Meltzer EO, Nayak AS, Malice MP. Combination of montelukast and loratadine provides added benefit for relief of symptoms of seasonal allergic rhinitis (pooled analysis). (abstr) *Eur Respir J*, 2004; 24: 132s.
391. Meltzer EO, ed. Allergic Rhinitis After Hours: The Relevance and Consequence of Nighttime Symptoms. *J Allergy Clin Immunol* 2004; 114: S133-53.
392. Meltzer EO. Introduction: Stuffy is also related to Sleepy and Grumpy- The link between rhinitis and sleep-disordered breathing. *J Allergy Clin Immunol* 2004; 114: S133-34.
393. Meltzer EO, Berman GD, Corren J, Pedinoff AJ, Doyle G, Waksman JA, Butkerait P, Cooper SA, Berlin RG, Wason S. Addition of ibuprofen to pseudoephedrine and chlorpheniramine in the treatment of seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 2004; 93: 452-59.
- 394a. Meltzer EO, Hamilos DL, Hadley JA, Lanza DC, Marple BF, Nicklas RA, Bachert C, Baraniuk J, Baroody FM, Benninger MS, Brook I, Chowdhury BA, Druce HM, Durham S, Ferguson B, Gwaltney JM, Kaliner M, Kennedy DW, Lund V, Naclerio R, Pawankar R, Piccirillo JF, Rohane P, Simon R, Slavin RG, Togias A, Wald ER, Zinreich SJ. Rhinosinusitis: Establishing definitions for clinical research and patient care. *J Allergy Clin Immunol* 2004; 114: S155-212.

PUBLICATIONS: ELI O. MELTZER, MD

- 394b. Meltzer EO, Hamilos DL, Hadley JA, Lanza DC, Marple BF, Nicklas RA, Bachert C, Baraniuk J, Baroody FM, Benninger MS, Brook I, Chowdhury BA, Druce HM, Durham S, Ferguson B, Gwaltney JM, Kaliner M, Kennedy DW, Lund V, Naclerio R, Pawankar R, Piccirillo JF, Rohane P, Simon R, Slavin RG, Togias A, Wald ER, Zinreich SJ. Rhinosinusitis: Establishing definitions for clinical research and patient care. *Otolaryngology-Head and Neck Surgery* 2004; 131: S1-62.
395. Meltzer EO. Nasal congestion. Schering-Plough monograph, December 2004.
396. Blaiss MS, Blessing-Moore J, Chipps BE, Gelfand EW, Meltzer EO. The pediatric asthma challenge: exploring strategies for improving diagnosis, monitoring, and adherence. *Medical Crossfire* 2004; 5: 4-16.
397. Meltzer EO, Hadley J, Blaiss M, Benninger M, Kimel M, Klineman L, Dupclay L, Garcia J, Leahy M, Georges G. Development of questionnaires to measure patient preferences for intranasal corticosteroids in patients with allergic rhinitis. *Otolaryngol Head Neck Surg* 2005; 132: 197-207.
398. Meltzer EO, Luo Y, Shen L, Guo Z, Schemm C, Hyang Y, Chen K, King P, Nave R, Banerji D, Rohatagi S. High protein binding of ciclesonide, a novel inhaled corticosteroid, may reduce the potential for suppressing hypothalamic-pituitary-adrenal axis function. (abstr) *Ann Allergy Asthma Immunol* 2005; 94: 176-77.
399. Meltzer EO. Patient considerations regarding intranasal corticosteroids. University of Wisconsin Medical School and Adelphi, Inc. monograph, February 2005.
400. Ostrom NK, Meltzer EO, Welch MJ. At what age can a child swallow a pill? (abstr) *J Allergy Clin Immunol* 2005; 115: S42.
401. Korenblat P, Meltzer E, Busse W, Hedgecock S, Fox H, Blogg M. Omalizumab, an anti-IgE antibody, significantly reduces emergency visits in patients with severe persistent asthma: a pooled analysis. (abstr) *J Allergy Clin Immunol* 2005; 115: S76.
402. Meltzer E, Berkowitz R, Grossbard E, Gallet C, Dion S, Shaver S, Bazelmans D, Lutz C, Musser T. Effects of intranasal R112, an inhibitor of syk-kinase, on the symptoms of seasonal allergic rhinitis: a 2 day park study. (abstr) *J Allergy Clin Immunol* 2005; 115: S139.
403. Busse WW, Casale TB, Dykewicz MS, Meltzer EO, Bird SR, Hustad CM, Zeldin RK. Efficacy of montelukast during allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity. (abstr) *J Allergy Clin Immunol* 2005; 115: S150-51.
404. Howarth PH, Persson CGA, Meltzer EO, Jacobson MR, Durham SR, Silkoff PE. Objective monitoring of nasal airway inflammation in rhinitis. *J Allergy Clin Immunol* 2005; 115: S414-41.
405. Meltzer EO, Berkowitz RB, Grossbard EB. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. *J Allergy Clin Immunol* 2005; 115: 791-6.
406. Bachert C, Meltzer EO, Staudinger H, Bloom M. Effect of mometasone furoate on the health related quality of life of patients with acute rhinosinusitis. (abstr) *Allergy Clin Immunol Int* 2005; Suppl 1: 52.
407. Meltzer EO, Bachert C, Bloom M, Staudinger H, Gates D. Efficacy of intranasal mometasone furoate for the treatment of ocular symptoms in patients with seasonal allergic rhinitis. (abstr) *Allergy Clin Immunol Int* 2005; Suppl 1: 264-65.
408. Meltzer EO, Staudinger H, Bloom M, Shneyer L. Efficacy of once-daily mometasone furoate in patients with seasonal allergic rhinitis and severe nasal congestion. (abstr) *Allergy Clin Immunol Int* 2005; Suppl 1: 265.

PUBLICATIONS: ELI O. MELTZER, MD

409. Meltzer EO, Stjarne P, Bloom M, Shneyer L, Stryszak P. Efficacy and safety of once-daily mometasone furoate in patients with nasal polyposis. (abstr) *Allergy Clin Immunol Int* 2005; Suppl 1: 291.
410. van Drunen C, Meltzer EO, Bachert C, Bosquet J, Fokkens WJ. Nasal allergies and beyond: a clinical review of the pharmacology, efficacy, and safety of mometasone furoate. *Allergy* 2005; 60 (Suppl. 80); 5-19.
411. Wenzel SE, Corren J, Kraft M, Meltzer EO, Nelson HS, Stoloff SW, Tashkin DP, Yawn BP. Management of asthma in primary care settings. *J Family Prac* 2005; Sept. Suppl: 1-31.
412. Meltzer E, Bardelas J, Goldsobel A, Kaiser H. A preference evaluation study comparing the sensory attributes of mometasone furoate and fluticasone propionate nasal sprays by patients with allergic rhinitis. *Treat Respir Med* 2005; 4: 289-296.
413. Meltzer EO. Evaluation of the optimal oral antihistamine for patients with allergic rhinitis. *Mayo Clin Proc* 2005; 80: 1170-1176.
414. Meltzer EO. The relationships of rhinitis and asthma. *Allergy and Asthma Proc* 2005; 26: 336-40.
415. Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. *J Allergy Clin Immunol* 2005; 116: 1289-95.
416. Wenzel SE, Corren J, Kraft M, Meltzer EO, Nelson HS, Stoloff SW, Tashkin DP, Yawn BP. Asthma pharmacotherapy: role of inhaled corticosteroids and adjunctive therapy in the management of asthma. *Clinical Courier* 2005; 23 (No. 52): 1-7.
417. Meltzer EO, Hampel FC, Ratner PH, Bernstein DI, Larsen LV, Berger WE, Finn AF, Marple BF, Roland PS, Wall GM, Brubaker MJ, Dimas C, Potts SL, Silver LH, Barnes JR. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 2005; 95: 600-6.
418. Meltzer EO, Philip G, Weinstein SF, LaForce CF, Malice MP, Dass SB, Santanello NC, Reiss TF. Montelukast Effectively Treats the Nighttime Impact of Seasonal Allergic Rhinitis. *Am J Rhinol* 2005; 19: 591-98.
419. Meltzer EO. Intranasal steroids: managing allergic rhinitis and tailoring treatment to patient preference. *Allergy and Asthma Proc* 2005; 26: 445-51.
420. Busse, WW, Casale TB, Dykewicz MS, Meltzer EO, Bird SR, Hustad CM, Grant E, Zeldin RK, Edelman JM. Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity. *Ann Allergy Asthma Immunol* 2006; 96: 60-8.
421. Meltzer EO, Sotomayor JL, Kundu S, Banerji D. Long-term safety profile of once-daily ciclesonide in children with persistent asthma of all severities. (abstr) *Ann Allergy Asthma Immunol* 2006; 96: 140-141.
422. Meltzer EO, Hampel FC, Fairchild CJ, Brubaker MJ, Wall GM. Improvements in quality of life, work, and activity with olopatadine nasal spray treatment of seasonal allergic rhinitis: results of two randomized controlled trials. (abstr) *Ann Allergy Asthma Immunol* 2006; 96: 189.
423. Meltzer EO, Bardelas J, Goldsobel A, Kaiser H. A crossover study by patients with allergic rhinitis (AR) comparing sensory attributes and preferences for the nasal sprays of mometasone furoate and fluticasone propionate. (abstr) *Ann Allergy Asthma Immunol* 2006; 96: 193.
424. Meltzer EO, Bachert C, Staudinger H. Mometasone furoate nasal spray improves health-related quality of life of patients with acute rhinosinusitis. (abstr) *Ann Allergy Asthma Immunol* 2006; 96: 194.

PUBLICATIONS: ELI O. MELTZER, MD

425. Berger WE, Pearlman DS, Lumry WR, Meltzer EO. Efficacy of desloratadine (DL) 5 mg compared with fexofenadine (FEX) 180 mg in patients with symptomatic allergic rhinitis (SAR). (abstr) *Ann Allergy Asthma Immunol* 2006; 96: 195.
426. Meltzer EO, Kunjibettu S, Hall N, Berger W, LaForce C. Efficacy and safety of ciclesonide (CIC) for the treatment of perennial allergic rhinitis (PAR). (abstr) *J Allergy Clin Immunol* 2006; 117: S259.
427. Stanford R, Meltzer E, Derebery J, Nathan R, Campbell U, Stang P. Rhinitis symptom sufferers report a significant symptom burden during an allergy season. (abstr) *J Allergy Clin Immunol* 2006; 117: S321.
428. Stang P, Meltzer E, Derebery J, Nathan R, Campbell U, Stanford RH. Infrequent treatment of symptoms among rhinitis symptom sufferers during an allergy season. (abstr) *J Allergy Clin Immunol* 2006; 117: S322.
429. Nathan RA, Derebery J, Meltzer E, Stang P, Campbell U, Stanford RH. Great comorbidity burden related to rhinitis symptom sufferers. (abstr) *J Allergy Clin Immunol* 2006; 117: S323.
430. Meltzer EO, Sacks H. Azelastine nasal spray significantly improves health related quality of life compared to cetirizine tablets in patients with seasonal allergic rhinitis (SAR). (abstr) *J Allergy Clin Immunol* 2006; 117: S324.
431. Meltzer EO, Jalowayski AA, Vogt K, Iezzoni D, Harris AG. Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. *Ann Allergy Asthma Immunol* 2006; 96: 363-368.
432. Gleason M, Meltzer EO, Mullen ALW, Nicol NH. Childhood allergic rhinitis: diagnosis and management tools for the healthcare professional. *Pediatric Rounds, SynerMed Communications* 2006;8:1-9.
433. Meltzer EO. Allergic Rhinitis: Managing the pediatric spectrum. *Allergy Asthma Proc* 2006;27:2-8.
434. Meltzer EO, Weinstein SF, Zitt MJ. Optimal management of community-acquired acute bacterial rhinosinusitis: the allergist's perspective. *Ann Allergy Asthma Immunol* 2006; 96: 390-7.
435. Berger WE, Lumry WR, Meltzer EO, Pearlman DS. Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. *Allergy Asthma Proc* 2006; 27: 214-223.
436. Meltzer EO, Derendorf H. The systemic safety of inhaled corticosteroid therapy: a focus on ciclesonide. *Ann Allergy Asthma Immunol* 2006; 97: 149-157.
437. Meltzer EO. Optimal management of a pediatric patient with asthma. Part 1: Establishing asthma control. www.medsitecme.com, July 2006.
438. Meltzer EO. Optimal management of a patient with asthma. Part 2: Asthma is a persistent disease. www.medsitecme.com, September 2006.
439. Meltzer EO. Optimal management of a patient with asthma. Part 3: Persistent use of medications improves outcomes. www.medsitecme.com, November 2006.
440. Meltzer EO, Welch MJ, Ostrom NK. Pill swallowing ability and training in children 6 to 11 years of age. *Clinical Pediatrics* 2006;45:725-733.
441. Bousquet J, van Cauwenberge P, Khaled NA and coauthors (including Meltzer EO). Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA²LEN). *Allergy* 2006;61:1086-1096.
442. Berger W, Hampel F, Bernstein J, Shah S, Sacks H, Meltzer E. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 2006; 97: 375-381.

PUBLICATIONS: ELI O. MELTZER, MD

443. Blaiss MS, Thompson AK, Juniper E, Meltzer EO. Quality of life in patients with allergic rhinitis. In *Current Review of Rhinitis*. Edited by Kaliner MA. Philadelphia: Current Medicine; 2006: 15-23.
444. Greiner AN, Meltzer EO. Pharmacologic rationale for treating allergic and nonallergic rhinitis. *J Allergy Clin Immunol* 2006; 118: 985-96.
- 445a. Meltzer EO, Hamilos DL, Hadley JA, Lanza DC, Marple BF, Nicklas RA, Adinoff AD, Bachert C, Borish L, Chinchilli VM, Danzig MR, Ferguson BJ, Fokkens WJ, Jenkins SG, Lund VJ, Mafee MF, Naclerio RM, Pawankar R, Ponikau JU, Schubert MS, Slavin RG, Stewart MG, Togias A, Wald ER, Winther B. Rhinosinusitis: Developing guidance for clinical trials. *J Allergy Clin Immunol* 2006; 118: S17-61.
- 445b. Meltzer EO, Hamilos DL, Hadley JA, Lanza DC, Marple BF, Nicklas RA, Adinoff AD, Bachert C, Borish L, Chinchilli VM, Danzig MR, Ferguson BJ, Fokkens WJ, Jenkins SG, Lund VJ, Mafee MF, Naclerio RM, Pawankar R, Ponikau JU, Schubert MS, Slavin RG, Stewart MG, Togias A, Wald ER, Winther B. Rhinosinusitis: Developing guidance for clinical trials. *Otolaryngol Head Neck Surg* 2006; 135: S31-80.
446. Meltzer EO, Wenzel S. The efficacy and safety of mometasone furoate delivered via a dry powder inhaler for the treatment of asthma. *J Asthma* 2006; 43: 765-72
- 446a. Bachert C, Meltzer EO. Effect of mometasone furoate nasal spray on quality of life of patients with acute rhinosinusitis. *Rhinology* 2007; 45: 190-6.
447. Ratner PH, Meltzer EO, van Bavel JH, Hampel F, Berger W, LaForce C, Wingertzahn MA, Darken PF, Kunjibettu S, Hall N, Saha T. Effects of ciclesonide nasal spray on seasonal and perennial allergic rhinitis symptoms.(abstr) *Ann Allergy Asthma Immunol* 2007; 98:A21.
448. Nathan R, Meltzer E, Derebery J, Stang P, Campbell U, Corrao M, Stanford R. Timing of allergic rhinitis symptoms varies with self-reported disease severity: data from a large household survey. (abstr) *Ann Allergy Asthma Immunol* 2007; 98:A93.
449. Meltzer E, Derebery J, Nathan R, Stang P, Campbell U, Corrao M, Stanford R. Use of medications and healthcare utilization varies by self-reported allergic rhinitis severity: data from a large household survey. (abstr) *Ann Allergy Asthma Immunol* 2007; 98:A94.
450. Stull DE, Meltzer EO, Krouse JH, Lund VJ, Long AA, Kim S. Development and validation of the congestion quantifier 5-item (CQ5): a screening tool for nasal congestion. (abstr) *Ann Allergy Asthma Immunol* 2007; 98:A94.
451. Meltzer EO, Derebery MJ, Boyle JM, Droar J. Intranasal corticosteroids that provide a rapid onset of action and 24-hour symptom relief may improve satisfaction with therapy in patients with allergic rhinitis. (abstr) *Ann Allergy Asthma Immunol* 2007; 98:A117-18.
452. Meltzer EO. Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis. *Ann Allergy Asthma Immunol* 2007; 98:12-21.
453. Meltzer E, Boyle J, Droar J. Intranasal corticosteroids that provide sustained efficacy may improve patient satisfaction and adherence to therapy. (abstr) *J Allergy Clin Immunol* 2007; 119: S142.
454. Nathan R, Meltzer E, Derebery J, Stang P, Campbell U, Corrao M, Stanford R. Symptom burden during the winter for allergic and non-allergic rhinitis sufferers. (abstr) *J Allergy Clin Immunol* 2007; 119: S226.
455. Meltzer E, Nathan R, Derebery J, Stang P, Campbell U, Corrao M, Stanford R. Subjective effects of allergic rhinitis on sleep quality and amount during the winter. (abstr) *J Allergy Clin Immunol* 2007; 119: S226.
456. Stanford R, Meltzer E, Nathan R, Derebery J, Stang P, Campbell U. Nasal spray device and formulation attributes may contribute to stopping treatment with prescription nasal sprays. (abstr) *J Allergy Clin Immunol* 2007; 119: S228.

PUBLICATIONS: ELI O. MELTZER, MD

457. Meltzer EO, Berger WE, Chadwick SJ, Gross G, LaForce CF, Garadi R, Crenshaw K, Wall GM. Patient comparison of sensory attributes of olopatadine and azelastine nasal sprays. (abstr) *J Allergy Clin Immunol* 2007; 119: S229.
458. Meltzer EO, Tripathy I, Lee J, Lim J, Ellsworth A, Philpot E. Once-daily fluticasone furoate nasal spray (FF) provides 24-hour relief of the nasal symptoms of seasonal allergic rhinitis (SAR) in children ages 2-11 years. (abstr) *J Allergy Clin Immunol* 2007; 119: S305.
459. Meltzer EO, Gillman SA. Efficacy of fexofenadine versus desloratadine in suppressing histamine-induced wheal and flare. *Allergy Asthma Proc* 2007; 28: 67-73.
460. Meltzer EO, Kunjibettu S, Hall N, Wingertzahn MA, Murcia C, Berger W, LaForce C. Efficacy and safety of ciclesonide, 200 mg once daily, for the treatment of perennial allergic rhinitis. *Ann Allergy Asthma Immunology* 2007; 98: 175-181.
461. Passalacqua G, Durham SR, and ARIA panelists (including Meltzer EO). Allergic rhinitis and its impact on asthma update: allergen immunotherapy. *J Allergy Clin Immunol* 2007; 119: 881-91.
462. Meltzer EO. How can we improve the treatment of allergic rhinitis? *Allergy Asthma Proc* 2007; 28:S2-3.
463. Blaiss MS, Meltzer EO, Derebery J, Boyle JM. Patient and healthcare-provider perspectives on the burden of allergic rhinitis. *Allergy Asthma Proc* 2007; 28: S4-10.
464. Ratner PH, Stoloff S, Meltzer EO, Hadley JA. Intranasal corticosteroids in the treatment of allergic rhinitis. *Allergy Asthma Proc* 2007; 28: S25-32.
465. Fokkens W, Lund V, Mullol J, Bachert C, Cohen N, Cobo R, Desrosiers M, Hellings P, Holmstrom M, Hytonen M, Jones N, Kalogjera L, Kennedy D, Klossek J, Meltzer E, Naclerio B, Passali D, Price D, Riechelmann H, Scadding G, Stammberger H, Thomas M, Voegels R, Wang D. European Position Paper on Rhinosinusitis and Nasal Polyps: Pocket Guide. *EPOS* 2007: 1-15.
466. Meltzer EO, Baena-Cagnani CE, Chervinsky P, Stewart GE, Bronksy EA, Lutsky BN. Once-daily mometasone furoate administered by dry powder inhaler for the treatment of children with persistent asthma. *Pediatric Asthma, Allergy & Immunology* 2007; 20: 67-81.
467. Meltzer EO. Allergic rhinitis: The impact of discordant perspectives of patient and physician on treatment decisions. *Clin Ther* 2007; 29: 1428-1440.
468. Meltzer EO, Gallet CL. Ethical Foundations of Clinical Research in the United States. *Monitor* 2007; 22: 35-38.
469. Meltzer EO, Gallet CL. Ethical Considerations for Those Involved in Clinical Research in the United States. *Monitor* 2007; 22: 39-44.
470. Meltzer EO. Building a Better Mousetrap - The Next Generation of Intranasal Steroid Delivery Devices. *US Respiratory Disease* 2007; 72-73.
471. Stull DE, Krouse J, Meltzer EO, Roberts L, Kim S, Frank L, Naclerio R, Lund V, Long A. Development and Validation of the Congestion Quantifier Seven-Item Test (CQ7): A Screening Tool for Nasal Congestion. *Value in Health* 2007; 10: 457-65.
472. Fairchild CJ, Meltzer EO, Roland PS, Wells D, Drake M, Wall GM. Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitis. *Allergy Asthma Proc* 2007; 28: 716-723.
473. Derebery JM, Meltzer EO, Boyle JM. Nasal allergies adversely affect sleep and productivity in children. (abstr) *Ann Allergy Asthma Immunol* 2008; 100: A3.
474. Meltzer EO, Simmons L, Boyle JM. Nasal allergies reduce quality of life in children. (abstr) *Ann Allergy Asthma Immunol* 2008; 100: A4.

PUBLICATIONS: ELI O. MELTZER, MD

475. Meltzer EO, Vasar M, Houle P, Douglass J, Silvey M, Wu W, Philpot E, Caldwell M. Fluticasone furoate nasal spray provides 24-hour relief of perennial allergic rhinitis symptoms. (abstr) *Ann Allergy Asthma Immunol* 2008; 100: A4.
476. Belafsky PC, Meltzer EO, Roth CR. The incidence of dysphonia and laryngitis in patients with asthma receiving inhaled corticosteroid treatment. (abstr) *Ann Allergy Asthma Immunol* 2008; 100: A31-32.
477. Korenblat P, Casale T, Meltzer E, Bhatnagar A. Nasal carbon dioxide for the symptomatic treatment of perennial allergic rhinitis. (abstr) *Ann Allergy Asthma Immunol* 2008; 100: A85.
478. Miller TA, Nathan RA, Meltzer EO. Chronic rhinosinusitis: a survey of allergists' practices. (abstr) *Ann Allergy Asthma Immunol* 2008; 100: A86.
479. Stull DE, Meltzer EO, Sandor D, Crespi S, Vernon MK. The CQ5: a monitor for nasal congestion. (abstr) *Ann Allergy Asthma Immunol* 2008; 100: A88-89.
480. Schatz M, Meltzer E, Nathan R, Derebery J, Mintz M, Kosinski M, Dalal A, Stanford R, Silvey MJ, Philpot E. Development and validation of a rhinitis control assessment questionnaire. (abstr) *Ann Allergy Asthma Immunol* 2008; 100: A89.
481. Meltzer E, Stahlman J, Leflein J, Meltzer S, Lim J, Dalal A, Prillaman B, Philpot E. A patient preference evaluation study comparing the sensory attributes of fluticasone furoate nasal spray with fluticasone propionate nasal spray. (abstr) *Ann Allergy Asthma Immunol* 2008; 100: A89.
482. Miller TA, Meltzer EO, Nathan RA. Diagnosing chronic rhinosinusitis: results from a survey of allergists' practices. (abstr) *Ann Allergy Asthma Immunol* 2008; 100: A92.
483. Hankin CS, Cox L, Lang D, Levin A, Gross G, Eavy G, Meltzer E, Burgoyne D, Bronstone A, Wang Z. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: Patterns of care, resource use, and costs. *J Allergy Clin Immunol* 2008; 121: 227-32.
484. Danzig M, Meltzer EO, Gates D. Mometasone furoate nasal spray increases the number of days with minimal symptoms in patients with acute rhinosinusitis. (abstr) *J Allergy Clin Immunol* 2008; 121: S52.
485. van Bavel J, LaForce C, Meltzer E, Chia V, Darken P, Wingertzahn M. Effectiveness of ciclesonide nasal aerosol in adult and adolescent patients with seasonal allergic rhinitis (SAR). (abstr) *J Allergy Clin Immunol* 2008; 121: S53.
486. Kaiser H, Meltzer E, Yang WH, Lasko B, Silvey M, Wu W, Philpot E. Fluticasone furoate nasal spray significantly improves nasal symptoms and peak nasal inspiratory flow in subjects with perennial allergic rhinitis. (abstr) *J Allergy Clin Immunol* 2008; 121: S54.
487. Philpot E, Meltzer EO, Nathan RA, Schatz M, Derebery J, Mintz M, Kosinski M, Dalal AA, Stanford R, Silvey M. Performance of a brief self administered six item questionnaire to test rhinitis control. (abstr) *J Allergy Clin Immunol* 2008; 121: S70.
488. Meltzer E, Gordon B, Derebery J, Blaiss M, Boyle J. Decreased quality of life and performance in children and adults with nasal allergy symptoms. (abstr) *J Allergy Clin Immunol* 2008; 121: S107.
489. Blaiss M, Simmons L, Meltzer E, Sheth K, Boyle J. Sleep impairment in adult and children with allergic rhinitis. (abstr) *J Allergy Clin Immunol* 2008; 121: S108.
490. Stull DE, Vernon MK, Meltzer EO, Canonica G, Sandor DW, Crespi S. Comparison of the congestions quantifier 5- & 7-item scales to monitor nasal congestion. (abstr) *J Allergy Clin Immunol* 2008; 121: S129.

PUBLICATIONS: ELI O. MELTZER, MD

491. Nathan R, Meltzer E, Derebery J, Stang P, Corrao M, Allen G, Stanford R. Prevalence of nasal symptoms in the United States: findings from the Burden of Allergic Rhinitis in America survey. (abstr) *J Allergy Clin Immunol* 2008; 121: S208.
492. Gordon B, Blaiss M, Meltzer E, Mahr T, Boyle J. Prevalence of seasonal and perennial allergic rhinitis in children and adults. (abstr) *J Allergy Clin Immunol* 2008; 121: S209.
493. Kerwin EM, Nathan RA, Meltzer EO, Ortega HG, Yancey SW, Schoaf L, Dorinsky PM. Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg diskus administered once daily. *Respir Med* 2008; 102: 495-504.
494. Meltzer EO, Stahlman JE, Leflein J, Meltzer S, Lim J, Dalal AA, Prillaman BA, Philpot EE. Preference of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: a randomized, multicenter, double-blind, single-dose, crossover study. *Clin Ther* 2008; 30:271-79.
495. Meltzer EO. Antibiotics and Nasal Steroids for Acute Sinusitis. (Letter to the editor) *JAMA* 2008; 299: 1422-1423.
496. Meltzer EO, Teper A, Danzig M. Intranasal Corticosteroids in the Treatment of Acute Rhinosinusitis. *Current Allergy and Asthma Reports* 2008; 8: 133-138.
497. Vasar M, Houle PA, Douglass J, Meltzer EO, Silvey MJ, Wu W, Caldwell M, Philpot E. Fluticasone furoate nasal spray: Effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. *Allergy Asthma Proc* 2008; 29:313-321.
498. Bousquet J, Wahn U, Meltzer EO, Fox H, Hedecock S, Thomas K, Fowler-Taylor A. Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases. *Eur RESpir Rev* 2008; 17: 1-9.
499. Meltzer EO, Kelley N, Hovell MF. Randomized, cross-over evaluation of mobile phone vs paper diary in subjects with mild to moderate persistent asthma. *The Open Respiratory Medicine Journal* 2008; 2: 72-79.
500. Derebery J, Meltzer E, Nathan RA, Stang PE, Campbell UB, Carrao M, Stanford R. Rhinitis symptoms and comorbidities in the United States: Burden of rhinitis in America survey. *Otolaryngol Head Neck Surg* 2008; 139: 198-205.
501. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. *Allergy* 2008; 63: 1292-1300.
502. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Ait-Khaled N.....Meltzer EO, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008. *Allergy* 2008; 63 (Suppl 86): 8-160.
503. Nathan RA, Meltzer EO, Derebery J, Campbell UB, Stang PE, Corrao MA, Allen G, Stanford R. The prevalence of nasal symptoms attributed to allergies in the United States: Findings from the burden of rhinitis in an America survey. *Allergy Asthma Proc* 2008; 29:600-608.
504. Meltzer EO, Garadi R, LaForce C, Chadwick SJ, Berger WE, Gross G, Edwards MR, Crenshaw K, Wall GM. Comparative study of sensory attributes of two antihistamine nasal sprays: Olopatadine 0.6% and azelastine 0.1%. *Allergy Asthma Proc* 2008; 29: 659-668.
505. Meltzer EO, Tripathy I, Maspero JF, Wu W, Philpot E. Safety and Tolerability of Fluticasone Furoate Nasal Spray Once Daily in Paediatric Patients Aged 6-11 Years with Allergic Rhinitis. *Clin Drug Invest* 2009; 29: 79-86.
506. Blaiss MS, Derebery MJ, Meltzer EO, Naclerio RM, Wingertzahn M. Regional Prevalence of Allergic Rhinitis Symptoms: Findings from the Pediatric Allergies in America Survey. (abstr) *Ann Allergy Asthma Immunol* 2009; 102: A9-10.

PUBLICATIONS: ELI O. MELTZER, MD

507. Naclerio RM, Derebery MJ, Meltzer EO, Blaiss MS, Wingertzahan M. Allergic Rhinitis and Common Secondary Symptoms: Findings from the Pediatric Allergies in America Survey. (abstr) *Ann Allergy Asthma Immunol* 2009; 102: A10. (abstr) *Ann Allergy Asthma Immunol* 2009; 102: A10.
508. Meltzer EO, Blaiss MS, Derebery MJ, Naclerio, Wingertzahan M. Prevalence of Conditions Associated With Allergic Rhinitis in Children and Adults. (abstr) *Ann Allergy Asthma Immunol* 2009; 102: A10-11.
509. Korenblat P, Weinstein S, Noonan M, Meltzer EO. Ciclesonide 80 µg Twice Daily or 160 µg Once Daily AM Significantly Maintained Lung Function Compared With Placebo In Patients With Asthma Who Have Previously Received An Inhaled Corticosteroid. (abstr) *Ann Allergy Asthma Immunol* 2009; 102: A44.
510. Weinstein S, Meltzer EO, LaForce C, Korenblat P. Ciclesonide 80 µg Twice Daily or 160 µg Once Daily AM Maintains Variables of Asthma Control In Adults With Stable Mild-To-Moderate Asthma Previously Treated With An Inhaled Corticosteroid. (abstr) *Ann Allergy Asthma Immunol* 2009; 102: A45.
511. Meltzer EO, Korenblat P, Nayak A, Weinstein S. Ciclesonide 80 µg Twice Daily or 160 µg Once Daily AM Is Well Tolerated in Adults With Mild-To-Moderate Asthma Previously Receiving An Inhaled Corticosteroid. (abstr) *Ann Allergy Asthma Immunol* 2009; 102: A45.
512. Meltzer E, Milgrom H, Teper A, Urdaneta E, Staudinger H, Skoner D. Long-Term Safety of Mometasone Furoate Administered Via A Dry Powder Inhaler To Children With Asthma. (abstr) *Ann Allergy Asthma Immunol* 2009; 102: A54.
513. Meltzer E, Andrews C, Journea G, Lim J, Garris C, Prillaman B, Philpot E. Patients Prefer Fluticasone Furoate Nasal Spray In A Sensory Attribute Comparison With Fluticasone Propionate Nasal Spray. (abstr) *Ann Allergy Asthma Immunol* 2009; 102: A115.
514. Meltzer EO, Munafo D, Chung W, Gopalan G, Varghese ST. Mometasone Furoate Nasal Spray Reduces Daytime Sleepiness and Reduces Work Absenteeism In Patients With Allergic Rhinitis-Related Breathing-Disordered Sleep. (abstr) *Ann Allergy Asthma Immunol* 2009; 102: A117.
515. Meltzer EO, Munafo D, Chung W, Gopalan G, Varghese ST. Mometasone Furoate Nasal Spray For The Treatment Of Nasal Symptoms In Subjects With Allergic Rhinitis And Breathing-Disordered Sleep. (abstr) *Ann Allergy Asthma Immunol* 2009; 102: A117.
516. Meltzer EO, Munafo D, Chung W, Gopalan G, Varghese ST. Use Of Mometasone Furoate Nasal Spray In The Treatment of Snoring And Obstructive Sleep Apnea-Hypopnea In Allergic Rhinitis Subjects With Breathing-Disordered Sleep. (abstr) *Ann Allergy Asthma Immunol* 2009; 102: A118.
517. Meltzer EO, Munafo D, Chung W, Gopalan G, Varghese ST. Mometasone Furoate Nasal Spray Significantly Improves Nasal Air Flow In Subjects With Perennial Allergic Rhinitis And Sleep Disturbance. (abstr) *Ann Allergy Asthma Immunol* 2009; 102: A118.
518. Meltzer EO, Munafo D, Chung W, Gopalan G, Varghese ST. Mometasone Furoate Nasal Spray Improves Nasal And Nighttime Symptoms Of Allergic Rhinitis And Job/Daily Activity Impairment. (abstr) *Ann Allergy Asthma Immunol* 2009; 102: A121.
519. Meltzer EO, Munafo D, Chung W, Gopalan G, Varghese ST. Mometasone Furoate Nasal Spray Improves Quality Of Life In Subjects With Perennial Allergic Rhinitis And Breathing-Disordered Sleep. (abstr) *Ann Allergy Asthma Immunol* 2009; 102: A121.
520. Meltzer EO, Lee J, Tripathy I, Lim J, Ellsworth A, Philpot E. Efficacy and safety of once-daily fluticasone furoate nasal spray in children with seasonal allergic rhinitis treated for 2 wk. *Pediatr Allergy Immunol* 2009; 20:279-286.

PUBLICATIONS: ELI O. MELTZER, MD

521. Meltzer EO, Nathan RA, Derebery J, Dalal AA, Stanford RH, Corrao MA, McMorris BJ. Physician Perceptions of the Treatment and Management of Allergic and Non-Allergic Rhinitis. *Allergy and Asthma Proc* 2009; 30: 75-83.
522. Meltzer EO, Nathan R, Derebery J, Stang PE, Campbell UB, Yeh WS, Corrao M, Stanford R. Sleep, quality of life, and productivity impact of nasal symptoms in the United States: Findings from the Burden of Rhinitis in America survey. *Allergy Asthma Proc* 2009; 30: 244-254.
523. Meltzer EO, Korenblat PE, Weinstein SF, Noonan M, Karafilidis J. Efficacy and safety evaluation of ciclesonide in mild-to-moderate persistent asthma previously treated with inhaled corticosteroids. *Allergy Asthma Proc* 2009; 30: 293-303.
524. LaForce C, van Bavel J, Meltzer EO, Wingertzahn MA. Efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol once daily for the treatment of seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 2009;103:166-173.
525. Meltzer EO, Blaiss MS, Derebery MJ, Mahr TA, Gordon BR, Sheth KK, Simmons AL, Wingertzahn MA, Boyle JM. Burden of allergic rhinitis: Results from the Pediatric Allergies in America survey. *J Allergy Clin Immunology* 2009; 124: S43-70.
526. Martin ML, Patrick DL, Bushnell DM, Meltzer EO; Gutierrez B; Parasuraman B. Development of the Asthma Treatment Satisfaction Measure. *Curr Med Res Opin* 2009; 25: 2495-2506.
527. Kaliner MA, Baraniuk JN, Benniger M, Bernstein JA, Lieberman P, Meltzer EO, Naclerio RM, Settupane RA, Farrar JR. Consensus definition of nonallergic rhinopathy, previously referred to as vasomotor rhinitis, nonallergic rhinitis, and/or idiopathic rhinitis. *WAO Journal* 2009;2: 119-120.
528. Meltzer EO. The Treatment of Vasomotor Rhinitis with Intranasal Corticosteroids. *WAO Journal* 2009; 2: 166-179.
529. Kaliner MA, Baraniuk JN, Benniger M, Bernstein JA, Lieberman P, Meltzer EO, Naclerio RM, Settupane RA, Farrar JR. Consensus description of inclusion and exclusion criteria for clinical studies of nonallergic rhinopathy (NAR), previously referred to as vasomotor rhinitis (VMR), nonallergic rhinitis, and/or idiopathic rhinitis. *WAO Journal* 2009; 2:180-184.+
530. Ratner PH, Meltzer EO, Teper A. Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. *Int J Pediatr Otorhinolaryngol* 2009; 73: 651-7.
531. Meltzer EO, Blaiss MS, Derebery J, Mahr TA, Gordon BR, Sheth KK, Simmons AL, Wingertzahn MA, Boyle JM. Burden of allergic rhinitis: Results from the Pediatric Allergies in America Survey. *J Allergy Clin Immunol* 2009; 124: S43-70.
532. Carr W, Tilles SA, Chippis BE, LaForce CF, Storms W, Meltzer EO, Lanier BQ. Comparison of olopatadine hydrochloride nasal spray 0.6% and azelastine hydrochloride nasal spray 0.1% in combination therapy with an intranasal steroid for the treatment of seasonal allergic rhinitis. (abstr) *Ann Allergy Asthma Immunol* 2009; 103: A28.
533. Meltzer EO, Schatz M, Marple B, Ledgerwood G, Harris L, Golla S, Garris C, Stanford R, Silvey MJ, Kosinski M. Longitudinal validation of the rhinitis control assessment test. (abstr) *Ann Allergy Asthma Immunol* 2009; 103: A28.
534. LaForce C, Weinstein C, Nathan R, Weinstein S, Staudinger H, Meltzer E. Patients satisfaction with a pressurized MDI integrated dose counter containing a fixed dose mometasone furoate/formoterol combination. (abstr) *Ann Allergy Asthma Immunol* 2009; 103: A60.

PUBLICATIONS: ELI O. MELTZER, MD

535. Nathan R, Weinstein S, Meltzer E, Nolte H, Maspero J. Safety of mometasone furoate/formoterol combination therapy for the treatment of persistent asthma. (abstr) *Ann Allergy Asthma Immunol* 2009; 103: A66.
536. Meltzer E, Nolte H, LaForce C. Low-dose mometasone furoate/formoterol therapy: safety and tolerability findings from a study investigating the effects of a new combination treatment for asthma. (abstr) *Ann Allergy Asthma Immunol* 2009; 103: A66.
537. Milgrom H, Berger WE, Meltzer EO. Consistency of improved lung function by inhaled mometasone furoate in children: findings from a clinical development program. (abstr) *Ann Allergy Asthma Immunol* 2009; 103: A67-68.
538. Berger WE, Milgrom H, Meltzer EO. Consistent reduction of daily SABA use with inhaled mometasone furoate: findings from a clinical development program in children with persistent asthma. (abstr) *Ann Allergy Asthma Immunol* 2009; 103: A69.
539. Meltzer EO, Wheeler W, Sacks H. Double-blind, placebo-controlled evaluation of a reformulation of azelastine nasal spray on nasal symptom scores and quality of life measures in patients with SAR. (abstr) *Ann Allergy Asthma Immunol* 2009; 103: A137.
540. Meltzer EO, Bensch G, Van Bavel JH, Wall GM. Safety of olopatadine hydrochloride nasal spray 0.6% in 6 to 11 year-old pediatric patients with seasonal allergic rhinitis. (abstr) *Ann Allergy Asthma Immunol* 2009; 103: A139.
541. Berger WE, Storms W, Meltzer EO, Wall GM. Efficacy of olopatadine hydrochloride nasal spray 0.6% in 6 to 11 year-old pediatric patients with seasonal allergic rhinitis. (abstr) *Ann Allergy Asthma Immunol* 2009; 103: A140.
542. Berger WE, Ratner PH, Casale TB, Meltzer EO, Wall GM. Safety and efficacy of olopatadine hydrochloride nasal spray 0.6% in pediatric subjects with allergic rhinitis. *Allergy Asthma Proc* 2009; 30: 612-23.
543. Stull DE, Meltzer EO, Krouse JH, Roberts L, Kim S, Frank L, Naclerio R, Lund V, Long A. The congestion quantifier five-item test for nasal congestion: Refinement of the congestion quantifier seven-item test. *Am J Rhinol Allergy* 2010;24: 34-38.
544. Sutherland ER, Camargo CA, Busse WW, Meltzer EO, Ortega HG, Yancey S, Emmett AH, Stempel DA. Comparative effect of body mass index on response to asthma controller therapy. *Allergy Asthma Proc* 2010; 31: 20-25.
545. Schatz M, Meltzer EO, Nathan R, Derebery MJ, Mintz M, Stanford RH, Dalal AA, Silvey MJ, Kosinki M. Psychometric validation of the Rhinitis Control Assessment Test: a brief patient-completed instrument for evaluating rhinitis symptom control. *Ann Allergy Asthma Immunol* 2010; 104: 118-124.
546. Krouse JH, Lund V, Fokkens W, Meltzer EO. Diagnostic strategies in nasal congestion. *Int J Gen Med* 2010;3:59-67.<http://www.dovepress.com/diagnostic-strategies-in-nasal-congestion-peer-reviewed-article-IJGM>. Published February 15, 2010.
547. Meltzer EO, Caballero F, Fromer LM, Krouse JH, Scadding G. Treatment of congestion in upper respiratory diseases. *Int J Gen Med*. 2010;3:69-91.
<http://www.dovepress.com/treatment-of-congestion-in-upper-respiratory-diseases-peer-reviewed-article-IJGM>. Published February 15, 2010.
548. Milgrom H, Meltzer EO, Berger WE. Improvements in the Ratio of Forced Expiratory Volume in One Second to Forced Vital Capacity in Asthmatic Children Receiving Inhaled Mometasone Furoate. (Abstr) *J Allergy Clin Immunol* 2010; 125:AB68.
549. Lanier BQ, Meltzer EO, Gates D, Shekar T, Teper A. Onset and duration of action of concomitant administration of mometasone furoate nasal spray with oxymetazoline nasal spray versus either drug alone and placebo in subjects with seasonal allergic rhinitis. (Abstr) *J Allergy Clin Immunol* 2010; 125:AB173.

PUBLICATIONS: ELI O. MELTZER, MD

550. Gross G, Meltzer EO, Gates D, Shekar T, Teper A. Impact of Concomitant Administration of Mometasone Furoate and Oxymetazoline Nasal Sprays vs Either Drug Alone or Placebo on Quality of Life in Patients with Seasonal Allergic Rhinitis. (Abstr) *J Allergy Clin Immunol* 2010; 125:AB174.
551. White M, Nolte H, Meltzer E, Nathan R. Asthma Symptom Control Using a Combination of Mometasone Furoate/Formoterol (MF/F): Grouped Analysis of Three Clinical Trials. (Abstr) *J Allergy Clin Immunol* 2010; 125:AB194.
552. Pearlman D, Nathan E, Nolte H, Weinstein S. Effect of Mometasone Furoate/Formoterol (MF/F) Combination Therapy on Nocturnal Awakenings in Subjects With Persistent Asthma. (Abstr) *J Allergy Clin Immunol* 2010; 125:AB194.
553. La Force C, Meltzer E, Nathan R, Nayak A, Nolte H, Pearlman D. Effect of Treatment with Mometasone Furoate/Formoterol Combination (MF/F) on Rescue Medication Use. (Abstr) *J Allergy Clin Immunol* 2010; 125:AB194.
554. Berger WE, Milgrom H, Meltzer E. Inhaled Mometasone Furoate Improved Efficacy in Pediatric Asthma Patients Regardless of Previous Inhaled Corticosteroid Therapy: Pooled Data From the Clinical Development Program. (Abstr) *J Allergy Clin Immunol* 2010; 125:AB195.
555. Teper A, Murphy KR, Meltzer EO, Berger WE. Reduction of Relief Medication Use in Children Receiving Inhaled Mometasone Furoate for Control of Mild Persistent Asthma. (Abstr) *J Allergy Clin Immunol* 2010; 125:AB195.
556. Meltzer E, Nolte H, LaForce C. Low-dose Mometasone Furoate/Formoterol: Efficacy and Safety Findings from a Study Investigating a New Combination Therapy in Subjects Whose Asthma was Inadequately Controlled Using Low-Dose Inhaled Corticosteroid. (Abstr) *J Allergy Clin Immunol* 2010; 125:AB196.
557. Murphy K, Meltzer E, Nolte H, Nathan R. Characterization of the Effect of Mometasone Furoate/Formoterol Treatment on Quality of Life: An Analysis of Multi-Trial AQLQ Findings. (Abstr) *J Allergy Clin Immunol* 2010; 125:AB196.
558. Meltzer EO, Andrews C, Journeay GE, Lim J, Prillaman BA, Garris C, Philpot E. Comparison of patient preference for sensory attributes of fluticasone furoate or fluticasone propionate in adults with seasonal allergic rhinitis: a randomized, placebo-controlled, double-blind study. *Annals Allergy Asthma Immunol* 2010; 104: 331-338.
559. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, Wenzel SE, Chon Y, Dunn M, Weng HH, Lin S. A randomized, controlled, phase 2 study of AMG 317, an IL-4R α antagonist, in patients with asthma. *Am J Respir Crit Care Med* 2010; 181: 788-796.
560. LaForce CF, Carr W, Tilles SA, Chipps BE, Storms W, Meltzer EO, Edwards M. Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis. *Allergy Asthma Proc* 2010; 31: 132-140.
561. Nathan RA, Dalal AA, Stanford RH, Meltzer EO, Schatz M, Derebery J, Mintz M, Thompson MA, DiBenedetti DB. Qualitative development of the rhinitis control assessment test (RCAT), an instrument for evaluating rhinitis symptom control. *Patient* 2010; 3: 91-99.
562. Meltzer EO, Munafo DA, Chung W, Gopalan G, Varghese ST. Intranasal mometasone furoate therapy for allergic rhinitis symptoms and rhinitis-disturbed sleep. *Ann Allergy Asthma Immunol* 2010; 105: 65-74.
563. Bousquet J, Schunemann HJ, Zuberbier T, Bachert C, Baena-Cagnani CE, Bousquet PJ, Brozek J, Canonica GW, Casale TB, Demoly P, ...Meltzer EO..., et al. Development and implementation of guidelines in allergic rhinitis – an ARIA-GA²LEN paper. *Allergy* 2010; 65: 1212-21.

PUBLICATIONS: ELI O. MELTZER, MD

564. Nathan RA, Blaiss M, Stoloff S, Murphy K, Meltzer EO. Asthma insight and management survey: Differences in asthma terminology understanding among patients and physicians. (Abstr) *Ann Allergy Asthma Immunol*; 2010: 105: A48.
565. Berger E, Noonan M, Teper A, Moreno-Cantu J, Struszak P, Meltzer EO. Changes in lung function observed in children after switching inhaled corticosteroid therapy to mometasone furoate administered via a drypowder inhaler. (Abstr) *Ann Allergy Asthma Immunol*; 2010: 105: A49.
566. Blaiss M, Meltzer EO, Murphy K, Nathan RA. Asthma insight and management (AIM): a national survey of asthma patients, the general population, and healthcare providers. (Abstr) *Ann Allergy Asthma Immunol*; 2010: 105: A49.
567. White M, Meltzer EO, Nathan RA, Nolte H. Improved asthma control with mometasone furoate/formoterol: a new combination treatment for persistent asthma. (Abstr) *Ann Allergy Asthma Immunol*; 2010: 105: A49-50.
568. Meltzer EO, Nathan RA, Blaiss M, Stoloff S, Murphy K. Patient-reported asthma burden and treatment practice in the united states: results of the asthma insight and management survey. (Abstr) *Ann Allergy Asthma Immunol*; 2010: 105: A50.
569. Murphy K, Meltzer EO, Nathan RA, Blaiss M, Stoloff S. Advances in asthma control and management in the united states: results of the asthma insight and management survey. (Abstr) *Ann Allergy Asthma Immunol*; 2010: 105: A50.
570. Murphy K, Meltzer EO, Nathan RA, Nolte H. Quality of life improvements in persistent asthma subjects receiving combined mometasone furoate and formoterol. (Abstr) *Ann Allergy Asthma Immunol*; 2010: 105: A51.
571. Meltzer EO, Wang B, Karafilidis J. A correlation analysis between nasal symptoms and quality of life following treatment with ciclesonide aqueous nasal spray in seasonal allergic rhinitis. (Abstr) *Ann Allergy Asthma Immunol*; 2010: 105: A118.
572. Meltzer EO, Wang B, Karafilidis J. A post-hoc analysis of the effect of ciclesonide aqueous nasal spray on nasal congestion in subjects with seasonal allergic rhinitis. (Abstr) *Ann Allergy Asthma Immunol*; 2010: 105: A119.
573. Blais M, Meltzer EO, Spann M, Fairchild C. Comprehensive report of efficacy, safety, QOL, and caregiver satisfaction in children receiving olopatadine, 0.6% nasal spray for the treatment of seasonal allergic rhinitis. (Abstr) *Ann Allergy Asthma Immunol*; 2010: 105: A119-120.
574. Fairchild C, Meltzer EO, Meuse P. Validation of a caregiver treatment satisfaction questionnaire for allergic rhinitis treatment for children. (Abstr) *Ann Allergy Asthma Immunol*; 2010: 105: A120.
575. Meltzer EO, Shah SR, Shekar T, Teper A. Mometasone furoate nasal spray reduces nighttime and early morning nasal congestion in patients with seasonal allergic rhinitis. (Abstr) *Ann Allergy Asthma Immunol*; 2010: 105: A123.
576. Meltzer EO, Lieberman P, Darter AL, LaForce CF, Tort MJ. Efficacy and tolerability of olopatadine hydrochloride nasal spray, 0.6% in a 2-week vasomotor rhinitis (vmr) trial. (Abstr) *Ann Allergy Asthma Immunol*; 2010: 105: A125-126.
577. Meltzer EO, Busse WW, Wenzel SE, Belozeroff V, Weng HH, Feng JY, Chon Y, Chiou CF, Globe D, Lin SL. Use of the asthma control questionnaire to predict future risk of asthma exacerbation. *J Allergy Clin Immunol* 2011; 127: 167-72.
578. Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. *Ann Allergy Asthma Immunol* 2011; 106: S12-S16.

PUBLICATIONS: ELI O. MELTZER, MD

579. Katial RK, Meltzer EO, Lieberman P, Ratner PH, Berger WE, Kaliner MA, Siegel CJ, Bukstein DA, Ciervo CA, Marple B. Suggested updated approaches to patient management. Guest Editorial, *Ann Allergy Asthma Immunol* 2011; 106: S17-S19.
580. Nathan RA, Stoloff SW, Blaiss M, Meltzer EO, Doherty DE, Murphy KR. Comparing Asthma in America (AIA) and Asthma Insight and Management (AIM) Surveys - Did Asthma Burden and Management Improve in the United States Between 1998 and 2009? (Abstr) *J Allergy Clin Immunol* 2011; 127:AB78.
581. Stoloff S, Nathan RA, Blaiss M, Meltzer EO, Doherty DE, Murphy KR. Physician-Reported Asthma Control and Management From the Asthma Insight and Management (AIM) Survey. (Abstr) *J Allergy Clin Immunol* 2011; 127:AB78.
582. Meltzer EO, Doherty DE, Nathan RA, Murphy KR, Stoloff SW, Blaiss M. The Overall Burden Experienced by Asthma Patients Interviewed in the Asthma Insight and Management (AIM) Survey. (Abstr) *J Allergy Clin Immunol* 2011; 127:AB79.
583. Doherty DE, Meltzer EO, Stoloff SW, Murphy KR, Nathan RA, Blaiss. Patient and Physician Differences in Understanding Asthma Symptom Deterioration Terminology From the Asthma Insight and Management (AIM) Survey. (Abstr) *J Allergy Clin Immunol* 2011; 127:AB80.
584. Prenner B, Meltzer EO, Desai SY, Karafilidis J, Walsh J. A Post-Hoc Analysis Of Asthma Control And Lung Function Following Treatment With Ciclesonide 80 mg HFA-MDI Twice Daily In Subjects With Mild-to-Moderate Persistent Asthma Previously Receiving Low Dose Fluticasone Propionate/Salmeterol. (Abstr) *J Allergy Clin Immunol* 2011; 127:AB85.
585. Nayak AS, Nathan RA, Meltzer EO, Weinstein SF, Nolte H. Mometasone Furoate/Formoterol Combination Therapy Increases Frequency of Days/Nights Free of Short-Acting β_2 -Agonist Use. (Abstr) *J Allergy Clin Immunol* 2011; 127:AB86.
586. Weinstein SF, Nathan RA, Meltzer EO, Gates D, Nolte H. Reduction in Asthma Deteriorations in Subjects With Persistent Asthma Uncontrolled on Low-, Medium-, or High-Dose Inhaled Corticosteroids: A Pooled Analysis From Three Clinical Trials Using Combined Mometasone Furoate/Formoterol. (Abstr) *J Allergy Clin Immunol* 2011; 127:AB86.
587. LaForce C, Meltzer EO, Nathan RA, Weinstein SF, Nolte H. Greater Reduction in Asthma Symptom Frequency During Treatment With Mometasone Furoate/Formoterol Combination Versus Monocomponents and Placebo. (Abstr) *J Allergy Clin Immunol* 2011; 127:AB158.
588. Berger WE, Noonan M, Teper A, Morneo-Cantu J, Stryszak P, Meltzer EO. Reduction of Nocturnal Awakenings With Mometasone Furoate Administered Via Dry Powder Inhaler in Children With Persistent Asthma Previously Receiving Other Inhaled Corticosteroids. (Abstr) *J Allergy Clin Immunol* 2011; 127:AB159.
589. Storms W, Meltzer EO, Derebery J, Ortiz G, Fromer L. The Nasal Allergy Survey Assessing Limitations (NASL) 2010 Survey: Allergic Rhinitis Is Associated with Substantial Sleep Disturbances. (Abstr) *J Allergy Clin Immunol* 2011; 127:AB217.
590. Lieberman P, Meltzer EO, LaForce CF, Darter AL, Tort MJ. Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis. *Allergy Asthma Proc* 2011; 32: 151-58.
591. Meltzer EO, Shekar T, Teper AA. Mometasone furoate nasal spray for moderate-to-severe nasal congestion in subjects with seasonal allergic rhinitis. *Allergy Asthma Proc* 2011;32:159-67.
592. Meltzer EO, Hamilos DL. Rhinosinusitis diagnosis and management for the clinician: A synopsis of recent consensus guidelines. *Mayo Clin Proc* 2011;86:427-443.
593. Greiner AN, Meltzer EO. Overview of the treatment of allergic rhinitis and nonallergic rhinopathy. *Proc Am Thorac Soc* 2011;8:121-131.

PUBLICATIONS: ELI O. MELTZER, MD

594. Meltzer EO, Munafo DA, Chung W, Gopalan G, Varghese ST. "Intranasal mometasone furoate therapy for allergic rhinitis symptoms and rhinitis-disturbed sleep." In Best of Sleep Medicine 2011. Ed. Teofilo Lee-Chiong. 2011. 231-233. Print.
595. Meltzer EO, Blaiss M, Fairchild CJ. Comprehensive report of olopatadine 0.6% nasal spray as treatment for children with seasonal allergic rhinitis. *Allergy Asthma Proc* 2011; 32: 213-220.
596. Revicki DA, Margolis MK, Thompson CL, Meltzer EO, Sandor DW, Shaw JW. Major symptom score utility index for patients with acute rhinosinusitis. *Am J Rhinology & Allergy* 2011; 25: 99-106.
597. Meltzer EO. The role of nasal corticosteroids in the treatment of rhinitis. *Immunol Allergy Clin N Am* 2011; 31: 545-60.
598. LaForce C, Weinstein C, Nathan RA, Weinstein SF, Staudinger H, Meltzer EO. Patient satisfaction with a pressurized metered-dose inhaler with an integrated dose counter containing a fixed-dose mometasone furoate/formoterol combination. *J Asthma* 2011; 48:625-31.
599. Skoner DP, Meltzer EO, Milgrom H, Stryszak P, Teper A, Staudinger H. Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo controlled trial in children 4-9 years old with mild persistent asthma. *J Asthma* 2011; 48: 848-59.
600. Chipps B, Spector S, Farrar J, Carr W, Meltzer E, Storms W, Kaliner M, Luskin A, Bukstein D, Oppenheimer J, Smart B, Derebery J, Harder J, Dykewicz M, Benninger M. Differences in recommendations between the allergic rhinitis and its impact on asthma update 201 and US rhinitis practice parameters. Letter to Editor. *J Allergy Clin Immunol* 2011; 127: 1640-41.
601. Casale TB, Korenblat PE, Meltzer EO, Yen K, Bhatnagar A. Nasal carbon dioxide for the symptomatic treatment of perennial allergic rhinitis. *Ann Allergy Asthma Immunol* 2011; 107: 364-370.
602. Meltzer EO, Carr W, Ginsberg D. MP29-02 in the symptomatic treatment of seasonal allergic rhinitis (SAR) –a comparative spring study. (Abstr) *Ann Allergy Asthma Immunol*; 2011: 107: A13.
603. Nathan R, Meltzer EO, Pearlman D, Nolte H, Weinstein S. Rapid and sustained improvements in lung function with combined mometasone furoate and formoterol in subjects with moderate or severe asthma. (Abstr) *Ann Allergy Asthma Immunol*; 2011: 107: A39-40.
604. Meltzer EO, Blaiss M, Nathan R, Murphy K, Stoloff S. Physician perspectives on asthma symptoms in their patients: asthma insight and management survey. (Abstr) *Ann Allergy Asthma Immunol*; 2011: 107: A40.
605. Maspero J, Meltzer EO, Nathan R, Weinstein S, Cherrez-Ojeda I, Gates D, Nolte H. Exposure-adjusted rates of treatment-related adverse events during mometasone furoate/formoterol asthma treatment: post hoc analysis of 6 mometasone furoate/formoterol trials. (Abstr) *Ann Allergy Asthma Immunol*; 2011: 107: A40.
606. Blaiss M, Meltzer EO, Murphy K, Nathan R, Stoloff S. Duration of asthma episodes reported by patients in the asthma insight and management survey. (Abstr) *Ann Allergy Asthma Immunol*; 2011: 107: A40-41.
607. Naclerio R, Meltzer EO, Wang B, Karafilidis J. Allergies in America survey: adult patients' perception of the effectiveness of their intranasal corticosteroid medications. (Abstr) *Ann Allergy Asthma Immunol*; 2011: 107: A116.
608. Meltzer EO, Jacobs RL, LaForce CF, Dorinsky PM, Kelley L, Dunbar SA. BDP HFA nasal aerosol 320mcg once daily is safe and effective in the treatment of nasal symptoms associated with perennial allergic rhinitis. (Abstr) *Ann Allergy Asthma Immunol*; 2011: 107: A118-119.

PUBLICATIONS: ELI O. MELTZER, MD

609. Carr W, Meltzer EO, Ginsberg D. MP29-02 significantly improves the rhinoconjunctivitis quality of life questionnaire (RQLQ) score in patients with seasonal allergic rhinitis (SAR). (Abstr) *Ann Allergy Asthma Immunol*; 2011; 107: A119.
610. Meltzer EO, Naclerio R, Wang B, Karafilidis J. Allergies in America survey: adult patients' perception of the sensory attributes and tolerability of prescription nasal allergy medications. (Abstr) *Ann Allergy Asthma Immunol*; 2011; 107: A120-121.
611. Meltzer EO, Kuna P, Nolte H, Nayak AS, LaForce C on behalf of the P04073 Study Investigators. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. *Eur Respir J* 2012; 39: 279-289.
612. Meltzer EO, Gross GN, Katial R, Storms WW. Allergic rhinitis substantially impacts patients quality of life: findings from the Nasal Allergy Survey Assessing Limitations. *J Fam Pract* 2012; 61 (suppl): S5-S10.
613. Stoloff SW, Hadley JA, Meltzer EO. Closing thoughts: implications of the findings from the National Allergy Survey Assessing Limitations for the management of allergic rhinitis in America. *J Fam Pract* 2012; 61 (suppl): S23-28.
614. Meltzer EO, Blaiss MS, Nathan RA, Doherty DE, Murphy KR, Stoloff SW. Asthma burden in the United States: Results of the 2009 Asthma Insight and Management survey. *Allergy and Asthma Proceedings*. Epublished ahead of print Dec 14, 2011. *Allergy Asthma Proc* 2012; 33: 36-46.
615. Blaiss MS, Nathan RA, Stoloff SW, Meltzer EO, Murphy KR, Doherty DE. Patient and physician asthma deterioration terminology: Results from the 2009 Asthma Insight and Management survey. *Allergy and Asthma Proceedings*. Epublished ahead of print Dec 14, 2011. *Allergy Asthma Proc* 2012; 33: 47-53.
616. Murphy KR, Meltzer EO, Blaiss MS, Nathan RA, Stoloff SW, Doherty DE. Asthma management and control in the United States: Results of the 2009 Asthma Insight and Management survey. *Allergy and Asthma Proceedings*. Epublished ahead of print Dec 14, 2011. *Allergy Asthma Proc* 2012; 33: 54-64.
617. Nathan RA, Meltzer EO, Blaiss MS, Murphy KR, Doherty DE, Stoloff SW. Comparison of the Asthma in America and Asthma Insight and Management surveys: Did asthma burden and care improve in the United States between 1998 and 2009? *Allergy and Asthma Proceedings*. Epublished ahead of print Dec 14, 2011. *Allergy Asthma Proc* 2012; 33: 65-76
618. Weinstein SF, Nathan RA, Meltzer EO, Gates D, Nolte H. Reduction in asthma deteriorations in subjects with persistent asthma not well controlled on low-, medium-, or high-dose inhaled corticosteroids: A pooled analysis from 3 clinical trials using combined mometasone furoate/formoterol. (Abstr) *World Allergy Organization Journal* Feb 2012; 5: S62, #187.
619. Pearlman D, Nathan RA, Meltzer EO, Nolte H, Weinstein SF. Effect of mometasone furoate/formoterol combination therapy on nocturnal awakenings in subjects with persistent asthma. (Abstr) *World Allergy Organization Journal* Feb 2012; 5: S63, #190.
620. Murphy K, Meltzer EO, Nathan RA, Nolte H. Quality of life improvements in persistent asthma subjects receiving combined mometasone furoate and formoterol. (Abstr) *World Allergy Organization Journal* Feb 2012; 5: S63, #191.
621. Meltzer EO, Nolte H, LaForce C. Efficacy and safety of combined mometasone furoate/formoterol 100/10 mg twice daily in subjects with asthma inadequately controlled on low-dose inhaled corticosteroids. (Abstr) *World Allergy Organization Journal* Feb 2012; 5: S63-64, #192.
622. Ratner P, Meltzer EO, Carr W, Ginsberg D. MP 29-02 (intranasal formulation of azelastine hydrochloride and fluticasone propionate in the treatment of ocular symptoms of seasonal allergic rhinitis. (Abstr) *J Allergy Asthma Immunol* 2012; 129: AB134.

PUBLICATIONS: ELI O. MELTZER, MD

623. Carr W, Meltzer EO, Finn A, Dorinsky PM, Kelley L, Dunbar A, Tantry SK. Effective nasal symptom relief and improvement in health-related quality of life in subjects with perennial allergic rhinitis following 6-week once-daily treatment with beclomethasone dipropionate hydrofluoroalkane nasal aerosol. (Abstr) *J Allergy Asthma Immunol* 2012; 129: AB188
624. Meltzer EO, Ratner PH, Testa M, Turner R, Spalding W, Karafilidis J. Satisfaction with and preference for ciclesonide hydrofluoroalkane nasal aerosol or mometasone furoate nasal aqueous spray in patients with perennial allergic rhinitis: results from a validation study. (Abstr) *J Allergy Asthma Immunol* 2012; 129: AB191.
625. Busse WW, Wenzel SE, Meltzer EO, Kerwin EM, Liu MC, Zhang N, Chon Y, Lin J, Lin S. Efficacy and safety of AMG 853 in asthma: results of a Phase 2, randomized double-blind, placebo-controlled study. (Abstr) *J Allergy Asthma Immunol* 2012; 129: AB202.
626. Meltzer EO, Gates D, Bachert C. Mometasone furoate nasal spray increases the number of minimal-symptom days in patients with acute rhinosinusitis. *Ann Allergy Asthma Immunol*. 2012;108:275-9.
627. Carr W, Bernstein J, Lieberman P, Meltzer EO, Bachert C, Price D, et al. A novel intranasal therapy of azelastine with fluticasone from the treatment of allergic rhinitis. *J Allergy Clin Immunol* 2012; 129:1282-1289.
628. Meltzer EO, Jacobs RL, LaForce CF, Kelley CL, Dunbar SA, Tantry SK. Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis. *Allergy Asthma Proc* 2012; 33: 249-57.
629. Meltzer EO, La Force C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial of efficacy and safety. *Allergy and Asthma Proc* 2012; 33: 324-332.
630. Meltzer, EO, Blaiss MS, Naclerio RM, Stoloff SW, Derebery MJ, Nelson HS, Boyle JM, Wingertzahn MA. Burden of Allergic Rhinitis: Allergies in America, Latin America, and Asia-Pacific Adult Surveys. *Allergy Asthma Proc* 2012; 33:S113-S141.
631. Nolte H, White M, Weinstein SF, Nathan RA, Gates D, Meltzer EO. Evaluation of diary data on asthma control factors managed with combined mometasone furoate and formoterol fumarate in patients with severe asthma. (abstr) *Ann Allergy, Asthma, Immunol* 2012; 109 (suppl): A55.
632. Murphy KR, Meltzer EO, Weinstein SF, Nathan RA, White M, Gates D, Nolte H. Effects of mometasone furoate and formoterol fumarate combination therapy on 4 quality of life domains in patients with moderate asthma. (abstr) *Ann Allergy, Asthma, Immunol* 2012; 109 (suppl): A55.
633. Meltzer EO, Korenblat PE, Lanier BQ, Kelley L, Dunbar SA, Tantry SK. Device and integrated dose counter performance of beclomethasone dipropionate nasal aerosol during daily use. (abstr) *Ann Allergy, Asthma, Immunol* 2012; 109 (suppl): A126-7.
634. Carr W, La Force C, Hadley J, Gever L, Meltzer EO. Efficacy of MP29-02 (Intranasal azelastine/fluticasone propionate) compared to commercial and non-commercial formulations of azelastine hydrochloride and fluticasone propionate for the treatment of seasonal allergies. (abstr) *Ann Allergy, Asthma, Immunol* 2012; 109 (suppl): A130-1.
635. Meltzer EO, Karafilidis J. A scintigraphy study evaluating the nasal and pulmonary deposition of a radiolabeled solution of ciclesonide hydrofluoroalkane nasal aerosol and a radiolabeled suspension of ciclesonide aqueous nasal spray in healthy subjects. (abstr) *Ann Allergy, Asthma, Immunol* 2012; 109 (suppl): A134.
636. Meltzer EO, Becker W, Shanga G. Objective responses to external nasal dilators in normal children. (abstr) *Ann Allergy, Asthma, Immunol* 2012; 109 (suppl): A135.

PUBLICATIONS: ELI O. MELTZER, MD

637. Meltzer EO, Becker W, Shanga G. Subjective responses to external nasal dilators in normal children. (abstr) *Ann Allergy, Asthma, Immunol* 2012; 109 (suppl): A135.
638. Bousquet J, Schunemann HJ, Samolinski B, et al (incl Meltzer EO). Allergic rhinitis and its impact on asthma (ARIA): Achievements in 10 years and future needs. *J Allergy Clin Immunol* 2012; 130:1049-62.
639. Carr WW, Ratner P, Munzel U, Murray R, Price D, Canonica GW, Mullol J, Virchow JC, Lieberman P, Meltzer E, Bachert C. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. *Allergy Asthma Proc* 2012; 33:450-458.
640. Busse WW, Wenzel SE, Meltzer EO, Kerwin EM, Liu MC, Zhang N, Chon Y, Budelsky AL, Lin J, Lin, S-L. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG853 in asthmatic patients. *J Allergy Clin Immunol* 2013; 131:339-45.
641. Meltzer EO, Schatz M, Nathan R, Garris C, Stanford RH, Kosinski M. Reliability, validity, and responsiveness of the Rhinitis Control Assessment Test in patients with rhinitis. *J Allergy Clin Immunol* 2013; 131:379-86.
642. Meltzer EO, Van Bavel JH, Raphael G, Ratner PH, Ding Y, Tantry S. Improvement of nasal congestion and sleep quality following once-daily treatment with beclomethasone dipropionate nasal aerosol in patients with seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 2013; 131(suppl) AB112.
643. Carr WE, Van Bavel J, Lieberman P, Hampel F, Meltzer EO, Rattner PH. MP29-02 provides rapid and more complete nasal symptom relief than two first-line therapies: a retrospective analysis of a randomized, double-blind, placebo-controlled trial. (abstr) *J Allergy Clin Immunol* 2013; 131(suppl) AB114.
644. Karafilides J, Huang H, Meltzer EO. A post-hoc responder analysis of improvement in symptoms following treatment with ciclesonide hydrofluoroalkane nasal aerosol in patients with seasonal and perennial allergic rhinitis. (abstr) *J Allergy Clin Immunol* 2013; 131(suppl) AB187.
645. Meltzer EO, Baena-Cagnani CE, Gates D, Teper A. Relieving nasal congestion in children with seasonal and perennial allergic rhinitis: efficacy and safety studies of mometasone furoate nasal spray. *World Allergy Organization Journal* 2013; 6:5.
646. Meltzer EO, Bernstein DI, Prenner BM, Berger WE, Shekar T, Teper AA. Mometasone furoate nasal spray plus oxymetazoline nasal spray: short-term efficacy and safety in seasonal allergic rhinitis. *Am J Rhinol Allergy* 2013; 27: 102-8.
647. Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW, Hadley J, Lieberman P, Hampel FC, Mullol J, Munzel U, Price D, Scadding G, Virchow JC, Wahn U, Murray R, Bousquet J. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. *Int Arch Allergy Immunol* 2013;161:369-377.
648. Meltzer EO. Pharmacotherapeutic strategies for allergic rhinitis: matching treatment to symptoms, disease progression, and associated conditions. *Allergy Asthma Proc* 2013;34:301-11.
649. Bielory L, Meltzer EO, Nichols KK, Melton R, Thomas RK, Bartlett JD. An algorithm for the management of allergic conjunctivitis. *Allergy Asthma Proc* 2013;34:408-20.
650. Meltzer EO, Korenblat PE, Lanier BQ, Kelley L, Tantry SK. Beclomethasone dipropionate nasal aerosol with an integrated dose counter: functionality and performance. *Allergy Asthma Proc* 2013;34:1-8. doi:10.2500/aap.2013.34.3707
651. Meltzer EO, Becker W, Shanga G. Objective and subjective responses to an external nasal dilator in congested children. (abstr) *Ann Allergy Asthma Immunol* 2013;111:A109.

PUBLICATIONS: ELI O. MELTZER, MD

652. Meltzer EO, Jacobs R, Janka L, Tantry SK. Once-daily treatment with beclomethasone dipropionate nasal aerosol improves nasal symptoms of perennial allergic rhinitis, regardless of symptom severity at baseline. (abstr) *Ann Allergy Asthma Immunol* 2013;111:A111.
653. Meltzer EO, Korenblat PE, Lanier BQ, Kelley L, Tantry SK. Beclomethasone dipropionate nasal aerosol with an integrated dose counter: functionality and performance. *Allergy Asthma Proc* 2013;34:534-41.
654. Berger WE, Prenner B, Turner R, Meltzer EO. A patient preference and satisfaction study of ciclesonide nasal aerosol and mometasone furoate aqueous nasal spray in patients with perennial allergic rhinitis. *Allergy Asthma Proc* 2013;34:542-550.

RESEARCH: ELI O. MELTZER, MD

1. A long-term efficacy and safety study of albuterol tablets in the treatment of reversible obstructive airways disease (bronchial asthma) in adults.
2. A long-term efficacy and safety study of albuterol tablets in the treatment of reversible obstructive airways disease (bronchial asthma) in children 6-14 years old.
3. A long-term efficacy and safety study of albuterol syrup in the treatment of reversible obstructive airways disease (bronchial asthma) in children 2-6 years old.
4. A clinical trial of azatadine syrup in pediatric patients with acute seasonal allergic rhinitis.
5. A long-term efficacy and safety study of albuterol aerosol in the treatment of reversible obstructive airways disease (bronchial asthma) in adults.
6. An efficacy and safety study comparing flunisolide aerosol and placebo (vehicle control) in steroid-dependent asthmatic children.
7. An efficacy and safety study comparing flunisolide aerosol and placebo (vehicle control) in steroid-independent pediatric patients whose asthma condition is inadequately controlled with nonsteroidal antiasthma medication.
8. Flunisolide aerosol in pediatric asthmatic patients; a long-term open trial.
9. Terfenadine in the treatment of seasonal allergic rhinitis.
10. An acceptability study comparing Theophyl chewable tablets and liquid theophylline in asthmatic children.
11. Clinical practice experiences with Vanceril inhaler: 100 Case Reports.
12. Oral bitolterol mesylate and oral metaproterenol. A dose ranging study in moderate/severe bronchial asthmatic patients.
13. A double-blind study evaluating aerosolized flunisolide in the modification of Eustachian tube dysfunction.
14. A double-blind metered-dose aerosol study comparing terbutaline sulfate with isoproterenol sulfate.
15. Dose dependent efficacy of fluocortin butyl (FCB) when administered four times daily for perennial rhinitis in adults.
16. An efficacy and safety evaluation of beclomethasone administered twice daily in the treatment of chronic steroid-dependent asthma in children.
17. An efficacy and safety evaluation of beclomethasone administered twice daily in the treatment of chronic steroid-dependent asthma in teenagers and adults.
18. Efficacy and tolerance in fluocortin butyl (FCB) when administered twice daily for perennial rhinitis in adults.
19. Bitolterol mesylate aerosol and theophylline drug interaction with 24-hour Holter monitoring in moderate/severe bronchial asthmatic patients.
20. A comparative study of nebulized terbutaline and isoetharine in theophylline stabilized asthmatic patients.
21. Efficacy and safety of fluocortin butyl (FCB) in pediatric patients with perennial rhinitis.
22. A comparative study of bitolterol mesylate aerosol and albuterol aerosol in patients with bronchial asthma.
23. A comparative efficacy and safety study of terfenadine, chlorpheniramine and placebo tablets in the treatment of seasonal allergic rhinitis/conjunctivitis.
24. Efficacy and safety of fluocortin butyl (FCB) compared with beclomethasone in patients with perennial rhinitis.
25. A comparative efficacy and safety study of procaterol HCl and metaproterenol SO₄ tablets in pediatric patients with reversible bronchial airway obstruction.

RESEARCH: ELI O. MELTZER, MD

26. A 10-hour duration of action study of albuterol tablets in bronchial asthma.
27. A double-blind, crossover study of the therapeutic equivalence of liquid and tablet formulations of procaterol HCl in pediatric patients with reversible bronchial airway obstruction.
28. A dose-ranging study of bitolterol mesylate solution in a closed system nebulizer with an actuator valve.
29. A dose-ranging study of the cardiopulmonary effects of an inhaled powder formulation albuterol (Rotacap with Rotahaler) in patients with reversible obstructive airway disease.
30. A clinical, pulmonary and pharmacokinetic evaluation of Theo-dur sprinkle in asthmatic children.
31. A double-blind placebo controlled long term (6 month) study of terfenadine tablets in the treatment of allergic rhinitis/conjunctivitis.
32. Comparative study of tixocortol pivalate and a placebo inhaler in the treatment of patients with asthma.
33. Dose-ranging study of bitolterol mesylate solution in an open continuous flow nebulizer system.
34. Comparative study of tixocortol pivalate nasal inhaler, beclomethasone nasal inhaler and a placebo nasal inhaler in the treatment of patients with allergic rhinitis.
35. A comparative efficacy and safety study of procaterol HCl and metaproterenol SO₄ syrup in pediatric patients with reversible bronchial airway obstruction.
36. Dose-ranging study of bitolterol mesylate metered-dose inhaler in pediatric asthmatic patients.
37. Comparative study of the efficacy of beclomethasone dipropionate as an aqueous nasal spray and a pressurized aerosol nasal spray in the treatment of seasonal rhinitis.
38. A single dose double-blind placebo-controlled cross-over study of the cardiopulmonary effects of parenteral preparations of albuterol in patients with chronic reversible obstructive airway disease.
39. A study of the safety and efficacy of terfenadine suspension in children in the treatment of acute pollenosis.
40. A double-blind, placebo-controlled evaluation of acrivastine in the treatment of seasonal allergic rhinitis.
41. Comparative trial of azelastine, albuterol sulfate and placebo in bronchial asthma.
42. A one year open study of the safety, tolerance and efficacy of fluocortin butyl in patients with perennial rhinitis.
43. The comparison of ketotifen syrup and placebo in the prophylaxis of bronchial asthma in children.
44. A long-term study of terfenadine tablets in the treatment of nasal allergy.
45. An open study of long-term acrivastine safety and efficacy in patients with allergic rhinitis or allergic dermatosis.
46. A one month comparison of bitolterol mesylate and isoproterenol solution administered from a continuous flow nebulizer to asthmatic patients.
47. Comparison of the cardiopulmonary effects of single doses of injectable albuterol and terbutaline in the treatment of acute asthma.
48. Double-blind trial comparing nedocromil sodium and placebo in the management of bronchial asthma.
49. Bitolterol mesylate metered-dose aerosol three month study in pediatric patients with asthma.

RESEARCH: ELI O. MELTZER, MD

50. A placebo controlled multicenter study of the efficacy and safety of procaterol metered-dose aerosol in out-patients with reversible airway obstruction.
51. An open dose-response study of the cardiopulmonary effects of subcutaneous albuterol, epinephrine and terbutaline in the treatment of acute asthma.
52. A comparative patient preference study of three nasal adapters for beclomethasone aerosol nasal spray.
53. A six week comparative evaluation of subcutaneous human IgE pentapeptide and placebo in the treatment of allergic rhinitis.
54. The efficacy and safety of tiprinast when administered as a nasal spray to subjects experiencing allergic rhinitis.
55. A double-blind placebo-controlled study of the efficacy of beclomethasone dipropionate aqueous nasal spray.
56. A comparison of mequitazine with brompheniramine in the treatment of seasonal allergic rhinitis.
57. A one week dose ranging trial of SKF 93944 in seasonal allergic rhinitis patients.
58. A long term evaluation of ketotifen in asthmatic children.
59. A six month study of the cardiopulmonary responses to procaterol delivered by a metered-dose inhaler in adult asthma.
60. An open label evaluation of the continued clinical response to terfenadine 60 mg tablets in the treatment of seasonal allergic rhinitis.
61. A double-blind parallel study of the efficacy of powdered albuterol delivered by rotacap vs. aerosolized albuterol delivered by metered-dose inhaler in children with chronic reversible obstructive airway disease.
62. An eight week evaluation of acrivastine plus pseudoephedrine in patients with allergic rhinitis.
63. A placebo-controlled evaluation of the safety and bronchodilating activity of single doses of 2, 4, 8, 12 or 16 mg of azelastine in patients with bronchial asthma.
64. A comparative safety and efficacy study of bitolterol mesylate and isoproterenol sulfate delivered by a metered-dose aerosol in pediatric patients with bronchial asthma.
65. A comparative efficacy, safety and theophylline pharmacokinetic study of Theo-dur and TheoBeads in pediatric asthma patients.
66. A double-blind, placebo-controlled, crossover evaluation of the safety and efficacy of azelastine in the treatment of perennial rhinitis.
67. Comparison of the relative effectiveness of aerosol procaterol, albuterol and placebo in the prevention of exercise-induced asthma.
68. A double-blind, placebo-controlled study of the effects of a new formulation of tiprinast meglumine nasal spray in patients with seasonal allergic rhinitis.
69. A double-blind, comparative study of the efficacy and safety of nedocromil sodium in the management of asthma.
70. Evaluation of the safety and efficacy of acute and chronic administration of azelastine in asthmatic patients subjected to an exercise challenge.
71. Evaluation of AccuLevel theophylline spiked sample test precision.
72. A one-year open study of the safety, tolerance and efficacy of azelastine in the treatment of perennial rhinitis.
73. Acrivastine plus pseudoephedrine HCl, acrivastine, pseudoephedrine HCl and placebo in six to twelve year old patients with allergic rhinitis.

RESEARCH: ELI O. MELTZER, MD

74. A dose ranging study of bitolterol mesylate solution in pediatric asthma patients using a continuous flow, open nebulizer system.
75. A double-blind, placebo- and clemastine-controlled evaluation of loratadine in patients with seasonal allergic rhinitis.
76. A comparative study of two formulations of flunisolide nasal spray in patients with perennial allergic rhinitis.
77. A three-month, double-blind, placebo-controlled study of the safety and efficacy of 2, 4, 6, or 8 mg of azelastine in patients with asthma.
78. A double-blind study of triamcinolone acetonide nasal aerosol and placebo in patients with seasonal allergic rhinitis.
79. LY171883 vs placebo in asthmatics using beta-agonist therapy.
80. Three month study of the comparative efficacy and safety of procaterol and isoproterenol aerosol inhalation in pediatric outpatients with reversible bronchial airway obstruction.
81. The effect of one week of oral AHR-11325 (10, 15 and 50 mg), brompheniramine (4 mg) or placebo in allergic rhinitis patients.
82. A comparison of bitolterol and metaproterenol administered to bronchial asthmatic patients from a metered-dose inhaler.
83. A study of the efficacy and safety of loratadine in patients 6-12 years of age with seasonal allergic rhinitis.
84. A parallel group study comparing the efficacy and safety of albuterol Rotacaps^R (200 mcg) vs. albuterol aerosol (180 mcg) administered to children ages 4-11 with chronic reversible obstructive airway disease (asthma).
85. A comparative study of triamcinolone acetonide and flunisolide nasal solution sprays in subjects with seasonal allergic rhinitis.
86. A one-month study of the safety and efficacy of procaterol syrup in 2-6 year old children with reversible bronchial airway obstruction.
87. A tolerance study of terfenadine-pseudoephedrine combination tablets in comparison to pseudoephedrine tablets in patients with seasonal or perennial allergic rhinitis.
88. A placebo-controlled comparison of azelastine, controlled release theophylline and combined azelastine-theophylline therapy in the management of patients with nonsteroid dependent bronchial asthma.
89. An open, long-term study of the safety and efficacy of cetirizine in chronic allergic diseases.
90. A crossover comparison of the duration of effectiveness of aerosol procaterol and albuterol in the prevention of exercise-induced asthma.
91. The role of ketotifen as an additive therapy in the prophylactic treatment of moderate asthma.
92. A controlled study of triamcinolone acetonide nasal aerosol and placebo in patients with perennial rhinitis.
93. The effects of rocastine, chlorpheniramine (4 mg) or placebo in adults with symptomatic seasonal allergic rhinitis.
94. A comparison of the therapies for children with chronic asthma of inhaled albuterol plus BID oral theophylline to inhaled albuterol plus QID inhaled beclomethasone to inhaled albuterol plus BID oral theophylline and QID inhaled beclomethasone.
95. A parallel study of the effectiveness and safety of azelastine, clemastine and placebo for the management of perennial allergic rhinitis.
96. A comparison of terfenadine 60 mg BID, chlorpheniramine 4 mg TID and placebo in patients with perennial allergic rhinitis.

RESEARCH: ELI O. MELTZER, MD

97. An open-label, long-term study of triamcinolone acetonide nasal aerosol in patients with perennial rhinitis.
98. LY171883 vs. placebo in theophylline-controlled asthmatics.
99. A comparison of the safety and efficacy of cromolyn sodium 4% nasal solution and terfenadine tablets in the treatment of allergic rhinitis.
100. A safety evaluation of metaproterenol sulfate liposome inhalant concentration.
101. A 12-week, placebo-controlled trial of oxitropium bromide for asthma.
102. A double-blind study of triamcinolone acetonide nasal aerosol and placebo in patients with perennial rhinitis.
103. An open-label, one month study of procaterol syrup in young children with reversible bronchial airway obstruction.
104. Comparison of efficacy and side effects of enprofylline, theophylline and placebo in patients with mild to moderate asthma.
105. The clinical evaluation of the safety and efficacy of astemizole as compared to terfenadine in the treatment of perennial allergic rhinitis.
106. Comparison of cetirizine with chlorpheniramine in the treatment of seasonal allergic rhinitis in children, 6-11 years of age.
107. A long-term, safety study of trimacinolone acetonide nasal aerosol in patients with perennial rhinitis.
108. Dose-ranging study of the comparative efficacy and safety of tazifylline and placebo in patients with allergic seasonal rhinitis.
109. A pharmacokinetic and pharmacodynamic study of metaproterenol in asthmatic children.
110. A study evaluating the efficacy and safety of daily administration of 100, 400 and 1600 mcg aqueous fluticasone propionate vs. placebo in patients with allergic seasonal rhinitis.
111. A placebo-controlled evaluation of the effectiveness and safety of azelastine and oral albuterol sulfate in the management of symptomatic bronchial asthma.
112. A parallel study of intranasal ipratropium bromide nasal spray versus placebo in nonallergic perennial rhinitis.
113. Placebo-controlled evaluation of the protective activity of azelastine in methacholine-induced bronchoprovocation.
114. An evaluation of two formulations of flunisolide nasal spray in patients with perennial allergic rhinitis.
115. A three-month study of the efficacy and safety of procaterol and metaproterenol in pediatric patients with asthma.
116. Multiple dose pharmacokinetic evaluation of Theo-Dur 450 mg tablets in adult asthmatic patients.
117. A study of triamcinolone acetonide nasal aerosol and placebo in pediatric patients with perennial allergic rhinitis.
118. A safety and efficacy evaluation of several single doses of salmeterol hydroxynaphthoate in asthmatic patients.
119. A comparison of terfenadine 60 mg BID and 120 mg BID in the treatment of patients with seasonal allergic rhinitis who are less than optimal responders to terfenadine 60 mg BID.
120. A study comparing two single doses of BMY 26517-31 to placebo in patients with exercise-induced bronchospasm.
121. A dose-ranging study of twice-daily intranasal administration of aqueous fluticasone propionate in adult patients with seasonal allergic rhinitis.

RESEARCH: ELI O. MELTZER, MD

122. Reduction of passive smoking in asthmatic children: a clinical trial. Tobacco-Related Disease Research Program, University of California, Berkeley, CA. CA Law AB75, #1RT509, State of California.
123. A single dose, duration of action comparative study of pirbuterol, albuterol and placebo aerosol.
124. A comparison of azelastine and clemastine fumarate to placebo in the management of perennial allergic rhinitis.
125. An albuterol-controlled, 12-week study of procaterol TID in outpatients with reversible bronchial airway obstruction.
126. A controlled study of HEPP (IgE pentapeptide) nasal solution as treatment of seasonal allergic rhinitis.
127. A comparison of the efficacy and duration of action of two different albuterol delivery systems: the DiskhalerTM vs. the Rotahaler^R.
128. A placebo controlled park study of Rynatan tablets in subjects with allergic rhinitis.
129. A placebo controlled park study of Rynatan suspension in subjects with allergic rhinitis.
130. A parallel comparison of intranasal atrovent nasal spray versus placebo in nonallergic perennial rhinitis.
131. Placebo controlled comparison of azelastine and oral albuterol sulfate in the management of symptomatic bronchial asthma.
132. A placebo-controlled study of once-versus twice-daily intranasal fluticasone propionate for patients with seasonal allergic rhinitis.
133. A tablet comparison study of Theo-Dur 300 mg TID and 450 mg BID.
134. Study of adrenal function in adult asthmatics during chronic treatment with 800, 1200 and 1600 mcg aerosolized triamcinolone acetone.
135. A clinical trial of four dosage regimens of salmeterol hydroxynaphthoate versus placebo in patients with chronic reversible obstructive airways disease.
136. Intranasal ipratropium bromide nasal spray versus placebo in allergic perennial rhinitis.
137. An open-label clinical evaluation of Uni-Dur^R, a twenty-four hour theophylline sustained release tablet.
138. BMY-26517/placebo group study of patients with chronic, asthma requiring bronchodilator therapy.
139. Petigetide for injection, an open label safety study.
140. A comparison of oral theophylline and aerosol beclomethasone dipropionate therapy of asthma.
141. A placebo-controlled assessment of flunisolide nasal spray as an adjunct in the treatment of sinusitis.
142. A placebo-controlled trial to evaluate once-daily versus twice-daily intranasal administration of aqueous fluticasone propionate versus beclomethasone dipropionate in patients with perennial allergic rhinitis.
143. A parallel group study of the safety, efficacy and duration-of-action of azelastine, albuterol sulfate repetabs and placebo tablets in subjects with chronic asthma.
144. The clinical evaluation of the safety and efficacy of astemizole suspension in the treatment of seasonal allergic rhinitis in children.
145. A placebo-controlled study to investigate RG-3988 aerosol in theophylline-dependent asthmatics.

RESEARCH: ELI O. MELTZER, MD

146. A comparative study of the efficacy and safety of nedocromil sodium nebulizer solution vs. placebo in the management of patients with reversible airway obstruction.
147. A comparison of the effectiveness and safety of azelastine, chlorpheniramine maleate, and placebo tablets in the management of patients with seasonal allergic rhinitis.
148. A placebo-controlled study of aqueous fluticasone propionate given once-versus twice-daily versus aqueous beclomethasone dipropionate versus placebo in adult and adolescent patients with seasonal allergic rhinitis.
149. A comparison of inhaled ipratropium bromide placebo when each is added to inhaled albuterol for maintenance treatment of patients with asthma.
150. A study to evaluate the safety and efficacy of terfenadine suspension the prophylactic treatment of children ages 6 through 12 with allergic asthma who experience seasonal exacerbations.
151. A stratified, group-sequential study to compare the efficacy of rising doses of MK-571 to placebo in patients with chronic stable asthma.
152. A study of cetirizine in the treatment of seasonal allergic rhinitis in children 6 to 11 years of age.
153. An evaluation of the therapeutic effect of oral ICI 204,219 on bronchial asthma.
154. Loratadine versus pseudoephedrine versus the combination versus placebo as treatment for seasonal allergic rhinitis.
155. A study of aqueous fluticasone propionate given once daily versus placebo in pediatric patients with seasonal allergic rhinitis.
156. A dose-ranging and duration-of-action trial of azelastine nasal spray (0.1%) in subjects with seasonal allergic rhinitis.
157. A comparative study of nedocromil sodium nebulizer solution versus placebo in children (6-12 years of age) with asthma induced by symptomatic respiratory infections.
158. A study of the comparative efficacy and safety of procaterol and albuterol aerosol in pediatric patients with reversible airway obstruction.
159. A clinical and electrocardiographic study of potential pharmacodynamic interactions of salmeterol hydroxynaphthoate and theophylline in patients with chronic reversible obstructive airways disease.
160. Open-label comparative safety and efficacy study of two theophylline formulations: TCR1 and Theo-Dur^R.
161. Auranifin versus placebo in the treatment of steroid-dependent asthma.
162. Crossover, dose-ranging study of inhaled ipratropium bromide and placebo in children with chronic asthma.
163. Evaluation of the applicability and sensitivity of the medical outcomes study short form 36 plus disease-specific questions to patients with asthma or allergic rhinitis.
164. A double-blind, randomized, parallel study comparing the safety and efficacy of terfenadine 60 mg BID, astemizole 10 mg QD and placebo in the treatment of seasonal allergic rhinitis in an "in the park" setting.
165. Comparison of duration of action and side effects of metaproterenol sulfate liposome (metasome) and alupent in asthmatics.
166. Evaluation of flunisolide nasal spray as an adjunct in the treatment of sinusitis.
167. A clinical trial of twelve week courses of salmeterol hydroxynaphthoate versus albuterol versus placebo in patients with chronic reversible obstructive airways disease.

RESEARCH: ELI O. MELTZER, MD

168. A pilot study of terfenadine 60 mg BID and placebo in the treatment of patients with mild to moderate atopic asthma who demonstrate a positive challenge to methacholine and exercise.
169. A trial to assess the safety and tolerability of azelastine nasal spray (0.1%) in subjects with perennial allergic rhinitis.
170. Histamine levels in nasal mucosa scraping of normal children and those with rhinitis and chronic otitis media.
171. A clinical study comparing the efficacy of intranasal triamcinolone acetonide spray and bioequivalent doses of intramuscular triamcinolone acetonide in patients with seasonal allergic rhinitis.
172. A placebo controlled study of azelastine and albuterol sulfate (Proventil Repetabs™) in chronic asthma.
173. The efficacy and safety of ophthalmic piroxicam in patients with seasonal allergic conjunctivitis.
174. A safety and efficacy study of Abbott-64077, QID for three weeks, in the treatment of seasonal allergic rhinitis.
175. A placebo- and positive-controlled evaluation of azelastine nasal spray (0.1%) in the management of subjects with seasonal allergic rhinitis.
176. A comparison of once daily triamcinolone acetonide and twice daily beclomethasone dipropionate in patients with perennial allergic rhinitis.
177. A trial of twice daily vs. four times daily regimens of inhaled beclomethasone dipropionate in steroid responsive patients with asthma.
178. A dose-response study of cetirizine in the treatment of seasonal allergic rhinitis in children 6 to 11 years of age.
179. The effectiveness and safety of oral ICI 204,219 in patients with seasonal allergic rhinitis.
180. Safety and efficacy of zileuton, 800 mg BID or 600 mg QID versus placebo in the treatment of moderate asthma.
181. A comparison with levocabastine, oxymetazoline and placebo in the treatment of seasonal allergic rhinitis.
182. A comparison of long-term prophylaxis with cefuroxime axetil versus placebo in preventing an acute episode of sinusitis in patients with a history of recurrent sinusitis.
183. A comparison of long-term maintenance therapy with cefuroxime axetil versus placebo after treatment of an episode of sinusitis in patients with a history of recurrent sinusitis.
184. Effect of 6 weeks therapy with oral ICI 204,219 on bronchial asthma.
185. Double-blind study to compare the efficacy of three doses of MK-0679 to placebo in patients with chronic stable asthma.
186. Beclomethasone dipropionate vs. cromolyn vs. placebo, effects in children with seasonal allergic rhinitis.
187. Pemirolast/placebo double-blind study of patients with a history of chronic, stable, reversible asthma requiring bronchodilator therapy.
188. Liposomal albuterol sulfate aerosol. Escalating dose tolerance safety and efficacy trial.
189. An efficacy trial of comparable plasma concentrations of triamcinolone acetonide given by inhalation (Azmecort) and intramuscular injection (Kenalog-40) in the management of mild to moderate asthma.
190. Efficacy of SCH 37370 in the treatment of mild to moderate asthma.

RESEARCH: ELI O. MELTZER, MD

191. A parallel group comparison of the efficacy and safety of fluticasone propionate aqueous nasal spray 200 mcg QD versus terfenadine 60 mg BID versus placebo in patients with seasonal allergic rhinitis.
192. A double-blind ascending single-dose study of formoterol suspension aerosol vs. placebo in normal volunteers.
193. Double-blind crossover evaluation of repirinast (Bay u 2372) compared to placebo in attenuation of antigen induced bronchospasm.
194. A cohort epidemiologic study to determine the effect of one year of triamcinolone acetonide on alternate day prednisone or alternate day prednisone plus inhalation or non-steroidal antiasthmatic therapy on growth patterns of asthmatic children.
195. Bioavailability and pharmacokinetic study of two formulations of flunisolide nasal spray in seasonal allergic rhinitis patients.
196. Inhaled fluticasone propionate vs. theophylline vs. placebo in adolescent and adult patients with mild to moderate asthma.
197. A comparative study of the safety and efficacy of cetirizine or placebo in patients with seasonal allergic rhinitis and asthma.
198. A study to determine the efficacy and safety of three different doses of budesonide delivered by the Turbuhaler to pediatric patients with glucocorticosteroid treated asthma.
199. A study of a single dose of 50 mcg salmeterol hydroxynaphthoate aerosol vs. 180 mcg albuterol aerosol vs. placebo in adolescents and adults with exercise induced bronchospasm.
200. Theophylline sprinkle extended release capsules, dose titration for 6-12 year olds.
201. A comparative trial of two doses of inhaled fluticasone propionate vs. placebo in patients aged 4 to 11 years with mild to moderate chronic asthma.
202. A tolerance study of aqueous film-coated 120 mg terfenadine tablets and placebo tablets administered QD in patients with seasonal or perennial allergic rhinitis.
203. A randomized placebo-controlled comparative study of the efficacy and safety of nedocromil sodium 0.5% nebulizer solution TID in the treatment of children 2-4 years of age with bronchial asthma.
204. A double-blind trial to examine the use of a rescue medication during 6 weeks of astemizole or terfenadine in patients with seasonal allergic rhinitis.
205. A placebo-controlled study of the efficacy and safety of two doses of budesonide delivered by the Turbuhaler to patients with chronic asthma not well controlled on non-steroid therapy.
206. A placebo-controlled study of the efficacy and safety of aqueous fluticasone propionate given twice daily versus placebo for four weeks in patients with perennial non-allergic rhinitis.
207. Clinical acceptability evaluation of bitolterol inhalation solution 0.2%.
208. A comparison of the effects of astemizole/pseudoephedrine, terfenadine/pseudoephedrine and placebo on sleep and nasal congestion in subjects with seasonal allergic rhinitis.
209. A study to compare the effects of high and low oral doses of ICI 204,219 with placebo given over 6 weeks to patients with asthma.
210. A double-blind comparison of ebastine and placebo in adult patients with seasonal allergic rhinitis.
211. An open-label, long term safety study of ebastine in patients with seasonal allergic rhinitis.
212. MK-0591 Multicenter dose ranging study in patients with moderate asthma.
213. A comparison of budesonide dry powder and placebo in the treatment of children with perennial allergic rhinitis.

RESEARCH: ELI O. MELTZER, MD

214. A placebo-controlled pilot study of the efficacy and safety of single intravenous doses of interleukin-1 receptor antagonist in patients with bronchial asthma.
215. A double-blind comparison of ebastine and placebo in children with seasonal allergic rhinitis.
216. Placebo-controlled comparison of Flunisolide and Beclomethasone Dipropionate in allergic rhinitis.
217. Single intravenous dose efficacy study of MDL 26,024GO in skin reactivity to prick allergen challenge in atopic individuals.
218. A study of the effectiveness of pirbuterol acetate delivered by an Autohaler™ inhalation device vs. pirbuterol acetate delivered by a conventional "press and breathe" metered dose inhaler.
219. A safety/efficacy study of double-strength beclomethasone dipropionate, two inhalations per nostril once daily vs. beclomethasone dipropionate twice daily vs. high dose beclomethasone dipropionate once daily vs. placebo.
220. Multicenter, randomized, double-blind, placebo-controlled, parallel group study comparing the safety and efficacy of five doses of Ro 24-5913 in the treatment of mild to moderate asthma.
221. Double-blind, placebo-controlled, evaluation of azelastine nasal spray (0.1%) in the management of subjects with seasonal allergic rhinitis inadequately controlled by azelastine 0.5mg tablets.
222. Reduction of passive smoking in asthmatic children: a follow-up. Tobacco-Related Disease Research Program, University of California, Berkeley, CA. CA Law AB75, #4RT0092, State of California.
223. A randomized, double-blind, comparative clinical trial of 12-week courses of salmeterol xinafoate rotadisk versus albuterol versus placebo in adolescent and adult patients with chronic reversible obstructive airways disease.
224. Acute pilot probe study of the flurbiprofen nasal spray to nasal allergen challenge in patients with allergic rhinitis.
225. Validation of quality of life questionnaire in patients with asthma using beclomethasone dipropionate.
226. A double-blind, placebo-controlled efficacy study of daily inhaled doses of 200, 400, 800 and 1600mcg triamcinolone acetonide (BID dosing) in moderate asthma.
227. A placebo-controlled trial of Accolate (ICI 204,219) in mild to moderate asthmatic patients needing chronic treatment: 13 weeks efficacy and up to a one year open label safety extension.
228. Phase II safety and efficacy study of Abbott - 73001 in patients with moderate asthma.
229. Placebo-controlled evaluation of the adjunctive therapy of azelastine nasal spray to terfenadine tablets in the management of seasonal allergic rhinitis.
230. A comparative trial assessing the long term safety of inhaled fluticasone propionate rotadisks via diskhaler 50mcg BID and 100mcg BID vs. placebo in patients aged 4 to 11 years with mild to moderate asthma.
231. A study comparing the efficacy and safety of Ro 24-5913 given twice daily with that of placebo for 4 weeks in the treatment of seasonal allergic rhinitis.
232. A double-blind, placebo-controlled study of the safety and efficacy of iodinated glycerol as adjunctive therapy in the treatment of subjects with chronic reversible obstructive airway disease.

RESEARCH: ELI O. MELTZER, MD

233. A study of the safety and efficacy of levocabastine nasal spray twice a day or four times a day in the treatment of seasonal allergic rhinitis.
234. A parallel group study of the safety and inhaled corticosteroid-sparing effect of azelastine in inhaled corticosteroid-dependent asthmatics.
235. A parallel group comparison of ebastine 10mg and 20mg versus placebo in patients with seasonal allergic rhinitis.
236. A 12-week study of HFA-134a salbutamol sulfate, HFA-134a salbutamol sulfate placebo formulation and the standard CFC 11/12 formulation of Ventolin in patients with reversible obstructive airways disease.
237. A double-blind, placebo-controlled, parallel group comparison of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate aqueous nasal spray in patients with seasonal allergic rhinitis.
238. A Phase III study of the effects of Zileuton, 400 mg QID and 600 mg QID compared to beclomethasone in moderate asthma.
239. A safety and efficacy study of loratadine zydys versus loratadine tablet in the treatment of patients with seasonal allergic rhinitis.
240. A multicenter, double-blind comparison of Accolate™ (ICI 204,219) with cromolyn sodium (INTAL, Fisons) in mild to moderate asthmatic patients.
241. A 2-day, placebo- and beclomethasone aqueous nasal spray-controlled study of the safety and efficacy of Azelastine HCL nasal solution) in the management of seasonal allergic rhinitis.
242. A single-blind, placebo-controlled, single-dose pilot study of the bronchodilator response to albuterol dry powder inhaler and metered dose inhaler in asthmatics.
243. An efficacy and safety study of mometasone furoate in perennial rhinitis.
244. A randomized trial to assess the topical versus systemic efficacy of fluticasone propionate rotadisks via diskhaler 500mcg BID, 100mcg BID, fluticasone propionate tablets 20mg QD, and placebo in adult patients with moderate asthma.
245. A comparison of ipratropium bromide nasal spray 0.03% (42 mcg/nostril) versus placebo administered twice a day in pediatric patients with allergic or nonallergic perennial rhinitis with an optional 6-month treatment comparison of ipratropium nasal spray 0.03% (42 mcg/nostril) versus beclomethasone dipropionate aqueous nasal spray (84 mcg/nostril).
246. A placebo-controlled study of the efficacy and safety of four weeks treatment with oral Pfizer CP-80,633 in adult patients with chronic, mild to moderate asthma.
247. A parallel-group park study to compare the onset of action of fluticasone propionate aqueous nasal spray QD versus beclomethasone dipropionate aqueous nasal spray BID for seasonal allergic rhinitis.
248. A study to compare the efficacy and safety of oral doses of Zeneca D2138 with placebo in subjects with bronchial asthma.
249. A long term study of the effects of intranasal beclomethasone dipropionate aqueous nasal spray on the growth and HPA axis function of children.
250. A study to determine the minimum effective dose of levocabastine nasal spray in the treatment of seasonal allergic rhinitis.
251. Nasal cytology - A multicenter study comparing the stained findings in smears of blown nasal secretions and epithelial scrapings.
252. A trial to assess the long term safety of fluticasone propionate Rotadisk^R via Diskhaler^R versus placebo in adult patients with moderate asthma.
253. A 12-month, open-label, follow-up of HFA-134a Salbutamol Sulfate.

RESEARCH: ELI O. MELTZER, MD

254. A pilot study to evaluate the efficacy, tolerability and safety of two doses of HOE 140 (Icatabant) in comparison to placebo in the treatment of chronic bronchial asthma.
255. Efficacy of Claritin^R versus Seldane^R versus placebo upon awakening in seasonal allergic rhinitis.
256. Comparative trial of salmeterol xinafoate rotadisk versus placebo in patients aged 4-11 years with reversible obstructive airways disease.
257. A study comparing duration of action and safety and efficacy of four dosage strengths of MDL 16,455A in the treatment of spring allergies.
258. An evaluation of quality of life and health economic measures in patients receiving MDL 16,455A in the treatment of spring allergies.
259. A crossover study comparing the effects of three oral doses of MK-0476 to placebo on exercise-induced bronchoconstriction 20 to 24 hours after dosing in asthmatics.
260. Attention and cognitive performance in children ages 6-10 years: a placebo-controlled pilot crossover study of the effects of first and second generation antihistamines in children with allergic rhinitis.
261. A placebo-controlled trial of the safety and efficacy of oral Bay x 1005 (100 mg BID vs. 250 mg BID vs. 500 mg BID vs. placebo for 6 weeks) in patients with asthma.
262. Long term safety of mometasone furoate in perennial rhinitis.
263. A trial of the effects of twelve-month courses of salmeterol xinafoate rotadisk versus placebo on methacholine-induced bronchial hyperresponsiveness in patients with chronic asthma.
264. Evaluation of undiluted albuterol inhalation solution in the treatment of acute asthma.
265. A trial of ATROVENT^R nasal spray 0.03% (42 mcg/nostril) alone, antihistamine alone, and the combination of ATROVENT^R nasal spray with an antihistamine in patients with seasonal allergic rhinitis.
266. A 12-month, open-label, safety and efficacy study of HFA-134a salbutamol sulfate and Ventolin in subjects with reversible obstructive airway disease.
267. A long term safety study of fluticasone propionate inhalation aerosol 100 mcg BID and 500 mcg BID versus placebo BID in adults with moderate asthma.
268. A 2-day, outdoor study of the safety and efficacy of cetirizine vs. loratadine and placebo in the treatment of seasonal allergic rhinitis.
269. Dose-ranging effect of Abbott-73001 on bronchial hyperresponsiveness to methacholine in patients with moderate asthma.
270. A placebo-controlled dose response study of Formoterol Turbuhaler 6, 12 and 24 ug administered twice daily in patients with asthma.
271. A long term safety study of mometasone furoate vs. triamcinolone acetonide in perennial rhinitis.
272. An evaluation of the safety, efficacy, and effect on asthma quality of life (AQL) of salmeterol in subjects receiving inhaled corticosteroids.
273. Comparison of 400 mcg HFA-134a beclomethasone dipropionate, 800 mcg CFC-11/12 beclomethasone dipropionate and placebo in subjects with asthma.
274. A dose ranging safety and toleration study of intranasal chlorpheniramine maleate solution in normal subjects.
275. Study of three dose levels of budesonide nebulizing suspension and placebo in asthmatic children aged eight years and younger.

RESEARCH: ELI O. MELTZER, MD

276. A double-blind, crossover study in exercise-induced bronchospasm to compare the safety and efficacy of cromolyn sodium inhalation-isotonic to cromolyn sodium inhalation-hypotonic using placebo control.
277. A study comparing the clinical effect of MK-0476 to placebo in patients with chronic asthma.
278. A comparison of four doses of Rhinocort^R aqua pump spray (Budesonide) and placebo in the treatment of adults and children with perennial allergic rhinitis.
279. A long-term surveillance study of Zileuton plus usual care versus usual care in patients with asthma.
280. A study of the prevalence of human rhinovirus in pediatric asthma patients with upper respiratory illness.
281. Safety and efficacy of mometasone furoate nasal spray vs. placebo in the treatment of elderly patients with perennial rhinitis.
282. Establishing the clinically important aeroallergens (pollens & mold spores) in California for skin testing the patient with respiratory allergy.
283. A placebo-controlled, parallel group comparison of the safety and efficacy of oral twice daily administration of SB 205312 with inhaled Vanceril in patients with mild to moderate asthma.
284. A randomized, double-blind, placebo-controlled, parallel-group evaluation of the safety and efficacy of cromolyn sodium inhalation solution in an isotonic formulation in pediatrics.
285. A multicenter placebo-controlled dose ranging study to assess and compare the activity of an oral administration of SR 27417A once a day during 12 weeks - in moderate asthmatic patients.
286. A placebo-controlled, parallel group, dose rising study to explore the safety, tolerability and preliminary pharmacokinetics of SB 205312 when given twice daily for a period of 7 days to pediatric patients (8-11 years) with mild to moderate asthma.
287. A six month safety/tolerance study of 120 mg MDL 16,455A BID and placebo BID in normal healthy subjects.
288. An efficacy study of RP 73401 DPI administered to moderate asthmatics.
289. A randomized open-label comparison of budesonide aqua pump spray, versus cromolyn sodium in the treatment of children with perennial allergic rhinitis.
290. A randomized open-label comparison of budesonide aqua pump spray, versus beclomethasone dipropionate in the treatment of adults with perennial allergic rhinitis.
291. Safety and efficacy of AA-2414 (ABT-001) in patients with moderate asthma.
292. A randomized, placebo-controlled study to determine the efficacy, maintenance effect, and safety of 200 ug and 400 ug Pulmicort^R Turbuhaler^R given once daily to adults with mild to moderate asthma.
293. A comparison of a daily dose of 100 mcg and 200 mcg of HFA-134a beclomethasone dipropionate with placebo in subjects with mild to moderate reversible obstructive airways disease.
294. An open, long-term study of the safety, tolerability, and efficacy of oral SB 205312 in patients with bronchial asthma.
295. Clinical use study comparing Nasalcrom^R Nasal Solution 4% to placebo nasal solution in the treatment of the symptoms associated with seasonal allergic rhinitis.
296. 4-week safety and efficacy study of HFA-134a salbutamol sulfate versus Ventolin in children with reversible obstructive airway disease.
297. A 2-day, outdoor, double-blind, parallel multicenter study of the safety and efficacy of cetirizine vs. loratadine and placebo in the treatment of seasonal allergic rhinitis.

RESEARCH: ELI O. MELTZER, MD

298. A stratified trial assessing the efficacy and safety of fluticasone propionate via the multi-dose powder inhaler, 50mcg bid, 100mcg qd, and placebo in subjects aged 4 to 11 years with chronic asthma.
299. A stratified, comparative trial of inhaled fluticasone propionate via the multi-dose powder inhaler 100mcg QD, 200mcg QD, 500mcg QD, and placebo in adolescent and adult subjects with chronic asthma.
300. A 2-week, placebo-controlled study to assess the safety and efficacy of UK-112,214 (160 and 320 mg BID) in the treatment of adults with seasonal allergic rhinitis.
301. A single-dose, four-way crossover comparison of salmeterol 50mcg and 100mcg via the DiskusTM salmeterol 50mcg via the metered-dose inhaler and placebo for the prevention of exercise-induced bronchospasm in adolescent and adult subjects with asthma.
302. Safety and efficacy study of loratadine zydys vs. loratadine tablets vs. placebo in the treatment of patients with seasonal allergic rhinitis.
303. A placebo-controlled, dose ranging study of Azmacort^R HFA-134a oral inhaler compared to Azmacort^R oral inhaler in the treatment of asthma.
304. A safety study of levocabastine nasal spray used continuously for six months.
305. A placebo-controlled study to investigate the effects of twelve weeks of MK-0476 therapy on exercise and methacholine-induced bronchoconstriction in asthmatics.
306. A placebo-controlled, clinical study of the safety and efficacy of ALLERVAX^R CAT using a cat exposure room challenge model.
307. A placebo-controlled evaluation of the effect of salmeterol on methacholine-induced bronchial hyperresponsiveness over twenty-four weeks in adolescent and adult subjects with asthma.
308. Safety and efficacy of Claritin-D in lessening the exacerbation of asthma associated with seasonal allergic rhinitis.
Pr. No. P95-090
309. A trial of Zafirlukast (AccolateTM) in mild-to-moderate asthmatic subjects requiring first chronic therapy: 13 weeks efficacy and up to 52 weeks open-label safety extension.
Pr. No. 9188IL/0086:0040
310. A parallel group study to evaluate the safety and efficacy of clemastine 0.5mg qid vs. clemastine 1.0 mg bid vs. placebo for allergy symptom relief.
Pr. No. HSC-305
311. A crossover study to evaluate the effects of chewable MK-0476 on exercise-induced bronchoconstriction in 6- to 14-year-old children (Tanner Stages I to V) with mild to moderate asthma.
Pr. No. 042-02
312. A study to investigate the efficacy and safety of GG167 administered twice or four times a day for the treatment of influenza A and B viral infections.
Pr. No. NAIA2008
313. A study to investigate the efficacy and safety of GG167 in the prevention and/or progression of influenza A and B viral infections.
Pr. No. NAIA2009
314. A dose ranging study of mometasone furoate pure dry powder in the treatment of asthma.
Pr. No. C94-127
315. A comparison of the safety and efficacy of pranlukast (SB 205312), 150 and 300 mg BID, with Claritin^R 10 mg UID in patients with seasonal allergic rhinitis.
Pr. No. 205312/048

RESEARCH: ELI O. MELTZER, MD

316. An open-label, four-week extension study to explore safety and efficacy of pranlukast (SB 205312), 300 mg BID, in patients with coexisting seasonal and perennial allergic rhinitis.
Pr. No. 205312/085
317. A single-dose, trial to assess the antagonism of oral Zafirlukast (Accolate™) on exercise-induced bronchoconstriction in pediatric subjects with exercise-induced asthma.
Pr. No. 9188IL/0075
318. A study of the efficacy and safety of fluticasone propionate aqueous nasal spray versus placebo followed by a one year open-label safety extension in subjects with perennial nonallergic rhinitis.
Pr. No. FLTA3010
319. A six month clinical trial to examine the efficacy and safety of salmeterol xinafoate 42mcg bid, beclomethasone dipropionate 84mcg qid, and placebo in adolescent and adult subjects with mild to moderate asthma.
Pr. No. SLGA5015
320. A comparison of the safety and efficacy of 2 oral doses of PDA-641 (10mg and 30mg TID) and placebo in mild to moderate asthmatics.
Pr. No. 0805A-205-US
321. A five-way crossover clinical trial of single doses of salmeterol 25, 50, and 100mcg via the Diskus™ (multidose powder inhaler), albuterol Rotacaps 200mcg via Rotahaler, and placebo in pediatric subjects aged 4-11 years with asthma.
Pr. No. SLGA2016
322. Azelastine nasal spray market research study.
Pr. No. 362
323. Dose-ranging study of mometasone furoate nasal spray in the treatment of children (ages 6-11) with seasonal allergic rhinitis.
Pr. No. C95-161
324. A double-blind, placebo-controlled trial to determine the effects of zafirlukast on subjects with both asthma and seasonal allergic rhinitis.
Pr. No. 9188IL/0092
325. A double-blind comparison of the safety and efficacy of two doses of BAY x 7195 aerosol with placebo in patients with asthma.
Pr. No. D95-016-11
326. A validation study of the intraday and interday precision of methacholine challenge procedures.
Pr. No. 95/04
327. Objective and subjective measurements of the effectiveness of mometasone furoate nasal spray vs. placebo in patients with seasonal allergic rhinitis.
Pr. No. P95-219
328. A double-blind, placebo-controlled study to determine the efficacy and safety of 1, 10 and 100mg D7193 in adult asthma patients.
Pr. No. 120
329. A double-blind, placebo controlled trial to assess the safety and efficacy of zafirlukast and loratadine in subjects with seasonal allergic rhinitis.
Pr. No. 9188IL/0126
330. A phase II, placebo-controlled study to evaluate the safety and efficacy of anti-IgE recombinant humanized monoclonal antibody (rhuMAb-E25) in subjects with moderate to

RESEARCH: ELI O. MELTZER, MD

- severe allergic asthma.
Pr. No. Q0694g
331. A study of the safety and efficacy of ABT-761 150mg, 300mg QD versus placebo in moderate asthma.
Pr. No. M95-411
332. A placebo-controlled, 12-week safety and efficacy study of albuterol dry powder inhaler and albuterol metered-dose inhaler in asthmatics.
Pr. No. DDPIAS-III-01-0694
333. A randomized study evaluating the effect of montelukast sodium to salmeterol in the inhibition of exercise-induced bronchoconstriction in adult asthmatics.
Pr. No. 064
334. A 6 and 12 month, open label, safety and efficacy study of HFA-143a beclomethasone dipropionate (BDP) in pediatric patients with asthma.
Pr. No. 1196-BRON
335. Efficacy and safety of mometasone furoate nasal spray in the treatment of acute episodes and recurrences of sinusitis.
Pr. No. C96-195
336. A placebo-controlled, parallel-group study of [R]-albuterol in the reversal of bronchoconstriction and in the management of asthma.
Pr. No. 051-024
337. Ninos Sanos: reducing environmental tobacco smoke exposure in Latino asthmatics. National Institutes of Health, NHLBI, 1R01 HL52835-01A2.
338. Exercise challenge dose response study of HFA-134a butixocort propionate, CFC-11/12 beclomethasone dipropionate and HFA-134a placebo in patients with reversible obstructive airway disease.
Pr. No. 1219-BUTI
339. An open-label, 12-month, safety study of Sprios™ dry powder inhaler (albuterol sulfate) in asthmatics.
Pr. No. DDPIAS-III-02-0995
340. A Long-term, Open-label, Safety study of Ebastine 20mg in Patients with Perennial Allergic Rhinitis
Pr. #RP 64305-141
341. One-year, evaluator-blind safety study of mometasone furoate nasal spray vs. beclomethasone dipropionate in children (ages 6-11) with perennial rhinitis.
Pr. No. C96-091
342. A six-week dose response study of RPR 106541T 10 mcg bid, 50 mcg bid and 400 mcg bid versus beclomethasone dipropionate 168 mcg bid versus placebo in chronic asthma.
Pr. No RPR 106541T-202
343. A placebo-controlled study examining the effect of fluticasone propionate aqueous nasal spray 200 mcg qd used in conjunction with an antibiotic in allergic subjects with recurrent sinusitis.
Pr. No. FLTA 4015
344. Placebo-controlled, dose ranging study of mometasone furoate dry powder compared to beclomethasone dipropionate in the treatment of asthma in subjects previously maintained on inhaled corticosteroids.
Pr. No. C96-134

RESEARCH: ELI O. MELTZER, MD

345. A Study of the Efficacy of Zileuton 1200mg BID, Controlled-Release (CR), and 600mg QID, Immediate Release (IR), and Placebo in Patients with Moderate Asthma.
Pr. #M95-337
346. A Single-Blind, Randomized, Parallel Group Comparison of the Efficacy and Safety of Beclomethasone Dipropionate Aqueous Nasal Spray Versus Cromolyn Sodium Nasal Solution Versus Placebo for Four Weeks in Subjects with Seasonal Allergic Rhinitis.
Pr. #BDPA 4001
347. A Comparative Bronchoprovocation Challenge Study of Two Albuterol Metered-Dose Inhalers in Patients With Stable Mild Asthma.
Pr. #94/11
348. Placebo-Controlled, Efficacy and Safety Study of Mometasone Furoate Dry Powder in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Beta-Agonists.
Pr. #C96-186
349. START - Inhaled Steroid Treatment As Regular Therapy in Early Asthma, A Study of the Effect of Early Intervention With Long-Term Inhaled Budesonide (Pulmicort® Turbuhaler®) In Newly Diagnosed Asthma.
Pr. #SD-004-0111
350. A Double-Blind Placebo Controlled Pilot Trial to Determine the Efficacy of Cisapride in Improving Respiratory Symptoms and Pulmonary Function in Asthmatics with Gastroesophageal Reflux (GER).
Pr. # CIS-USA-84
351. A Named-Patient Safety Study of Pulmicort [Budesonide] Nebulizing Suspension in Severe, Oral Steroid-Dependent Asthmatic Patients Aged Six Months to Eight Years.
Pr. #04-3121
352. A Twelve-Month, Double-Blind, Between-Patient, Placebo-Controlled Trial Comparing the Safety, Tolerability and Efficacy of 12 mcg and 24 mcg Twice Daily Formoterol Dry Powder Capsules for Inhalation, Delivered by a Single-Dose Inhaler (Aeroliser™), in Children with Asthma in Need of Daily Treatment with Inhaled Bronchodilators and Anti-Inflammatory Treatment.
Pr. #049
353. A Dose-ranging, Safety and Efficacy trial with Zafirlukast (ACCOLATE) in the Treatment of Pediatric Subjects with Mild-to-moderate Asthma; Up to a 52 Week Open Label Safety Extension.
Pr. #9188IL-0139
354. A Double-Blind, Placebo-Controlled Study to Assess the Clinical Effect of Montelukast in Patients with Seasonal Allergic Rhinitis.
Pr. #068
355. An Open Multicenter Study for the Validation of a Caregiver Asthma Diary (Pediatric).
Pr. # EPO7001.010
356. A Comparison of the Onset of Action of Claritin-D and Semprex-D in Patients with Moderate to Severe Seasonal Allergic Rhinitis.
Pr. # SPX D-97-01
357. A Clinical Study of the Effects of Three Types of Adhesive Nasal Strips on Nasal Airflow Resistance.
Pr. #CL970003

RESEARCH: ELI O. MELTZER, MD

358. The Cultural Adaptation into Hispanic of the Asthma Quality of Life Questionnaire (adult version).
Pr. #AQLQ
359. The Cultural Adaptation into Hispanic of the Rhinoconjunctivitis Quality of Life Questionnaire (adult version).
Pr. #95.3253
360. A Placebo-Controlled Parallel Study Comparing the Efficacy and Safety of Three Dosage Strengths of Fexofenadine HCl (15, 30 and 60 Mg BID) in Pediatric Patients (Ages 6 to 11 Years) in the Treatment of Seasonal Allergic Rhinitis.
Pr. #PJPR0066
361. A Placebo-Controlled Parallel Study Comparing the Efficacy and Safety of Fexofenadine HCl 120 MG and 180 MG QD in the Treatment of Autumn Seasonal Allergic Rhinitis.
Pr. #MO16455B/3081
362. An Evaluation of Quality of Life and Work, Study and Daily Activity Impairment Measures in Patients Receiving Fexofenadine HCl 120 MG and 180 MG in the Treatment of Autumn Seasonal Allergic Rhinitis.
Pr. #MO16455B/3004
363. The Evaluation of Three Norastemizole Doses (15 mg, 30, 45 mg) and Loratadine When Administered to Subjects with Seasonal Allergic Rhinitis.
Pr. #110-008
364. A Placebo-Controlled Evaluation of Histamine Skin Test Reactivity Following Single and Multiple Doses of Astelin® Nasal Spray.
Pr. #364/C970003
365. A Placebo-Controlled, Multicenter Study Evaluating the Effect of Montelukast Sodium Compared to Inhaled Beclomethasone Dipropionate in Adult Asthmatics.
Pr. #MK-070
366. A One-Day, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Clemastine Triple Combination (CTC), TheraFlu Sinus and Placebo in the Treatment of Seasonal Allergic Rhinitis.
Pr. #HSC-306
367. A Placebo-Controlled Study to Investigate the Efficacy and Safety of Inhaled Zanamivir (GG167) 10mg Administered Twice a Day for Five Days In the Treatment of Symptomatic Influenza A and B Viral Infections in Adolescents and Adults.
Pr. #NAIA 3002
368. An Evaluation of Pulmicort Respules (Budesonide Nebulizing Suspension) Versus Intal (Cromolyn sodium) Nebulizer Solution on Asthma-Related Outcomes in Children Two to Six Years Old.
Pr. #DX-RES-2000
369. A Placebo-Controlled, Comparison of Inhaled Fluticasone Propionate (88mcg BID) with Oral Zafirlukast (20mg BID) in Subjects With Mild to Moderate Asthma.
Pr. #FLTA 5001
370. A Comparative Study of Inhaled Fluticasone Propionate 88mcg BID Versus Zafirlukast 20mg BID in Asthmatic Subjects Who Are Currently Receiving Low Dose Inhaled Corticosteroids.
Pr. #FLTA 4035

RESEARCH: ELI O. MELTZER, MD

371. A Comparative Study of the Efficacy and Safety of Zyrtec vs. Claritin and Placebo in the Treatment of Chronic Idiopathic Urticaria.
Pr. #L-0342
372. A Study of Albuterol Controlled Release Suspension in the Treatment of Children With Asthma.
Pr. #05
373. Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate HFA-227 Metered Dose Inhaler in the Treatment of Asthma in Subjects Previously Maintained on short-acting Inhaled Beta-Agonists.
Pr. #C97-226
374. Pr. #C97-226
375. Placebo-Controlled, Dose-Ranging Study of Mometasone Furoate HFA-227 Metered Dose Inhaler Compared to Beclomethasone Dipropionate (Vanceril 84 mcg Double Strength) in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids.
Pr. #C97-208-10
376. A Placebo-Controlled Study Examining the Effect of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD in Subjects with an Acute Episode of Recurrent Sinusitis.
Pr. #FLTA 4033
377. A Placebo-controlled, 12-week Safety and Efficacy Study of Beclomethasone Dipropionate Dry Powder Inhaler and Beclomethasone Dipropionate Metered-dose Inhaler in Asthmatics.
Pr. #DPIBDP-03
378. Dose Ranging Study of SCH 34117 in the Treatment of Patients with Seasonal Allergic Rhinitis.
Pr. #C98-001
379. A Comparison of Zafirlukast (ACCOLATE) with Placebo in Pediatric Subjects with Mild-to-Moderate Asthma.
Pr. #9188IL/0150
380. A Phase II/III Placebo-Controlled, Efficacy, Safety and Dose Response Study of Azmacort® (triamcinolone acetonide) HFA-134a Inhalation Aerosol 225 mcg, 450 mcg and 900 mcg Administered Once Daily for 12 Weeks in the Treatment of Mild Persistent and Moderate Persistent Asthma in 800 Adolescents and Adults.
Pr. #RG5016Y-204
381. A Study of the Efficacy and Safety of Tylenol® Allergy Sinus (AS) Compared with Claritin® in the Treatment of Seasonal Allergic Rhinitis
Pr. #97-034
382. A Placebo-Controlled Study to Investigate the Safety and Efficacy of Omeprazole, 10 mg qd and 20 mg qd in Preventing Heartburn.
Pr. #171
383. A Placebo-Controlled Study to Compare Concomitant Montelukast and Loratadine With Intranasal Beclomethasone in Patients With Seasonal Allergic Rhinitis.
Pr. #077
384. A Comparison of the Effect of Two Doses of Levalbuterol with Ventolin® on Pulmonary Function in Subjects with Mild-To-Moderate Asthma.
Pr. #051-027
385. Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate Dry Powder Inhaler in the Treatment of Asthma in Children Previously Maintained on Inhaled Corticosteroids.
Pr. #C97-300

RESEARCH: ELI O. MELTZER, MD

386. Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate Dry Powder Inhaler in the Treatment of Asthma in Children Previously Maintained on Beclomethasone Dipropionate (Vanceril® 84 mcg Double Strength).
Pr. #C97-380
387. A Placebo-Controlled Comparison of the Safety and Efficacy of Claritin vs. Fexofenadine vs. Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis.
Pr. #P97-344
388. A Parallel-Group Chronic Asthma Study Comparing Montelukast With Placebo in 2- to 5-Year-Old Patients.
Pr. #072
389. A Long-Term Open-Label Study to Evaluate the Safety of HFA Flunisolide in Adult and Adolescent Patients with Mild to Moderate Asthma.
Pr. #ANC-MD-02-000
390. Efficacy and Safety of SCH 34117 in the Treatment of Patients With Seasonal Allergic Rhinitis.
Pr. #C98-223
391. Efficacy and Safety of SCH 34117 in the Patients With Seasonal Allergic Rhinitis.
Pr. #C98-224
392. Efficacy and Safety of 800 mcg or 400 mcg of Mometasone Furoate Nasal Spray or Placebo in the Treatment of Acute Episodes of Sinusitis.
PR # C97-251
393. A Study Comparing the Clinical Effect of Concomitant Montelukast + Loratadine with Montelukast, Loratadine, and Inhaled Beclomethasone in Patients With Chronic Asthma.
Pr. #074
394. A Phase III 7-month placebo-controlled trial with a 5-month open label extension period to assess safety and tolerability, steroid reduction, pharmacokinetics, and pharmacodynamics of subcutaneous rhuMAb-E25 in children (6-12 years) with allergic asthma requiring daily treatment with inhaled corticosteroids.
Pr. #rhuMAb-E25 01 010
395. The Evaluation of Three Norastemizole Doses (30mg, 60mg 90mg) and Loratadine When Administered to Subjects with Seasonal Allergic Rhinitis.
Pr. #110-024
396. One-Year Study of the Effects of Mometasone Furoate Dry Powder Inhaler versus Placebo on Growth of Children with Asthma.
Pr. #C97-384
397. Efficacy and Safety of SCH 34117 in the Treatment of Patients With Seasonal Allergic Rhinitis (Four Weeks Treatment).
Pr. #C98-225
398. A Double-Dummy, Comparison of Inhaled Fluticasone Propionate (88 mcg BID) versus Zafirlukast (20mg BID) over 12 Weeks in Subjects with Persistent Asthma.
Pr. # FAS40023
399. The Pharmacodynamics and Safety of Levalbuterol Syrup in Pediatric Subjects with Mild-to-Moderate Asthma.
Pr. #051-202

RESEARCH: ELI O. MELTZER, MD

400. Long Term Safety of Mometasone Furoate HFA 227 Nasal Aerosol in Perennial Allergic Rhinitis.
Pr. #C97-302
401. A Comparison of the Ease of Teaching Correct Inhaler Technique and Patient Device Preference Between Pulmicort Turbuhaler® (budesonide inhalation powder) and Several Pressurized Metered Dose Inhalers in Patients with Asthma.
Pr. #DX-PUL-1002
402. A Double-Blind Study of Inhaled Fluticasone Propionate (88mcg BID) Versus Montelukast Sodium (10mg QD) in Subjects Currently Receiving Beta Agonists Alone.
Pr. #FLTA4039
403. A Study Comparing the Efficacy and Safety of Fexofenadine HCl 120mg q.d., Cetirizine HCl 10 mg q.d., and Placebo q.d. in the Treatment of Perennial Allergic Rhinitis.
Pr. #M016455M/309
404. Phase II Placebo-Controlled Eight Week Study of Efficacy and Safety of Inhaled CP-325,366 in Adults with Persistent Asthma.
Pr. #264-101-5012
405. A Phase I Safety and Pharmacokinetic Study of IL-4R Comparing Two Aerosol Delivery Devices.
Pr. #013.0009
406. An Open-label Placebo-Controlled Study to Compare the Endocrine Effects of Aerobid Inhaler System (flunisolide), Flovent Inhalation Aerosol (fluticasone propionate), and Oral Prednisone in patients with Mild to Moderate Asthma.
Pr. #AER-MD-08-000
407. A Placebo-Controlled Study of Ro 64-0796 (also known as GS 4104) in Children with Influenza.
Pr. #WV15758
408. A Placebo-Controlled Trial Evaluating the Safety and Efficacy of the DISKUS Formulations of Salmeterol 50mcg BID and Fluticasone Propionate 250mcg BID Individually and in Combination as Compared to Placebo in COPD Subjects.
Pr. #SFCA3007
409. A Placebo-Controlled Study of the Clinical Effect of Nebulized L-808,065 in Patients with Chronic Asthma.
Pr. #004-00A
410. Randomized, Double-Blind, Placebo-Controlled, Crossover Trial to Assess the Effect of Zafirlukast (Accolate) 20mg Twice Daily when Administered with Food on Exercise-Induced Bronchoconstriction in Subjects with Asthma.
Pr. #9188US/0025
411. An Evaluation of Safety and Tolerance of Cromolyn Sodium Following the Administration of a Nasal Solution to Pediatric Subjects
Pr. #M3235\0002
412. A Parallel Study Comparing the Efficacy and Safety of Fexofenadine HCl 120 mg qd., 180 mg qd., Cetirizine 10 mg qd., and Placebo qd. In the Treatment of Perennial Allergic Rhinitis
Pr. #M016455M/3097

RESEARCH: ELI O. MELTZER, MD

413. A Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous SB 240563 (250mg and 750mg) in Patients with Asthma
Pr. # SB 240563-006
414. Four-Week, Double-Blind, Safety and Efficacy Study of Beclomethasone Dipropionate Nasal Aerosol vs. Placebo in Children (Age 3-5) with Perennial and/or Seasonal Allergic Rhinitis
Pr. # C98-641-07
415. Dose Ranging Study of Mometasone Furoate HFA-227 nasal Aerosol in the Treatment of Patients with Seasonal Allergic Rhinitis
Pr. #C97-297
416. Safety and Efficacy Study of HFA-134a Albuterol Sulfate Delivered from a Press-and-Breathe MDI, HFA-134a Albuterol Sulfate Delivered from the Autohaler™ Inhalation Device, and HFA-Placebo in Patients with Asthma
Pr. #1332-SILV
417. Multi-Center, Randomized Comparison of the Efficacy, Onset of Action and Safety of a Single Dose of Fexofenadine 180 mg vs. Loratadine 10 mg vs. Placebo in Treating Seasonal Allergic Rhinitis in an Outdoor Environment
Pr. #M016455/4104
418. A 12-Week Comparison of Daily Doses of 100 mcg and 200 mcg of HFA-134a Beclomethasone Dipropionate in the Autohaler™ Device Versus Placebo in Pediatric Patients with Symptomatic Asthma
Pr. #1343-BRON
419. Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Adults
Pr. #013.0014
420. Development and Validation of a Questionnaire to Measure Health-Related Quality of Life in Adults with Allergic Rhinitis: The Relationship of Allergic Rhinitis, Sleep Quality and Daytime Fatigue
Pr. #MCS99001
421. A Twelve-Month Safety Study of 90mg Norastemizole in Subjects with Seasonal Allergic Rhinitis/Perennial Allergic Rhinitis
Pr. #110-029
422. Phase IIA Multicenter, Randomized, Double-Blind, Double-Dummy, Active and Placebo-Controlled, Parallel Group, Dose-Response Study of the Efficacy, Safety, and Tolerability of Six Weeks Oral Dosing with CJ-13,610 Compared to Montelukast and Placebo in Adults with Persistent Asthma
Pr. #253-102
423. Efficacy and Safety of SCH 34117 and Cetirizine in the Treatment of Subjects with Seasonal Allergic Rhinitis
Pr. #P00384
424. A Placebo-Controlled Pilot Study Evaluating the Effects of Montelukast Sodium versus Salmeterol Xinafoate on Beta-agonist Induced Bronchodilation following Challenge – (Exercise) Induced Bronchoconstriction
Pr. #113-00
425. The Evaluation of Norastemizole (30 mg) and Loratadine When Administered to Subjects with Seasonal Allergic Rhinitis
Pr. #110-032

RESEARCH: ELI O. MELTZER, MD

426. A Study to Assess the Growth Effects of a One-Year Course of Fluticasone propionate Aqueous Nasal Spray (200mcg QD) Versus Placebo in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis
Pr. #FNM40017
427. Efficacy and Safety of SCH 29851 8 mg QD in Subjects with Seasonal Allergic Rhinitis
Pr. #P00677
428. An open-label extension of rhuMAb-E25 treatment to children with allergic asthma who participated in the one-year study (rhuMAb-E25 Protocol No. 01 010)
Pr. #rhuMAb-E25 01 010 Extension 1
429. Efficacy and Safety of SCH 34117 + Pseudoephedrine, BID, vs its Components in the Treatment of Subjects with Seasonal Allergic Rhinitis
Pr. #P00355
430. A Placebo-Controlled Comparative Trial of Albuterol Delivery by a New, Hand-Held, Ultrasonic Metered Dose Solution Inhaler (MSI) Compared to a Standard Metered Dose Inhaler (MDI) in Moderate Persistent Asthmatic Children (≥ 4 Years of Age and ≤ 12 Years of Age)
Pr. #7102-JAUS-02
431. Efficacy and Safety of SCH 34117 in Subjects with Seasonal Allergic Rhinitis and Concurrent Asthma
Pr. #P00214
432. A Phase II, Placebo-controlled, Study of AG7088 Nasal Spray, 2% Suspension for the Treatment of Natural Rhinovirus Infection in the General Population Including Patients with a History of Chronic Respiratory Disease
Pr. #AG7088-304
433. A Placebo-Controlled Study with SCH 34117 in the Treatment of Subjects > 12 Years of Age with Perennial Allergic Rhinitis
Pr. #P00217
434. A Placebo Controlled Comparative Trial of Albuterol Delivery by a New, Hand-Held, Ultrasonic Metered Dose Solution Inhaler (MSI) Versus a Standard Metered Dose Inhaler (MDI) in Patients with Bronchial Asthma
Pr. #7102-JAUS-04
435. A Placebo-Controlled, Cross-Over Study Evaluating the effect of a Single Dose of LDP-977 on the Acute Bronchodilator Response in Asthmatics
Pr. #L97799-018
436. An Open-Label, Multiple-Dose, Study to Evaluate the Safety of Beclomethasone Dipropionate and Reliability of the To-Be-Marketed Spiros Dry Powder Inhaler in patients with Asthma
Pr. #DPIBDP-07
437. A Parallel-Group, Placebo-Controlled, 12-Week Study of Fluticasone Propionate 44mcg BID and 88mcg BID delivered via CFC MDI and a Valved Holding Chamber with Facemask in Subjects with Asthma Age 24 months to 47 months
#FMS30058
438. **Salmeterol vs. Montelukast for Asthmatics who Require more Therapy (SMART Study).** A Randomized, Double-Blind Multicenter Study to Evaluate the Effect of Adding Either Montelukast Sodium or Salmeterol Xinafoate to Inhaled Fluticasone in Adult Asthmatics
#120

RESEARCH: ELI O. MELTZER, MD

439. A Pilot Study to Evaluate Objective Measurements in Normal and Allergic Rhinitis Subjects
#X99-047
440. A Placebo-Controlled, Therapeutic Confirmatory Study Evaluating the Safety and Efficacy of 0.31 mg and 0.63 mg Levalbuterol and 1.25 mg and 2.5 mg Racemic Albuterol and Placebo
#051-031
441. A Placebo-Controlled, 12-Week Study of Fluticasone Propionate 44mcg BID and 88mcg BID delivered via CFC MDI and a Valved Holding Chamber with Facemask in Subjects with Asthma Age 6 months to 23 months
#FMS30059
442. Parallel-Group Study Comparing the Effect on Linear Growth of Montelukast With Placebo and Inhaled Beclomethasone in Pediatric Patients (Prepubertal, Tanner Stage I) With Mild Asthma
#097
443. Validation of a Nocturnal Rhinitis Quality of Life Questionnaire: Pre-Test Phase
#RG5029Y.US1.900
444. A Comparison of the Safety and Efficacy of Three Once Daily Doses of BAY 19-8004 with Placebo and Montelukast 10 mg Daily in Patients with Symptomatic Asthma
#100245
445. A Multicenter, Randomized, Double-Blind, Placebo-controlled Study of the Effect of Long-Term Treatment with Rhinocort® Aqua (Budesonide) Nasal Spray in Children with Perennial Allergic Rhinitis
#SD-005-0414
446. A Parallel-Group Study Evaluating the Protective Effects of the Salmeterol Xinafoate/Fluticasone Propionate Combination Product (50/100mcg BID via DISKUS) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who Require Chronic Inhaled Corticosteroid Therapy for the Treatment of Persistent Asthma
#SAS40024
447. A Parallel-Group Study Evaluating the Protective Effects of the Salmeterol Xinafoate/Fluticasone Propionate Combination Product (50/250mcg BID via DISKUS) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who Require Chronic Inhaled Corticosteroid Therapy for the Treatment of Persistent Asthma
#SAS40025
448. A Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients With Seasonal Allergic Rhinitis-Spring Study
#162-00
449. A Placebo-Controlled, Parallel-Group, Multiple-Dose, Multicenter, 12-Week Study to Compare the Safety and Efficacy of Beclomethasone Dipropionate via the To-Be-Marketed Spiros Dry Powder Inhaler to Vanceril Metered-Dose Inhaler in Patients with Asthma
#DPIBDP-06
450. A Placebo-Controlled Study to Assess the Safety and Tolerability of Fexofenadine HCL 30 mg Twice a Day During Treatment of Children 2 through 5 Years of Age with Allergic

RESEARCH: ELI O. MELTZER, MD

- Rhinitis
#M016455I/3112
451. A Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100 mcg DISKUS Inhaler BID versus Fluticasone Propionate 250 mcg DISKUS Inhaler BID in Adolescents and Adults with Moderate Persistent Asthma
#SAS40027
452. Clinical and Objective measurements of the Effectiveness of Desloratadine 5 mg vs. Placebo in Subjects with Symptomatic Seasonal Allergic Rhinitis (SAR)
#P00765
453. A Single Dose Study to Examine Anti-histamine and Sedation Potential of Concentrated Oral Liquid Formulations of Chlorpheniramine Maleate in Healthy Volunteers
#2000047
454. A Parallel Group Comparison of 200mcg Fluticasone Propionate Aqueous nasal Spray, Placebo and 10 mg Encapsulated Loratadine Administered (No more than Once Daily) As-Needed in Subjects with Seasonal Allergic Rhinitis
#FNM30030
455. A Multicenter, Placebo-Controlled, Open-Label Study to Evaluate the Safety of Olizumab in Moderate to Severe Persistent Asthma Subjects Already Treated With Other Therapies (ALTO).
#Q2143g
456. An open-label extension study of Xolair™ (omalizumab) in moderate to severe, persistent asthma subjects who completed study Q2143g (ALTO)
#2195g
457. A Placebo-controlled, Parallel Group Study Assessing the Efficacy and Safety of Oral Fexofenadine HCl Tablets 30 mg Twice A Day in Pediatric Subjects (6 to 11 Years) in the Treatment of Seasonal Allergic Rhinitis
#M016455C/3212
458. Phase II Safety and Efficacy Study of Nebulized Recombinant Human IL-4 Receptor in Asthma
#013.0017
459. A Randomized, Double-Blind, Double Dummy, Parallel Group Comparison of Fluticasone Propionate Inhalation Powder (50mcg BID) via DISKUS® with Oral Montelukast (5mg QD) Chewable Tablets in Children 6-12 Years of Age with Persistent Asthma
#FPD40012
460. A Placebo-Controlled, Environmental Study of PATANOL® Nasal Spray versus ASTELIN® in the Treatment of Seasonal Allergic Rhinitis
#C-00-33
461. A Phase IIa Cross-Over Study of Once Daily Inhalations of Three Doses of AlbuLast™ in Adults with Mild to Moderate Asthma
#AIR01-004
462. A Multicenter, Parallel-Group Study Investigating the Clinical Effect of L-858674 in Patients With Seasonal Allergic Rhinitis – A Pilot Study During the Fall Season
#003
463. Phase II Safety and Efficacy Study of Nebulized Recombinant Human IL-4 Receptor in Asthma Patients Using Inhaled Corticosteroids
#013.0019

RESEARCH: ELI O. MELTZER, MD

464. A 2-Period Study in Subjects with Allergic Rhinitis to Assess the Response and Variability of Nasal Airway Resistance to Allergen Provocation
#002
465. Multi-Symptom Allergy Sinus Efficacy and Safety Study
#AD-99-02
466. Efficacy, Safety and Tolerability Study of Daily Dosing with Levalbuterol, Racemic Albuterol and Placebo in Pediatric Subjects 2-5 Years Old with Asthma.
#051-032
467. A Multicenter, Parallel-Group Study Comparing Montelukast With Placebo in Pediatric Patients Aged 2 Through 14 Years With Seasonal Allergic Rhinitis
#219-00
468. A Placebo and Loratadine Controlled Parallel-Group Study of Montelukast in Patients With Seasonal Allergic Rhinitis – Spring 2001 Study
#235-00
469. A Placebo-Controlled, Multi-Dose Study of the Potential Effects of Ciclesonide and Fluticasone Propionate on HPA-Axis in Adult Asthma Patients
#XRP1526B-102
470. A Double-Blind, Placebo-Controlled, Parallel Group Study of Four Doses of Loteprednol Etabonate Nasal Spray (100µg, 200µg, 400µg and 800µg) with Flonase® (200µg) as an Open Active-Control in the Treatment of Adults and Adolescents with Allergic Rhinitis Induced by Grass Pollen
#H-01075-3212
471. A Placebo-Controlled Efficacy and Safety Study of a Once-Daily PM and Twice Daily Regimens of Mometasone Furoate Administered Via Dry Powder Inhaler in Subjects With Asthma Who Were Previously Maintained On Inhaled Corticosteroids
#P01545
472. A Multicenter, Randomized, Parallel Group Study Of The Efficacy, Safety, Health Care Utilization and Health Related Quality Of Life With Nasacort® AQ (triamcinolone acetonide aqueous) Nasal Spray and Flonase® (fluticasone propionate) Nasal Spray In The Treatment Of Patients with Seasonal Allergic Rhinitis
#NAS.US1.435
473. A Study of the Efficacy and Safety of Zyrtec® (Cetirizine HCl) Syrup vs. Claritin® (Loratadine) Syrup vs. Placebo in the Treatment of Children with Seasonal Allergic Rhinitis
#A1431009
474. A Randomized, Open Label, Cross Over Trial, Assessing Correct Use And Patient Preference of Fluticasone Propionate Inhalation Powder (100 mcg bid) via the Diskus Versus Fluticasone Propionate Aerosol via The Metered Dose Inhaler (88 mcg bid) in Subjects At Least 12 Years of Age with Persistent Asthma Currently Receiving Short Acting Beta Agonists Alone
#FPD40016
475. A Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Seasonal Allergic Rhinitis Over a 4-Week Treatment Period – Fall 2001
#240-00
476. Chronic-Dose Comparison of the Efficacy and Safety of Albuterol-HFA-MDI (*SALAMOL*TM), Albuterol-HFA-BOI (*SALAMOL EASI-BREATHE*TM) and *PROVENTIL*[®] HFA in Mild-to-Moderate Asthmatics

RESEARCH: ELI O. MELTZER, MD

- #BNP-301-4-167
477. A Phase III Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Efficacy, Safety and Dose Response Study of Ciclesonide Metered Dose Inhaler 100mcg/day, 200 mcg/day, and 400mcg/day (ex-valve) Administered Once Daily and 400mcg/day (ex-valve) Administered Twice Daily for 12-weeks in the Treatment of Mild to Moderate Persistent Asthma in Adolescents and Adults
#XRP1526B-322
478. A Placebo-Controlled Study to Assess the Safety and Efficacy of Dey Beclomethasone Dipropionate Monohydrate Nasal Spray 0.042% in Adolescent and Adult Patients with Seasonal Allergic Rhinitis
#DL-047
479. A placebo-controlled, 12-week trial evaluating the efficacy and safety of the fluticasone propionate/salmeterol DISKUS combination product 250/50mcg once daily fluticasone propionate/salmeterol DISKUS combination product 100/50mcg twice daily versus fluticasone propionate DISKUS 250mcg once daily versus placebo in symptomatic adolescent and adult subjects with asthma that are not controlled on short acting beta 2-agonists alone
#SAS30022
480. A Phase II, Placebo-Controlled, Double-Blind, Parallel Group, Dose-Finding Study to Evaluate the Effectiveness of 28 days of Treatment with LDP-977 in Adult Asthmatics
#M97700-023
481. A Single Center, Placebo-Controlled, Ascending-Dose Safety and Tolerability Study of INS37217 Aqueous Nasal Spray in Healthy Non-Rhinitic Volunteers and Healthy Volunteers with Perennial Allergic Rhinitis
#07-101
482. A Dose Response Comparison of the Topical Efficacy of HFA-134a Beclomethasone Dipropionate versus Fluticasone Propionate in Subjects with Persistent Asthma
#1434-BRON
483. A 12-week, placebo and active controlled, parallel group study evaluating the safety and efficacy of Formoterol fumarate (10 µg bid) delivered by the multi-dose dry powder inhaler (MDDPI) versus placebo versus albuterol pMDI qid in patients with persistent asthma
#CFOR258 F2302
484. A Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis
#246-00
485. 16-Week Comparison of Asthma Control in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50 mcg BID, Fluticasone Propionate DISKUS 100 mcg BID, Salmeterol Xinafoate DISKUS 50 mcg BID, or Oral Montelukast 10 mcg QD
#SAS40036
486. An efficacy and safety study of fluticasone propionate aqueous nasal spray (FP) in subjects with seasonal allergic rhinitis (SAR)
#R1810221
487. Study of the efficacy and patient preference of albuterol delivered via the Pocketchamber™ (PC) versus the Aerochamber Plus™ (ac) in patients with asthma.
#001

RESEARCH: ELI O. MELTZER, MD

488. A double-blind, placebo-controlled, safety and efficacy study of three doses of INS37217 nasal spray in subjects with symptomatic perennial allergic rhinitis
#07-102
489. A multicenter, double-blind, randomized, parallel groups placebo-controlled study to assess the efficacy and safety of fexofenadine 120 mg bid in patients with mild to moderate persistent asthma
#M016455P/3001
490. A multicenter, double-blind, randomized, placebo-controlled, parallel study to assess the safety and tolerability of fexofenadine HCL 30 mg in children with allergic rhinitis.
#M016455T/3002
491. Phase II, randomized, three-arm, double-blind, placebo controlled, evaluation of the safety and efficacy of Doxepin hydrochloride 0.04% Civamide (Zucapsaicin) 0.01%, and placebo nasal solution in the treatment of subjects with vasomotor rhinitis
#WL-1002-03-01
492. An open-label, one year long-term safety study of ciclesonide metered dose inhaler 50 µg/Day to 200 µg/Day (Ex Valve) Administered Once Daily or fluticasone dry powder inhaler (Flovent® Rotadisk®) 50 µg or 100 µg Administered Twice Daily for the treatment of children with persistent asthma
#XRP1526B-344/68
493. A phase II study comparing the efficacy and safety of oral efletirizine immediate release (IR) 7 mg, 10 mg, and 15 mg tablets administered twice a day and oral efletirizine extended release (ER) 35 mg tablets administered once a day in the morning for two weeks versus the placebo in subjects suffering from seasonal allergic rhinitis.
#A00321
494. The evaluation of tecastemizole administered to subjects with seasonal allergic rhinitis
#110-073
495. Evaluation of a newly developed preference questionnaire for intranasal corticosteroids in patients with allergic rhinitis treated with Nasacort® AQ (triamcinolone acetonide) nasal spray 220 mcg and Nasonex® (mometasone furoate) nasal spray 200 mcg – a pilot study
#4006
496. A twelve-week, randomized, double-blind, double-dummy, placebo-controlled trial of Symbicort™ (80/4.5 mcg) versus its mono products (budesonide and formoterol) in children (>12 years of age) and adults with asthma
#SD-039-0716
497. A phase IIIa, multi-center, randomized, double-blind, parallel-group, placebo-controlled study on the efficacy and safety of fexofenadine HCL 180 mg once daily in chronic idiopathic urticaria
#M016455A/4121
498. An efficacy and safety study of levalbuterol, racemic albuterol and placebo in subjects twelve years of age and older with asthma
#051-353
499. A randomized, placebo-controlled, crossover study to assess the antihistamine activity and sedation potential of a new loratadine lingual spray formulation versus Claritin® tablets in healthy volunteers
#001
500. A multicenter, randomized, double-blind, double-dummy, placebo controlled, parallel

RESEARCH: ELI O. MELTZER, MD

- group, four-week study assessing the efficacy of fluticasone propionate aqueous nasal spray 200 mcg QD versus montelukast 10mg QD in adolescent and adult subjects with asthma and seasonal allergic rhinitis who are receiving concurrent open-label Advair Diskus[†] 100/50 mcg BID
#SAM40066
501. A placebo- and active-controlled efficacy and safety study of a once-daily fixed combination tablet of desloratadine 5 mg/pseudoephedrine 120 mg (SCH483 [5/120]) in subjects with seasonal allergic rhinitis
#P01861
502. A randomized, multicenter, placebo-controlled parallel group study of four months duration per patient treatment to evaluate the safety and efficacy of treatment with 24 µg b.i.d. and 12 µg b.i.d. formoterol, double-blind, and 12 µg b.i.d. formoterol with additional on-demand formoterol doses, open-label, in adolescent and adult patients with persistent stable asthma
#CFOR258D2307
503. A randomized, double-blind, placebo-controlled trial of Astelin® (azelastine hydrochloride) nasal spray, Clarinex® (desloratadine) and Astelin® nasal spray plus Claritin® (loratadine) in patients with seasonal allergic rhinitis
#414
504. A placebo-controlled, efficacy and safety study of olopatadine nasal spray for the treatment of seasonal allergic rhinitis
#C-02-37
505. A multicenter, double-blind, randomized, parallel study comparing the efficacy and safety of fexofenadine 120 mg BID, fexofenadine 240 mg QD, and placebo in subjects with perennial allergic rhinitis
#M016455TM/3001
506. A multicenter, randomized, parallel-group, double-blind efficacy and safety study of INS37217 nasal spray versus placebo in subjects with perennial allergic rhinitis
#07-105
507. A randomized, double-blind, placebo-controlled trial of Astelin® (azelastine hydrochloride) nasal spray 137 mcg plus Allegra (fexofenadine hydrochloride 60 mg) in patients with seasonal allergic rhinitis
#415
508. A randomized, double-blind, placebo-controlled trial of Astelin® (azelastine hydrochloride) nasal spray 137 mcg at a dosage of one spray per nostril twice daily in patients with seasonal allergic rhinitis
#420
509. An open label pilot study of Astelin® (azelastine hydrochloride) nasal spray 137 mcg in the treatment of nasal congestion in patients with seasonal allergic rhinitis
#421
510. Distribution of the clearance and terminal-phase half-life of tecastemizole 30 mg (population pharmacokinetic screen)
#110-083
511. A multicenter, double-blind, randomized study investigating the clinical effect of montelukast on allergic rhinitis in patients with seasonal allergic rhinitis and chronic asthma – Spring 2003 study
#269-00

RESEARCH: ELI O. MELTZER, MD

512. An efficacy and safety study of levalbuterol 90 mcg, racemic albuterol 180 mcg and placebo in subjects twelve years or older with asthma
#051-355
513. Efficacy and safety of 200 mcg QD or 200 mcg BID mometasone furoate nasal spray (MFNS) vs. amoxicillin vs. placebo as primary treatment of subjects with acute rhinosinusitis
#P02683
514. A randomized, double-blind, parallel-group multicenter efficacy and safety phase IIB pilot study of esomeprazole 40mg twice daily versus placebo twice daily in adult asthmatics treated for 4 months
#SD-NEE-0003
515. A comparison of fexofenadine HCL 180 mg, desloratadine 5 mg and placebo in suppression of wheal and flare induced by histamine
#M016455A/4145
516. An open-label, multi-center study to evaluate the performance and patient satisfaction of fluticasone propionate/salmeterol HFA with counter in asthma or COPD subjects at least 12 years of age
#SAS30033
517. An open-label, multi-center study to evaluate the performance and patient satisfaction of albuterol HFA with counter in asthma or COPD subjects at least 4 years of age
#SB030003
518. Term safety study of olopatadine nasal spray
#C-01-92
519. A twelve week, randomized, double-blind, parallel group trial comparing the efficacy, safety and tolerability of a 20mg daily dose of IPL512, 602 oral tablets to placebo in patients with mild to moderate persistent asthma
#AVE0547A/2001
520. A randomized, double-blind, placebo-controlled multicenter, parallel-group dose-response study evaluating the safety and efficacy of oral NGD 2000-1 dibesylate tablets in patients with mild to moderate asthma
#NC-00-004
521. Dose ranging study of Ro 27-2441 in patients with persistent asthma not treated with inhaled corticosteroids.
#BA16631-A
522. A multicenter, parallel study comparing the efficacy and safety of PULMOCORT RESPULES® (budesonide inhalation suspension) at 0.5 mg, QD, 1.0 mg QD, 1.0 BID, 2.0 BID and PULMICORT TURBUHALER ® (budesonide) at 400 mcg BID in adolescents (12 Years of Age and Older) and adults with moderate to severe asthma
#SD-004- 0764
523. A parallel-group study investigating the clinical effect of L-000888839 in patients with seasonal allergic rhinitis – a pilot study during the fall season
#005
524. A 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long term treatment in adolescents and adults receiving either fluticasone propionate/salmeterol DISKUS BID or fluticasone propionate DISKUS BID (or placebo BID if asymptomatic)
#SAM40086

RESEARCH: ELI O. MELTZER, MD

525. A placebo-controlled, parallel-group study investigating the clinical effects of montelukast in patients with perennial allergic rhinitis
#265
526. A twelve-week, active-controlled study of SYMBICORT® pMDI administered once daily in children and adolescents 6 to 15 years of age with asthma – SPROUT
#SD-039-0725
527. A twelve-week, placebo- and active-controlled study of SYMBICORT® pMDI administered once daily in adults and adolescents with asthma – STEM
#SD-039-0726
528. Qualitative assessment of patient diary questions to assess patient perception of the onset of effect if asthma medication using cognitive debriefing methodology.
#A2-3269
529. 3-week, open-label, uncontrolled, multicenter study evaluating the functionality of the Foradil® Certihaler® device in patients with asthma
#CFOR258F2304A
530. Efficacy and Safety of 200mcg QD or 200mcg BID Mometasone Furoate Nasal Spray (MFNS) vs. Amoxicillin vs. Placebo as Primary Treatment of Subjects with Acute Rhinosinusitis
#P02692
531. A 1 year, randomized, double-blind, parallel-group, placebo-controlled, multicenter evaluation of efficacy, safety, pharmacokinetics and pharmacodynamics of omalizumab in children (6 - <12 years) with moderate-severe, persistent, inadequately controlled allergic asthma.”
#CIGE025AIA05
532. Psychometric Evaluation of Patient Satisfaction with Asthma Treatment
#HRA 23-371B
533. A Multicenter, double-blind, placebo-controlled, randomized, parallel-group study to evaluate the clinical effect of oral Montelukast versus placebo during the allergy season in patients with seasonal aeroallergen sensitivity and chronic asthma which is also active during allergy season
#289
534. A Multicenter, Randomized, Double-Blind Parallel Group Study of the Effects of
535. Ciclesonide HFA-MDI 640 µg/day & beclomethasone HFA-MDI 640 µg/day on lens opacification in adult subjects w/ moderate to severe persistent asthma
#XRP1526B – 3027
536. A Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Mast Cell Inhibitor, R-926112, in Patients with Symptomatic Seasonal Allergic Rhinitis in a Park Setting
#R-926112-004
537. A randomized, controlled study of roflumilast (250 mcg and 500 mcg) versus placebo in patients with asthma. A 24-week, multicenter, multinational, double-blind, parallel group clinical study
#BY217/M2-023
538. Ability to swallow with and without the aid of a pill cup in pediatrics subjects ages >6 to <12 years of age
#M016455C/6001

RESEARCH: ELI O. MELTZER, MD

539. A 3-week, open-label, uncontrolled, multicenter study evaluating the functionality of the Foradil® Certihaler® device in patients with asthma
#CFOR258 F2306
540. 12 week study to assess the efficacy and safety of Symbicort® pMDI 160/4.5 µg x 2 actuations once-daily (QD) compared to Symbicort pMDI 80/4.5 µg x 2 actuations QD, Symbicort pMDI 80/4.5 µg x 2 actuations twice-daily (BID) and to budesonide pMDI 160 µg x 2 actuations QD in asthmatic subjects 12 years of age and older
D5896C0001
541. A placebo controlled study of the efficacy and safety of desloratadine vs. fexofenadine 180 mg. in the treatment of subjects with symptomatic seasonal allergic rhinitis (SAR)
P04053-11
542. Pediatric Questionnaire on Asthma Control: Initial Validation Study
GHO102199
543. Crossover study comparing the effect of L-000888839 with placebo & concomitant administration of L-000888839 plus montelukast in adults with chronic asthma
#008
544. A placebo-controlled, dose ranging study, to assess the efficacy and safety of 4 doses of QAB149 (50, 100, 200 & 400 ug) delivered via a multiple dose inhaler, and 1 dose of QAB149 (400 µg) delivered via a single dose inhaler, in adult and adolescent patients (12–75 years old inclusive) with stable, persistent asthma
CQAB149A2216
545. A four-week, placebo-controlled, study of ventolin HFA MDI delivered TID with facemask and valved holding chamber (Aerochamber Plus;) in subjects birth to<24 months in age with symptoms of bronchospasm (i.e. wheeze, cough, dyspnea or chest tightness) consistent with obstructive airways disease.
SB030001
546. A Phase 3 clinical trial designed to assess the efficacy and safety of ciclesonide applied as a nasal spray at three dose levels (100 mg, 200mg, or 25mg, once daily) in the treatment of perennial allergic rhinitis (PAR) in patients 6–11 years of age
BY9010/M1-403
547. Pharmacodynamics of the 88 mcg BID dose of the hydrofluoroalkane propellant formulation of inhaled fluticasone propionate following administration via the metered dose inhaler in pediatric subjects 4 to 11 years of age with asthma
FAP 19052
548. A preference evaluation of Nasonex nasal spray (unscented vs. Flonase nasal spray (scented) in subjects with symptomatic allergic rhinitis (AR) single-dose cross-over
P04207
549. A placebo-and active-controlled (ciclesonide metered dose inhaler), dose range finding study of ciclesonide administered by dry powder inhaler (Ultrahaler®) in adult and adolescent patients with persistent asthma.
AVE2635A/2001
550. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 100 mcg for 4 weeks in adult and adolescent subjects (12 years of age) with perennial allergic rhinitis (PAR)
#FFR30002

RESEARCH: ELI O. MELTZER, MD

551. Randomized double-blind trial of Astelin[®] (azelastine hydrochloride) nasal spray compared to Zyrtec[®] (cetirizine) in patients with seasonal allergic rhinitis
MP 426
552. A randomized, double-blind, placebo-controlled study evaluating the effects of MN-001 in subjects with mild to moderate asthma
#MN-001-CL-001
553. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of once-daily, intranasal administration of GW685698X aqueous nasal spray 50mcg and 100mcg for 12 weeks in pediatric subjects ages 2 to <12 years with perennial allergic rhinitis (PAR)
#FFR30008
554. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 50mcg and 100mcg for 2 weeks in pediatric subjects Ages 2 to <12 years with seasonal allergic rhinitis (SAR)
#FFR100010
555. randomized, double-blind, placebo-controlled, single-dose, 3-period crossover study to determine the effect of PLA-902 on exercise-induced bronchoconstriction
#PLA-902
556. Pilot efficacy and safety field trial of Desloratadine administered concomitantly with Oxybutynin, in subjects with seasonal allergic rhinitis and post-nasal drip
#SP4258
557. safety and efficacy of olopatadine hydrochloride nasal spray in pediatric patients
#C-04-20
558. Safety and bioequivalence of Triamcinolone Acetonide Nasal Spray compared w/ Nasacort AQ[®] nasal spray 55 mcg in the relief of signs & symptoms of SAR
#CPL-404
559. A randomized, double-blind, placebo-controlled, parallel-group study of ciclesonide] metered-dose inhaler administered at a daily dose of 160 ug either in a once-daily (160 ug qd) or a twice-daily (80 ug bid) regimen for 12 weeks in adults and adolescents with mild to moderate persistent asthma treated previously with inhaled corticosteroids
#XRP1526B/3030
560. A 3-week multicenter study investigating patient use and functionality of the Foradil[®] Certihaler[®] device in patients with asthma
#CFOR258F2309
561. A multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 µg administered either in a once-daily in the morning regimen (160 µg qd AM) for 16 weeks or in a 160 µg AM regimen for 12 weeks preceded by a twice-daily regimen (80 µg bid) for 4 weeks, or in an 80 µg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids
#XRP1526B/3031
562. A phase II multi-center, randomized, double-blind, active and placebo--controlled 7 day study of mast cell inhibitor, R926112, in patients with symptomatic seasonal allergic rhinitis
#C-926112-005
563. Qualitative Research Into Asthma Control

RESEARCH: ELI O. MELTZER, MD

- #25-586A
564. A placebo- and active-controlled, parallel-group, dose-finding study of formoterol fumarate given by dry powder inhalation using the Ultrahaler® in adult and adolescent patients with persistent asthma
#AVE2635A-2003
565. Randomized, multicenter, crossover study to evaluate sensory attributes of olopatadine 0.6% nasal spray and Astelin® in patients with allergic rhinitis
#C-03-49
566. A Pilot Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair® DISKUS 250/50 mcg BID as Assessed by the Development of Laryngitis and Oropharyngeal Candidiasis in Adults with Mild Persistent Asthma
#NONE0-1-00081
567. A Phase III Multicenter Study to Demonstrate the Sensitivity and Specificity of Aridol (Mannitol) Challenge to Predict Bronchial Hyperresponsiveness as Manifested by a Positive Exercise Challenge in Subjects Presenting with Signs and Symptoms Suggestive of Asthma but Without a Definitive Diagnosis
#DPM-A-305
568. Childhood asthma control test: Longitudinal validation study.
8ADA106614
569. Efficacy and safety of combination Loratadine/Montelukast QD vs Pseudoephedrine and placebo in the treatment of subjects with seasonal allergic rhinitis.
#P04095
570. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily intranasal administration of GW685698X aqueous nasal spray 100mcg for 6 weeks in adult and adolescent subjects 12 years of age and older with perennial allergic rhinitis (PAR).
FFR106080
571. Assessment of safety, tolerability, and pharmacokinetics of Zileuton Injection in patients with asthma.
CTI-04-C05-201
572. A multicenter, randomized, double-blind, triple dummy, placebo-controlled, parallel group, four-week study assessing the efficacy of fluticasone propionate aqueous nasal spray 200 mcg QD versus Montelukast 10 mg QD in adolescent and adult subjects with asthma and seasonal allergic rhinitis who are receiving Advair DISKUS® 100/50mcg BID or placebo BID.
ADA103578
573. Randomized, double-blind, placebo-controlled trial of the safety and efficacy of MP03-33 in patients with seasonal allergic rhinitis.
430
574. Psychometric evaluation of the asthma control outcome and risk assessment measures.
A2-3721
575. A placebo-controlled, parallel-group, clinical trial designed to assess the safety and efficacy of Ciclesonide (200 mcg and 100 mcg, once daily) applied as a nasal spray for two weeks in the treatment of seasonal allergic rhinitis (SAR) in patients 6 to 11 years of age.
BY9010/M1-417
576. A Multi-Center, No Drug Treatment, Cross-Sectional Survey Study to Develop and

RESEARCH: ELI O. MELTZER, MD

- Validate the Rhinitis Control Assessment Questionnaire (RCAQ) in Adult and Adolescent Subjects 12 Years of Age and Older with Non-Infectious Allergic Rhinitis
FFU 108675
577. Pilot polysomnography study in subjects with seasonal allergic rhinitis who report sleep disturbances and daytime somnolence
P04827
578. A Randomized, Cross-Over Design Study Evaluating a Traditional Paper Symptom Diary vs. the VOCEL® Mobile Diary in Subjects 12 years and Older with Mild to Moderate Persistent Asthma Receiving Alvesco® 80 µg BID
CICLE-L-01335
579. Double-Blind Multi-Centre, Placebo-Controlled, Clinical Study to Evaluate the Clinical Equivalence of 128 mcg of Budesonide Nasal Spray (Apotex Inc., Canada) vs. 128 mcg of Rhinocort Aqua® Nasal Spray (AstraZeneca, USA) for the Indication of Seasonal Allergic Rhinitis
BUDE-NASO-01NB01-CE
580. Psychometric Evaluation of the Asthma Control Outcome and Risk Assessment Measures
UBC A2-3721C
581. A multicenter, randomized, double-blind, placebo-controlled parallel group 8-week study to evaluate the efficacy and safety of chewable Montelukast when initiated at the start of the school year in pediatric patients with chronic asthma
340-00
582. A Clinical Study to Evaluate the Safety and Efficacy of Claritin 12-Hour 5 mg Loratadine Tablet BID vs. Placebo Tablet in the Treatment of Allergic Rhinitis
CL2006-03
583. An eight week, randomized, double-blind, parallel group, multicenter trial comparing the efficacy and safety of Oral IPL512,602 to placebo in subjects with moderate to severe persistent asthma inadequately controlled on inhaled corticosteroids
2002
584. A Patient Preference Evaluation Study of Fluticasone Nasal Spray and Fluticasone Propionate Aqueous Nasal Spray in Subjects with Allergic Rhinitis
FFU108556
585. A phase3, double-blind, placebo-controlled, multi-center, randomized study evaluating the safety and efficacy of SPRC-AB01, Tobramycin Solution for nasal inhalation, in post-surgical subjects with chronic rhinosinusitis
SPRC-AB01-003
586. Safety Study of Olopatadine Nasal Spray
C-05-69
587. A placebo-controlled, stratified, multicenter, 12-week study comparing the safety and efficacy of fluticasone and formoterol combination (FlutiForm™ 100/10µg or 250/10µg twice daily) in a single inhaler (SkyePharma HFA pMDI) with the administration of placebo of fluticasone (100/10µg or 250/10µg twice daily) and formoterol (10µg twice daily) alone in adult patients with asthma
2028-3-004
588. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the

RESEARCH: ELI O. MELTZER, MD

- Safety and Efficacy of Multiple Dosing Regimens of Nasal CO2 in the Treatment of Allergic Rhinitis
C211
589. A randomized, double-blind, placebo controlled, 3 arm, parallel group, phase 2 study investigating the efficacy, tolerability and pharmacokinetics of MAP0010 in asthmatic children and adolescents
0010-CL-P201
590. A double-blind placebo-controlled, randomized, parallel-group, single-site study of Nasonex Nasal Spray in subjects with mild-moderate obstructive sleep apnea-hypopnea (OSAHS) associated with perennial allergic rhinitis (PAR) using home-monitored cardio-respiratory methodology
P04726
591. Assessment of the content validity of the asthma Quality of Life Questionnaire (AQLQ) in patients with moderate to severe asthma
A2-4158 000
592. A Placebo-Controlled Study of the Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure
P04295
593. Inhaler Technique Evaluation for Pediatric Asthma
HRA 25-587A
594. A comparative study of the efficacy and tolerability of maintenance treatment of patients with mild/moderate persistent asthma with Asmanex Twisthaler 220 mcg QD PM versus “Asmanex” Placebo QD PM
P04654
595. Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 years or older) with Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy
#BY9010/M1-490
596. Study to Evaluate Efficacy & Safety of GW685698X 200mcg BID GW685698X 200mcg & 400mcg QD in AM, & GW685698X 200mcg & 400mcg QD in the Evening Compared w/ Pbo for 8 Wks in Subjects 12+ w/persistent asthma
#FFA106783
597. Placebo Controlled Study of Nasonex in the Treatment of Seasonal Allergic Rhinitis
#P05067
598. A Randomized, Double-blind, Placebo-controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 317 in Subjects With Moderate to Severe Asthma
#20060161
599. Randomized, double-blind, placebo controlled trial of the safety and efficacy of MP03-36 and MP03-33 in patients with perennial allergic rhinitis
#MP434
600. Active-Controlled Trial of the Safety and Tolerability of MP03-36 in Patients with Perennial Allergic Rhinitis
#MP436

RESEARCH: ELI O. MELTZER, MD

601. A Double-Blind, Placebo Controlled, Randomized Study to Evaluate the Clinical Effect of Oral Montelukast Versus Placebo in Persistent Asthma Which is Also Active During Allergy Seasons in Pediatric Patients with Seasonal Aeroallergen Sensitivity
#336
602. A two-week, randomised, double-blind study assessing the Onset of Effect Questionnaire (OEq) administered daily versus weekly in adult subjects (≥ 18 years of age) with mild to moderate asthma, receiving SYMBICORT® pMDI 80/4.5 μg x 2 actuations twice daily or budesonide HFA pMDI 80 μg x 2 actuations twice daily
#D5896C00023
603. A double-blind, randomized, placebo-controlled, dose-ranging study to assess the efficacy and safety of ciclesonide HFA nasal aerosol in adult and adolescent patients 12 years and older with seasonal allergic rhinitis (SAR)
#BY9010/M1-602
604. A 26-week placebo-controlled efficacy and safety study of mometasone furoate/formoterol fumarate combination formulation compared with mometasone furoate and formoterol monotherapy in subjects with persistent asthma previously treated with low-dose inhaled glucocorticosteroids
#P04073
605. A 26-week placebo-controlled efficacy and safety study of mometasone furoate/formoterol fumarate combination formulation compared with mometasone furoate and formoterol monotherapy in subjects with persistent asthma previously treated with medium-dose inhaled glucocorticosteroids
#P04334
606. A 26 week treatment, randomized, multi center, double blind, double dummy, parallel-group study to assess the safety of indacaterol (300 and 600 μg o.d.) in patients with moderate to severe persistent asthma using salmeterol (50 μg b.i.d.) as an active control
#CQAB149B2338
607. Randomized, double-blind, placebo-controlled trial of the safety and efficacy of MP03-36 in patients with seasonal allergic rhinitis
#439
608. A phase II, double-blind, placebo-controlled, multi-center, randomized study evaluating the safety and efficacy of SPRC-AB01, tobramycin solution for nasal inhalation, in post-surgical subjects with chronic sinusitis
SPRC-AB01
609. A randomized, double-blind, placebo-controlled study to evaluate the efficacy of Ziluten controlled-release (CR) tablets versus placebo in adult patients with asthma poorly controlled on moderate dose inhaled corticosteroids (ICS)
CTI-03-C07-401
610. Efficacy and safety of concurrent administration of mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray administered once daily (QD) vs. oxymetazoline twice daily (BID), mometasone furoate QD, and placebo in the treatment of subjects with seasonal allergic rhinitis
P04500
611. A randomized, double-blind, placebo-controlled, active comparator, one-week, cross-over, multicenter study to evaluate the efficacy and patient preference of nasal spray characteristics of once-daily, intranasal administration of 110mcg fluticasone furoate nasal

RESEARCH: ELI O. MELTZER, MD

- spray and 200mcg fluticasone propionate nasal spray in adult subjects with seasonal allergic rhinitis
FFU105927
612. Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy (Bronchodilation) and Safety of 4 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (2 µg, 5 µg, 10 µg, 20 µg) Delivered by the Respimat® Inhaler in Patients with Asthma
#1222.6
613. Efficacy and safety of 200 mcg BID mometasone furoate nasal spray (MFNS) vs placebo as adjunctive treatment to antibiotics in relief of symptoms of acute bacterial sinusitis
P04824
614. A randomized, double blind, placebo controlled, parallel group, study investigating the safety and efficacy over 12 weeks treatment period of MAP0010 in asthmatic infants and children 12 months to 8 years of age
#0010-CL-P301
615. Validation of patient-reported outcomes in patients with moderate to severe asthma
#20070787
616. A randomized, double-blind, placebo-controlled, parallel-group study comparing the bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (APOTEX, INC.) to that of Nasacort® AQ Nasal Spray (Aventis Pharmaceutical Products, Inc.) in the treatment of seasonal allergic rhinitis
TRIA-NASO-05RB02-CE
617. Test for respiratory and asthma control in kids (TRACK)
CTI-07-503
618. Safety and efficacy of olopatadine HCl nasal spray in 6-11 year old patients
C-07-01
619. Evaluation of successful use of a breath-actuated inhaler: a prospective, randomized, open-label, 2 arm parallel study
IXR-304-04-167
620. Exploratory study to measure the effect of Breathe Right Strips on nasal patency in healthy children
B3340547
621. Randomized, double-blind trial of MP29-02 nasal spray compared to placebo, azelastine hydrochloride nasal spray, and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis
#4002
622. A randomized, double blind, active controlled, phase 3 extension study investigating the safety and efficacy over 40 weeks of 2 doses of MAP0010 in asthmatic infants and children (aged 12 months to 8 years at enrollment into the MAP0010-CL-P301 study)
#0010-CL-P301X
623. A multi-center, randomized, double blind, placebo controlled parallel group study of the safety of Levocetirizine Dihydrochloride Oral Liquid Formulation b.i.d. dosing in children aged 2 to 6 years suffering from allergic rhinitis or chronic urticaria of unknown origin
A00426
624. A randomized, double-blind, double-dummy, placebo-controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily

RESEARCH: ELI O. MELTZER, MD

- and salmeterol 50mcg administered twice daily compared with placebo for 28 days in adolescent and adult subjects with persistent asthma.
B2C109575A
625. Placebo-controlled study of mometasone furoate nasal spray (MFNS) 200 mcg QD in the relief of nasal congestion associated with seasonal allergic rhinitis (SAR)
P05529
626. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study Comparing the Safety and Efficacy of MAP0010 (0.135 mg And 0.25 mg) with Placebo in 12-Month-Old to 8-Year-Old Children with Asthma
#0010-CL-P302
627. Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults & Adolescents 12 and Older w/ PAR
#FFR110537
628. A randomized, double-blind, active-controlled, Phase 3 extension study investigating the safety and efficacy over 40 weeks of 2 doses of MAP0010 in asthmatic children (12 months to 8 years old at the time of enrollment into the MAP0010-CL-P301 Study)
0010-CL-P301X
629. A double-blind, randomized, multicenter, cross-over evaluation of the sensory attributes of Olopatadine 0.6% and Azelastine 137 mcg nasal sprays in patients with allergic rhinitis (Sensory II)
SMA-08-21
630. Double-blind, randomized, placebo-controlled, multi-center, parallel group, dose-ranging study of MK0633 in adult patients with chronic asthma
007
631. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide in the Treatment of Seasonal Allergic Rhinitis
C215
632. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Sublingual Immunotherapy (SLIT) in Adults Sensitized to the Standardized Allergenic Extract, Cat Hair (*Felis domesticus*)
ALI002-08
633. A double-masked, randomized, parallel group comparison of seasonal allergic rhinitis treatment with olopatadine 0.6% and azelastine 0.1% when treatments are used in combination with fluticasone propionate 50 mcg nasal spray
#SMA-08-23
634. A multicenter, randomized study starting with a 4-week, 2-way crossover double-blind treatment phase comparing the efficacy and safety of Combivent® CFC MDI to albuterol HFA MDI followed by a 4-week open-label Combivent Respimat® treatment phase when all study drugs are used for symptom relief “as needed” in patients with moderate-to-severe asthma (GINA 2007 Treatment Steps 3 to 5)
#1012.57
635. A double-blind, randomized, placebo-controlled, parallel-group, multi-center, dose-range-finding study to assess the efficacy and safety of BDP HFA nasal aerosol in adult and adolescent patients (12 years and older) with seasonal allergic rhinitis (SAR)
BDP-AR-201
636. Safety of PATANASE® Nasal Spray in Patients with Perennial Allergic Rhinitis

RESEARCH: ELI O. MELTZER, MD

- # C-08-32
637. Pulmonary safety of Staccato® Loxapine for inhalation in patients with asthma
AMDC-004-105
638. Randomized, double-blind trial of MP29-02 nasal spray compared to placebo, azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis
MP4006
639. A phase 4, multicenter, double-blind, randomized, placebo-controlled study of the safety and tolerance of Regadenoson in subjects with asthma or chronic obstructive pulmonary disease (COPD)
#3606-CL-3001
640. A double-blind, randomized, placebo-controlled, parallel group exploratory study of the safety and efficacy of JNJ-39758979 in the treatment of adults with persistent asthma
39758979ASH2001
641. A double-masked, randomized, multi-center study examining the safety and efficacy of olopatadine 0.6% and azelastine 137 mcg nasal sprays in a two-week vasomotor rhinitis trial
SMA-09-03
642. Phase 2b, randomized study to evaluate the efficacy and safety of subcutaneous MEDI-258 in adults with uncontrolled asthma
CP198
643. Randomized, double-blind, placebo-controlled trial of the safety and efficacy of mp03-36 (0.15% solution) and mp03-33 (0.10% solution) in children ages >6 to <12 with perennial allergic rhinitis
MP441
644. A randomized, double-blind, placebo controlled, multiple dose phase 2 study to determine the safety and efficacy of amg 853 in subjects with inadequately controlled asthma
#20080615
645. A 6- month randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of once daily ciclesonide HFA nasal aerosol (80 and 160 µg) in the treatment of perennial allergic rhinitis (PAR) in subjects 12 years and older
#060-633
646. A randomized, multi-center, parallel group, double blind, study to assess the safety of QMF Twisthaler® (500/400 µg)and mometasone furoate Twisthaler® (400 µg) in adolescent and adult patients with persistent asthma.
#CQMF149A2210
647. A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to assess the efficacy and safety of different doses of indacaterol in adult patients with persistent asthma, using salmeterol as an active control.
#CQAB149B2357
648. A long-term, randomized, double-blind study of the safety, tolerability and efficacy of aclidinium bromide at two dosage levels when administered to patients with moderate to severe, stable chronic obstructive pulmonary disease.
#LAS-MD-35
649. A Randomized, Double-blind, Single-dose Efficacy Study of 0.05% Oxymetazoline Fine Mist Spray in Adult Subjects Suffering from Nasal Congestion.
#2010042

RESEARCH: ELI O. MELTZER, MD

650. Qualitative Interviews with Patients who have Asthma.
#10-1378A
651. A 6-Month Open-Label, Long-Term Safety Extension Study of Once Daily Ciclesonide HFA Nasal Aerosol (160 µg) in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older.
#060-635
652. A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax versus Placebo in Subjects 12 years and older with Persistent Asthma.
ABS-AS-301
653. A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone Propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma while Treated with Short Acting Beta₂-agonist.
LPA112186
654. A Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 µg bid with placebo: a 6-week efficacy and safety study in children aged 6 to <12 years with asthma.
D589GC00001
655. A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 weeks in patients with moderate persistent asthma.
#204.418
656. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol (320 mcg, once daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Adult and Adolescent Subjects (12 Years of Age and Older).
BDP-AR-302
657. A randomized, dose-ranging, placebo-controlled trial to evaluate the effects of phenylephrine HCl immediate release tables on nasal congestion in subjects with seasonal allergic rhinitis
CL2010-06
658. Psychometric evaluation of a novel questionnaire designed to assess patient satisfaction with and preference of intranasal corticosteroids administered via HFA aerosol or aqueous suspension used for the treatment of allergic rhinitis
#060-301
659. A prospective, open label, Assessment of the Albuterol ProAir HFA MDI integrated dose counter
ABM-AS-307
660. A randomized, double-blind, placebo-controlled, parallel-group study comparing the bioequivalence of ciclesonide nasal spray (APOTEX, Inc.) to that of Omnaris nasal spray (Sepracor, Inc.) in the treatment of seasonal allergic rhinitis
CICE-NASU-05SB03-CE

RESEARCH: ELI O. MELTZER, MD

661. A randomized, placebo- controlled, parallel group study to assess the efficacy, safety, and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma
CQAW039A2201
662. A randomized, placebo-controlled trial to evaluate the effects of Phenylephrine HCl 30 mg Extended Release Tablets on nasal congestion in subjects with allergic rhinitis
CL2011-06
663. A randomized, double-blind, placebo-controlled, parallel-group, multi-center study to assess the efficacy and safety of BDP HFA Nasal Aerosol in pediatric subjects (6 to 11 years of age) with seasonal allergic rhinitis (SAR)
BDP-AR-305
664. A 12-week, double-blind, randomized, multi-centre, parallel-group study evaluating the efficacy, safety, and patient use (User Study) of Symbicort® (budesonide/formoterol) Breath Actuated Metered Dose Inhaler (BA MDI) 2x160/4.5 µg twice daily compared with Symbicort (budesonide/formoterol) AC (actuation counter) pMDI® 2x160/4.5 µg twice daily and budesonide AC pMDI 2 x 160 µg twice daily in adult and adolescent asthmatics
D5890C00003
665. An open label randomized two period two-way crossover study to evaluate efficacy, patient preference and satisfaction with Ciclesonide Nasal aerosol versus Mometasone Furoate Aqueous Suspension used for the treatment of allergic rhinitis
#060-302
666. Double-blind, double-masked, randomized, placebo-controlled, cross-over study of the bronchoprotective effect of generic levalbuterol tartrate HFA and Xopenex HFA® (levalbuterol tartrate) metered-dose inhaler (MDI) formulations against methacholine-induced bronchoconstriction in asthmatic subjects
C-2010-05
667. A 12-month, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Reslizumab (3.0 mg/kg) in the reduction of clinical asthma exacerbations and change in lung function in patients (12-75 years of age) with eosinophilic asthma
C3072/3082
668. A 12-Week randomized, double-blind, placebo-controlled, parallel group, safety and efficacy study of ciclesonide nasal aerosol in subjects 6-11 years with perennial allergic rhinitis# SEP 060-306
669. A 12-week dose-ranging study to evaluate the efficacy and safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) administered twice daily compared with placebo in adolescent and adult subjects with persistent asthma uncontrolled on non-steroidal therapy
FpS-AS-201
670. A multicenter, consumer product evaluation of a single dose of Phenylephrine HCl 30mg Extended Release Tablets (Sinus Comfort)
CL2012-03
671. A randomized, placebo-controlled, dose-ranging, multi-centre trial of QAW039 (1- 450 mg p.o.) to investigate the effect on FEV₁ and ACQ in patients with moderate-to-severe, persistent, allergic asthma, inadequately controlled with ICS therapy
CQAW039A2206

RESEARCH: ELI O. MELTZER, MD

672. A 2-week randomized, double blind, placebo controlled, parallel group, safety and efficacy study of Ciclesonide Nasal Aerosol in subjects 6 to 11 years with seasonal allergic rhinitis
060-305
673. Non-invasive neurostimulation of the Vagus Nerve for the relief of acute bronchoconstriction due to asthma
BC-US-06
674. Evaluation of hypoallergenicity of an amino acid-based infant formula
09.55 PED
675. A phase 2, multicenter, parallel-group, randomized, double-blind, placebo- and active comparator-controlled, combination study of S 555739 and Cetirizine HCl in adult patients with seasonal allergic rhinitis
1210D1526
676. A double-blind, placebo-controlled, four-way crossover study to compare the safety and efficacy of ONO-6950 20 mg and 200 mg QD versus placebo and Montelukast (Singulair) in asthmatic patients who exercise-induced bronchoconstriction
ONO6959POU004
677. ACQ, AQLQ, RQLQ Equivalence Study
1788A
678. Asthma Control Diary (ACD) Equivalence Study
1643A
679. A phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel group study of two doses of inhaled R940343 in patients with mild to moderate allergic asthma
C-940343099
680. A multi-center, randomized, double-blind, vehicle-controlled, cross-over evaluation of the effects of KD1157 nasal spray on nasal challenge with allergen
KD1157-AR02
681. A multi-center 52-week study to assess the safety of Albuterol *Spiromax*® in subjects with asthma
#ABS-AS-307
682. A randomized, placebo-controlled, Phase IIb dose-finding study of CYT003-QbG10, a TLR9-agonist, in patients with moderate to severe allergic asthma not sufficiently controlled on current standard therapy (GINA steps 3+4)
#CYT003-QbG10 12
683. 12-week Comparison of Efficacy and Safety of Albuterol Spiromax ® Versus Placebo in Subjects 12 years and older with Persistent Asthma
#ABS-AS-301
684. Single-Dose Study to Assess the Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients with Exercise-Induced Bronchoconstriction (EIB)
#ABS-AS-302
685. Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week, Clinical Study Designed to Assess the Efficacy and Safety of BDP Nasal Aerosol (80 mcg, once daily) in Pediatric Subjects (4 to 11 Years of Age) With Perennial Allergic Rhinitis (PAR)
#BDP-AR-306

RESEARCH: ELI O. MELTZER, MD

686. One Year, Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects with House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma
#P05607

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

1. Long Term Treatment of Asthma. The American Academy of Allergy and Immunology, Hollywood, Florida, March 21, 1983.
2. Effect of Dosing Schedule on Efficacy and Safety of Beclomethasone Dipropionate Aerosol in Chronic Asthma. The American Academy of Allergy and Immunology, Hollywood, Florida, March 23, 1983.
3. The Safety of Egg-Containing Vaccines for Egg-Allergic Patients. Pediatric Immunology and Allergy Division, University of California, San Diego, August 2, 1983.
4. Treatment of Serous Otitis Media with Intranasal Flunisolide Spray. The American Academy of Pediatrics, San Francisco, California, October 23, 1983.
5. Rhinometry. The American Academy of Pediatrics, San Francisco, California, October 24, 1983.
6. Current Concepts in the Diagnosis and Treatment of Asthma and Allergic Diseases. School of Human Services, San Diego State University, San Diego, California, November 10, 1983.
7. Seminal Fluid Hypersensitivity. Pediatric Immunology and Allergy Division, University of California, San Diego, February 7, 1984.
8. Rotahaler - A New Mode of Delivery of Albuterol Powder of Inhalation Treatment of Asthma. The American Academy of Allergy and Immunology, Chicago, Illinois, March 5, 1984.
9. Rhinometric, Clinical and Cytologic Evaluation of Allergic Rhinitis Treated with Beclomethasone Dipropionate as Pressurized Aerosol or Aqueous Nasal Spray. The American Academy of Allergy and Immunology, Chicago, Illinois, March 5, 1984.
10. The "Traditional" Approach to the Management of Atopic Diseases. The California Acupuncture College, San Diego, California, June 6, 1984.
11. Allergic Rhinitis: Therapeutic Considerations. Cromolyn in Allergy Symposium, Victoria, British Columbia, Canada, June 23, 1984.
12. Vernal Conjunctivitis. Pediatric Immunology and Allergy Division. University of California, San Diego, August 7, 1984.
13. The Use of Corticosteroids in the Treatment of Asthma. Key Pharmaceuticals Flunisolide Symposium, Los Angeles, California, October 15, 1984.
14. Evaluation of the Stuffy Nose Kid. The Asthma and Allergy Foundation of America, San Diego, California, October 20, 1984.
15. Current Concepts in the Use of Corticosteroids for the Treatment of Rhinitis. Berlex Symposium, Cedar Knolls, New Jersey, December 5, 1984.
16. New Horizons in the Management of Asthma. Pediatric Grand Rounds, University of Utah, Salt Lake City, Utah, January 3, 1985.
17. The Treatment of Acute Asthma with Injectable Albuterol: A Comparison Study of the Intravenous, Intramuscular and Subcutaneous Routes. The American Academy of Allergy and Immunology, New York, New York, March 19, 1985.
18. Enhancing Compliance in Medical Care. The American Academy of Allergy and Immunology, New York, New York, March 20, 1985.
19. Tracheobronchial Aspiration of Foreign Bodies. Pediatric Immunology and Allergy Division, University of California San Diego, May 14, 1985.
20. Nasal Allergy: Diagnostic and Therapeutic Considerations. Fisons Symposium, Scottsdale, Arizona, October 5, 1985.
21. Theophylline Toxicity. Pediatric Immunology and Allergy Division, University of California, San Diego, February 4, 1986.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

22. Cromolyn in Respiratory Disease: Rhinitis. Fisons Symposium, St. Petersburg, Florida, February 22, 1986.
23. Rhinitis and Sinusitis: Current Diagnosis and Therapeutic Approaches. The California Medical Association, Los Angeles, California, March 2, 1986.
24. Update on Upper Respiratory Allergy: Rhinitis. The American Academy of Allergy and Immunology, New Orleans, Louisiana, March 24, 1986.
25. Clinical Pharmacology of Rhinitis. The American Academy of Allergy and Immunology, New Orleans, Louisiana, March 26, 1986.
26. How to Win the Race with a Running Nose. Grand Rounds, Children's Hospital and Health Center, San Diego, California, May 9, 1986.
27. Nasal Allergy. Fisons Symposium, Toronto, Ontario, May 17, 1986.
28. Ocular and Nasal Allergic Disorders. Fisons Symposium, Colorado Springs, Colorado, June 21, 1986.
29. Allergic Rhinitis: Current Choices in Therapy. Merrell Dow Symposium, Carmel, California, August 16, 1986.
30. Kawasaki's Syndrome. Pediatric Immunology and Allergy Division, University of California, San Diego, August 26, 1986.
31. Rhinitis, Therapeutic Considerations. The American College of Allergists, Las Vegas, Nevada, January 17, 1987.
32. Rhinomanometry. The American College of Allergists, Las Vegas, Nevada, January 18, 1987.
33. Azelastine for Perennial Allergic Rhinitis: Clinical and Rhinomanometric Evaluation. The American College of Allergists, Las Vegas, Nevada, January 19, 1987.
34. Nasal Cytology. The American Academy of Allergy and Immunology, Washington, DC, February 19, 1987.
35. Causes and Treatment of Nasal Symptoms. The American Academy of Allergy and Immunology, Washington, DC, February 23, 1987.
36. New H₁ Antihistamines and Rhinitis. The American Academy of Allergy and Immunology, Washington, DC, February 23, 1987.
37. Evaluating the Safety of Pseudoephedrine in Comparison to a Pseudoephedrine/Terfenadine Combination. The American Academy of Allergy and Immunology, Washington, DC, February 24, 1987.
38. Clinical Experiences of Azelastine in Rhinitis. Wallace Laboratories Azelastine Symposium, New Orleans, Louisiana, May 8, 1987.
39. Clinical Rhinomanometric and Cytological Assessments of Rhinitis. New Directions and Dimensions in the Treatment of Allergic Rhinitis Symposium, Chicago, Illinois, July 17, 1987.
40. Environmental Pollutants and Allergens - Recognition and Control. Current View in Allergy and Immunology (audio tape/slides), September, 1987.
41. Diagnosis and Treatment of Nasal Allergy. Symposium: Cromolyn Sodium: Coming of Age in the United States. Santa Fe, New Mexico, October 17, 1987.
42. Rhinomanometry. American College of Allergists, Boston, Massachusetts, November 15, 1987.
43. Clinical Efficacy Studies of Loratadine. Symposium: Nonsedating Antihistamines, American College of Allergists, Boston, Massachusetts, November 15, 1987.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

44. Diagnostic and Therapeutic Techniques for Nasal Disorders. American College of Allergists, Boston, Massachusetts, November 16, 1987.
45. Treatment of Seasonal Allergic Rhinitis with Triamcinolone Acetonide Nasal Aerosol. American College of Allergists, Boston, Massachusetts, November 16, 1987.
46. Diagnostic Testing of Children with Nasal Symptoms. American Academy of Pediatrics, San Diego, California, February 5, 1988.
47. Treatment of Nasal Disease. American Academy of Pediatrics, San Diego, California, February 5, 1988.
48. Antihistamines in Airway Diseases. Allergies in Dermatology Symposium, Kauai, Hawaii, February 18, 1988.
49. The Efficacy of Antihistamines as Asthma Treatment. University of California, San Diego, February 23, 1988.
50. Comparison of Intranasal Cromolyn Sodium and Oral Terfenadine for Allergic Rhinitis. The American Academy of Allergy and Immunology, Anaheim, California, March 14, 1988.
51. Nasal Provocation Challenges: A Therapeutic Tool. The American Academy of Allergy and Immunology, Anaheim, California, March 14, 1988.
52. Nasal Cytology. National Symposium on Nasal Functions in Health and Disease. Providence, Rhode Island, April 13, 1988.
53. Clinical Aspects of Rhinitis Therapy. North Central Allergy Society, Mayo Clinic, Rochester, Minnesota, April 16, 1988.
54. Anticholinergic Treatment of Nasal Disorders. International Forum on Anticholinergics. European Congress on Diseases of the Chest, Dublin, Ireland, July 12, 1988.
55. The Use of Beta₂-Agonists: Aerosol versus Oral. Riker Laboratories Asthma Symposium, Laguna Niguel, California, October 8, 1988.
56. Evaluation of Two Formulations of Flunisolide Nasal Spray in Patients with Perennial Allergic Rhinitis. American College of Allergy and Immunology, Los Angeles, California, November 12, 1988.
57. Diagnostic Consideration in Rhinitis. American College of Allergy and Immunology, Los Angeles, California, November 14, 1988.
58. Allergic Rhinitis: Current Choices in Therapy. Binational Pediatric Conference, American Academy of Pediatrics, San Diego, California, December 3, 1988.
59. Office Procedures and Organization. The American Academy of Allergy and Immunology, San Antonio, Texas, February 28, 1989.
60. Medication Induced Performance Decrements: Antihistamines and Decongestants. American College of Occupational Medicine, New York, New York, April 6, 1989.
61. Allergies and Asthma. School of Nursing, San Diego State University, April 13, 1989.
62. Rhinitis: Diagnosis and Treatment. Thomas Jefferson University, Philadelphia, Pennsylvania, June 13, 1989.
63. Anticholinergic Treatment of Nasal Disorders: International Experience. VIII International Symposium on Infection and Allergy of the Nose. Baltimore, Maryland, June 14, 1989.
64. Overview of Allergic Rhinitis. Schering Symposium, Dana Point, California, June 16, 1989.
65. The Use of Antihistamines in Lower Airway Disease. Schering Antihistamine Symposium, Dana Point, California, June 17, 1989.
66. Medical Management of Rhinitis. Symposium: The Rhinologic/Allergic-Immunologic Interface. Otolaryngology Division, Cedar Sinai Medical Center, Los Angeles, California, June 24, 1989.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

67. Allergic Rhinitis. Pediatric Grand Rounds, Minneapolis Children's Medical Center, Minneapolis, Minnesota, July 25, 1989.
68. Performance Effects of Antihistamines. Merrell Dow Histamine and Disease Symposium, Carlsbad, California, August 25, 1989.
69. The Effect of Allergic Rhinitis and Antihistamine Therapy on the Quality of Life. Merrell Dow Histamine and Disease Symposium, Carlsbad, California, August 26, 1989.
70. Histamine and Antihistamines in Lower Airway Disease. New Frontiers in Antihistamine Therapy Symposium. Hospital Satellite Network, Denver, Colorado, October 25, 1989.
71. Allergic Rhinitis: Current Concepts. Allied Health Practitioners Program, American College of Allergy and Immunology, Orlando, Florida, November 13, 1989.
72. Rhinomanometry. American College of Allergy and Immunology, Orlando, Florida, November 13, 1989.
73. Anticholinergic Agents in the Treatment of Rhinitis. American College of Allergy and Immunology, Orlando, Florida, November 15, 1989.
74. Management of Allergic Rhinitis. Tufts University School of Medicine, Teleconference, San Diego, California, February 15, 1990.
75. Nasal Disease in the Allergic Patient. Allied Health Care Symposium, American Academy of Allergy and Immunology, Baltimore, Maryland, March 24, 1990.
76. Vocal Cord Dysfunction. Syntex, Diagnosis of the Day, Case Study. American Academy of Allergy and Immunology, Baltimore, Maryland, March 25, 1990.
77. Adverse Events. Clinical Research Coordinator Symposium, American Academy of Allergy and Immunology, Baltimore, Maryland, March 26, 1990.
78. Antihistamines: The Bad News and the Good News. Orange County Society of Allergy and Clinical Immunology, Santa Ana, California, April 25, 1990.
79. Allergic Rhinitis. Allergy for the Practitioner Symposium. Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, April 28, 1990.
80. Use of Cromolyn Sodium in the Nose and Eyes. It's Place Versus Other Therapies. Fisons Symposium, Scottsdale, Arizona, May 5, 1990.
81. Recognizing Subtle Allergic Disease in Children. Pediatric Allergy and Otolaryngology Seminar, Children's Hospital and Health Center, San Diego, California, June 29, 1990.
82. New and Old Pharmacotherapy of Respiratory Allergy. Pediatric Allergy and Otolaryngology Seminar, Children's Hospital and Health Center, San Diego, California, June 29, 1990.
83. The Advantages and Disadvantages of Antihistamine-Decongestant Combinations. Sandoz Practical Issues in Managing Allergic Rhinitis Roundtable, Carlsbad, California, June 30, 1990.
84. The Effects of Topical Intranasal Fluticasone Propionate on Nasal Mucosal Cells in Patients with Allergic Rhinitis. European Academy of Allergology and Clinical Immunology, Glasgow, Scotland, July 10, 1990.
85. Allergic Rhinitis. Scripps Clinic and Research Foundations Primary Care Conference. San Diego, California, August 26, 1990.
86. Allergic Rhinitis: Current Concepts. Allied Health Professionals Program, American College of Allergy and Immunology. Los Angeles, California, September 9, 1990.
87. Allergy and Asthma. School of Nursing, College of Health and Human Services, San Diego State University, San Diego, California, September 13, 1990.
88. Evaluation of Pemirolast, A New Non-Bronchodilator, Antiallergy Medication for Patients with Asthma. American Academy of Pediatrics. Boston, Massachusetts, October 7, 1990.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

89. Pediatric Allergy. Literature Review Course, American College of Allergy and Immunology. San Francisco, California, November 9, 1990.
90. Antihistamine Use in Allergy Patients with Bronchial Asthma. Symposium: Non-Sedating Antihistamines: New Uses-Novel Research. American College of Allergy and Immunology. San Francisco, California, November 12, 1990.
91. Comparative Safety of H₁ Antihistamines. Symposium: New H₁ Antihistamines: State-of-the-Art Perspectives. American College of Allergy and Immunology. San Francisco, California, November 14, 1990.
92. Treating Allergic Rhinitis: Overview and Update. Pfizer Insight Into Allergies Symposium, Lake Buena Vista, Florida, December 7, 1990.
93. Management of Allergic Rhinitis. Pharmacy Update 1991. California Employee Pharmacist Association. San Diego, California, February 17, 1991.
94. Nasal Disease and the Allergic Child. Allergy for the Health Care Professional Course. American Academy of Allergy and Immunology. San Francisco, California, March 4, 1991.
95. The Use of Anticholinergic Agents in the Treatment of Nasal Disorders. Symposium: Update: Research on the Use of Intranasal Anticholinergic Agents. San Francisco, California, March 6, 1991.
96. The "Snotty-Nose" Kid: Allergy or Infection? American Academy of Pediatrics, Spring Session. San Diego, California, March 16, 1991.
97. Topical Therapy for Allergic Rhinitis. American Academy of Pediatrics, Spring Session. San Diego, California, March 18, 1991.
98. Evaluation of the Stuffy, Runny-Nosed Kid. Wheezes and Sneezes Conference, Valley Children's Hospital, Yosemite National Park, California, April 26, 1991.
99. Management of Upper Respiratory Allergies. Wheezes and Sneezes Conference, Valley Children's Hospital, Yosemite National Park, California, April 26, 1991.
100. Nasal Cytology. Scientific Programme: Allergic and Non-Allergic Rhinitis: Clinical Aspects. Copenhagen, Denmark, June 6, 1991.
101. Allergies and the Risks of Self Medicating. Grand Rounds, Sharp Memorial Hospital, San Diego, California, July 31, 1991.
102. Allergic Rhinitis: Issues in Patient Management. Audioconference series jointly sponsored by Baylor College of Medicine and the University of California, San Diego, October 29, 30, 31, December 3, 4, 1991.
103. Diagnostic Evaluation of Upper Respiratory Diseases. La Sociedad Venezolana De Alergia E Inmunologia, Barquisimeto, Venezuela, November 8, 1991.
104. Management of Upper Respiratory Diseases. La Sociedad Venezolana De Alergia E Inmunologia, Barquisimeto, Venezuela, November 9, 1991.
105. Pediatric Allergy. Literature Review Course. American College of Allergy and Immunology, New York, New York, November 15, 1991.
106. What is the Joint Council of Allergy and Immunology and What Does it Do? American College of Allergy and Immunology, New York, New York, November 15, 1991.
107. Allergic Rhinitis. Symposium: Histamine-Induced Disease: Impact of New Research on Treatment Algorithms. American College of Allergy and Immunology, New York, New York, November 18, 1991.
108. Understanding and Applying the Resource Based Relative Value Schedule. American Association of Certified Allergists, Antigua, West Indies, January 13, 1992.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

109. The Joint Council of Allergy and Immunology: An Overview of Socio-Economic Issues. American Association of Certified Allergists, Antigua, West Indies, January 17, 1992.
110. Histamine and Antihistamines in Asthma. Current Concepts in Pediatric Medicine Course, Children's Hospital and Health Center, San Diego, California, February 7, 1992.
111. CPT Coding for Allergy and Immunology. American College of Allergy and Immunology, Dallas, Texas, February 15, 1992.
112. Anticholinergic Agents: The Risks and Benefits in Asthma and Rhinitis. American Academy of Allergy and Immunology, Orlando, Florida, March 7, 1992.
113. Treatment of Chronic Rhinitis. American Academy of Allergy and Immunology, Orlando, Florida, March 10, 1992.
114. Newer Antihistamines. American Academy of Allergy and Immunology, Orlando, Florida, March 11, 1992.
115. Consequences of Pharmacologic Intervention in Allergic Disorders. University of Texas Medical Branch at Galveston, Symposium, American College of Physicians, San Diego, California, March 28, 1992.
116. Allergic Rhinitis Update. Glaxo Teleconference Educational Network, 1992. March 19, March 23, April 15, April 30, May 4, and May 6.
117. Treatment of Allergic Rhinitis in the Child. European Congress of Allergology and Clinical Immunology, Paris, France, May 12, 1992.
118. Environmental Controls and Symptomatic Pharmacotherapy for Allergic Rhinitis. American College of Allergy and Immunology, Washington, DC, May 20, 1992.
119. State of the Union of Allergy/Immunology Practice in the 90's. California Society of Allergy and Clinical Immunology, Los Angeles, California, June 6, 1992.
120. Nasal Cytology and Its Clinical Correlations. The Upper Airway Symposium, American College of Allergy and Immunology, Nashville, Tennessee, July 10, 1992.
121. Pharmacotherapy of Nasal Disorders with Cromolyn, Nedocromil and Anticholinergic Agents. The Upper Airway Symposium, American College of Allergy and Immunology, Nashville, Tennessee, July 11, 1992.
122. Diagnosis and Management of Allergic Rhinitis. Symposium: Allergic Airway Disease: Complications and Control. University of Wisconsin School of Medicine, San Diego, California, October 14, 1992.
123. Adverse Reactions with Topical Corticosteroids. Glaxo Conference, Chicago, Illinois, November 13, 1992.
124. Pediatric Allergy. Literature Review Course. American College of Allergy and Immunology, Chicago, Illinois, November 13, 1992.
125. Socioeconomic and Political Factors Affecting the Practice of Allergy. American College of Allergy and Immunology, Chicago, Illinois, November 14, 1992.
126. Diagnostic Evaluation of Nasal Disease. Medical College of Pennsylvania, Grand Cayman, BWI, November 20, 1992.
127. Histamine and Antihistamines in Asthma. Medical College of Pennsylvania, Grand Cayman, BWI, November 21, 1992.
128. The Risks of Central Nervous System and Cardiovascular Effects with Antihistamine Therapy. Terfenadine Symposium. Osaka, Japan, February 19, 1993.
129. Newer Antihistamines: Are They Worth the Price? American Academy of Allergy and Immunology. Chicago, Illinois, March 13, 1993.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

130. Sinusitis Management: The Role of Adjunctive Therapy. American Academy of Allergy and Immunology. Chicago, Illinois, March 15, 1993.
131. Tissue Sampling of the Nasal Mucosa. American Academy of Allergy and Immunology. Chicago, Illinois, March 16, 1993.
132. Non-Steroidal Pharmacologic Treatment of Chronic Rhinitis. American Academy of Allergy and Immunology. Chicago, Illinois, March 17, 1993.
133. Old, New and Emerging Pharmacotherapy for Rhinitis: Risks and Benefits. Long Island Allergy Society, Woodbury, New York, April 28, 1993, and Allergy Division, Columbia University School of Medicine, New York, New York, April 29, 1993.
134. Allergic Rhinitis: Diagnosis and Treatment. Allergic Diseases State of the Art Simulcast, American Academy of Allergy and Immunology. Milwaukee, Wisconsin, May 7, 1993.
135. Controversies Related to Antihistamine Therapy. University of Southern California School of Medicine. La Jolla, California, May 8, 1993.
136. Advances in the Pharmacotherapy of Allergic Rhinitis. California Inland Allergy Society, Riverside, California, June 8, 1993.
137. A Practical Approach to the "Snotty Nose" Child. Children's Hospital, San Diego, June 11, 1993.
138. Current Management of Sinusitis. Children's Hospital, San Diego, June 12, 1993.
139. Mechanisms of Action of Topical Corticosteroids in Rhinitis. Glaxo Symposium, Santa Barbara, California, July 31, 1993.
140. Is Successful Control of Perennial Rhinitis Achievable? European Academy of Allergology and Clinical Immunology, Rotterdam, Netherlands, September 12, 1993.
141. Topical Corticosteroids in Rhinitis. American Academy of Allergy and Immunology, Orlando, Florida, October 6, 1993.
142. New Drugs for Allergy. American Academy of Allergy and Immunology, New York, New York, October 10, 1993.
143. The Pathophysiology and Treatment of Allergic Rhinitis. American College of Allergy and Immunology, Atlanta, Georgia, November 13, 1993.
144. Nasal Cytology and Its Role in Differential Diagnosis. American College of Allergy and Immunology, Atlanta, Georgia, November 14, 1993.
145. The Art of Medical Homiletics. American College of Allergy and Immunology, Atlanta, Georgia, November 15, 1993.
146. The Prevalence, Economic and Medical Impact of Tobacco Smoking. American College of Allergy and Immunology, Atlanta, Georgia, November 17, 1993.
147. Central Nervous System Adverse Effects of H₁ Antagonists. American Academy of Allergy and Immunology, Anaheim, California, March 5, 1994.
148. Patients with Nasal Disease: How to Obtain the Cells, What is Found, and What Happens with Treatment. American Academy of Allergy and Immunology, Anaheim, California, March 7, 1994.
149. Newer Antihistamines: Therapeutic Considerations. American Academy of Allergy and Immunology, Anaheim, California, March 8, 1994.
150. Clinical Aspects of Treatment of Allergic Rhinitis. International Symposium on Allergic and Infectious Rhinosinusitis. Jerusalem, Israel, April 26, 1994.
151. Pharmacotherapy of Nasal Disorders with Cromolyn and Anticholinergic Agents. International Symposium on Allergic and Infectious Rhinosinusitis. Jerusalem, Israel, April 26, 1994.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

152. New Trends in Antihistamine Treatment. International Symposium on Allergic and Infectious Rhinosinusitis. Jerusalem, Israel, April 26, 1994.
153. Nasal Cellular Changes Following Pharmacologic Intervention. International Congress of Allergology and Clinical Immunology. Stockholm, Sweden, June 28, 1994.
154. Debating Today's Treatment for Allergic Rhinitis. International Congress of Allergology and Clinical Immunology. Stockholm, Sweden, June 28, 1994.
155. New Directions in the Treatment of Allergic Rhinitis. San Diego State University. San Diego, California, August 22, 1994.
156. Pharmacotherapy: Are You a Prudent Prescriber? American College of Allergy and Immunology, San Francisco, California, November 5, 1994.
157. Recurrent Sinusitis in Children. American College of Allergy and Immunology, San Francisco, California, November 7, 1994.
158. Fluticasone Propionate: Clinical Perspectives of Efficacy and Safety for Nasal Disease. Glaxo Symposium. San Diego, California, January 17, 1995.
159. Health Related Quality of Life: Outcomes Studies of Rhinitis and Asthma. American Association of Certified Allergists. M/S Windward NCL, San Juan, Puerto Rico, January 23, 1995.
160. Nasal Cytology: Techniques and Findings. American Academy of Allergy and Immunology, New York, New York, February 25, 1995.
161. Tobacco: What is Going Up in Smoke and How to Get it Down. American Academy of Allergy and Immunology, New York, New York, February 26, 1995.
162. Performance Deficits in Allergic Rhinitis: Are We Compounding the Problem with Medication? UCLA School of Medicine, Dallas, Texas, March 4, 1995.
163. Antihistamines: Cardiovascular Effects. UCLA School of Medicine, Dallas, Texas, March 5, 1995.
164. Evaluation of the Allergic Child. Panamerican Congress of Pediatric Allergy and Immunology, Sao Paulo, Brazil, March 20, 1995.
165. Management of Rhinitis. Panamerican Congress of Pediatric Allergy and Immunology, Sao Paulo, Brazil, March 20, 1995.
166. Rhinitis, Sinusitis, Conjunctivitis: Pathophysiology and Treatment. Review for the American Board of Allergy and Immunology. American College of Allergy, Asthma and Immunology. Chicago, Illinois, April 6, 1995.
167. Breaking the Cycle of Chronic Rhinosinusitis. American Academy of Physician Assistants, Las Vegas, Nevada, May 30, 1995.
168. Allergic and Nonallergic Rhinitis: Diagnosis and Treatment. American Academy of Physician Assistants, Las Vegas, Nevada, May 31, 1995.
169. Tobacco: What is Going Up in Smoke and How to Get it Down. American Academy of Allergy, Asthma and Immunology, Egg Harbor, Wisconsin, June 3, 1995.
170. New Directions in the Management of Nasal Allergies. Medicine Grand Rounds, San Francisco Kaiser Permanente Hospital, San Francisco, California, June 14, 1995.
171. The Clinical Response of Corticosteroid-Naive Asthma Patients to the Metered Dose Inhalation of Fluticasone Propionate. Glaxo Symposium, San Diego, California, June 16, 1995.
172. Strategy for Treating the Congestion of Sinusitis. European Congress of Allergology and Clinical Immunology, Madrid, Spain, June 29, 1995.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

173. Patient/Physician Compliance Issues. Schering-Plough Roundtable Program, Napa Valley, California, July 8, 1995.
174. Pharmacotherapeutic Options in the Treatment of Rhinitis. Boehringer Ingelheim Seminar. New Orleans, Louisiana, September, 18, 1995.
175. Allergic and Nonallergic Rhinitis: Can Ipratropium Bromide Nasal Spray Make a Difference? Boehringer Ingelheim meeting, Chantilly, Virginia, September 21, 1995.
176. When is Anticholinergic Therapy of Value: Considerations in Allergic and Nonallergic Rhinitis. American College of Allergy, Asthma, and Immunology, Dallas, Texas, November 10, 1995.
177. Antismoking: Targets and Tactics. American College of Allergy, Asthma, and Immunology, Dallas, Texas, November 11, 1995.
178. Effective Lectures: The Art of Medical Homiletics. American College of Allergy, Asthma and Immunology, Dallas, Texas, November 13, 1995.
179. Antihistamine Therapy: Balancing the Actions. American College of Allergy, Asthma and Immunology, Dallas, Texas, November 13, 1995.
180. Current Treatment of Allergic Rhinitis. Hoechst Marion Roussel Consultant Meeting, Tucson, Arizona, December 1, 1995.
181. Asthma Treatment Strategies: Patient Cases. Schering/Key Speakers Meeting, Naples, Florida, December 8, 1995.
182. Physician-Patient Communication: Developing a Therapeutic Alliance. Schering Corporation Speakers Bureau Meeting, Dana Point, California, February 10, 1996.
183. Sinusitis: Therapeutic Strategies and Modalities. Continuing Medical Education, University of Wisconsin, Chicago, Illinois, February 13, 1996.
184. Management of Allergic Diseases: Cost, Safety, and Side Effects. Video conference, The Chronic Airway Disease Connection: Redefining Rhinitis. UCLA School of Medicine, New York City, New York, March 2, 1996.
185. Risk and Benefit Ratio of Newer Antihistamines. American Academy of Allergy, Asthma and Immunology, New Orleans, Louisiana, March 17, 1996.
186. The Role of Anticholinergic Therapy in Asthma and Rhinitis. American Academy of Allergy, Asthma and Immunology, New Orleans, Louisiana, March 19, 1996.
187. Asthma Disease Management. The National Managed Health Care Congress. Washington, DC April 30, 1996.
188. Antihistamine Update. Pfizer Audioconference Series, Impact Communications, New York, New York, April 11, May 2, May 3, May 9, 1996.
189. Smoking Cessation: What Can be Done for Our Patients. Mercy Medical Center, Allergy, Immunology and Asthma Symposium, Appleton, Wisconsin, May 11, 1996.
190. Today's Management of Allergic Rhinitis. Mercy Medical Center, Allergy, Immunology and Asthma Symposium, Appleton, Wisconsin, May 11, 1996.
191. The Pharmacologic Basis for the Treatment of Perennial Allergic Rhinitis and Nonallergic Rhinitis with Intranasal Corticosteroids. European Academy of Allergy and Clinical Immunology, Budapest, Hungary, June 5, 1996.
192. Is Successful Control of Rhinitis Achievable? The San Diego Academy of Family Physicians, 40th Annual Postgraduate Symposium, San Diego, California, June 30, 1996.
193. Sinusitis: An interactive panel. Current Concepts in Pediatric Allergy and Otolaryngology 1996. Children's Hospital and Health Center, Coronado, California, July 7, 1996.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

194. Nasal Cytology. Allergic and Non-Allergic Rhinitis: Clinical Aspects Workshop. Chicago, Illinois, July 19, 1996.
195. The Impact of Allergic Rhinitis on the Quality of Life. Hoechst Marion Roussel meeting, Orlando, Florida, August 20, 1996.
196. New Concepts in the Treatment of Allergic Rhinitis. Sociedad Mexicana De Alergia E Inmunologia Clinica, Tijuana, Mexico, August 23, 1996.
197. Diagnosis and Management of Sinusitis. Sociedad Mexicana De Alergia E Inmunologia Clinica, Tijuana, Mexico, August 23, 1996.
198. Allergic Rhinitis, It's Nothing to Sneeze At. Parkview Hospital, Grand Rounds, Ft. Wayne, Indiana, August 26, 1996; Lutheran Hospital, Grand Rounds, Ft. Wayne, Indiana, August 27, 1996; Bryan Hospital, Grand Rounds, Bryan, Ohio, August 28, 1996; Flint Osteopathic Hospital, Grand Rounds, Flint, Michigan, August 29, 1996; Children's Hospital, Grand Rounds, Detroit, Michigan, August 30, 1996.
199. Searching for The Ideal Antihistamine. The Asthma and Allergy Foundation of America, Greater Kansas City Chapter, Kansas City, Missouri, September 12, 1996; Grand Rounds, St. Luke's Hospital, Kansas City, Missouri, September 13, 1996.
200. The Latest Word on Antihistamines: Third Generation Compounds. American Academy of Otolaryngic Allergy, Washington, DC, September 27, 1996.
201. Effect of Seasonal Allergic Rhinitis on Daily Life: Comparative Outdoor Study of Cetirizine, Loratadine and Placebo. UCB Symposium, New York, New York, October 6, 1996.
202. Quality of Life Measures in Allergic Rhinitis. Rhone-Poulenc Rorer Symposium, Chicago, Illinois, October 12, 1996.
203. Experience with Azelastine Nasal Spray in The Treatment of Allergic Rhinitis. Wallace Laboratories Consensus Conference, Denver, Colorado, October 25, 1996.
204. Smoking Cessation. American College of Allergy, Asthma and Immunology, Boston, Massachusetts, November 11, 1996.
205. Pharmacology of Topical Corticosteroids. American College of Allergy, Asthma and Immunology, Boston, Massachusetts, November 11, 1996.
206. Allergic Rhinoconjunctivitis. Chief Residents Program American Academy of Allergy, Asthma and Immunology., Palm Springs, California, November 23, 1996.
207. Why to consider Azelastine Nasal Spray for the Treatment of Seasonal Allergic Rhinitis. Wallace Symposium, New Orleans, Louisiana, December 11, 1996.
208. Guidelines for the Management of Asthma. Center for Behavioral Epidemiology and Community Health, San Diego State University, San Diego, California, December 16, 1996.
209. Nose Woes: Update on the Management of Allergic Rhinitis. Otolaryngology Grand Round, Mt. Sinai Hospital, New York, New York, January 23, 1997; Internal Medicine Grand Rounds, Metropolitan Hospital, New York, New York, January 23, 1997; Otolaryngology Grand Rounds, Bellevue Hospital, New York, New York, January 23, 1997; Allergy/Clinical Immunology Grand Rounds, Mt. Sinai Hospital, New York, New York, January 24, 1997.
210. Patients with Nasal Disease: How to Obtain the Nasal Cells, What is Found, and What Happens with Treatment. American Academy of Allergy, Asthma and Immunology. San Francisco, California, February 22, 1997.
211. Allergic and Non-Allergic Rhinitis: Diagnosis and Treatment. American Academy of Allergy, Asthma and Immunology, Allied Health Professional Course. San Francisco, California, February 24, 1997.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

212. The Role of Anticholinergic Therapy in Asthma and Rhinitis. American Academy of Allergy, Asthma and Immunology, San Francisco, California, February 25, 1997.
213. New Antihistamines. American Academy of Allergy, Asthma and Immunology, San Francisco, California, February 25, 1997.
214. Tobacco: What's Going Up in Smoke and How to Get it Down. Greater Washington Allergy, Asthma and Immunology Society. Bethesda, Maryland, March 4, 1997.
215. Nose Woes: Update on the Management of Allergic Rhinitis. Pediatric House Staff/Faculty Conference, Howard University Medical Center. Washington, D.C., March 5, 1997.
216. Choosing an Antihistamine. Allergy-Immunology Division, Children's National Medical Center. Washington, D.C., March 5, 1997.
217. Nose Woes: Update on Allergic Rhinitis. Medicine Ground Rounds, University of Connecticut, Farmington, Connecticut, March 18, 1997; Otolaryngology Department Residents, University of Connecticut, Farmington, Connecticut, March 18, 1997.
218. Considerations on Choosing an Antihistamine, Allergists of Connecticut, Hartford, Connecticut, March 18, 1997.
219. The Therapeutic Index of H₁ Antagonists. UCB Pharma Regional Conference. Vancouver, British Columbia, Canada, April 14, 1997.
220. Antihistamines for Allergic Disease. Hawaii Allergy Society. Honolulu, Hawaii, April 28, 1997.
221. Allergic Rhinitis: Nothing to Sneeze At. Kuakini Medical Center, Honolulu, Hawaii, April 28, 1997; Castle Medical Center, Kailua, Hawaii, April 29, 1997; Maui Memorial Hospital, Kahalui, Hawaii, May 1, 1997; Saint Francis West Hospital, Honolulu, Hawaii, May 2, 1997; Hilo Medical Center, Hilo, Hawaii, May 3, 1997.
222. Pharmacological Treatment Options for Allergic Rhinitis and Asthma. European Academy of Allergology and Clinical Immunology, Rhodes, Greece, June 2, 1997.
223. Quality of Life and Rhinitis. European Academy of Allergology and Clinical Immunology, Rhodes, Greece, June 5, 1997.
224. Allergic Rhinitis: Nothing to Sneeze At. Grand Rounds, Children's Hospital and Health Center, San Diego, California, July 11, 1997.
225. Nose Woes: Update on the Management of Allergic Rhinitis. San Diego Osteopathic Medical Association, San Diego, California, September 11, 1997.
226. The Therapeutic Effectiveness of Mometasone Furoate Aqueous Nasal Spray as Measured Subjectively and Objectively in Patients with Seasonal Allergic Rhinitis. European Respiratory Society, Berlin, Germany, September 22, 1997.
227. U.S. Experience with Azelastine Nasal Spray. International Congress of Allergology and Clinical Immunology, Cancun, Mexico, October 20, 1997.
228. The Effects of Antihistamines on the Quality of Life of Rhinitis Patients. International Congress of Allergology and Clinical Immunology, Cancun, Mexico, October 22, 1997.
229. National Heart Lung Blood Institute Guidelines for the Management of Asthma. University of Wisconsin Medical School CME Symposium. San Francisco, California, November 15, 1997.
230. Allergic Rhinoconjunctivitis. American Academy of Allergy, Asthma and Immunology, Family Practice Chief Residents Program, Phoenix, Arizona, November 22, 1997.
231. Nose Woes: Update on Rhinitis. Grand Rounds, Scripps Memorial Hospital, Encinitas, Encinitas, California, November 24, 1997.
232. Tobacco Cessation: How To Save Your Patient From Going Up In Smoke. Los Angeles Society of Allergy, Asthma and Clinical Immunology. Los Angeles, California, December 11, 1997.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

233. The Uses of Cytology and Rhinomanometry in the Evaluation of Nasal Diseases. Western Society of Allergy and Immunology, Maui, Hawaii, January 21, 1998.
234. Antihistamines: Newer and Better. Western Society of Allergy and Immunology, Maui, Hawaii, January 22, 1998.
235. Diagnosis and Treatment of Allergic Rhinitis. Texas Academy of Family Physicians, Dallas, Texas, January 29, 1998.
236. NHLBI Guidelines for The Management of Asthma: Bridging The Gap Between Consensus and Care. University of Wisconsin, Dallas, Texas, January 31, 1998.
237. Rhinitis - Asthma: How to Manage the Dynamic Duo. Primary Medicine Today Conference, Long Beach, California, February 28, 1998.
238. Treating Rhinitis: What to Do, What to Do? American Academy of Allergy, Asthma and Immunology, Washington, DC, March 15, 1998.
239. Antihistamine Therapy for Respiratory and Dermatologic Diseases. Hoechst Marion Roussel Symposium, Bogota, Columbia, March 24, 1998.
240. Antihistamine Therapy for Respiratory and Dermatologic Diseases. Hoechst Marion Roussel Symposium. Lima, Peru, March 27, 1998.
241. Treating Allergic Rhinitis: Issues and Options. Kentucky Society for Allergy and Asthma, Lexington, Kentucky, April 4, 1998.
242. Tobacco Cessation: How to Prevent Your Patients from Going Up in Smoke. Kentucky Society for Allergy and Asthma, Lexington, Kentucky, April 4, 1998.
243. Allergic Rhinitis: Nothing to Sneeze At. Utah Society of Allergy and Asthma. Salt Lake City, Utah, May 2, 1998.
244. New Approaches for the Diagnosis and Management of Asthma. California Academy of Physician Assistants, San Diego, California, May 27, 1998.
245. Navigating the Web with regard to allergic rhinitis and asthma: a physician's guide to medical information on the WWW. Projects In Knowledge, San Diego, California, June 6, 1998.
246. Allergic Rhinitis Market Overview. Glaxo Wellcome Medical/Pharmacy Directors Consultant Meeting. Dana Point, California, June 11, 1998.
247. Nose Woes: Update on Rhinitis. San Diego Academy of Family Physicians, Coronado, California, June 19, 1998.
248. Objective Assessments of Rhinitis Therapy. European Academy of Allergology and Clinical Immunology, Birmingham, United Kingdom, June 24, 1998.
249. Antihistamines: Newer and Better. San Antonio Allergy Society, San Antonio, Texas, July 7, 1998.
250. Allergic Rhinitis: Nothing To Sneeze At. Grand Rounds, Columbia Conroe Regional Medical Center, Conroe, Texas, July 8, 1998; Department of Continuing Medical Education, Memorial City Medical Center, Houston, Texas, July 9, 1998.
251. Antihistamines. Aspen Allergy Conference, The Given Biomedical Institute. Aspen, Colorado, August 1, 1998.
252. Recent Advances in Allergic Rhinitis and Intranasal Corticosteroids. Schering-Plough programs: Cape Town, South Africa, August 18, 1998; Durban, South Africa, August 20, 1998; Pretoria, South Africa, August 25, 1998; Johannesburg, South Africa, August 26, 1998.
253. Antihistamines: Newer and Better. Gold Coast Allergy Society, Santa Barbara, California, September 10, 1998.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

254. The Cost of Untreated Allergic Rhinitis. Pro/Com Managed Care Clinical Advisory Board, Coronado California, October 3, 1998.
255. Sneezing, Stuffy and Sniffy? What a Doc Can Do. Westchester Allergy Society, Rye Brook, New York, October 8, 1998.
256. Changing Trends in Allergy Pharmacotherapeutics. Continuing Medical Education Associates Internal Medicine Program, San Diego, California, October 12, 1998.
257. Nasal Obstruction: Methods to Measure. Schering-Plough consultants meeting, Kenilworth, New Jersey, November 18, 1998.
258. Allergic Rhinoconjunctivitis. Chief Residents' Program, American Academy of Allergy Asthma and Immunology, Phoenix, Arizona, November 21, 1998.
259. Cromolyn Sodium: Its Contribution to the Management of Allergic Rhinitis. Pharmacia/Upjohn meeting, Austin, Texas, December 12, 1998.
260. Antihistamines: Efficacy, Safety and Cost Considerations. Janssen Consultants Meeting, Brussels, Belgium, January 29, 1999.
261. Rhinitis: Update on Management. National Jewish Medical and Research Center, Annual Update on Allergy, Asthma and Clinical Immunology. Keystone, Colorado, February 6, 1999.
262. Allergic Rhinitis. Allergy and Immunology Fellows-In-Training Program, American Academy of Allergy Asthma and Immunology, Orlando, Florida, February 25, 1999.
263. Topical Versus Systemic Therapy of Allergic Rhinitis: Efficacy and Safety Issues. American Academy of Allergy Asthma and Immunology, Orlando, Florida, February 27, 1999.
264. Non-Allergic Rhinitis: Pathophysiology and Management. American Academy of Allergy Asthma and Immunology, Orlando, Florida, February 28, 1999.
265. Do Nasal Corticosteroids Affect Growth in Children? American Academy of Allergy Asthma and Immunology, Orlando, Florida, March 3, 1999.
266. Sneezing, Snuffy and Stuffy! What a Doc Can Do. Primary Medicine / Children's Hospital and Health Center, Long Beach, California, April 10, 1999.
267. Treatment of Perennial Allergic Rhinitis. Allergy Educators Meeting, Schering-Plough, Tucson, Arizona, April 25, 1999.
268. Sinusitis: A New Look At An Old Disease. Allergy Educators Meeting, Schering-Plough, Tucson, Arizona, April 25, 1999.
269. Patient Considerations in Managing Allergic Rhinitis: Diagnosis, Lifestyle, Compliance. American Academy of Allergy, Asthma & Immunology, American Thoracic Society, Honolulu, Hawaii, May 2, 1999.
270. Allergic Rhinitis: Nothing to Sneeze At. Hoechst Marion Roussel Respiratory Disease National Visiting Professors Program. Sacramento, California, June 3, 1999.
271. Intranasal Glucocorticoids in the Treatment of Acute and Recurrent Sinusitis. European Academy of Allergology and Clinical Immunology, Brussels, Belgium, July 6, 1999.
272. Current Concepts in The Management of Rhinitis in Children. Children's Hospital and Health Center, San Diego, California, July 18, 1999.
273. The Potential for Intranasal Corticosteroids in the Treatment of Sinusitis. Schering-Plough Consultants, Lake Kariba, Zimbabwe, July 29, 1999.
274. Managing Allergic Rhinitis: The US Perspective. Schering-Plough programs: Pretoria, South Africa, August 3, 1999; Johannesburg, South Africa, August 4, 1999; Durban, South Africa, August 5, 1999; Cape Town, South Africa, August 6, 1999.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

275. Sinusitis: A New Look at an Old Disease. Allergy Educator's Meeting, Schering-Plough, San Diego, California, August 22, 1999.
276. Sniffling and Sneezing: What's A Doc to Do? American Academy of Pediatrics, Chapter 3, San Diego, California, September 23, 1999.
277. Treating Asthma Inflammation: If Not Now, When? American Academy of Pediatrics, Chapter 4, Children's Hospital of Orange County, Orange, California, October 5, 1999.
278. Diagnosis and Management of Rhinitis: Joint Task Force Practice Parameters. Rhone-Poulenc Rorer Leadership Conference, Palm Springs, California, October 23 and 24, 1999.
279. Allergic Rhinitis: Nothing to Sneeze At. American College of Physicians, American Society of Internal Medicine, New Britain General Hospital, Connecticut, Scottsdale, Arizona, November 8, 1999.
280. Rhinitis and Sleep Complications. American College of Allergy, Asthma and Immunology, Chicago Illinois, November 11, 1999.
281. The Use of Intranasal Corticosteroids in the Management of Rhinosinusitis. Schering-Plough Consultants Meeting, Chicago, Illinois, November 12, 1999.
282. How Big is Allergic Rhinitis: Epidemiology and Disease Magnitude. American College of Allergy, Asthma and Immunology, Chicago, Illinois, November 14, 1999.
283. Nose Woes: Update on Rhinitis. American College of Allergy, Asthma and Immunology, Chicago, Illinois, November 14, 1999.
284. Allergic Rhinoconjunctivitis. Family Practice Chief Resident's Program, American Academy of Allergy, Asthma & Immunology. Phoenix, Arizona, November 19, 1999.
285. Clinical Overview of Allergic Rhinitis. 3M Pharmaceuticals consultants meeting, St. Paul, Minnesota, December 14, 1999.
286. Update on the Management of Allergic Rhinitis in the new Millennium. Hong Kong Otorhinolaryngological Society, Hong Kong Institute of Allergy, Hong Kong, January 24, 2000.
287. Update on the Management of Allergic Rhinitis in the New Millennium. Second Congress of the Federation of Immunological Societies of Asia-Oceania, Fifth Asian Research Symposium in Rhinology, Bangkok, Thailand, January 27, 2000.
288. The Future of Antiinflammatory Therapy. Second Congress of the Federation of Immunological Societies of Asia-Oceania, Fifth Asian Research Symposium in Rhinology, Bangkok, Thailand, January 27, 2000.
289. New Perspectives on Allergic Rhinitis. Malaysian Society of Allergy and Immunology, Malaysian Pharmaceutical Society, Kuala Lumpur, Malaysia, January 29, 2000.
290. Intranasal Corticosteroids: Benefits and Risks of the Formulations. Astra-Zeneca program. La Jolla, California, February 9, 2000.
291. Allergic Rhinitis. American Academy of Allergy, Asthma and Immunology, San Diego, California, March 2, 2000.
292. Professional Ethics: A Physician's Perspective. American Academy of Allergy, Asthma and Immunology, San Diego, California, March 3, 2000.
293. The Mechanism of Nasal Inflammation. American Academy of Allergy, Asthma and Immunology, San Diego, California, March 4, 2000.
294. Safety and Efficacy of Intranasal Corticosteroids. MedLearning Inc., San Diego, California, March 5, 2000.
295. Allergic Rhinitis: Diagnosis and Treatment. Grossmont Family Medicine Residency, Grossmont Hospital, La Mesa, California, March 21, 2000.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

296. Allergic Rhinitis Overview. GlaxoWellcome Advisory Board, Scottsdale, Arizona, April 5, 2000.
297. Sneezzy, Sniffy and Stuffy! What a Doc Can Do. Medical World Conferences, Long Beach, California, April 6, 2000.
298. Does Rhinitis Compromise Nighttime Sleep and Daytime Productivity? European Academy of Allergology and Clinical Immunology, Lisbon, Portugal, July 2, 2000.
299. Optimal Patient Care: Guidelines, Stepwise Management and Choices. European Academy of Allergology and Clinical Immunology, Lisbon, Portugal, July 2, 2000.
300. State-of-the-Art Pharmacologic Management of Allergic Rhinitis. European Academy of Allergology and Clinical Immunology, Lisbon, Portugal, July 4, 2000.
301. New Paradigms in the Management of Sinusitis. Immunology Educational Institute of New England, Los Angeles, California, July 15, 2000.
302. Treatment of Upper Airway Diseases. Warner Lambert Consultants Meeting, Morris Plains, New Jersey, July 27, 2000.
303. Sinusitis: A Newer Look at an Old Disease. American Academy of Pediatrics, Visiting Professor Program, University of Nevada, School of Medicine, Las Vegas, Nevada, August 31, 2000.
304. Sneezzy, Sniffy and Stuffy! What a Doc Can Do. American Academy of Pediatrics, Visiting Professor Program, University of Nevada, School of Medicine, Las Vegas, Nevada, September 1, 2000.
305. Research in Pediatrics: A Responsibility and an Opportunity. American Academy of Pediatrics, Visiting Professor Program, University of Nevada, School of Medicine, Las Vegas, Nevada, September 1, 2000.
306. Allergic Rhinitis with Concomitant Asthma: Considerations in Management. Schering-Plough Advisory Meeting, New York, New York, September 16, 2000.
307. Tobacco Smoking: What Happens When It Goes Up and How Can We Get It Down. Washington State Society of Allergy, Asthma and Immunology (William E. Pierson MD Lectureship), Seattle, Washington, September 20, 2000.
308. Sniffy, Sneezzy, Stuffy! What a Doc Can Do. University of Washington, Children's Hospital and Medical Center (William E. Pierson, MD Lectureship), Seattle, Washington, September 21, 2000.
309. Intranasal Glucocorticosteroids in the Treatment of Acute and Recurrent Sinusitis. International Congress of Allergology and Clinical Immunology, Sydney, Australia, October 17, 2000.
310. Rhinosinusitis: Update on Management. International Congress of Allergology and Clinical Immunology, Sydney, Australia, October 18, 2000.
311. The Relationship of the Upper and Lower Airways. Schering/Key Pharmaceuticals Conference, Las Vegas, Nevada, October 28, 2000.
312. The Clinical and Economic Burden of Allergic Rhinitis. American College of Allergy, Asthma and Immunology, Seattle, Washington, November 3, 2000.
313. Tobacco's Role in Disease and the Health Professional's Role in Smoking Cessation. American College of Allergy, Asthma and Immunology, Seattle, Washington, November 4, 2000.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

314. Low Dose Fluticasone is More Effective than Montelukast for the Treatment of Persistent Asthma. American College of Allergy, Asthma and Immunology, Seattle, Washington, November 6, 2000.
315. How Practice Parameters on Rhinitis Can Increase Allergy Specialist Consultations. American College of Allergy, Asthma and Immunology, Seattle, Washington, November 7, 2000.
316. Allergic Rhinitis Update. San Diego State University Student Health Services, San Diego, California, November 9, 2000.
317. Allergic Rhinoconjunctivitis. American Academy of Allergy, Asthma and Immunology Family Practice Chief Residents' Program, Phoenix, Arizona, November 17, 2000.
318. Therapeutic Interventions for Allergic Rhinitis. The Dannemiller Memorial Educational Foundation, Dallas, Texas, December 3, 2000.
319. The Clinical and Economic Burdens of Allergic Rhinitis. Western Society of Allergy, Asthma and Immunology, Lanai, Hawaii, January 23, 2001.
320. Sinusitis: Update on Management. Western Society of Allergy, Asthma and Immunology, Lanai, Hawaii, January 23, 2001.
321. Clinical Evidence for Antileukotriene Therapy in the Treatment of Allergic Rhinitis. International Meetings and Science, Lanai, Hawaii, January 26, 2001.
322. The Allergic Nose. Children's Hospital and Health Center, American Academy of Pediatrics, San Diego, California, March 2, 2001.
323. Efficacy of Budesonide Therapy in Rhinitis: Implications for Compliance. AstraZeneca Respiratory Consultants Forum, Rancho Mirage, California, March 3, 2001.
324. Ethics in Clinical Research. American Academy of Allergy and Immunology, New Orleans, Louisiana, March 16, 2001.
325. Pharmacological Treatment of Nasal Diseases. American Academy of Allergy, Asthma and Immunology, New Orleans, Louisiana, March 17, 2001.
326. Professional Ethics for Physicians. American Academy of Allergy, Asthma and Immunology, New Orleans, Louisiana, March 19, 2001.
327. New Paradigms in the Management of Sinusitis. Immunology Educational Institute of New England, Los Angeles, California, March 25, 2001.
328. New Paradigms in the Management of Sinusitis. Immunology Educational Institute of New England, New York, New York, April 1, 2001.
329. Efficacy of Budesonide Therapy in Rhinitis: Implications for Compliance. AstraZeneca Respiratory Consultants Forum, Beverly Hills, California, April 21, 2001.
330. Rhinitis: The Risks and Benefits of Nasal Steroid Therapy. Glaxo Managed Care Advisory Board, Phoenix, Arizona, April 28, 2001.
331. Efficacy, Safety, and Patient Preference of Intranasal Steroids in the Treatment of Allergic Rhinitis. Aventis Respiratory National Visiting Professor Program, Las Vegas, Nevada, April 29, 2001.
332. The Relationship Between Upper and Lower Airway Diseases: The role of antileukotrienes for treatment. Merck Frosst Medical Advisory Council Meeting, Annecy, France, May 5, 2001.
333. The Potential Role of Antileukotrienes in the Treatment of Allergic Rhinitis and Comorbid Conditions. European Academy of Allergology and Clinical Immunology, Berlin, Germany, May 11, 2001.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

334. How Can Sinusitis Be Medically Managed. European Academy of Allergology and Clinical Immunology, Berlin, Germany, May 12, 2001.
335. The Role of Antileukotrienes in the Treatment of Allergic Rhinitis and Comorbid Conditions. Merck Research Update Symposium, San Francisco, California, May 18, 2001.
336. The Common Links Between Upper and Lower Airway Diseases. Merck Respiratory Consultants' Meeting, Bernalillo, New Mexico, June 9, 2001.
337. Sneezzy, Sniffy, Stuffy. What a Doc Can Do. San Diego Academy of Family Physicians, Coronado, California, June 30, 2001.
338. Allergic Rhinitis: Update on Management. Rockwood Clinic, Spokane, Washington, July 12, 2001.
339. Expanding Indications for Antileukotrienes. Intermountain West Allergy Association, Coeur d'Alene, Idaho, July 13, 2001.
340. Older and Newer Antihistamines. Intermountain West Allergy Association, Coeur d'Alene, Idaho, July 14, 2001.
341. Considerations for Choosing Intranasal Corticosteroids for the Treatment of Allergic Rhinitis. Aventis Respiratory National Visiting Professor Program, Laguna Niguel, California, August 11, 2001.
342. A New Generation in Antiallergic Therapy: Desloratadine. Argentina Association of Allergy and Clinical Immunology, Buenos Aires, Argentina, August 17, 2001.
343. Allergic Rhinitis and its Impact on Asthma (ARIA): Pediatric Aspects. Argentina Association of Allergy and Clinical Immunology, Buenos Aires, Argentina, August 18, 2001.
344. Overview of Allergic Rhinitis. Medical Liaison Group, Sepracor Inc., Scottsdale, Arizona, August 22, 2001.
345. Montelukast: Clinical Development Program for Allergic Rhinitis. Merck Otolaryngology National Consultants Meeting, Chicago, Illinois, October 13, 2001.
346. Emerging Role of Antileukotrienes in the Management of Upper Respiratory Diseases. American Osteopathic Association, San Diego, California, October 23, 2001.
347. Allergic Rhinoconjunctivitis. American Academy of Allergy Asthma and Immunology, Family Practice Chief Residents Program, Phoenix, Arizona, November 9, 2001.
348. The Roadmap for the Development of Drugs: From Preclinical Studies to Postmarketing Surveillance. American College of Allergy Asthma and Immunology, Orlando, Florida, November 16, 2001.
349. The Role of Antileukotrienes for Upper Airway Diseases. American College of Allergy Asthma and Immunology, Orlando, Florida, November 16, 2001.
350. Options for Pharmacotherapy of Allergic Rhinitis in Children, Pharmacia Pediatric Multidisciplinary Roundtable, Aventura, Florida, November 30, 2001.
351. Sinusitis: A New Look at an Old Disease. Immunology Educational Institute of New England, Sacramento, California, December 1, 2001.
352. Case Studies in the Management of Allergy and Asthma. Astra Zeneca Dinner Program, San Diego, California, December 3, 2001.
353. Allergic Rhinitis: Current Therapies. Rigel Inc. Staff Program. San Francisco, California, January 16, 2002.
354. Overview of Current Methods of Clinical Assessment of Rhinitis and Guidelines for Developing New Tools. Aventis Program, Las Vegas, Nevada, January 19, 2002.
355. Case Studies in the Management of Rhinitis, Astra Zeneca Dinner Program, La Jolla, California, January 23, 2002.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

356. Therapeutic Options for Allergic Rhinitis. Pfizer Dinner Program, San Diego, California, January 24, 2002.
357. Current Therapies and Future Directions in the Treatment of Upper Respiratory Allergic Disorders. Allergy Asthma and Immunology Foundation of Northern California, San Francisco, California, February 9, 2002.
358. Management of Sinusitis. Immunology Educational Institute of New England. San Diego, California, February 24, 2002.
359. ARIA (Allergic Rhinitis and Its Impact on Asthma): Pediatric Issues. American Academy of Allergy, Asthma and Immunology, New York, New York, March 2, 2002.
360. Assessments of Allergic Rhinitis in Clinical Trials: What Should We Measure? American Academy of Allergy, Asthma and Immunology, New York, New York, March 3, 2002.
361. Nasal Cytology. American Academy of Allergy, Asthma and Immunology, New York, New York, March 4, 2002.
362. Approach to the Patient with Refractory Rhinitis. American Academy of Allergy, Asthma and Immunology, New York, New York, March 5, 2002.
363. Clinical Profile of Desloratadine in Allergic Rhinitis. Schering-Key Allergy Imperatives Meeting, San Francisco, California, March 16, 2002.
364. Intranasal Corticosteroids: Dosing Options. Dey Consultants Meeting, Napa, California, April 12, 2002.
365. Antihistamines in Allergic Rhinitis: Predictability of Response and Selection of Therapy. North Shore-Long Island Jewish Health System, San Diego, California, April 17, 2002.
366. Allergic Rhinitis: Selection of Antihistamine Therapy. The Academy of Family Practice Physicians of Santa Clara County, San Jose, California, April 22, 2002.
367. Antihistamines: Considerations When Selecting the Therapeutic Agent. Schering-Plough Brazilian Regional Programs, Porto Alegre, April 29, 2002; Curitiba, April 29, 2002; Rio de Janeiro, April 30, 2002; Campinas, April 30, 2002; Sao Paulo, May 1, 2002; Belo Horizonte, May 2, 2002; Brasilia, May 2, 2002.
368. Nasal Congestion. State University of Sao Paulo, Department of Otorhinolaryngology, Sao Paulo, Brazil, May 1, 2002.
369. Allergic Rhinitis: A Local Manifestation of a Systemic Disease. Schering-Plough Allergy Imperatives Meeting, Miami, Florida, May 4, 2002.
370. Clinical Profile of Desloratadine in Allergic Rhinitis. Schering-Plough Allergy Imperatives Meeting, Miami, Florida, May 4, 2002.
371. Antihistamine Therapy: Current Concepts and Treatment Strategies. Schering/Key Allergy Imperatives National Teleconferences. San Diego, California, May 7, 8 and 9, 2002.
372. Clinical Profile of Desloratadine in Allergic Rhinitis. Schering-Plough Allergy Imperatives Meeting, Los Angeles, California, May 18, 2002.
373. Allergic Rhinitis. Department of Otolaryngology. University of California, San Diego, La Jolla, California, May 31, 2002.
374. The Clinical Burdens of Rhinitis. Children's Hospital and Health Center, San Diego, California, June 28, 2002.
375. Rhinitis: The Benefits and Risks of Therapeutic Options. Children's Hospital and Health Center, San Diego, California, June 28, 2002.
376. Management of Sinusitis. Immunology Educational Institute of New England. Los Angeles, California, July 13, 2002.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

377. Sneezzy, Sniffy, Stuffy! What a Clinician Can Do. GSK Primary Care Program, San Diego, California, August 21, 2002.
378. Management of Sinusitis. Immunology Educational Institute of New England, Dallas, Texas, September 14, 2002.
379. The Role of Antileukotrienes for Upper Airway Diseases. American Academy of Otolaryngic Allergy, San Diego, California, September 21, 2002.
380. Management of Sinusitis. Immunology Educational Institute of New England, Cerritos, California, September 28, 2002.
381. Antihistamines for Allergic Rhinitis: Predictability of Response and Selection of Therapy. Ohio Society of Allergy Asthma and Immunology, Scottsdale, Arizona, October 3, 2002.
382. Are Antileukotrienes Valuable for Diseases Other Than Asthma? Ohio Society of Allergy Asthma and Immunology, Scottsdale Arizona, October 4, 2002.
383. Sinusitis: Current Concepts in Management. Immunology Educational Institute of New England, Charlotte, North Carolina, October 26, 2002.
384. Sinusitis: Current Concepts in Management. Immunology Educational Institute of New England, Pittsburgh, Pennsylvania, October 27, 2002.
385. Stuffy, Sniffy and Sneezzy! What a Doc Can Do. AstraZeneca Primary Care Program, Atlanta, Georgia, October 29, 2002.
386. ARIA Guidelines for the Management of Allergic Rhinitis. AstraZeneca Specialists Care Program, Atlanta, Georgia, October 30, 2002.
387. The Value of Intranasal Corticosteroids for Rhinosinusitis. American College of Allergy, Asthma and Immunology, San Antonio, Texas, November 15, 2002.
388. The P2Y₂ Receptor Antagonist, INS37217, Given Intranasally, is Well Tolerated and Decreases Saccharin Transport Time in Subjects With and Without Perennial Allergic Rhinitis. American College of Allergy, Asthma and Immunology, San Antonio, Texas, November 17, 2002.
389. Outcomes Measures for Evaluating Treatments of Allergic Rhinitis. American College of Allergy, Asthma and Immunology, San Antonio, Texas, November 18, 2002.
390. No Growth Suppression in Children Treated with Fluticasone Propionate Aqueous Nasal Spray for One Year. American College of Allergy, Asthma and Immunology, San Antonio, Texas, November 18, 2002.
391. Sinusitis. Current Concepts in Management. Immunology Educational Institute of New England, Phoenix, Arizona, November 23, 2002.
392. Stuffy, Sniffy, Sneezzy! What a Doc Can Do. AstraZeneca Program at Wilcox Medical Center, Lihue, Hawaii, January 9, 2003.
393. Clinical Concerns in the Management of Allergies and Asthma. AstraZeneca Program at Pearl City Medical Group, Pearl City, Hawaii, January 10, 2003.
394. Stuffy, Sniffy, Sneezzy! What a Doc Can Do. Hawaii Consortium for Continuing Medical Education, Kapiolani Hospital, Honolulu, Hawaii, January 13, 2003.
395. The ARIA Guidelines for the Management of Allergic Rhinitis. AstraZeneca Specialists Physicians Program, Honolulu, Hawaii, January 13, 2003.
396. Stuffy, Sniffy, Sneezzy! What a Doc Can Do. AstraZeneca Primary Care Physicians Program, Honolulu, Hawaii, January 14, 2003.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

397. Nose Woes: Current Concepts in the Management of Allergic Rhinitis. Family Practice Update in Clinical Medicine. Professional Education Services Group CME Broadcast Series Taping, Chicago, Illinois, January 18, 2003.
398. Selecting a Nonsedating H₁-Receptor Antagonist. Aventis Respiratory Speaker Academy Program, Las Vegas, Nevada, February 1, 2003.
399. Intranasal Steroids in the Treatment of Allergic Rhinitis. Aventis Respiratory Speaker Academy Program, Las Vegas, Nevada, February 1, 2003.
400. Managing the Seasons: Treating Allergic Rhinitis in Primary Care. Allergic Disease Visiting Educators Program, Professional Education Services Group, San Diego, California, February 8, 2003.
401. Management of Allergic Reactions Throughout the Life Cycle: Approaches to Allergic Rhinitis. National Institute of Allergy and Infectious Diseases, National Jewish Medical and Research Center, Bethesda, Maryland, February 10, 2003.
402. Case Studies of Allergic Rhinitis. National Institute of Allergy and Infectious Diseases, National Jewish Medical and Research Center, Bethesda, Maryland, February 10, 2003.
403. Assessment and Efficacy of Pharmacotherapy in Allergic Rhinitis. University of Wisconsin Medical School/Enable Center for Continuing Education CME Teleconference Series, February 19, February 20, March 12, March 27, April 2, May 7, May 14, August 20, August 21, 2003.
404. Therapeutic Options in the Treatment of Seasonal Allergic Rhinitis. GlaxoSmithKline Teleconference Series, February 24, February 25, February 27, March 17, March 20, 2003.
405. Ethics in Clinical Research. American Academy of Allergy Asthma and Immunology, Denver, Colorado, March 7, 2003.
406. Ethical Business Relations Between Pharmaceutical Companies and Healthcare Professionals. American Academy of Allergy Asthma and Immunology, Denver, Colorado, March 8, 2003.
407. Approach to the Patient with Refractory Rhinitis. American Academy of Allergy Asthma and Immunology, Denver, Colorado, March 9, 2003.
408. Are Antileukotrienes Valuable? Johns Hopkins Asthma and Allergy Center; University of Maryland Division of Pulmonology; Maryland Allergy and Asthma Society; Baltimore, Maryland, March 19, 2003.
409. Sinusitis: Current Concepts in Management. Immunology Educational Institute of New England, San Diego, California, March 22, 2003.
410. Sinusitis: Current Concepts in Management. Immunology Educational Institute of New England, Phoenix, Arizona, March 23, 2003.
411. The Clinical Potential of Antileukotrienes. Merck Medical Education Program for Healthcare Professionals. La Jolla, California, March 24, 2003.
412. Asthma Management 2003. Genentech National Meeting, Phoenix, Arizona, March 27, 2003.
413. Managing the Seasons: Treating Allergic Rhinitis in Primary Care. Professional Education Services Group, San Diego, California, April 3, 2003.
414. Upper Airway Diseases: Presentation and Management. American College of Allergy Asthma and Immunology. Review Course for American Board of Allergy and Immunology Recertification, Dallas, Texas, April 4, 2003.
415. Emerging Therapeutic Strategies for Asthma Management. Academy of Managed Care Pharmacy, Minneapolis, Minnesota, April 10, 2003.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

416. Sinusitis: Current Concepts in Management. Immunology Educational Institute of New England, Los Angeles, California, April 13, 2003.
417. Are Antileukotrienes Valuable? Merck Medical Education Program for Healthcare Professionals, Tucson, Arizona, April 23, 2003.
418. Are Antileukotrienes Valuable? Merck Medical Education Program for Healthcare Professionals, Phoenix, Arizona, April 24, 2003.
419. Managing the Seasons: Treating Allergic Rhinitis in Primary Care. Professional Education Services Group, San Diego, California, May 6, 2003.
420. Stuffy, Sniffy, Sneezy! What a Doc Can Do. GlaxoSmithKline Dinner Program, San Diego, California, May 29, 2003.
421. Rhinosinusitis: Symptom Scoring Systems. American Academy of Allergy, Asthma and Immunology, Bethesda, Maryland, May 31, 2003.
422. Omalizumab: Efficacy and Safety in Treating Asthma. Genentech/Novartis Regional Advisory Board, La Jolla, California, June 14, 2003.
423. Stuffy, Sniffy, Sneezy! What a Doc Can Do. Pennsylvania Allergy and Asthma Association, Hershey, Pennsylvania, June 21, 2003.
424. Rhinosinusitis: Update on Management. Pennsylvania Allergy and Asthma Association, Hershey, Pennsylvania, June 21, 2003.
425. The Relationships Between Upper and Lower Airway Diseases. Intermountain West Allergy Association, Coeur d'Alene, Idaho, July 25, 2003.
426. How to Dance with a Porcupine: Ethical Business Relations Between Pharmaceutical Companies and Healthcare Professionals. Intermountain West Allergy Association, Coeur d'Alene, Idaho, July 26, 2003.
427. Omalizumab: Scientific Principles and Practical Clinical Issues. Genentech and Novartis Nurses Dinner Program, La Jolla, California, September 4, 2003.
428. New Therapeutic Strategies for Rhinitis. World Allergy Organization Congress, Vancouver, Canada, September 9, 2003.
429. Quality of Life in Allergic Rhinitis and Asthma. World Allergy Organization Congress, Vancouver, Canada, September 11, 2003.
430. Omalizumab: A Novel Anti-IgE in Clinical Studies for Asthma. World Allergy Organization Congress, Vancouver, Canada, September 11, 2003.
431. The Relationships of Upper and Lower Airway Diseases. Dallas/Ft. Worth Allergy Society, Irving, Texas, September 23, 2003.
432. Evaluating Rhinitis Patients – What are the Potential Measures? University of Texas Southwestern, Division of Allergy and Immunology. Dallas, Texas, September 24, 2003.
433. Rhinosinusitis: Update on Management. Pediatric Nurse Practitioners and Nurses Course, Children's Hospital and Health Center, San Diego, California, October 4, 2003.
434. Rhinosinusitis: Update on Management. Mexican College of Allergy, Asthma and Clinical Immunology, Acapulco, Mexico, October 16, 2003.
435. New Antiinflammatory Treatments for Asthma. Mexican College of Allergy, Asthma and Clinical Immunology, Acapulco, Mexico, October 17, 2003.
436. Medications for Nasal Disease: Advantages and Challenges. Schering Consultants Meeting, Short Hills, New Jersey, October 20, 2003.
437. Meeting the Goals of Pediatric Asthma Therapy with the Use of Inhaled Corticosteroids and Other Antiinflammatory Therapies. American Academy of Pediatrics, New Orleans, Louisiana. November 2, 2003.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

438. The Truth About Omalizumab. American College of Allergy, Asthma and Immunology, New Orleans, Louisiana, November 9, 2003.
439. Measuring Quality of Life in Rhinitis. American College of Allergy, Asthma and Immunology, New Orleans, Louisiana, November 10, 2003.
440. New Therapeutic Strategies for Rhinitis. Astra Zeneca Medical Information Scientists. Kohala Coast, Hawaii, January 26, 2004.
441. The Relationships of Upper and Lower Airway Diseases. Western Society of Allergy Asthma and Immunology, Hualalai, Hawaii, January 29, 2004.
442. Rhinosinusitis: A New Look at an Old Condition. Western Society of Allergy Asthma and Immunology, Hualalai, Hawaii, January 30, 2004.
443. Start Treatment with Appropriate Antibiotic Respiratory Therapy: A Novel Approach to The Empiric Treatment of Respiratory Tract Infections. Pri-Med Institute Updates, San Diego, California, March 7, 2004.
444. Choosing the Right Prescription Antihistamine for School-age Children. Aventis Teleconference Series, March 8, 2004; April 29, 2004; May 17, 2004.
445. Choosing the Right Prescription Antihistamine for your Patients. Aventis Teleconference Series, March 10, 2004; March 11, 2004; March 25, 2004; March 29, 2004; April 8, 2004; April 22, 2004; April 28, 2004; May 3, 2004; May 5, 2004; May 10, 2004; May 20, 2004; May 24, 2004; May 25, 2004; May 26, 2004.
446. Ethics in Clinical Research. American Academy of Allergy Asthma and Immunology, San Francisco, California, March 19, 2004.
447. Controversies of Allergic Rhinitis Treatment with Antileukotrienes. American Academy of Allergy Asthma and Immunology, San Francisco, California, March 21, 2004.
448. Importance and Limitations of Controlled Clinical Trials for Allergic Diseases. American Academy of Allergy Asthma and Immunology, San Francisco, California, March 21, 2004.
449. Comparative Pharmacokinetics and Pharmacodynamics of Respiratory Corticosteroids. American Academy of Allergy Asthma and Immunology, San Francisco, California, March 22, 2004.
450. Evolution of Rhinosinusitis Definitions. American Academy of Allergy Asthma and Immunology, San Francisco, California, March 23, 2004.
451. Managing Nose Woes. Aventis National Speakers Program. Tacoma, Washington, April 13, 2004.
452. The Relationships of Upper and Lower Airway Diseases. Washington State, Society of Allergy Asthma and Immunology. Seattle, Washington, April 14, 2004.
453. New Antiinflammatory Treatments for Asthma. Sharp Healthcare Continuing Medical Education. San Diego, California, April 21, 2004.
454. Evidence to Support the Allergic Rhinitis-Asthma Connection. Schering Consultants Meeting, Chicago, Illinois, April 27, 2004.
455. Is There a Role for Intranasal Corticosteroids in Acute Rhinosinusitis? European Academy of Allergology and Clinical Immunology, Amsterdam, Netherlands, June 13, 2004.
456. Allergic Rhinitis in Children: How Frequent, What Pollens, Which Antihistamine? European Academy of Allergology and Clinical Immunology, Amsterdam, Netherlands, June 14, 2004.
457. Pharmacologic Management of Allergic Rhinitis. Access Medical Group, Department of Continuing Medical Education, Costa Mesa, California, July 17, 2004.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

458. Current Treatments for Rhinitis. Pediatric Otolaryngology Interdisciplinary Meeting. San Diego, California, August 13, 2004.
459. Overview of the Asthma Guidelines. National Jewish Medical and Research Center, Denver, Colorado, September 27, 2004.
460. The Pediatric Asthma Challenge: Exploring Strategies for Improving Diagnosis, Monitoring and Adherence. Medical Crossfire, University of Medicine and Dentistry of New Jersey, San Francisco, California, October 10, 2004.
461. The Relationships of Rhinitis and Asthma. American College of Allergy, Asthma and Immunology, Boston, Massachusetts, November 12, 2004.
462. Practical Aspects of the Use of Omalizumab. American College of Allergy, Asthma and Immunology, Boston, Massachusetts, November 14, 2004.
463. "Doctor, I've Got Sinus." American College of Allergy, Asthma and Immunology, Boston, Massachusetts, November 15, 2004.
464. Objective Tests for Allergic Rhinitis: The Role of Histology and Nasal Challenges. 9th Asian Research Symposium in Rhinology and 10th Trans-Pacific Allergy and Immunology Society Congress. Mumbai, India, November 21, 2004.
465. Evidence-Based Quality of Life Assessments and Treatments of Allergic Rhinitis. 9th Asian Research Symposium in Rhinology and 10th Trans-Pacific Allergy and Immunology Society Congress. Mumbai, India, November 23, 2004.
466. Allergic Rhinitis: Managing the Pediatric Spectrum. Southwest Allergy Forum/Eastern Allergy Conference/ Texas Allergy, Asthma and Immunology Society, Combined Meeting on Allergy, Asthma and Immunology, Puerto Vallarta, Mexico, January 12, 2005.
467. The Relationships of Upper and Lower Airway Diseases. Southwest Allergy Forum/Eastern Allergy Conference/ Texas Allergy, Asthma and Immunology Society, Combined Meeting on Allergy, Asthma and Immunology, Puerto Vallarta, Mexico, January 16, 2005.
468. Update on the Classification and Management of Rhinosinusitis. Dey, L.P. Consultants Meeting, Napa, California, January 25, 2005.
469. The Science of Asthma. National Jewish Medical and Research Center Program, Breathe-Work-Play: Advancing Asthma Care in the Community, Dallas, Texas, January 29, 2005.
470. Allergic Rhinitis: Issues and Options. Educational Review Systems CME Teleconference Series, February 21, 2005, March 7, 2005, March 9, 2005, April 14, 2005, May 5, 2005, September 22, 2005, October 6, 2005, November 21, 2005.
471. Clinical Trial Ethics. American Academy of Allergy, Asthma and Immunology, San Antonio, Texas, March 18, 2005.
472. Methodologic Considerations in Design and Implementation of Randomized Clinical Trials. American Academy of Allergy, Asthma and Immunology, San Antonio, Texas, March 19, 2005.
473. Effects of Intranasal R112, an Inhibitor of Syk-kinase, on the Symptoms of Seasonal Allergic Rhinitis: a 2 Day Park Study. American Academy of Allergy, Asthma and Immunology, San Antonio, Texas, March 20, 2005.
474. Evidence-Based Management of Allergic Responses: Allergic Rhinitis and Urticaria. Sanofi-Aventis Teleconference Series, March 30, 2005, April 7, 2005, May 11, 2005, May 18, 2005, July 28, 2005.
475. Treating Allergic Rhinitis: Mechanism-Based Evaluation and Therapeutic Strategies. Pri-Med Update Series, Dallas, Texas, March 31, 2005.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

476. Treatments for Rhinitis. University of California, San Diego, Division of Otolaryngology-Head and Neck Surgery, Core Curriculum Lecture Series, La Jolla, California, April 8, 2005.
477. The Science of Asthma. Pri-Med Update Series, Portland, Oregon, April 29, 2005.
478. The Science of Asthma. Pri-Med Update Series, Las Vegas, Nevada, May 21, 2005.
479. Rhinitis: A Practical Approach. Post Graduate Institute of Medicine, Respiratory and Allergic Disease Foundation, Dallas, Texas, June 6, 2005.
480. Treating Allergic Rhinitis: Mechanism-based Evaluation and Therapeutic Strategies. Pri-Med Update Series, San Jose, California, June 17, 2005.
481. As Easy As ABC: Treating the Pediatric Allergic Rhinitis Patient. World Allergy Organization Congress, Munich, Germany, June 28, 2005.
482. Tangible Benefits of Antiinflammatory Intranasal Corticosteroid Treatment in Allergic Rhinitis and Acute Rhinosinusitis. World Allergy Organization Congress, Munich, Germany, June 29, 2005.
483. Allergic Rhinitis: Identifying Patient Symptoms and Implementing a Comprehensive Management Strategy. Johns Hopkins University teleconference series, August 23, 2005; August 25, 2005; August 30, 2005; August 31, 2005; September 1, 2005; September 7, 2005; September 8, 2005; September 20, 2005; September 22, 2005; September 28, 2005.
484. Rhinosinusitis: A New Look at an Old Condition. Boston City Wide Allergy and Immunology Series, Boston, Massachusetts, September 13, 2005.
485. The Science of Asthma. National Jewish Medical and Research Center Program, Breathe-Work-Play: Advancing Asthma Care in the Community, Los Angeles, California, September 17, 2005.
486. Profiling Antihistamines for the Treatment of Allergic Disease. American College of Allergy Asthma and Immunology, Anaheim, California, November 4, 2005.
487. Practical Aspects of the Use of Omalizumab. American College of Allergy Asthma and Immunology, Anaheim, California, November 6, 2005.
488. Long-Term Safety Profile of Once-Daily Ciclesonide in Children with Persistent Asthma of All Severities. American College of Allergy Asthma and Immunology, Anaheim, California, November 7, 2005.
489. Mometasone Furoate Nasal Spray for Management of Nasal Congestion. Schering Plough L.E.A.D. Teleconference Program. December 13, 2005.
490. Evolution of Rhinosinusitis Definitions and Guidance for Clinical Trials. Schering Plough Consultants Meeting, Coral Gables, Florida, January 14, 2006.
491. Ethics in Clinical Research. American Academy of Allergy, Asthma and Immunology. Miami Beach, Florida, March 3, 2006.
492. Journal Club: High Impact Publications for Rhinitis, Sinusitis and Ocular Disease. American Academy of Allergy, Asthma and Immunology. Miami Beach, Florida, March 6, 2006.
493. Practical Approaches to School Age Asthma Care. Merck Program, Tucson, Arizona, March 20, 2006.
494. Congestion: A Management Challenge in Allergic Rhinitis. Schering-Plough Teleconference Series. April 26, 2006; May 3, 2006; May 4, 2006.
495. Allergic Rhinitis. Mexican National Congress of Clinical Immunology and Allergy. Tijuana, Mexico, June 29, 2006.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

496. Treatment Options in Upper and Lower Airway Disease. National Jewish Medical and Research Center Program, Breathe, Work and Play – Diagnosis and Treatment of Upper and Lower Airway Diseases, Indianapolis, Indiana, September 16, 2006.
497. Allergic Rhinitis: Burden of Illness. GlaxoSmithKline Allergist and Otolaryngologist National Advisory Board for Rhinitis, Dallas, Texas, November 4, 2006.
498. Current Prevalence and Resource Utilization of Patients with Allergic Rhinitis. American College of Allergy, Asthma and Immunology, Philadelphia, Pennsylvania, November 12, 2006.
499. Assessing the Rhinitis Patient. American College of Allergy, Asthma and Immunology, Philadelphia, Pennsylvania, November 13, 2006.
500. Ethics in Clinical Research. American Academy of Allergy, Asthma and Immunology, San Diego, California, February 23, 2007.
501. Pathophysiology of Allergic Rhinitis and Comorbid Conditions. American Academy of Allergy, Asthma and Immunology, San Diego, California, February 23, 2007.
502. Management of Allergic Rhinitis and Asthma in the Patient with Sleep Disordered Breathing. American Academy of Allergy, Asthma and Immunology, San Diego, California, February 25, 2007.
503. Rhinitis Outcomes Measures in Private Practice. American Academy of Allergy, Asthma and Immunology, San Diego, California, February 25, 2007.
504. Improving Treatment of Childhood Allergies. Sanofi Aventis Allegra Teleconference Series. March 14, 2007; March 20, 2007; March 21, 2007; March 28, 2007; March 29, 2007, April 11, 2007; April 24, 2007; May 1, 2007; May 14, 2007; June 18, 2007.
505. Cysteinyl Leukotrienes: Important Mediators in the Pathogenesis of Allergic Rhinitis. Glendale, Arizona. March 15, 2007.
506. State of the Science. Pathophysiology of Allergic Rhinitis: Impact on Target Organs. Greater Phoenix Allergy and Asthma Society. Paradise Valley, Arizona, March 15, 2007.
507. Clinical Trial Evidence of Effects of Intranasal Mometasone Furoate on Rhinosinusitis. Schering-Plough Consultants Workshop, Dallas, Texas, March 24, 2007.
508. Allergic Rhinitis in Children: Looking Beyond the Sniffles. Peerpoint Medical Education Institute CME Teleconference Series. March 27, 2007; March 29, 2007; April 9, 2007; April 30, 2007; May 2, 2007.
509. Impact of Nasal Congestion in Allergic Rhinitis and Polyposis. Schering-Plough Teleconference Series. April 4, 2007; April 5, 2007; April 25, 2007; April 26, 2007.
510. Managing Ocular Allergies: Recent Advances in Treatment. SRxA Institute for Professional Education in conjunction with Medical Education Resources CME Teleconference Series. May 10, 2007; May 15, 2007; May 16, 2007.
511. Nasonex Speaker Training Web Conference. Schering-Plough, Advanced Health Media. May 24, 2007; July 30, 2007.
512. Veramyst Speaker Training Web Conference. GlaxoSmithKline, June 14, 2007.
513. Allergic Rhinitis: Understanding the Burden of the Disease and Introducing Fluticasone Furoate Nasal Spray. GlaxoSmithKline Teleconference Series. July 14, 2007; July 24, 2007; August 7, 2007; August 30, 2007; September 11, 2007; September 18, 2007.
514. Pathophysiology of Allergic Rhinitis: Impact on Comorbid Conditions. California Society of Allergy, Asthma and Immunology, Office of Continuing Medical Education, Keck School of Medicine, University of Southern California, San Francisco, California, July 27, 2007.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

515. Emerging Therapies for the Treatment of Allergic Rhinitis. California Society of Allergy, Asthma and Immunology, Office of Continuing Medical Education, Keck School of Medicine, University of Southern California, San Francisco, California, July 28, 2007.
516. Allergic Rhinitis: Treatment Gaps and Unmet Needs. Schering-Plough/Merck Respiratory Joint Venture Consultants Meeting. Chicago, Illinois, September 7, 2007.
517. Congestion: A Management Challenge in Allergic Rhinitis. Schering-Plough Program. San Diego, California, September 20, 2007.
518. Practitioner's Edge: The New Asthma Treatment Guidelines – Application in Clinical Practice. American College of Allergy, Asthma and Immunology, Dallas, Texas, November 11, 2007. www.practitionersedge.com
519. Nasal Allergies Adversely Affect Sleep and Productivity in Children. American College of Allergy, Asthma and Immunology, Dallas, Texas, November 11, 2007.
520. Nasal Allergies Reduce Quality of Life in Children. American College of Allergy, Asthma and Immunology, Dallas, Texas, November 11, 2007.
521. Fluticasone Furoate Nasal Spray Provides 24-hour relief of Perennial Allergic Rhinitis Symptoms. American College of Allergy, Asthma and Immunology, Dallas, Texas, November 11, 2007.
522. Medical Crossfire – Allergic Rhinitis: Impact and Action Plan for the Use of Over the Counter and Prescription Agents. American College of Allergy, Asthma and Immunology, Dallas, Texas, November 12, 2007.
523. Pathophysiology of Allergic Rhinitis and Comorbid Conditions. Department of Otolaryngology, Tulane University Health Sciences Center, New Orleans, Louisiana, November 13, 2007.
524. Allergic Rhinitis: Impact on Comorbid Conjunctivitis and Sinusitis. World Allergy Congress, Bangkok, Thailand, December 5, 2007.
525. Problem-Based Learning: An Interactive Case Discussion of Pediatric Asthma. AstraZeneca Program. Seattle, Washington, December 17, 2007; Tacoma, Washington, December 17, 2007; Eugene, Oregon, December 18, 2007; Portland, Oregon, December 18, 2007; Orange, California, December 19, 2007.
526. Rhinitis: Links to Asthma. CME under joint sponsorship of AKH, Inc. and Medical Communications Media, Inc. in conjunction with the Western Society of Asthma, Allergy and Immunology, Kailua-Kona, Hawaii, January 22, 2008.
527. Nasal Allergy Symptoms: Year-Round Active Management with Intranasal Steroids. Schering-Plough Telesymposium Series, February 13, 2008; February 19, 2008.
528. Congestion: A Management Challenge in Allergic Rhinitis. Schering-Plough Program, San Diego, California, February 20, 2008.
529. Treatment Considerations for Nasal Polyposis and Allergic Rhinitis. Schering-Plough Telesymposium Series, March 5, 2008; March 10, 2008.
530. Rhinosinusitis: Current Concepts in Management. American Academy of Allergy, Asthma and Immunology, Philadelphia, Pennsylvania, March 15, 2008.
531. Chronic Sinusitis With and Without Polyps. American Academy of Allergy, Asthma and Immunology, Philadelphia, Pennsylvania, March 16, 2008.
532. Rhinitis Outcomes Measures in Allergy/Immunology Practice. American Academy of Allergy, Asthma and Immunology, Philadelphia, Pennsylvania, March 16, 2008.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

533. The Future of Nasal Corticosteroids. SRxA Institute for Professional Education. CME program Guidelines versus treatment plans: where are we acutally heading with rhinitis treatment? Philadelphia, Pennsylvania, March 18, 2008.
534. Improving Outcomes for Patients with Allergic Rhinitis: An Update from Philadelphia. CME program, Alcon, University of Florida, PeerView Institute, March 2008.
www.peerviewpress.com/r1/s476
535. Update on Sublingual Immunotherapy. CME teleconference through joint sponsoring of Medical Education Collaborative and MarCom CME International. March 26, 2008.
536. Update on Sublingual Immunotherapy. San Diego Allergy Society. San Diego, California, April 8, 2008.
537. Unmet Needs with Current Allergic Rhinitis Therapies; The Omnaris Clinical Overview. Sepracor Speaker Training Meeting, Lake Buena Vista, Florida, April 12, 2008.
538. Formulation Considerations with Intranasal Corticosteroids for Allergic Rhinitis Therapy; The Omnaris Clinical Overview. Sepracor Speaker Training Meeting, St. Louis, Missouri, April 26, 2008.
539. Advances in Immunotherapy for Allergic Rhinitis. Integrity Continuing Education – National Jewish Medicine and Research Center CME. Los Angeles, California, April 29, 2008; San Francisco, California, April 30, 2008.
540. New Advances in the Treatment of Seasonal and Perennial Allergic Rhinitis. Sepracor Telesymposium. May 5, 2008.
541. Management of Allergic Rhinitis with an Intranasal Corticosteroid. Sanofi-Aventis Program. La Jolla, California, May 12, 2008.
542. Olopatadine Nasal Spray: Product Profile and Competitive Data. Alcon Advisory Meeting, New York, New York, May 17, 2008.
543. Non-allergic Rhinitis: Classification and Management. Alcon Advisory Meeting, New York, New York, May 17, 2008.
544. New Advances in the Treatment of Seasonal and Perennial Allergic Rhinitis. Sepracor Program. La Jolla, California, May 29, 2008.
545. Treatment Strategies for Nasal Symptoms of Allergic Rhinitis. European Allergology and Clinical Immunology. Barcelona, Spain, June 9, 2008.
546. Individualized Care for the Patient with Allergic Rhinitis: A Case-Based, Guideline-Driven Review. 1 hour Primary CME program, Chester Education Group, July 2008.
www.primarycme.org
547. Implementing National Asthma Education and Prevention Program Guidelines on Children. Schering-Plough Pediatric Advisory Board Meeting, Washington DC, August 16, 2008.
548. Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Health Care Professional. Network for Continuing Medical Education (NCME) and the Primary Care Network (PCN). Los Angeles, California, September 6, 2008.
549. Allergic Rhinitis. Sylvia and Thomas Bodamer Symposia in Allergies and Immunology, Scripps Clinic, San Diego, California, September 9, 2008.
550. Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Health Care Professional. Network for Continuing Medical Education (NCME) and Primary Care Network (PCN), Phoenix, Arizona, September 19, 2008.
551. Allergic Rhinitis: A Management Challenge in Clinical Practice. Schering-Plough Nasonex Symposium, Tokyo, Japan, September 13, 2008.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

552. Treating Nasal Allergies in Japan and the United States. Schering-Plough Dinner Program, Utsynomiya, Japan, September 16, 2008.
553. Treatment Advances in Allergic Rhinitis. Sepracor/Neo-Health Inc., Specialists Teleconferences, October 14, 2008; October 27, 2008; November 3, 2008; November 17, 2008; December 1, 2008; December 9, 2008.
554. Treatment Advances in Allergic Rhinitis. Sepracor/Neo-Health Inc., Primary Care Physician Teleconferences, October 29, 2008; November 24, 2008; December 3, 2008; December 4, 2008; January 26, 2009; January 27, 2009.
555. Once-Daily Asmanex for Maintenance Treatment of Asthma in Children. Schering-Plough Teleconference Series. October 16, 2008; October 20, 2008; October 22, 2008; December 15, 2008.
556. Overview of Traditional Inhaled Drug Delivery Systems. American College of Allergy, Asthma and Immunology, Seattle, Washington, November 8, 2008.
557. Prevalence of Conditions Associated with Allergic Rhinitis in Children and Adults. American College of Allergy, Asthma and Immunology, Seattle, Washington, November 9, 2008.
558. Practitioner's Edge: Improving Outcomes for Patients with Allergic Rhinitis and Asthma. American College of Allergy, Asthma and Immunology, Seattle, Washington, November 10, 2008.
559. Allergic Rhinitis: A Management Challenge in Clinical Practice. Schering-Plough Program. Tokyo, Japan, February 9, 2009; Osaka, Japan, February 10, 2009; Tokyo, Japan, February 12, 2009; Tokyo, Japan, February 13, 2009.
560. Inhaled Corticosteroids as Foundation Therapy for Persistent Asthma: Role of Asmanex Twisthaler. Schering-Plough Program. Tokyo, Japan, February 11, 2009.
561. Single-Agent Inhaled Corticosteroid Once-Daily Maintenance Treatment for Asthma. Schering-Plough Asmanex Teleconference Series. February 17, 2009; February 18, 2009; February 19, 2009; March 4, 2009; March 5, 2009.
562. Chronic Sinusitis With and Without Polyps. American Academy of Allergy, Asthma & Immunology. Washington DC, March 14, 2009.
563. Rhinosinusitis: Update on Management. American Academy of Allergy, Asthma & Immunology. Washington DC, March 15, 2009.
564. Nasal Allergy Symptoms in Pediatric Patients. Schering-Plough Nasonex Teleconference Series. April 15, 2009; April 22, 2009; October 5, 2009; October 28, 2009; November 18, 2009.
565. Case in Point: Problem-Based Peer Discussion in Allergic Rhinitis Webcam and Webconferences. Sepracor/Neo-Health Inc, April 20, 2009; April 21, 2009; April 28, 2009; April 30, 2009; May 4, 2009; May 6, 2009.
566. Expert Access Dialogues Webcam and Webconferences on the Treatment of Allergic Rhinitis. Sepracor/Neo-Health Inc, May 4, 2009; May 11, 2009; May 14, 2009.
567. Meeting Patient Needs: A Peer-to-Peer Discussion of the Treatment for Allergic Rhinitis CME program. Sponsored by Medical Education Resources and the SRxA Institute for Professional Education. Beverly Hills, California, May 14, 2009. Pasadena, California, May 14, 2009. San Francisco, California, May 18, 2009. San Jose, California, May 19, 2009.
568. Burden of Allergic Rhinitis. Mexican College of Clinical Immunology and Allergy. Los Cabos, Baja California, May 28, 2009.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

569. Treating the Symptoms of Allergic Rhinitis. GlaxoSmithKline Program. La Jolla, California, June 17, 2009.
570. Unmet Needs and Treatment Gaps. MAP Pharmaceuticals Advisory Meeting. Palo Alto, California, June 20, 2009.
571. Problem-Based Learning Asmanex Telesymposia. Schering Plough, July 1, 2009; July 7, 2009; July 9, 2009.
572. Intranasal Corticosteroids as Therapy for Adenoidal Hypertrophy. Schering-Plough Allergy Advisory Board meeting. Chicago, Illinois, July 24, 2009.
573. Differentiating Factors in The Intranasal Corticosteroid Therapy Class. Schering-Plough Web-based Allergy Advisory Board Teleconference, August 26, 2009.
574. Problem-Based Learning Nasonex Pediatric Telesymposia. Schering-Plough. October 5, 2009; October 28, 2009; November 18, 2009.
575. Current Guideline Recommendations for Therapy of Allergic Rhinitis. National Jewish Health Consensus Panel. Denver, Colorado, October 8, 2009.
576. Respiratory Roundtable: The Role of Alvesco in The Maintenance Treatment of Asthma. Sepracor Web-conference series. October 13, 2009; October 21, 2009; October 22, 2009; October 27, 2009; October 29, 2009.
577. Respiratory State of the Nation: Findings From The Asthma Insight and Management (AIM) Survey. Schering-Plough Symposium, San Diego, California, November 3, 2009; Miami Beach, Florida, November 6, 2009.
578. Problem-Based Learning Asmanex Pediatric Telesymposia. Schering-Plough. November 4, 2009; November 11, 2009; November 12, 2009.
579. Longitudinal Validation of the Rhinitis Control Assessment Test (RCAT). American College of Allergy, Asthma and Immunology, Miami Beach, Florida, November 9, 2009.
580. Practitioner's Edge: Differentiating Asthma and COPD in the Allergist's Office. American College of Allergy, Asthma and Immunology, Miami Beach, Florida, November 9, 2009.
581. Case in Point: Problem-Based Peer Discussion in Asthma. Sepracor Alvesco Web-Conference Series. November 19, 2009; November 23, 2009; November 24, 2009; December 14, 2009; December 15, 2009; December 16, 2009; December 21, 2009.
582. Improving Allergic Rhinitis Treatment Acceptability in Pediatric Patients. World Allergy Congress, Sanofi-Aventis Symposium. Buenos Aires, Argentina, December 7, 2009.
583. Optimal Therapy for Allergic Rhinitis. World Allergy Congress, Nycomed Symposium. Buenos Aires, Argentina, December 9, 2009.
584. Chronic Rhinosinusitis Treatment: Evidence for the Use of Corticosteroids and Antibiotics. World Allergy Congress. Buenos Aires, Argentina, December 10, 2009.
585. Asthma Insight and Management Survey Results. Schering Corporation Symposium. New Orleans, Louisiana, February 26, 2010.
586. The Effect of The Upper Airway on Sleep and What Does it Mean for My Patients? American Academy of Allergy, Asthma and Immunology, New Orleans, Louisiana, March 2, 2010.
587. Treating the Symptoms of Allergic Rhinitis. GlaxoSmithKline Teleconference. March 11, 2010.
588. Safety of Immunotherapy and the Role of Epinephrine Auto-Injector. Dey Consultants Meeting, Chicago, Illinois, March 13, 2010.
589. Burden of Allergic Rhinitis. Harold B. Kaiser Honoraria Lectureship, 12th Annual Allergy and Asthma Conference, Minneapolis, Minnesota, March 19, 2010.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

590. Case in Point: Problem-Based Peer Discussion in Asthma. Sepracor Program. San Diego, California, March 24, 2010; Dallas, Texas, April 1, 2010.
591. Case in Point: Problem-Based Peer Discussion in Asthma, Sepracor Program. Okemos, Michigan, May 11, 2010; Bloomfield Hills, Michigan, May 12, 2010; Troy, Michigan, May 12, 2010; Taylor, Michigan, May 12, 2010; Ann Arbor, Michigan, May 12, 2010.
592. Allergic Rhinitis: An Overview. Sepracor National Managers Meeting. Atlanta, Georgia, June 30, 2010.
593. Asthma: Insights from Guidelines and Clinical Practice. Sepracor National Managers Meeting. Atlanta, Georgia, June 30, 2010.
594. The 2010 FDA Drug Safety Communication on The Use of Long-Acting Beta₂-Agonists and Inhaled Corticosteroids in The Maintenance Treatment of Asthma. Sepracor teleconference, July 13, 2010.
595. Managing Patients with Asthma: A Clinicians Perspective. Merck Regional Meeting. Rye Brook, New York, August 11, 2010; Washington DC, August 12, 2010.
596. Allergic Conjunctivitis. Ista Problem Based Learning Program. Houston, Texas, August 26, 2010.
597. Allergic Rhinitis: An Overview. CME, The Sylvia and Thomas Bodamer Symposium in Allergy and Immunology, Scripps Clinic and Research Center, La Jolla, California, September 7, 2010.
598. An Option for the Treatment of Asthma. Merck Medical Forums Program. San Diego, California, September 20, 2010; La Jolla, California, September 22, 2010; Tucson, Arizona, September 28, 2010; Phoenix, Arizona, November 13, 2010.
599. Heterogeneity in Asthma. Merck Peer Discussion Group. Tucson, Arizona, September 29, 2010.
600. Problem Based Learning: Interactive Asthma Cases Discussion. Tucson Allergy Society. Tucson, Arizona, September 29, 2010.
601. Current Treatment of Rhinosinusitis. Congress of The Argentine Association of Respiratory Medicine. Buenos Aires, Argentina, October 11, 2010.
602. Allergic Rhinitis and Asthma: One Disease or Only Just Coincidence? Congress of The Argentine Association of Respiratory Medicine. Buenos Aires, Argentina, October 12, 2010.
603. Case in Point: Problem-Based Peer Discussion on Allergic Rhinitis. Sunovion Program. Houston, Texas, October 25, 2010; Scottsdale, Arizona, October 26, 2010.
604. Respiratory Thought Leader Exchange on The Treatment of Allergic Rhinitis. Sunovion Program. Glendale, Arizona, October 26, 2010.
605. Burden of Rhinitis. American College of Allergy, Asthma and Immunology, Phoenix, Arizona, November 12, 2010.
606. Practitioner's Edge: Epinephrine for The Treatment of Anaphylaxis: Questions and Controversies. American College of Allergy, Asthma and Immunology, Phoenix, Arizona, November 14, 2010.
607. What Does a Doctor Do? Hoover Elementary School, Los Angeles, California, January 10, 2011.
608. Problem Based Learning Asthma Cases. Merck Program. Lewis Gale Pulmonary Associates/Asthma and Allergy Center of Roanoke. Roanoke, Virginia, January 18, 2011.
609. A Therapeutic Option for Patients with Asthma. Merck Program. Roanoke, Virginia, January 18, 2011.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

610. Problem Based Learning – Interactive Adult Asthma Case Discussion. Merck Program. Banner Good Samaritan Medical Center, Phoenix, Arizona, February 18, 2011; Veteran’s Administration Medical Center, Phoenix, Arizona, February 18, 2011.
611. Proper Use of Pollen Data in Clinical Research. American Academy of Allergy, Asthma and Immunology, San Francisco, California, March 19, 2011.
612. National Allergy Survey Assessing Limitations (NASL 2010). Allergists for Israel, San Francisco, California, March 20, 2011.
613. Allergic Rhinitis. CBS, The Doctors. Los Angeles, California, March 25, 2011.
614. Respiratory State of the Nation: Results from the Asthma Insights and Management Survey (AIM). Merck Program, Tulsa, Oklahoma, March 29, 2011; Chicago, Illinois, April 16, 2011.
615. Respiratory State of the Nation: Results from the Asthma Insights and Management Survey (AIM). San Diego Allergy Society. Del Mar, California, April 12, 2011.
616. Treatment of Inflammation in Asthma. Sunovion Teleconference Program. April 11-14, 2011; April 18-21, 2011.
617. Problem Based Learning: An Interactive Discussion of a Case of a Child with Rhinitis. Alcon Program, La Jolla, California, April 27, 2011.
618. Case in Point: Problem-based Peer Discussion on Allergic Rhinitis. Sunovion Program, Scottsdale, Arizona, May 3, 2011.
619. Burden of Allergic Rhinitis. Inland Empire Allergy Society, Alcon Program, Riverside, California, May 11, 2011.
620. Burden of Allergic Rhinitis. Nebraska Academy of Allergy Asthma and Immunology, Sunovion Program, Omaha, Nebraska, May 19, 2011.
621. Treatment of Inflammation in Asthma. Boys Town National Research Hospital, Sunovion Program, Boys Town, Nebraska, May 20, 2011.
622. The Burden of Allergic Rhinitis. Orange County Society of Allergy and Clinical Immunology. Alcon Program. Costa Mesa, California, June 23, 2011.
623. Clinical Considerations in The Assessment and Management of Asthma. Merck Program. Harrisburg, Pennsylvania, June 24, 2011.
624. A Therapeutic Option for Patients with Asthma. Merck Program. Hershey, Pennsylvania, June 25, 2011.
625. Allergic Rhinitis: Effect on Sleep. Florida Allergy, Asthma and Immunology Society. Amelia Island, Florida, July 8, 2011.
626. Burden of Allergic Rhinitis. Sunovion Program. San Diego, California, July 13, 2011.
627. Improving the Recognition and Management of Anaphylaxis: A Guideline-Based Approach. CME Integrity Continuing Education. Los Angeles, California, July 27, 2011.
628. Improving the Recognition and Management of Anaphylaxis: A Guideline-Based Approach. CME Integrity Continuing Education. San Diego, California, July 28, 2011.
629. Proper Use of Pollen Data in Clinical Trials. Pan-American Aerobiology Association, San Diego, California, August 9, 2011.
630. Case in Point: Problem-Based Peer Discussion on Allergic Rhinitis. Allergy, Asthma and Immunology Society of San Antonio. Sunovion Program, San Antonio, Texas, August 18, 2011.
631. Clinical Considerations in The Assessment and Management of Asthma. Merck Peer Discussion Group. Chandler, Arizona, September 8, 2011.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

632. Heterogeneity in Asthma. Merck Peer Discussion Group. Phoenix, Arizona, September 8, 2011.
633. Improving the Recognition and Management of Anaphylaxis: A Guideline-Based Approach. CME Integrity Continuing Education. San Francisco, California. September 22, 2011; West Los Angeles, California. September 24, 2011.
634. Clinical Considerations in the Assessment and Management of Asthma. Merck Peer Discussion Group. Encinitas, California. September 27, 2011.
635. Guidelines for the Diagnosis and Management of Anaphylaxis: Insights for the Primary Care Practitioner. Primary Care Education, Integrity Continuing Education. Dallas, Texas, October 28, 2011.
636. The Links Between Allergic Rhinitis and Asthma. American College of Allergy, Asthma and Immunology. Boston, Massachusetts, November 4, 2011.
637. MP29-02 in the Symptomatic Treatment of Seasonal Allergic Rhinitis – A Comparative Spring Study. American College of Allergy, Asthma and Immunology. Boston, Massachusetts, November 7, 2011.
638. Walk Through Guidelines for Diagnosis and Management of Sinusitis and Rhinosinusitis. American College of Allergy, Asthma and Immunology. Boston, Massachusetts, November 8, 2011.
639. Asthma Control: Importance of Reaching the Small Airways and Providing Low Systemic Exposure. Sunovion Web Conferences. November 9, 2011; November 10, 2011; November 17, 2011; November 22, 2011; December 19, 2011.
640. Guide for The Diagnosis and Management of Anaphylaxis: Insights for The Primary Care Practitioner. Primary Care Network CME. Anaheim, California, November 16, 2011.
641. Improving the Recognition and Management of Anaphylaxis: A Guideline-based Approach. Integrity Continuing Education. Beverly Hills, California, November 16, 2011; Phoenix, Arizona, November 30, 2011.
642. Morbidity and Comorbidities of Children with Allergic Rhinitis. World Allergy Congress, Cancun, Mexico, December 5, 2011.
643. A post-hoc Analysis of Asthma Control and Lung Function Following Treatment with Ciclesonide 80 mcg Twice Daily in Patients with Mild-to-Moderate Persistent Asthma Previously Receiving Low Dose Fluticasone Propionate/Salmeterol. World Allergy Congress, Cancun, Mexico, December 6, 2011.
644. A Walk Through The Guidelines for The Diagnosis and Treatment of Rhinosinusitis. World Allergy Congress, Cancun, Mexico, December 6, 2011.
645. Asthma Control: Importance of Reaching The Small Airways and Providing Low Systemic Exposure. Sunovion Program, Valencia, California, December 16, 2011.
646. Anaphylaxis: Issues in Management. Mylan/Dey National Sales Meeting. Orlando, Florida, January 19, 2012.
647. Clinical Considerations in the Assessment and Management of Asthma. Merck Program. Puyallup, Washington, February 8, 2012; Corvallis, Oregon, February 9, 2012.
648. A Comprehensive Approach to Asthma Mangement: An Interactive Case-based Discussion. Merck Program. Tacoma, Washington, February 8, 2012; Eugene, Oregon, February 9, 2012.
649. Asthma Control: Importance of Reaching The Small Airways and Providing Low Systemic Exposure. Sunovion Program. East Palo Alto, California, February 21, 2012; Beverly Hills, California, February 23, 2012.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

650. Difficult Cases: Sleep Disorders in Children. American Academy of Allergy Asthma and Immunology, Orlando, Florida, March 2, 2012.
651. Non-allergic Rhinitis: Insights to the Pathophysiology, Classification and Clinical Management. American Academy of Allergy Asthma and Immunology, Orlando, Florida, March 2, 2012.
652. A Walk Through the Guidelines for the Diagnosis and Management of Rhinosinusitis. American Academy of Allergy Asthma and Immunology, Orlando, Florida, March 2, 2012.
653. Asthma Control: Importance of Reaching the Small Airways and Providing Low Systemic Exposure. Sunvoion Programs. Colorado Springs, Colorado, March 14, 2012; Greenwood Village, Colorado, March 15, 2012.
654. Anaphylaxis. CME Program. Providence Tarzana Medical Center, Tarzana, California, March 16, 2012.
655. A Comprehensive Approach to Asthma Management: An Interactive Case-based Discussion. Merck Program. Bethlehem, Pennsylvania, March 19, 2012; Philadelphia, Pennsylvania, March 20, 2012; Gulph Mills, Pennsylvania, March 20, 2012.
656. Problem-Based Learning: Peer Discussion in Asthma. Sunovion Teleconference Program, April 3, 2012; April 30, 2012.
657. Asthma Control: Importance of Reaching the Small Airways and Providing Low Systemic Exposure. Sunovion Program. Scottsdale, Arizona, April 10, 2012.
658. Anaphylaxis: Strategies for Diagnosis, Prevention, and Treatment. CME, Integrity Continuing Education. Beverly Hills, California, April 12, 2012.
659. An Allergist's View of Allergic Rhinitis. Teva Program, Dallas, Texas, April 19, 2012.
660. Addressing the Burden of Allergic Rhinitis: Advancing Care to Improve Patient Outcomes. Integrity Continuing Education, Beverly Hills, California, June 19, 2012; San Diego, California, June 20, 2012.
661. Problem-Based Learning: Peer Discussion in Asthma. Sunovion Web-Conference Program. June 25, 2012; July 12, 2012.
662. Allergic Rhinitis: Addressing Unmet Needs. Teva Program, Miami, Florida, July 21, 2012; San Antonio, Texas, July 25, 2012; Boerne, Texas, July 25, 2012; Austin, Texas, July 26, 2012; San Diego, California, July 28, 2012.
663. Improving Patient Choice in the Management of Allergic Rhinitis. American Academy of Physician Assistants in Allergy, Asthma, and Immunology. CME Global Education Group and TREAT Education. San Antonio, Texas, August 4, 2012.
664. Allergic Rhinitis: Addressing Unmet Needs. Teva Kansas Programs.
 - Kansas City Allergy Society, Leawood Kansas, August 14, 2012
 - Clay Platte Family Medicine Clinic, Kansas City, Missouri, August 15, 2012.
 - Department of Allergy and Immunology, University of Kansas Medical Center, Kansas City, Kansas, August 15, 2012.
 - Pediatric Care Associates, Overland Park, Kansas, August 15, 2012.
 - Clinicians and Pharmacists, Kansas City, Missouri, August 15, 2012.
665. Allergic Rhinitis: Addressing Unmet Needs. Teva Program. Filipino Medical Society, San Diego, California, August 16, 2012.
666. Introducing Zetonna (ciclesonide) Nasal Aerosol: A New Dry Option for Allergic Rhinitis. Sunovion Teleconference Program. August 29, 2012; October 22, 2012; October 24, 2012.
667. Introducing Zetonna (ciclesonide) Nasal Aerosol: A New Dry Option for Allergic Rhinitis. Sunovion Program. Tucson, Arizona, September 6, 2012.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

668. Considerations in Asthma Control: Assessing Both Impairment and Risk. Merck Webcast Program. September 11, 2012.
669. Anaphylaxis: Strategies for Diagnosis, Prevention and Treatment. Integrity Continuing Education. Sacramento, California, September 12, 2012; Los Angeles, California, September 19, 2012; Phoenix, Arizona, September 20, 2012; Los Angeles, Pediatric Society, Anaheim, California, September 21, 2012; Seattle, Washington, October 16, 2012; San Francisco, California, October 17, 2012; San Diego, California, October 18, 2012; British Columbia Chapter of Pediatrics, Vancouver, British Columbia, Canada, October 25, 2012; Pomona, California, November 13, 2012.
670. Introducing Zetonna (ciclesonide) Nasal Aerosol: A New Dry Option for Allergic Rhinitis. Sunovion Program, San Diego California, September 24, 2012.
671. Zetonna (ciclesonide) Nasal Aerosol: A Dry Alternative for the Treatment for Allergic Rhinitis. Sunovion Teleconference Program, September 25, 2012; October 24, 2012.
672. Allergic Rhinitis: What's New. Teva Program. San Diego Allergy Society, San Diego, California. September 27, 2012.
673. Allergic Rhinitis: Addressing Unmet Needs. Teva Programs. Greater Louisville Allergy Society. Louisville, Kentucky, October 1, 2012; Blue Grass Allergy Society, Lexington, Kentucky, October 2, 2012.
674. Allergic Rhinitis: Addressing Unmet Needs. Teva Programs. Bath, Ohio, October 3, 2012; Toledo, Ohio, October 4, 2012.
675. Allergic Rhinitis: Addressing Unmet Needs. Teva Programs. Fort Wayne, Indiana, October 9, 2012; Indianapolis, Indiana, October 10, 2012; Shelbyville, Indiana, October 11, 2012.
676. An Advanced Treatment for Symptom Relief of Seasonal Allergic Rhinitis. Meda Program. Seattle, Washington, October 12, 2012; Phoenix, Arizona, October 15, 2012.
677. Anaphylaxis: Strategies for Diagnosis, Prevention and Treatment. CME, Integrity Continuing Education. Seattle, Washington, October 16, 2012; San Francisco, California, October 17, 2012; San Diego, California, October 18, 2012.
678. Introducing Zetonna (ciclesonide) Nasal Aerosol: A New Dry Option for Allergic Rhinitis. Sunovion Program. New Mexico Allergy Society. Albuquerque, New Mexico, October 21, 2012.
679. Anaphylaxis: Strategies for Diagnosis, Prevention and Treatment. CME, Integrity Continuing Education. British Columbia Pediatric Society, Vancouver, British Columbia, October 25, 2012.
680. Allergic Rhinitis: Addressing Unmet Needs. Teva Programs. Sacramento, California, October 29, 2012; Roseville, California, October 30, 2012; Davis, California, October 30, 2012.
681. An Advanced Treatment for Symptom Relief of Seasonal Allergic Rhinitis. Meda Program. Beverly Hills, California, November 1, 2012
682. Anaphylaxis Action Plan: Are You Engaging and Empowering Your Rhinitis. Mylan Product Theatre. Anaheim, California, November 11, 2012.
683. Chronic Hypertrophic Sinusitis. American College of Allergy, Asthma and Immunology. Anaheim, California, November 11, 2012.
684. A Child with Rhinitis: A Problem-Based Learning Interactive Case Discussion. Alcon Program. Anaheim, California, November 11, 2012.
685. Anaphylaxis: Strategies for Diagnosis, Prevention and Treatment. Integrity Continuing Education. Pomona, California, November 13, 2012.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

686. Introducing Zetonna (ciclesonide) Nasal Aerosol: A New Dry Option for Allergic Rhinitis. Sunovion Programs. Loyola Medical Center, Department of Otolaryngology, Maywood, Illinois, November 14, 2012; Schaumburg, Illinois, November 14, 2012; Troy, Michigan, November 15, 2012.
687. Introducing Zetonna (ciclesonide) Nasal Aerosol: A New Dry Option for Allergic Rhinitis. Sunovion WebCast, November 19, 2012.
688. Allergic Rhinitis: The Burden of Illness – an International Problem. The 2nd International Allergy, Asthma and Immunology Conference. Jerusalem, Israel, November 28, 2012.
689. New Therapeutic Options for Allergic Rhinitis. The 2nd International Allergy, Asthma and Immunology Conference. Jerusalem, Israel, November 29, 2012.
690. Allergic Rhinitis: Addressing Unmet Needs. Teva Program. Oklahoma City, Oklahoma, January 7, 2013; Brookfield, Wisconsin, January 9, 2013; Wausau, Wisconsin, January 10, 2013; Marshfield, Wisconsin, January 10, 2013.
691. Introducing Zetonna (ciclesonide) Nasal Aerosol: A New Dry Option for Allergic Rhinitis. Sunovion Programs. San Jose, California, January 23, 2013; San Mateo, California, January 24, 2013; Palo Alto, California, January 24, 2013.
692. Allergic Rhinitis: Addressing Unmet Needs. Teva Program. San Antonio, Texas, February 20, 2013.
693. Anaphylaxis: Recognition and Management. American Association of Allergists and Immunologists of Indian Origin. San Antonio, Texas, February 22, 2013.
694. Zetonna (ciclesonide) Nasal Aerosol: A Dry Alternative for the Treatment for Allergic Rhinitis. Sunovion Program. San Antonio, Texas, February 22, 2013.
695. Comorbidities in Asthma: Which Matter Most? American Academy of Allergy Asthma and Immunology. San Antonio, Texas, February 23, 2013.
696. Rethinking Anaphylaxis. Mylan Program. San Antonio, Texas, February 24, 2013.
697. Allergic Rhinitis: Addressing Unmet Needs. Teva Programs. Wilkes-Barre, Pennsylvania, March 5, 2013; Easat Stroudsburg, Pennsylvania, March 5, 2013; Bethlehem, Pennsylvania, March 5, 2013; Allentown, Pennsylvania, March 6, 2013; Doylestown, Pennsylvania, March 6, 2013; Summit, New Jersey, March 6, 2013; Clifton, New Jersey, March 7, 2013; Oakland, New Jersey, March 7, 2013; Queensbury, New York, March 11, 2013; Syracuse, New York, March 12, 2013; Skaneateles, New York, March 12, 2013; Ithaca, New York, March 13, 2013; Bufflao, New York, March 14, 2013; Horsham, Pennsylvania, March 18, 2013; Freehold, New Jersey, March 19, 2013; Holondel, New Jersey, March 19, 2013; Tom's River, New Jersey, March 19, 2013; Philadelphia, Pennsylvania, March 20, 2013; Woodbury, New Jersey, March 20, 2013; Trenton, New Jersey, March 21, 2013.
698. Adult with Rhinitis: Problem Based Learning, an Interactive Case Discussion. Teva Programs: Capital District Allergy Society, Albany, New York, March 11, 2013; Finger Lakes Allergy Society, Pittsford, New York, March 13, 2013; Buffalo Allergy Society, Buffalo, New York, March 14, 2013; Philadelphia Allergy Society, Philadelphia, Pennsylvania, March 21, 2013.
699. Allergic Rhinitis: Addressing Unmet Needs. Teva Connect Teleconferences. March 25, 2013; March 26, 2013; March 27, 2013; March 29, 2013.
700. Understanding Delivery Options for the Treatment of Allergic Rhinitis. Sunovion Programs. Salt Lake City, April 1, 2013; Draper, UT, April 2, 2013; Los Gatos, CA, April 3, 2013; San Jose, CA, April 4, 2013; Napa, CA, April 4, 2013.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

701. Allergic Rhinitis: Addressing Unmet Needs. Teva Programs. San Jose, California, April 17, 2013; Monterey, California, April 18, 2013.
702. Problem-Based Learning: Peer Discussion in Asthma. Sunovion Web-conference Program. April 16, 2013; April 18, 2013; April 22, 2013.
703. Allergic Rhinitis: Addressing Unmet Needs. Teva Program. Fullerton, California, April 23, 2013.
704. Problem-Based Learning, An Interactive Case Discussion: Adult with Rhinitis. Teva Program. Costa Mesa, California, April 23, 2013.
705. Morbidity and Comorbidities in Children with Allergic Rhinitis. World Allergy Organization Online Symposium. Recorded April 25, 2013.
706. MP 29-02 (azelastine hydrochloride/fluticasone propionate): A New Product for the Treatment of Allergic Rhinitis. National Jewish Health CME Symposium: "Moving Towards Clarity: Innovations and Advancements in Allergic Rhinitis Care." Denver, Colorado, June 13, 2013.
707. MP 29-02, A New Product for the Treatment of Allergic Rhinitis: Overview of Clinical Studies and Experience from the United States. Meda Symposium, EAACI-WAO Congress, Milan, Italy, June 24, 2013.
708. Anaphylaxis: Considerations for Timely and Safe Treatment. CME, Integrity CE. Children's Hospital Colorado, Aurora, Colorado, July 17, 2013.
709. Allergic Rhinitis: Controlling the Burden of Disease. CME, Integrity CE. Nevada Academy of Family Physicians. Las Vegas, Nevada, August 3, 2013.
710. Allergic Rhinitis: Addressing Unmet Needs. Teva Product Theater, American Academy of Family Physicians, San Diego, California, September 26, 2013.
711. Options for the Treatment of Allergic Rhinitis: Is Over-the-Counter Good Enough or Does the Allergist Need to be Involved? Columbus Allergy Society, Columbus, Ohio, September 30, 2013.
712. Problem Based Learning, An Interactive Case Discussion: Adult with Allergic Rhinitis. Teva Program, Cincinnati Allergy Society, Cincinnati, Ohio, October 1, 2013.
713. Allergic Rhinitis: Controlling the Burden of Disease. CME, Integrity CE. Los Angeles Pediatric Society, Anaheim, California, October 11, 2013.
714. Insights Into the Risk Factors, Diagnosis, and Immunologic Mechanisms of Allergic Rhinitis. Merck Programs, Cherry Hill, New Jersey, October 15, 2013; Allentown, Pennsylvania, October 16, 2013; Bethlehem, Pennsylvania, October 16, 2013; Fort Worth, Texas, October 17, 2013.
715. Anaphylaxis: Considerations for Timely and Safe Treatment. CME, Integrity CE. Idaho Chapter, American Academy of Pediatrics, Boise, Idaho, October 30, 2013.
716. Options for the Treatment of Allergic Rhinitis: Is Over-the-Counter Good Enough or Does the Allergist Need to be Involved? American College of Allergy Asthma and Immunology, Baltimore, Maryland, November 8, 2013.
717. Problem Based Learning, An Interactive Case Discussion: Child with Rhinitis. Alcon Program, Baltimore, Maryland, November 9, 2013.
718. Pharmacotherapy for Chronic Rhinosinusitis. American College of Allergy Asthma and Immunology, Baltimore, Maryland, November 10, 2013.
719. An Advanced Treatment for Symptom Relief of Seasonal Allergic Rhinitis. Meda Program. San Diego Allergy Society-San Diego Otolaryngology Society combined meeting. San Diego, California, November 14, 2013.

SELECTED PRESENTATIONS: ELI O. MELTZER, MD

720. Insights Into the Risk Factors, Diagnosis, and Immunologic Mechanisms of Allergic Rhinitis. Merck Programs, Phoenix, Arizona, November 19, 2013; Tucson, Arizona, November 20, 2013.
721. Anaphylaxis: Considerations for Timely and Safe Treatment. CME, Integrity CE. Grand Rounds, Long Beach Memorial Medical Center, Long Beach, California, November 22, 2013.
722. Insights Into the Risk Factors, Diagnosis, and Immunologic Mechanisms of Allergic Rhinitis. Merck Program, Inland Empire Allergy Society, Riverside, California, December 4, 2013.
723. Allergic Rhinitis: Effects on Sleep. Teva Advisory Board Meeting, Dallas, Texas, December 13, 2013.
724. Anaphylaxis: Considerations for Timely and Safe Treatment. CME, Integrity CE. Houston Pediatric Society, Houston, Texas, January 14, 2014.
725. Thinking Differently About Allergic Rhinitis. MSD National Symposium. Hangzhou, China, January January 18, 2014.
726. The Role of Cysteinyl Leukotrienes and Montelukast in Allergic Rhinitis. MSD Regional Symposium. Shanghai, China, January 19, 2014; Suzhou, China, January 20, 2014; Jinan, China, January 21, 2014; Beijing, China, January 22, 2014; Guangzhou, China, January 23, 2014.